Datasets:

chuyin0321

/

news-stocks

like 1

Follow

chuyin0321 2

ILMN

With shares of the gene sequencing giant Illumina (NASDAQ: ILMN) collapsing by 53% over the last three years due to a combination of a botched acquisition attempt and weakness in its core business, shareholders are doubtlessly wondering whether the stock's decline is finished, or if it's just getting started. With the naming of a new chief technology officer (CTO) on August 9 and a new CEO on September 5, at a minimum investors can have confidence that something about the company's strategy is going to change. The new CEO will take over on September 25, which, in conjunction with the new CTO, will help Illumina break with the management team responsible for its acquisition of Grail, a cancer testing business.Continue reading

Motley Fool

Is the Worst Over for Illumina Stock?

https://finance.yahoo.com/m/a59d8de4-82f6-3e93-95ff-522ac7daca82/is-the-worst-over-for.html

a59d8de4-82f6-3e93-95ff-522ac7daca82

IMNM

EXTON, Pa., August 09, 2023--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update."We believe combining Immunome and Morphimmune’s technologies represents a major step in our long-term strategy of creating a preeminent oncology therapeutics company," stated Purnanand Sarma, PhD, President and CEO of Immunome. "Targeted cancer therapies have made great strides in recent years, and the possible synergy between Morphimmune’s Targeted Effector Platform and Immunome’s proprietary Discovery Engine presents an opportunity to discover and develop truly novel therapies that can help cancer patients. We look forward to completing the merger by the end the year."HighlightsImmunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies. In June 2023, Immunome and Morphimmune, a private biotechnology company focused on developing targeted oncology therapeutics, announced that the two companies entered into a definitive merger agreement. The closing of the transaction is subject to customary closing conditions, including the effectiveness of the registration statement on Form S-4 to be filed by Immunome, and the receipt of required stockholder approvals from Immunome and Morphimmune stockholders.The combined company, which will operate as Immunome, will feature a synergistic platform expected to enable the development of best-in-class targeted cancer therapies across multiple modalitiesClay B. Siegall, Ph.D., current Morphimmune President & CEO and former co-founder & CEO of Seagen, Inc., to serve as Chairman and CEO of combined companyA concurrent $125 million private placement investment with leading institutional investors will support development of a combined pipeline expected to submit three investigational new drug applications (INDs) within 18 months of closingImmunome Published Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity. In May 2023, Immunome announced the publication of data highlighting efficacy of its preclinical IL-38 blocking antibody, titled "IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation," in the peer-reviewed journal mAbs. The data in the article demonstrates that antibody-based targeting of IL-38 leads to activation of the immunostimulatory anti-tumor mechanisms within the tumor microenvironment in preclinical testing.Story continuesFinancial HighlightsCollaboration Revenue: Collaboration Revenue from the Collaboration Agreement with AbbVie for the three months ended June 30, 2023 was $4.3 million.Research and development (R&D) expenses: R&D expenses for the three months ended June 30, 2023 were $5.7 million.General and administrative (G&A) expenses: G&A expenses for the three months ended June 30, 2023 were $4.2 million.Net loss: Net loss for the three months ended June 30, 2023 was $5.6 million, or $0.46 per share.Cash and cash equivalents: As of June 30, 2023, cash and cash equivalents totaled $38.4 million.About ImmunomeImmunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop antibody therapeutics to improve patient care. The company’s focus is on discovering and developing therapeutics in oncology internally and in collaboration with its partners.Immunome’s proprietary Discovery Engine identifies novel therapeutic antibodies and their targets through an unbiased interrogation of human memory B cells, highly educated components of the immune system, isolated from patients. Memory B cells are key elements in the human immune system response to disease as they produce specific, high-affinity antibodies that bind to cancer antigens or pathogens. Immunome’s Discovery Engine incorporates high-throughput screening to enable efficient, unbiased, broad, and deep functional evaluation of patient memory B cell repertoires to identify antibodies directed at novel targets. The functional data Immunome generates differentiates Immunome’s approach from those that use deep sequencing of B cells to identify dominant clones that are common within and across patients and assumes genomic dominance is a hallmark of therapeutic utility.For more information, visit www.immunome.com.Forward-Looking StatementsCautionary Statement Regarding Forward-Looking StatementsCertain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). These include, but are not limited to, statements regarding the anticipated completion and effects of the proposed merger and private placement and related timing; the combined company’s planned clinical programs, including the timeline for filing of INDs and planned clinical trials; the potential of the combined company’s product candidates; the expected trading of the combined company’s stock on Nasdaq; management of the combined company; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Immunome undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as "anticipates," "believes," "plans," "expects," "projects," "future," "intends," "may," "will," "should," "could," "estimates," "predicts," "potential," "continue," "guidance," and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, the outcome of any legal proceedings that may be instituted against Morphimmune or Immunome following the announcement of the merger; the inability to complete the merger, including due to the inability to concurrently close the merger and the private placement of common stock or due to failure to obtain approval of the stockholders of Immunome; delays in obtaining, adverse conditions contained in, or the inability to obtain necessary regulatory approvals or complete regular reviews required to complete the merger, if any; the inability to recognize the anticipated benefits of the merger, which may be affected by, among other things, competition, the ability of the combined company to grow and successfully execute on its business plan; costs related to the merger; changes in the applicable laws or regulations; the timing for achievement of milestones and the corresponding receipt of milestone payments; the possibility that the combined company may be adversely affected by other economic, business, and/or competitive factors; the risk that regulatory approvals for the combined company’s programs and product candidates are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the post-combination combined company or the expected benefits of the merger; the combined company’s ability to manage future growth; the combined company’s ability to manage clinical trials or studies; the risk that pre-clinical data may not be predictive of clinical data; the complexity of numerous regulatory and legal requirements that the combined company needs to comply with to operate its business; the reliance on the combined company’s management; the prior experience and successes of the combined company’s management team are not indicative of any future success; the dependence on the success of Morphimmune’s targeted effector platform and Immunome’s human memory B cell platform; the failure to obtain, adequately protect, maintain or enforce the combined company’s intellectual property rights; and other risks and uncertainties indicated from time to time described in Immunome’s Annual Report on Form 10-K for the year ended December 31, 2022, the Registration Statement, once available, relating to the merger, including those under "Risk Factors" therein, and in Immunome’s other filings with the SEC. Immunome cautions that the foregoing list of factors is not exclusive and not to place undue reliance upon any forward-looking statements which speak only as of the date made. Moreover, Morphimmune and Immunome operate in a very competitive and rapidly changing environment. New risks emerge from time to time. Except as required by law, Immunome undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in their expectations.Changes and Additional Information About the Proposed Merger and Where to Find ItThis communication is not intended to be, and is not, a substitute for the proxy statement or any other document that Immunome has filed or may file with the Securities and Exchange Commission ("SEC") in connection with the proposed merger.In connection with the proposed merger, Immunome has filed a registration statement on Form S-4 (File No. 333-273792) (the "Registration Statement") with the SEC that includes a proxy statement/prospectus of Immunome, that will be both the proxy statement to be distributed to holders of Immunome’s common stock in connection with its solicitation of proxies for the vote by Immunome’s stockholders with respect to the proposed merger and other matters as may be described in the Registration Statement, as well as the prospectus relating to the offer and sale of the securities to be issued in the proposed merger. The Registration Statement, including the proxy statement/prospectus contained therein, contains important information about the proposed merger and the other matters to be voted upon at a meeting of Immunome’s stockholders to be held to approve the proposed merger and other matters (the "Merger Special Meeting"). Immunome may also file other documents with the SEC regarding the proposed merger. Immunome stockholders and other interested persons are advised to read the Registration Statement, including the proxy statement/prospectus contained therein, as well as any amendments or supplements thereto, because they contain important information about the proposed merger. When available, the definitive proxy statement/prospectus will be mailed to Immunome stockholders as of a record date to be established for voting on the proposed merger and the other matters to be voted upon at the Merger Special Meeting.No Offer or SolicitationThis press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall neither constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.Participants in the SolicitationImmunome, Morphimmune, and their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from Immunome’s stockholders with respect to the proposed merger. Information regarding the persons who may be deemed participants in the solicitation of proxies from Immunome’s stockholders in connection with the proposed merger are contained in the proxy statement/prospectus forming a part of the Registration Statement and will be contained in the definitive proxy statement/prospectus relating to the proposed merger, when available, which will be filed with the SEC.IMMUNOME, INC.Condensed Balance Sheets(In thousands, except share data)(unaudited)June 30, 2023December 31, 2022AssetsCurrent assets:Cash and cash equivalents$38,416$20,323Prepaid expenses and other current assets1,1102,326Total current assets39,52622,649Property and equipment, net1,203681Operating right-of-use asset, net174284Restricted cash100100Deferred offering costs432332Total assets$41,435$24,046Liabilities and stockholders’ equityCurrent liabilities:Accounts payable$3,699$2,400Accrued expenses and other current liabilities5,0254,931Deferred revenue, current17,668—Total current liabilities26,3927,331Deferred revenue, non-current5,705—Other long-term liabilities—62Total liabilities32,0977,393Commitments and contingencies (Note 7)Stockholders’ equity:Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at June 30, 2023 and December 31, 2022, respectively——Common stock, $0.0001 par value; 200,000,000 shares authorized; 12,200,433 and 12,128,843 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively11Additional paid-in capital135,165132,653Accumulated deficit(125,828)(116,001)Total stockholders’ equity9,33816,653Total liabilities and stockholders’ equity$41,435$24,046IMMUNOME, INC.Condensed Statements of Operations(In thousands, except share and per share data)(unaudited)Three Months Ended June 30,Six Months Ended June 30,2023202220232022Collaboration revenue$4,263$—$6,627$—Operating expenses:Research and development5,7165,7179,62913,795General and administrative4,3203,2097,2426,785Total operating expenses10,0368,92616,87120,580Loss from operations(5,773)(8,926)(10,244)(20,580)Interest income21624173Net loss$(5,557)$(8,924)$(9,827)$(20,577)Per share information:Net loss per share of common stock, basic and diluted$(0.46)$(0.74)$(0.81)$(1.70)Weighted-average common shares outstanding, basic and diluted12,197,80112,127,38512,190,18212,125,156IMMUNOME, INC.Condensed Statement of Cash Flows(In thousands)(unaudited)Six Months ended June 30,20232022Cash flows from operating activities:Net loss$(9,827)$(20,577)Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Depreciation and amortization195224Amortization of right-of-use asset11033Share-based compensation2,2572,637Changes in operating assets and liabilities:Prepaid expenses and other assets1,2164,448Accounts payable1,2762,182Accrued expenses and other current liabilities(33)(3,342)Deferred revenue23,373—Other long-term liabilities(62)(41)Net cash provided by (used in) operating activities18,505(14,436)Cash flows from investing activities:Purchases of property and equipment(446)(176)Net cash used in investing activities(446)(176)Cash flows from financing activities:Proceeds from exercise of stock options—32Proceeds from issuance of common stock under ATM, net34—Net cash provided by financing activities3432Net increase (decrease) in cash and cash equivalents and restricted cash18,093(14,580)Cash and cash equivalents and restricted cash at beginning of period20,42349,329Cash and cash equivalents and restricted cash at end of period$38,516$34,749Supplemental disclosures of cash flow information:Issuance of common stock to certain board of directors in lieu of accrued compensation$221$—Deferred offering costs in accrued expenses and other current liabilities$100$—Property and equipment included in accounts payable$23$—Property and equipment included accrued expenses and other current liabilities$248$—View source version on businesswire.com: https://www.businesswire.com/news/home/20230809342526/en/ContactsImmunome ContactCorleen RocheChief Financial OfficerImmunome, [email protected] ContactLaurence WattsManaging DirectorGilmartin, [email protected] ContactAndrew MielachVice President, Account ManagementLifeSci [email protected]

Business Wire

Immunome Reports Second Quarter 2023 Financial Results

https://finance.yahoo.com/news/immunome-reports-second-quarter-2023-120000922.html

2b7ef87f-1bd0-3b1e-86ad-280c0f18b61b

IMNM

A fortuitous chain of events led to a merger and a $125 million PIPE financing deal, both of which are expected to be completed next month.Continue reading

American City Business Journals

Inside the deal: How Immunome and MophImmune came to a merger agreement

https://finance.yahoo.com/m/d79e03fe-b1e0-31bd-947f-0b4582bd0ac7/inside-the-deal-how-immunome.html

d79e03fe-b1e0-31bd-947f-0b4582bd0ac7

IMPL

Impel Pharmaceuticals (NASDAQ:IMPL) First Quarter 2023 ResultsKey Financial ResultsRevenue: US$4.37m (up 149% from 1Q 2022).Net loss: US$30.1m (loss widened by 12% from 1Q 2022).US$1.27 loss per share (further deteriorated from US$1.17 loss in 1Q 2022).earnings-and-revenue-growthAll figures shown in the chart above are for the trailing 12 month (TTM) periodImpel Pharmaceuticals Revenues and Earnings Miss ExpectationsRevenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 63%.Looking ahead, revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US.Performance of the American Biotechs industry.The company's shares are down 42% from a week ago.Risk AnalysisYou should always think about risks. Case in point, we've spotted 5 warning signs for Impel Pharmaceuticals you should be aware of, and 3 of them make us uncomfortable.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.Join A Paid User Research SessionYou’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

Simply Wall St.

Impel Pharmaceuticals First Quarter 2023 Earnings: Misses Expectations

https://finance.yahoo.com/news/impel-pharmaceuticals-first-quarter-2023-121424461.html

4073ddc5-842d-3bbc-a910-331cb3dced9c

IMPL

Impel PharmaceuticalsReal-World Assessment Suggests that Concomitant Preventive and Acute Medication Use Decreases in Patients Using TrudhesaAdditional Poster Underscores the Need for Non-Oral Treatment Options Given the Prevalence of Pre-Existing Gastrointestinal Disorders Among Those Prescribed TrudhesaSEATTLE, June 15, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will present new real-world data adding to the growing body of evidence supporting Trudhesa® (dihydroergotamine mesylate [DHE]) nasal spray (0.725 mg per spray) as an effective acute therapy for migraine management. The findings will be featured in two poster presentations during the 65th Annual Scientific Meeting of the American Headache Society (AHS), taking place June 15-18, 2023, in Austin, Texas.Preliminary real-world findings from an assessment of medical and pharmacy claims data for patients with migraine who were treated with Trudhesa in the United States provide new evidence suggesting that concomitant preventive (with the exception of the anti-CGRP monoclonal antibody class) and acute medication use generally decreases in patients taking Trudhesa between the 12-month baseline and 90-day follow-up period. Importantly, an increase in antinausea medications was not observed following Trudhesa use, whereas these medications are commonly used with DHE administered intravenously.“DHE has an established safety and efficacy profile, often providing long-lasting relief for even the toughest of migraine attacks. However, until Trudhesa, nasal delivery options couldn’t reach the upper nasal space, where DHE can be rapidly absorbed,” said Zubair Ahmed, M.D., a headache specialist and neurologist at the Cleveland Clinic. “Trudhesa has been an important addition to migraine care as it provides patients with the reliable relief of DHE in a new and easy-to-use delivery technology that can provide relief in as early as 15 minutes and, importantly, be administered at any point during an attack. This real-world evidence indicates that patients who respond to Trudhesa will likely continue to respond long-term, providing an additional benefit of potentially reducing the need for using daily oral concomitant preventative and acute medications.”Story continuesA second poster on real-world demographic and clinical characteristics, as well as baseline comorbidities among patients with migraine who were treated with Trudhesa, found that most patients were females between the ages of 36 and 45 years, and had comorbidities that include headache syndromes other than migraine, other neurological conditions, other pain disorders, sleep disorders, gastrointestinal (GI) disorders, and psychiatric disorders. In contrast to other epidemiological studies, in this real-world patient population, GI comorbidities were more common, which may be due to many of these patients not being able to achieve migraine relief with oral routes of administration.“Through our ongoing research, we continue to find that Trudhesa has great potential for patients who don’t find the relief they are searching for from other preventative and acute options," said Sheena Aurora, M.D., Vice President Medical Affairs, Impel Pharmaceuticals. "We are pleased to share these new insights about Trudhesa use in the real-world setting with researchers and clinicians from around the world at the AHS Annual Meeting.”All presentations will be accessible on the AHS website at www.americanheadachesociety.org. Following are the presentation details of Trudhesa data being presented:Title: “Real-World Assessment of Concomitant Medication Use in Patients Using INP104 in the United States” (Poster #P-161)Date & Time: Friday, June 16, 12:35 – 1:50 p.m. Central Time (CT)Title: “Real-World Assessment of Baseline Demographic and Clinical Characteristics Among Patients Using INP104 in the United States” (Poster #P-160)Date & Time: Saturday, June 17, 12:45 – 2:00 p.m. CTTitle: “Safety of INP104 in Migraine Patients With Cardiovascular Risk Factors: Post Hoc Subgroup Analysis of the Phase 3 STOP 301 Study” (Poster #P-175)Date & Time: Friday, June 16, 12:35 – 1:50 p.m. CTTitle: “Assessment of the Potential for Drug-Drug Interactions Between INP104 and Gepants for Migraine Management” (Poster #P-17)Date & Time: Friday, June 16, 12:35 – 1:50 p.m. CTTitle: “A Cross-Sectional Survey of Prevailing Opinions from Headache Specialists Regarding Status Migrainosus Management” (Poster #P-04)Date & Time: Saturday, June 17, 12:45 – 2:00 p.m. CTTitle: “Safety of Concomitant Triptan and INP104 Use From the Phase 3 STOP 201 Study in Migraine Patients” (Poster #P-174)Date & Time: Saturday, June 17, 12:45 – 2:00 p.m. CTTrudhesa uses Impel’s proprietary Precision Olfactory Delivery (POD®) technology and is the first and only migraine nasal spray which delivers DHE – a proven, well-established migraine therapeutic – quickly to the bloodstream through the vascular-rich upper nasal space. Trudhesa bypasses the gut and reduces potential absorption issues, offering rapid, sustained, and consistent symptom relief without nausea commonly associated with injection or infusion DHE – even when administered hours after the onset of a migraine attack.About MigraineApproximately 31 million adults in the U.S. are living with migraine,1 and there is a need for more treatment options. In a survey of nearly 4,000 U.S. patients using oral acute prescription medication for migraine, 96 percent said they were dissatisfied with at least one aspect of their treatment—including lack of sustained relief, inconsistent relief, and lack of relief from a rapid-onset attack. Nearly half (48%) said they can still have pain two hours after taking medication and 38 percent say their headache returns within 24 hours of getting relief.2 Additionally, there is a need for non-oral routes of administration given the high prevalence of gastrointestinal issues among people with migraine.About Trudhesa® (dihydroergotamine mesylate) Nasal SprayTrudhesa® is approved by the FDA for the acute treatment of migraine with or without aura in adults in the U.S. Using Impel’s proprietary POD® technology, Trudhesa gently delivers DHE3—a proven, well-established therapeutic—quickly to the bloodstream through the vascular-rich upper nasal space. Trudhesa bypasses the gut and potential absorption issues, offering the potential for rapid, sustained, and consistent relief without injection or infusion, even when administered hours after the start of a migraine attack.4Trudhesa is a single use, drug-device combination product containing a vial of DHE (4 mg DHE in a 1 mL solution that is clear and colorless to faintly yellow) and a POD® device. Prior to initiation of Trudhesa, a cardiovascular evaluation is recommended. For patients with risk factors predictive of coronary artery disease who are determined to have a satisfactory cardiovascular evaluation, it is strongly recommended that administration of the first dose of Trudhesa take place in the setting of an appropriately equipped healthcare facility.Trudhesa is designed to be self-administered. Once assembled, Trudhesa should be primed before initial use by releasing 4 sprays. A patient should use Trudhesa immediately after priming. The recommended dose of Trudhesa is 1.45 mg administered as two metered sprays into the nose (one spray of 0.725 mg into each nostril). The dose may be repeated, if needed, a minimum of 1 hour after the first dose. A patient should not use more than 2 doses of Trudhesa within a 24-hour period or 3 doses within a 7-day period. A patient should use or discard Trudhesa within 8 hours once the vial has been opened or the product has been assembled. A consumer assembly video is available on www.TRUDHESA.com and please refer to the Instructions for Use for more details.The most common adverse reactions (incidence ≥2%) to Trudhesa were nasal congestion, nasal discomfort, nausea, product taste abnormal, and product package associated injury. For more information about Trudhesa and Full Prescribing Information, including BOXED WARNING, please visit, www.TRUDHESA.com.About Impel Precision Olfactory Delivery (POD®) TechnologyImpel’s proprietary POD® technology is able to deliver a range of therapeutic molecules and formulations into the vascular-rich upper nasal space, believed to be a gateway for unlocking the previously unrealized full potential of these molecules. By delivering predictable doses of drug directly to the upper nasal space, Impel’s precision performance technology has the goal of enabling increased and consistent absorption of drug, overriding the high variability associated with other nasal delivery systems, yet without the need for an injection. While an ideal target for drug administration, to date no technology has been able to consistently deliver drugs to the upper nasal space. By utilizing this route of administration, Impel Pharmaceuticals has been able to demonstrate blood concentration levels for its investigational therapies that are comparable to intramuscular (IM) administration and can even reach intravenous (IV)-like systemic levels quickly, which could transform the treatment landscape for a broad range of disorders. Importantly, the POD® technology offers propellant-enabled delivery of dry powder and liquid formulations that eliminates the need for coordination of breathing, allowing for self- or caregiver-administration in a manner that may improve patient outcome, comfort, and potentially, compliance.About Dihydroergotamine Mesylate (DHE)DHE was approved for the treatment of migraine in 19468 and has more than 70 years of therapeutic use.3 Migraine treatment with DHE has demonstrated efficacy independent of when the treatment is initiated. Unlike other available treatments for migraine, DHE is known to bind to multiple receptors theorized to be implicated in migraine onset and duration.5Trudhesa® Indication and Important Safety InformationIndicationTrudhesa® is used to treat an active migraine headache with or without aura in adults. Do not use Trudhesa to prevent migraine when you have no symptoms. It is not known if Trudhesa is safe and effective in children.Important Safety InformationSerious or potentially life-threatening reductions in blood flow to the brain or extremities due to interactions between dihydroergotamine (the active ingredient in Trudhesa) and strong CYP3A4 inhibitors (such as protease inhibitors and macrolide antibiotics) have been reported rarely. As a result, these medications should not be taken together.Do not use Trudhesa if you: Have any disease affecting your heart, arteries, or blood circulation.Are taking certain anti-HIV medications known as protease inhibitors (such as ritonavir or nelfinavir).Are taking a macrolide antibiotic such as clarithromycin or erythromycin.Are taking certain antifungals such as ketoconazole or itraconazole.Have taken certain medications such as triptans or ergot-type medications for the treatment or prevention of migraine within the last 24 hours.Have taken any medications that constrict your blood vessels or raise your blood pressure.Have severe liver or kidney disease.Are allergic to ergotamine or dihydroergotamine.Before taking Trudhesa, tell your doctor if: You have high blood pressure, chest pain, shortness of breath, heart disease; or risk factors for heart disease (such as high blood pressure, high cholesterol, obesity, diabetes, smoking, strong family history of heart disease or you are postmenopausal, or male over 40); or problems with blood circulation in your arms, legs, fingers, or toes.You have or had any disease of the liver or kidney.You are taking any prescription or over-the-counter medications, including vitamins or herbal supplements.You are pregnant, planning to become pregnant or are nursing, or have ever stopped medication due to an allergy or bad reaction.This headache is different from your usual migraine attacks.The use of Trudhesa should not exceed dosing guidelines and should not be used on a daily basis. Serious cardiac (heart) events, including some that have been fatal, have occurred following the use of dihydroergotamine mesylate, particularly with dihydroergotamine for injection, but are extremely rare.You may experience some nasal congestion or irritation, altered sense of taste, sore throat, nausea, vomiting, dizziness, and fatigue after using Trudhesa.Contact your doctor immediately if you experience:Numbness or tingling in your fingers and toesSevere tightness, pain, pressure, heaviness, or discomfort in your chestMuscle pain or cramps in your arms or legsCold feeling or color changes in 1 or both legs or feetSudden weaknessSlurred speechSwelling or itchingThe risk information provided here is not comprehensive. To learn more, talk about Trudhesa with your healthcare provider or pharmacist. The FDA-approved product labeling can be found at www.Trudhesa.com or 1-800-555-DRUG. You can also call 1-833-TRUDHESA (1-833-878-3437) for additional information.About Impel PharmaceuticalsImpel Pharmaceuticals is a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs. Impel offers treatments that pair its proprietary POD® technology with well-established therapeutics. In September 2021, Impel received U.S. FDA approval for its first product, Trudhesa® nasal spray, which is approved in the U.S. for the acute treatment of migraine with or without aura in adults. In addition to Trudhesa, the Company continues to address patient needs via licensing and partnerships.Cautionary Note on Forward-Looking StatementsThis press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, the potential clinical benefits of Trudhesa®, the market opportunities of Trudhesa within the migraine market, the speed of uptake and market growth of Trudhesa, the effectiveness of the Trudhesa sales force, the timing of announcements of clinical results and clinical development activities of Impel’s product candidates, and Impel’s cash runway. Forward-looking statements can be identified by words such as: “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect” or the negative or plural of these words or similar expressions. These statements are subject to numerous risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including but not limited to, Impel’s ability to maintain regulatory approval of Trudhesa, its ability to execute its commercialization strategy for Trudhesa, its ability to develop, manufacture and commercialize its other product candidates including plans for future development of its POD® devices and plans to address additional indications for which Impel may pursue regulatory approval, whether results of preclinical studies or clinical trials will be indicative of the results of future trials, and the effects of COVID-19 on its clinical programs and business operations. Many of these risks are described in greater detail in Impel’s filings with the Securities and Exchange Commission. Any forward-looking statements in this press release speak only as of the date of this press release. Impel assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.Impel, POD, Trudhesa and the Impel logo are registered trademarks of Impel Pharmaceuticals Inc. To learn more about Impel Pharmaceuticals, please visit our website at https://impelpharma.com.Contact:Melyssa WeibleElixir Health Public RelationsPhone: (1) 201-723-5805Email: [email protected]______________________________1 R. B. Lipton, M. E. Bigal, M. Diamond, F. Freitag, M. L. Reed, W. F. Stewart. Migraine prevalence, Disease Burden, and the Need for Preventive Therapy. Neurology 2007;68;343-349 DOI: 10.1212/01.wnl.0000252808.97649.212 Impel Neuropharma. (2020). INP104-301. Table 3.8.2.3 Smith TR.; Winner P.; Aurora SK.; Jeleva M.; Hocevar-Trnka J.; Shrewsbury SB.; STOP 301: A Phase 3, Open-Label Study Of Safety, Tolerability, And Exploratory Efficacy Of INP104, Precision Olfactory Delivery (POD®) Of Dihydroergotamine Mesylate, Over 24/52 Weeks In Acute Treatment Of Migraine Attacks In Adult Patients. Headache. 2021; 00: 1– 13. https://doi.org/10.1111/head.141844 Aurora SK, et al. J Headache Pain. 2013;14(Suppl 1):P143.5 Impel Neuropharma. (2020). INP104-301. Table 3.3.6.

GlobeNewswire

Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache Society

https://finance.yahoo.com/news/impel-pharmaceuticals-present-real-world-120000087.html

f9044efd-c19e-3d9d-9cee-a1cb5f01e1e4

IMUX

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.So, the natural question for Immunic (NASDAQ:IMUX) shareholders is whether they should be concerned by its rate of cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). First, we'll determine its cash runway by comparing its cash burn with its cash reserves. Check out our latest analysis for Immunic Does Immunic Have A Long Cash Runway?You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. When Immunic last reported its balance sheet in June 2023, it had zero debt and cash worth US$77m. Importantly, its cash burn was US$68m over the trailing twelve months. That means it had a cash runway of around 14 months as of June 2023. While that cash runway isn't too concerning, sensible holders would be peering into the distance, and considering what happens if the company runs out of cash. Depicted below, you can see how its cash holdings have changed over time.debt-equity-history-analysisHow Is Immunic's Cash Burn Changing Over Time?Because Immunic isn't currently generating revenue, we consider it an early-stage business. Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. With cash burn dropping by 12% it seems management feel the company is spending enough to advance its business plans at an appropriate pace. While the past is always worth studying, it is the future that matters most of all. So you might want to take a peek at how much the company is expected to grow in the next few years.Story continuesHow Easily Can Immunic Raise Cash?While Immunic is showing a solid reduction in its cash burn, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Companies can raise capital through either debt or equity. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.Immunic's cash burn of US$68m is about 89% of its US$77m market capitalisation. Given just how high that expenditure is, relative to the company's market value, we think there's an elevated risk of funding distress, and we would be very nervous about holding the stock.So, Should We Worry About Immunic's Cash Burn?On this analysis of Immunic's cash burn, we think its cash burn reduction was reassuring, while its cash burn relative to its market cap has us a bit worried. Considering all the measures mentioned in this report, we reckon that its cash burn is fairly risky, and if we held shares we'd be watching like a hawk for any deterioration. Separately, we looked at different risks affecting the company and spotted 5 warning signs for Immunic (of which 2 don't sit too well with us!) you should know about.Of course Immunic may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Companies Like Immunic (NASDAQ:IMUX) Could Be Quite Risky

https://finance.yahoo.com/news/companies-immunic-nasdaq-imux-could-115831678.html

fac862b9-212d-3010-ab51-35158c9ce50c

IMUX

NEW YORK, Sept. 6, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry and investor conferences in September:September 13-14: BioPharm America™. Patrick Walsh, Chief Business Officer of Immunic, will attend this conference in Research Triangle Park, North Carolina. To schedule a meeting, please use the BioPharm America™ partneringONE® system.September 26-28: 2023 Cantor Global Healthcare Conference. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will participate in a fireside at this conference in New York on Thursday, September 28, 2023, at 3:00 pm ET. A webcast of the presentation will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations. An archived replay will be available on the company's website for a period of 90 days after the conference.About Immunic, Inc. Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and moderate-to-severe ulcerative colitis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, where it is currently in preparations for a phase 2 clinical trial. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: www.imux.com.Story continuesCautionary Statement Regarding Forward-Looking Statements This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in industry and investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, increasing inflation, impacts of the Ukraine – Russia conflict on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on February 23, 2023, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.Contact InformationImmunic, Inc. Jessica Breu Head of Investor Relations and Communications +49 89 2080 477 09 [email protected] IR Contact Rx Communications Group Paula Schwartz +1 917 633 7790 [email protected] Media Contact KOGS Communication Edna Kaplan +1 617 974 8659 [email protected], Inc. Logo (PRNewsfoto/Immunic, Inc.) CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-to-participate-in-industry-and-investor-conferences-in-september-301916883.htmlSOURCE Immunic, Inc.

PR Newswire

Immunic to Participate in Industry and Investor Conferences in September

https://finance.yahoo.com/news/immunic-participate-industry-investor-conferences-103000638.html

a23add47-b4e4-3540-b677-f17892f6e018

IMXI

Inherently, investors gravitate toward strong buy value stocks, in much the same way that audience members of a horror film might grip their armrests. As humans, we’re basically hardwired – especially in the modern age – to respond positively to discounts. Unless we’re talking about real estate or rare valuable items, most folks shun bidding wars.But before you load up on value stocks, you may want to consider an even more attractive category: fundamentally discounted enterprises – typically against earnings or sales metrics – that Wall Street analysts endorse. That’s right, every idea on this list featured a strong buy consensus view among top market experts prior to the Aug. 2 opening bell.While it’s always risky going against the grain with discounted securities, these top value stocks get the nod of approval from those whose job it is to comprehensively research compelling market ideas. On that note, below are the bargain names that can go places.InvestorPlace - Stock Market News, Stock Advice & Trading TipsPatrick Industries (PATK)man's hand holding wads of cash. stocks to buy. Stocks With 1000% UpsideSource: Vova Shevchuk / Shutterstock.comA major manufacturer and distributor of component products and building products, Patrick Industries (NASDAQ:PATK) serves the recreational vehicle, marine, manufactured housing, and residential housing markets, among several others. Although a boring name among strong buy value stocks, its wide relevance should entice forward-thinking investors. Since the beginning of this year, PATK gained nearly 40% of its equity value, an impressive haul.Even better, according to Wall Street analysts, PATK benefits from a strong buy consensus view. This assessment breaks down as four buys, one hold, and significantly zero sell ratings. Overall, the experts’ average price target lands at $94.20, implying almost 11% upside potential. Further, the high-side price target comes in at $105, implying over 23% growth.Lastly, Patrick delivers the goods on the financial front. Operationally, its three-year revenue growth rate (per-share basis) lands at 25.7%, above 91.9% of its peers. Yet PATK trades at a trailing-year sales multiple of 0.5, lower than 70.8% of sector rivals. Thus, it’s one of the top value stocks to consider.Story continuesInternational Money Express (IMXI)An image of a street sign post with directions labeled "Buy", "Hold", and "Sell"Source: PX Media / ShutterstockAdmittedly a tough idea for conservative investors, those who seek to load up on value stocks may nevertheless find intrigue with International Money Express (NASDAQ:IMXI). Per its public profile, International Money provides a platform for the electronic movement of money and data from the U.S. to Latin America and the Caribbean. It offers wire transfers, telewire, money orders, and other processing services to customers.While the company presents a risky profile, IMXI up until the opening bell of the Aug. 2 session ranked among the strong buy value stocks. However, thanks to a downgrade to “hold” by JMP Securities analyst David Scharf, IMXI is now technically a moderate buy. Still, the average expert price target for shares still stands at a lofty $29.50, implying 52% upside potential.On the financials, International Money prints a three-year revenue growth rate of 18.5%, above 71.78% of sector rivals. Also, IMXI trades at a forward multiple of 9.36, much lower than the sector median stat of 28.1x.Titan Machinery (TITN)Man holding stacks of money. Unknown Millionaire-Maker cryptosSource: Epic Cure / ShutterstockHeadquartered in West Fargo, North Dakota, Titan Machinery (NASDAQ:TITN) is one of the largest U.S. dealers of agricultural and construction equipment. Its network of full-service dealer locations extends throughout much of this country. As well, Titan features European stores located in Bulgaria, Germany, Romania, Serbia, and Ukraine. While geopolitics presents a rough situation for TITN, it also cynically imbues the underlying narrative with indelible relevance.Perhaps not surprisingly, TITN ranks among the strong buy value stocks. Among six analysts, five of them rate Titan a buy while one rates it a hold. Conspicuously, the five most recent ratings are all buys. Overall, the experts’ average price target lands at $41.60, implying nearly 34% upside potential. The high-side target is $50, implying almost 61% growth.For those that want to load up on value stocks on the cheap, it’s difficult to overlook Titan. Its three-year revenue growth rate impresses at 18.4%. Nevertheless, TITN trades at a trailing-year sales multiple of only 0.31, favorably below nearly 71% of its rivals.Gray Television (GTN)A person draws a stock chart on a chalkboard.Source: Zurijeta / Shutterstock.comHeadquartered in Atlanta, Georgia, Gray Television (NYSE:GTN) represents the largest owner of top-rated local television stations and digital assets in the U.S., per its corporate profile. It goes on to state that Gray currently owns and/or operates television stations and leading digital properties in 94 television markets that collectively reach approximately 24% of domestic television households.Still, it’s a risky idea among speculative top value stocks. In the trailing one-year period, GTN lost 54% of its equity value. Right there, most investors will be tempted to run and I wouldn’t blame them. However, GTN also classifies as one of the strong buy value stocks, enjoying a unanimous optimistic rating among three experts. Further, their average price target stands at $16.33, implying nearly 82% upside potential.Interestingly, Gray prints a three-year revenue growth rate of 23% and a trailing-year net margin of nearly 10%. Both stats are impressive. As well, GTN trades at 1.44x free cash flow, which sits on a subterranean level. Again, it’s a tough call but the experts do like it.Catalyst Pharmaceuticals (CPRX)hands at desk near laptop computer, with one hand holding a pile of hundred dollar bills. Bank stocksSource: shutterstock.com/CC7A commercial-stage biopharmaceutical firm, Catalyst Pharmaceuticals (NASDAQ:CPRX) focuses on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases. These conditions include Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK antibody-positive myasthenia gravis (MuSK-MG), and other neurological and neuromuscular disorders. Although scientifically compelling, Catalyst presents high risks, with shares down more than 25% since the start of the year.Despite the obvious market concerns, CPRX rings up the register as one of the strong buy value stocks. Per TipRanks, five analysts presently cover Catalyst, with four of them rating shares a buy. The worst rating is a hold. Overall, the experts’ average price target comes to $22.40, implying over 66% upside potential. Further, the high-side target clocks in at $25, implying almost 86% growth.Compared to other speculative biotech firms, Catalyst offers a relatively sensible financial canvas. For example, it enjoys a robust balance sheet, backed by a cash-to-debt ratio of nearly 39X. Also, it features solid revenue growth and high-profit margins. Lastly, CPRX is undervalued at a forward multiple of less than 12.ACM Research (ACMR)tree growing on coin of stacking with green bokeh background; growth stocksSource: Freedom365day / Shutterstock.comA specialist in the development, manufacturing, and sales of semiconductor process equipment, ACM Research (NASDAQ:ACMR) is an important background player in the broader tech industry. While ACM probably doesn’t rate as a household name for most consumers, the company’s processes are critical to advanced semiconductor device manufacturing. So, indirectly speaking, ACM likely impacts our lives significantly.To be sure, ACMR represents a mixed bag. Since the start of this year, shares gained nearly 25% of equity value. While a reasonable performance, over the past 365 days, ACMR gave up almost 31%. Still, analysts are more than impressed with the enterprise. Not only does it rank among strong buy value stocks, but it’s also a unanimous assessment among six experts. Moreover, their average price target lands at $20.38, implying 70% upside potential.Financially, ACM benefits from a stable balance sheet, strong top-line expansion, and decent profit margins. Despite these attributes, the market prices ACMR at a forward multiple of only 12.15, below 82% of the competition. Therefore, if you want to load up on value stocks at a heavy discount, ACMR could be a viable idea.Harmony Biosciences (HRMY)Stocks to buy: smartphone with the words "buy" and "sell" displayed on the screen. The user's finger is about to press buy. Stock charts are in the background of the image. Momentum StocksSource: Chompoo Suriyo / Shutterstock.comAnother enticing but risky biotech play, Harmony Biosciences (NASDAQ:HRMY) focuses on the research, drug development, and treatment for neurologic disorder of sleep-wake state instability. According to The Insight Partners, the global market for the treatment of neurological disorders related to sleep disruption may hit a valuation of nearly $4.54 billion in 2027. That’s up from almost $2.03 billion in 2018.Still, HRMY represents one of the riskiest value plays available. Since the start of the year, shares fell almost 39%. That said, analysts peg HRMY as one of the strong buy value stocks to consider. Right now, the assessment breaks down as four buys, one hold and zero sells. Also, the experts’ average price target stands at $59.80, implying nearly 84% upside potential.Regarding the financials, Harmony offers some tempting stats. For example, the biotech’s Altman Z-Score comes in at 5.85, implying a very low risk of imminent bankruptcy. Additionally, the market prices shares at a forward multiple of 14.64. As a discount to projected earnings, Harmony ranks better than 72.41% of its peers.On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare.More From InvestorPlaceChatGPT IPO Could Shock the World, Make This Move Before the AnnouncementMusk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.The $1 Investment You MUST Take Advantage of Right NowThe Rich Use This Income Secret (NOT Dividends) Far More Than Regular InvestorsThe post 7 ‘Strong Buy’ Value Stocks You Should Be Loading Up On Now appeared first on InvestorPlace.

InvestorPlace

7 ‘Strong Buy’ Value Stocks You Should Be Loading Up On Now

https://finance.yahoo.com/news/7-strong-buy-value-stocks-184419591.html

e3ac02f0-13ea-34e9-b62c-7a8cc2b877e1

IMXI

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.' Loss making companies can act like a sponge for capital - so investors should be cautious that they're not throwing good money after bad.In contrast to all that, many investors prefer to focus on companies like International Money Express (NASDAQ:IMXI), which has not only revenues, but also profits. While this doesn't necessarily speak to whether it's undervalued, the profitability of the business is enough to warrant some appreciation - especially if its growing. View our latest analysis for International Money Express How Fast Is International Money Express Growing?If a company can keep growing earnings per share (EPS) long enough, its share price should eventually follow. So it makes sense that experienced investors pay close attention to company EPS when undertaking investment research. It certainly is nice to see that International Money Express has managed to grow EPS by 36% per year over three years. If growth like this continues on into the future, then shareholders will have plenty to smile about.It's often helpful to take a look at earnings before interest and tax (EBIT) margins, as well as revenue growth, to get another take on the quality of the company's growth. Our analysis has highlighted that International Money Express' revenue from operations did not account for all of their revenue in the previous 12 months, so our analysis of its margins might not accurately reflect the underlying business. EBIT margins for International Money Express remained fairly unchanged over the last year, however the company should be pleased to report its revenue growth for the period of 22% to US$610m. That's encouraging news for the company!Story continuesIn the chart below, you can see how the company has grown earnings and revenue, over time. Click on the chart to see the exact numbers.earnings-and-revenue-historyOf course the knack is to find stocks that have their best days in the future, not in the past. You could base your opinion on past performance, of course, but you may also want to check this interactive graph of professional analyst EPS forecasts for International Money Express.Are International Money Express Insiders Aligned With All Shareholders?It should give investors a sense of security owning shares in a company if insiders also own shares, creating a close alignment their interests. Shareholders will be pleased by the fact that insiders own International Money Express shares worth a considerable sum. To be specific, they have US$33m worth of shares. That shows significant buy-in, and may indicate conviction in the business strategy. Even though that's only about 4.9% of the company, it's enough money to indicate alignment between the leaders of the business and ordinary shareholders.Should You Add International Money Express To Your Watchlist?If you believe that share price follows earnings per share you should definitely be delving further into International Money Express' strong EPS growth. Further, the high level of insider ownership is impressive and suggests that the management appreciates the EPS growth and has faith in International Money Express' continuing strength. The growth and insider confidence is looked upon well and so it's worthwhile to investigate further with a view to discern the stock's true value. It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with International Money Express , and understanding this should be part of your investment process.The beauty of investing is that you can invest in almost any company you want. But if you prefer to focus on stocks that have demonstrated insider buying, here is a list of companies with insider buying in the last three months.Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Does International Money Express (NASDAQ:IMXI) Deserve A Spot On Your Watchlist?

https://finance.yahoo.com/news/does-international-money-express-nasdaq-134400292.html

865511b4-7741-3fdf-8c62-b557240beb7f

INBX

SAN DIEGO, Aug. 29, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that it has entered into a securities purchase agreement for a private placement financing (the "PIPE") that is expected to result in gross proceeds of approximately $200 million. The financing was limited to certain of the Company's existing investors, which included participation from RA Capital Management as the lead investor, Viking Global Investors, Perceptive Advisors, and TCGX.Inhibrx, Inc. logo (PRNewsfoto/Inhibrx, Inc.)In the PIPE, Inhibrx is selling an aggregate of 3,621,314 shares of its common stock at a price of $19.35 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 6,714,636 shares of common stock at a purchase price of $19.3499 per pre-funded warrant. Each pre-funded warrant has an exercise price of $0.0001 per share of common stock and is immediately exercisable and remains exercisable until exercised in full. The PIPE is expected to close by August 31, 2023, subject to customary closing conditions.The securities to be sold in the PIPE, including the shares of common stock underlying the pre-funded warrants, have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Inhibrx has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock and the shares of common stock underlying the pre-funded warrants issued in the PIPE.This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.Story continuesAbout Inhibrx, Inc. Inhibrx is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. For more information, please visit www.inhibrx.com.Forward-Looking Statements Inhibrx cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Inhibrx's current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding: the anticipated proceeds to be received in the proposed PIPE, expected timing of closing of the proposed PIPE, the timing of registration of the securities sold in the PIPE with the Securities and Exchange Commission, Inhibrx's and its investigators' judgments and beliefs regarding the strength of Inhibrx's pipeline and the observed safety and efficacy to date of its therapeutic candidates; whether a trial is registration-enabling; future clinical development of Inhibrx's therapeutic candidates, including any potential for approval or accelerated approval. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Inhibrx's business, including, without limitation, risks and uncertainties regarding: the initiation, timing, progress and results of its preclinical studies and clinical trials, and its research and development programs; its ability to advance therapeutic candidates into, and successfully complete, clinical trials; its interpretation of initial, interim or preliminary data from its clinical trials, including interpretations regarding disease control and disease response; the timing or likelihood of regulatory filings and approvals; the successful commercialization of its therapeutic candidates, if approved; the pricing, coverage and reimbursement of its therapeutic candidates, if approved; its ability to utilize its technology platform to generate and advance additional therapeutic candidates; the implementation of its business model and strategic plans for its business and therapeutic candidates; its ability to successfully manufacture therapeutic candidates for clinical trials and commercial use, if approved; its ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the scope of protection it is able to establish and maintain for intellectual property rights covering its therapeutic candidates; its ability to enter into strategic partnerships and the potential benefits of these partnerships; its estimates regarding expenses, capital requirements and needs for additional financing and financial performance; and other risks described from time to time in Inhibrx's filings with the SEC, including under the heading "Risk Factors" in Inhibrx's Annual Report on Form 10-K filed with the SEC on March 6, 2023 and subsequently filed reports. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Inhibrx undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.Investor and Media Contact:Kelly Deck, [email protected] original content to download multimedia:https://www.prnewswire.com/news-releases/inhibrx-announces-200-million-private-placement-financing-301912081.htmlSOURCE Inhibrx Inc.

PR Newswire

Inhibrx Announces $200 Million Private Placement Financing

https://finance.yahoo.com/news/inhibrx-announces-200-million-private-130000621.html

f74c88b6-6562-3914-b67e-04c5465c542f

INBX

In this piece, we will take a look at the 12 best high risk high reward stocks to buy now. If you want to skip our background on investing, then head on over to 5 Best High Risk High Reward Stocks To Buy Now. Investing is a risky endeavor, as is anything that involves the future. After all, no one really knows what's going to happen tomorrow, and the best that we can do is read the tea leaves to wager a guess at future outcomes. When it comes to stocks, these tea leaves include a wide variety of financial ratios and technical indicators that are often combined to paint a detailed picture of a firm's future.The ratios are part of financial analysis that is called fundamentals based investing. Rather self explanatory on the surface, it involves pouring over countless financial metrics in a firm's balance sheet and then combining them to gain a better picture of its performance. One of the most common ratios is the price to earnings ratio, and it is often used to gauge market sentiment about a company. A firm's earnings per share measures its profitability while its price is the amount that investors are willing to pay for the stock. A ratio of the two determines when the shares are undervalued or overvalued, and they come in several flavors which you can check out by reading 10 Best Inexpensive Stocks To Buy Right Now.Naturally, the higher the P/E ratio is, the more risky a stock is since its price can significantly drop should it fail to grow earnings over the long term. The premise behind a high price to earnings is that investors are confident about a company's ability to deliver earnings growth in the future and as a result, they are willing to pay for these earnings today. As an illustration, consider the example of one of the more well known growth stories of our time. Advanced Micro Devices, Inc. (NASDAQ:AMD), known for competing with the much larger semiconductor firm Intel Corporation (NASDAQ:INTC) had been unprofitable as recently as 2017.Story continuesAs AMD started to become profitable, its P/E ratio soared to 178 in 2019 and remained above 100 for the next year before sitting around the 70 mark. Investors were betting that AMD would rapidly grow its market share since it is only one of the few companies that has the license to manufacture and sell semiconductors manufactured with the x86 microarchitecture, and the only one that can compete at scale with Intel. AMD's P/E ratio soared to 515 for its March quarter after the firm's profits dropped during the semiconductor downturn currently going on.Another financial ratio, and one that is relatively less known is the price to sales ratio. While the P/E ratio measures a firm's value relative to its bottom line profit, the price to sales ratio measures the value relative to its revenue. It was introduced to current financial nomenclature by none other than Ken Fisher of Fisher Investments. Mr. Fisher is one of the stock market gurus who is known for his sharp insights into the market and his uncanny ability to separate market trends from market chatter.According to the legendary investor, the price to sales ratio is a tool to simply measure the popularity of a stock. He believes that revenue is a better indicator of a firm's value and P/E ratios end up being affected by accounting rules and principles that determine net income. In an article for the American Association of Individual Investors (AAII) in June 1984, he wrote:Price-sales ratios measure the popularity of the stock. This is helpful for a number of investment theories. A long-held standard of such legendary investors as Warren Buffett, Philip Fisher, Benjamin Graham, John Templeton and others is to buy unpopular stocks of good companies. But first, you must know if a stock is popular or not.It is becoming common to view low price-earnings stocks as synonymous with low popularity. I have nothing against the low price-earnings school and view low price-earnings ratios as a viable way to seek above-average reward at below-average risk. But low price-earnings ratios are not a strong measure of popularity. They are too elastic.Too much attention is focused on current earnings. Earnings are a result—not a cause. At best, they result from a lot of accounting assumptions trickling their way through an operating company’s books. The basic factors affecting the value of a stock tie more closely into the income statement’s top half—a company’s product position and cost structure allowing it to do a certain amount of business. Employing the price-sales ratio as another tool of analysis helps put stocks in their proper perspective.At the same time, high price to sales can also signal potential risks similar to the P/E ratio since both value firms significantly higher than what their fundamentals approach. However, Mr. Fisher's research is quite interesting when it compares the returns of P/E stocks and P/S stocks. Take a look:We decided to compare the lowest 25% price-sales ratio stocks in the list versus the lowest 25% price-earnings ratio stocks.. . . The results:- The seven lowest price-sales ratio stocks averaged gains of +63.57%.- The nine lowest price-sales ratio stocks averaged gains of +56.11%.- The nine lowest price-earnings ratio stocks averaged gains of +28.67%.- At the same time, the DJIA averaged a gain of 20.3%.So, we decided to take a look at some high risk, high reward stocks with the top picks being Xenon Pharmaceuticals Inc. (NASDAQ:XENE), Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), and Karuna Therapeutics, Inc. (NASDAQ:KRTX).12 Best High Risk High Reward Stocks To Buy NowPhoto by Karolina Grabowska from PexelsOur Methodology To compile our list of high risk high reward stocks, we compiled an initial list of firms with P/S ratios greater than 20. Then, the number of hedge funds that had invested in them out of the 910 part of Insider Monkey's second quarter of 2023 database was determined and the top 12 stocks are as follows.12 Best High Risk High Reward Stocks To Buy Now12. Aurora Innovation, Inc. (NASDAQ:AUR)Number of Hedge Fund Investors In Q2 2023: 17Latest P/S Ratio: 732.25Aurora Innovation, Inc. (NASDAQ:AUR) is a software firm that is developing self driving products and technologies. The firm had great first and second quarters as it narrowed its net loss for the first half of 2023 by a strong 66% and also reduced the loss per share.As of Q2 2023 end, 17 out of the 910 hedge funds polled by Insider Monkey had invested in Aurora Innovation, Inc. (NASDAQ:AUR). Along with Xenon Pharmaceuticals Inc. (NASDAQ:XENE), Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), and Karuna Therapeutics, Inc. (NASDAQ:KRTX), it is a high risk and high reward stock that hedge funds are buying.11. Avadel Pharmaceuticals plc (NASDAQ:AVDL)Number of Hedge Fund Investors In Q2 2023: 20 Latest P/S Ratio: 622.72 Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a drug manufacturer that sells products for sleeping disorders. Despite being unprofitable, the firm's shares are up by a strong 97% year to date, with a commercial drug launch in the U.S. and FDA approval acting as some tailwinds.Insider Monkey's second quarter of 2023 survey of 910 hedge funds revealed that 20 had bought Avadel Pharmaceuticals plc (NASDAQ:AVDL)'s shares. Out of these, the firm's biggest shareholder is Jeffrey Gendell's Tontine Asset Management since it holds a stake worth $88.9 million.10. Inhibrx, Inc. (NASDAQ:INBX)Number of Hedge Fund Investors In Q2 2023: 20 Latest P/S Ratio: 1,370 Inhibrx, Inc. (NASDAQ:INBX) is a biotechnology firm that is developing cancer and tumor treatments. Despite the fact that the firm has missed analyst EPS estimates in three of its four latest quarters, the stock is rated Strong Buy on average.Insider Monkey took a look at 910 hedge fund portfolios for this year's June quarter and discovered that 20 had invested in the company. Andreas Halvorsen's Viking Global is Inhibrx, Inc. (NASDAQ:INBX)'s largest stakeholder, owning 6.6 million shares that are worth $172 million.9. Enovix Corporation (NASDAQ:ENVX)Number of Hedge Fund Investors In Q2 2023: 20 Latest P/S Ratio: 1,870Enovix Corporation (NASDAQ:ENVX) is a battery company headquartered in Fremont, California. The firm beat analyst EPS estimates for its second quarter earnings, and Oppenheimer has rated the stock as a Strong Buy and set a price target of $36.By the end of 2023's second quarter, 20 out of the 910 hedge funds tracked by Insider Monkey had held a stake in Enovix Corporation (NASDAQ:ENVX). Peter S. Park's Park West Asset Management is the company's biggest hedge fund investor since it owns $97 million worth of shares.8. Geron Corporation (NASDAQ:GERN)Number of Hedge Fund Investors In Q2 2023: 20 Latest P/S Ratio: 2,570 Geron Corporation (NASDAQ:GERN) is a biotechnology firm making treatments for severe liver diseases. It scored a win in August when the FDA accepted its drug filing for an anemia treatment.Insider Monkey scoured through 910 hedge fund portfolios and discovered 20 Geron Corporation (NASDAQ:GERN) investors as of Q2 2023 end. Out of these, the firm's largest shareholder is Peter Kolchinsky's RA Capital Management due to its $101 million stake.7. Relay Therapeutics, Inc. (NASDAQ:RLAY)Number of Hedge Fund Investors In Q2 2023: 21 Latest P/S Ratio: 1,310 Relay Therapeutics, Inc. (NASDAQ:RLAY) is another biotechnology company. It develops treatments for genetic disorders and cancer. The shares are rated Strong Buy on average and its second quarter results saw both revenue and earnings per share drop.During June 2023, 21 out of the 910 hedge funds polled by Insider Monkey had held the firm's shares. Relay Therapeutics, Inc. (NASDAQ:RLAY)'s biggest stakeholder is Eli Casidin's Casdin Capital since it owns 5.9 million shares that are worth $75.3 million.6. Verona Pharma plc (NASDAQ:VRNA)Number of Hedge Fund Investors In Q2 2023: 22 Latest P/S Ratio: 3,190 Verona Pharma plc (NASDAQ:VRNA) makes treatments for lung diseases such as asthma. The stock hasn't done so well this year, as it is down 23% year to date. However, Wedbush has rated the shares as Outperform, and the stock is rated Strong Buy on average. Verona Pharma plc (NASDAQ:VRNA)'s second quarter results saw it smash analyst EPS estimates out of the park, primarily due to a reversal of accrued costs and lower research and development expenses.22 out of the 910 hedge funds part of Insider Monkey's Q2 2023 database had held a stake in Verona Pharma plc (NASDAQ:VRNA). Out of these, the largest hedge fund investor is Peter Kolchinsky's RA Capital Management through a $133 million stake.Xenon Pharmaceuticals Inc. (NASDAQ:XENE), Verona Pharma plc (NASDAQ:VRNA), Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), and Karuna Therapeutics, Inc. (NASDAQ:KRTX) are some high risk, high reward stocks to buy now.Click to continue reading and see 5 Best High Risk High Reward Stocks To Buy Now. Suggested Articles:16 Most Shorted Stocks Right Now12 Best Dividend Stocks For Steady Growth30 Countries with Highest Rates of EmigrationDisclosure: None. 12 Best High Risk High Reward Stocks To Buy Now is originally published on Insider Monkey.

Insider Monkey

12 Best High Risk High Reward Stocks To Buy Now

https://finance.yahoo.com/news/12-best-high-risk-high-021627516.html

01f35fe7-0402-36a6-8ec1-ee96db6ff52b

INCY

WILMINGTON, Del., August 22, 2023--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September:Wells Fargo 2023 Healthcare Conference on Thursday, September 7, 2023 at 8:45 am (EDT)Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023 at 11:20 am (EDT)Bank of America 2023 Global Healthcare Conference on Thursday, September 14, 2023 at 8:15 am (BST)The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.About IncyteIncyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.View source version on businesswire.com: https://www.businesswire.com/news/home/20230822167395/en/ContactsMediaCatalina Loveman+1 302 498 [email protected] InvestorsGregory Shertzer+1 302 274 [email protected]

Business Wire

Incyte to Present at Upcoming Investor Conferences

https://finance.yahoo.com/news/incyte-present-upcoming-investor-conferences-120000665.html

a4f062cb-1124-3ff7-b722-23f80e784dc9

INCY

It has been about a month since the last earnings report for Incyte (INCY). Shares have lost about 0.7% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Incyte due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.Beats on Q2 Earnings and Revenue EstimatesIncyte reported second-quarter 2023 adjusted earnings of 99 cents per share, which beat the Zacks Consensus Estimate of 87 cents. The company recorded earnings of $1.01 per share in the year-ago quarter.Total revenues came in at $954.6 million, up 5% year over year. The figure beat the Zacks Consensus Estimate of $920 million owing to higher net product revenues from Jakafi and Opzelura.Quarter in DetailJakafi’s (a first-in-class JAK1/JAK2 inhibitor approved for polycythemiavera, myelofibrosis and refractory acute graft-versus-host disease) revenues came in at almost $682.3 million, up 14% from the year-ago quarter’s number. This was primarily driven by growth in patient demand across all indications. Jakafi's sales beat the Zacks Consensus Estimate of $647 million.Opzelura (ruxolitinib) cream generated $80 million in sales. The figure grew almost 384% year over year and beat the consensus estimate of $78 million. This was due to growth in patient demand and label expansion in the indication of atopic dermatitis (AD).In July 2022, the FDA approved Opzelura cream 1.5% for the topical treatment of non-segmental vitiligo in adult and pediatric patients aged 12 years and older. Opzelura is also approved by the FDA for the topical short-term and non-continuous chronic treatment of mild to moderate AD.The newly approved medicine, Zynyz (retifanlimab-dlwr), generated first-quarter sales of $0.57 million. The company obtained an accelerated approval of Zynyz earlier in March for treating metastatic or recurrent locally advanced merkel cell carcinoma. Story continuesNet product revenues of Iclusig were almost $29.09 million, up 11% year over year. The figure also beat the Zacks Consensus Estimate of $26.53 million.Pemazyre generated $21.6 million in sales, indicating a year-over-year increase of 14%. However, the figure missed the Zacks Consensus Estimate of $24.05 million.Minjuvi's revenues totaled $13.16 million, up 198% from the prior-year quarter’s number. The revenues significantly beat the Zacks Consensus Estimate of $6.89 million.Jakafi is marketed by Incyte in the United States and by Novartis as Jakavi outside the country. The drug’s royalty revenues from Novartis for commercialization in ex-U.S. markets surged 8% to $90.5 million. Jakavi royalties beat the Zacks Consensus Estimate of $89 million.Incyte also receives royalties from sales of Tabrecta (capmatinib) for the treatment of adult patients with metastatic non-small-cell lung cancer. Its partner, Novartis, has exclusive worldwide development and commercialization rights for Tabrecta. The drug’s product royalty revenues amounted to $4.8 million, up 34% year over year.Olumiant’s (baricitinib) product royalty revenues totaled $32.01 million, up 6% year over year. However, the figure missed the Zacks Consensus Estimate of $36.83 million.Incyte has a collaboration agreement with Eli Lilly for Olumiant. The drug is a once-daily, oral JAK inhibitor discovered by Incyte and licensed to LLY. It is approved for several types of autoimmune diseases.Adjusted research and development expenses totaled $367.9 million, up 15% from the year-ago quarter’s actual, owing to higher investments in late-stage pipeline development. Adjusted selling, general and administrative expenses amounted to $263 million, up 12% from the prior-year quarter’s number. This was due to expenses related to supporting the launch of Opzelura for the treatment of vitiligo.Incyte’s cash and cash equivalents totaled $3.4 billion as of Jun 30, 2023 compared with $3.1 billion as of Mar 31, 2023.2023 Guidance UpdatedBased on its second-quarter performance, Incyte updated its previously issued guidance for 2023. The company now expects Jakafi revenues in the range of $2.58-$2.63 billion compared with the earlier projection of $2.55-$2.63 billion.Pipeline and Regulatory UpdatesEarlier yesterday, the company entered into a collaboration and supply agreement with Replimune Group, Inc. The agreement is aimed at advancing Replimune’s lead product candidate, RP1, in combination with INCB99280, Incyte’s small-molecule oral PD-L1 inhibitor, in patients with cutaneous squamous cell carcinoma.The clinical study is expected to start in early 2024. Under the agreement, Incyte will initiate and sponsor the clinical study and Replimune will supply RP1 to Incyte for the same. The companies will equally share the costs of the study.How Have Estimates Been Moving Since Then?It turns out, estimates review have trended upward during the past month.VGM ScoresCurrently, Incyte has a subpar Growth Score of D, however its Momentum Score is doing a bit better with a C. Following the exact same course, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Incyte has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.Performance of an Industry PlayerIncyte belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, BioMarin Pharmaceutical (BMRN), has gained 6.1% over the past month. More than a month has passed since the company reported results for the quarter ended June 2023.BioMarin reported revenues of $595.28 million in the last reported quarter, representing a year-over-year change of +11.5%. EPS of $0.54 for the same period compares with $0.59 a year ago.For the current quarter, BioMarin is expected to post earnings of $0.45 per share, indicating no change from the year-ago quarter. The Zacks Consensus Estimate has changed +20.3% over the last 30 days.BioMarin has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of F.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportIncyte Corporation (INCY) : Free Stock Analysis ReportBioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Why Is Incyte (INCY) Down 0.7% Since Last Earnings Report?

https://finance.yahoo.com/news/why-incyte-incy-down-0-153128312.html

b6e2188e-07c2-31b8-bcd4-f55a47a77a3f

INFA

Investors looking for stocks in the Internet - Software sector might want to consider either StoneCo Ltd. (STNE) or Informatica Inc. (INFA). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.StoneCo Ltd. and Informatica Inc. are sporting Zacks Ranks of #2 (Buy) and #5 (Strong Sell), respectively, right now. This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that STNE is likely seeing its earnings outlook improve to a greater extent. But this is just one factor that value investors are interested in.Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.STNE currently has a forward P/E ratio of 16.66, while INFA has a forward P/E of 24.18. We also note that STNE has a PEG ratio of 0.30. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. INFA currently has a PEG ratio of 4.27.Another notable valuation metric for STNE is its P/B ratio of 1.42. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, INFA has a P/B of 3.07.Story continuesBased on these metrics and many more, STNE holds a Value grade of A, while INFA has a Value grade of F.STNE sticks out from INFA in both our Zacks Rank and Style Scores models, so value investors will likely feel that STNE is the better option right now.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportStoneCo Ltd. (STNE) : Free Stock Analysis ReportInformatica Inc. (INFA) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

STNE or INFA: Which Is the Better Value Stock Right Now?

https://finance.yahoo.com/news/stne-infa-better-value-stock-154010929.html

4bbfa56c-05f7-33ce-a078-d0230cee3f92

INFA

On September 8, 2023, Amit Walia, the CEO of Informatica Inc (NYSE:INFA), sold 262,633 shares of the company. This move is part of a series of insider sell transactions that have been taking place over the past year.Who is Amit Walia?Warning! GuruFocus has detected 5 Warning Sign with INFA. Click here to check it out. INFA 30-Year Financial DataThe intrinsic value of INFAAmit Walia is the Chief Executive Officer of Informatica Inc. He has been with the company for several years, leading it through various stages of growth and development. His leadership has been instrumental in shaping the company's strategic direction and driving its success in the market.About Informatica IncInformatica Inc is a leading provider of enterprise data integration software and services. The company's solutions are used by organizations worldwide to access, integrate, and trust their information assets. Informatica's product portfolio includes data integration, data quality, data security, and master data management solutions, among others.Insider Sell AnalysisOver the past year, the insider has sold a total of 365,834 shares and purchased 0 shares. This recent transaction of 262,633 shares represents a significant portion of the insider's total sell transactions for the year.The insider transaction history for Informatica Inc shows a clear trend of insider sells over the past year, with 21 insider sells and 0 insider buys. This could be an indication of the insider's confidence in the company's future performance.Informatica Inc CEO Amit Walia Sells 262,633 SharesAs seen in the insider trend image above, there is a clear trend of insider selling over the past year. This could be a signal to investors about the company's future performance.Stock Price and ValuationOn the day of the insider's recent sell, shares of Informatica Inc were trading for $21.27 apiece. This gives the stock a market cap of $6.189 billion.The relationship between insider sell transactions and the stock price can be complex. While insider selling can sometimes be a bearish signal, it's important to consider the context. In this case, the insider's sell transactions over the past year have not resulted in a significant decrease in the stock price. This could suggest that the market has confidence in the company's future performance despite the insider's sell transactions.In conclusion, while the insider's recent sell transaction is noteworthy, it's important for investors to consider the broader context and other factors when making investment decisions.This article first appeared on GuruFocus.

GuruFocus.com

Informatica Inc CEO Amit Walia Sells 262,633 Shares

https://finance.yahoo.com/news/informatica-inc-ceo-amit-walia-170145567.html

078fa395-3e54-3d13-b597-f009b1a8b35d

INFI

A Cambridge biotech is laying off most of its staff in the wake of a failed merger agreement. Infinity Pharmaceuticals Inc. (Nasdaq: INFI) announced after market close on Tuesday that it would be letting go of 21 people — about 78% of its workforce, which would leave just six staffers. Infinity had been set to reverse these fortunes by merging with another company, MEI Pharma Inc. (Nasdaq: MEIP).Continue reading

American City Business Journals

Cambridge biotech cuts most staffers after merger falls apart

https://finance.yahoo.com/m/1cab9926-4ef7-3f2d-b45a-946f210b9401/cambridge-biotech-cuts-most.html

1cab9926-4ef7-3f2d-b45a-946f210b9401

INFI

Cambridge biotech Infinity Pharmaceuticals is clearing out its C-suite in the wake of a failed merger agreement that had already cost 21 jobs.Continue reading

American City Business Journals

Three execs leave Infinity Pharmaceuticals after failed merger, layoffs

https://finance.yahoo.com/m/d96c159b-46b1-32cb-b494-baf9b887654e/three-execs-leave-infinity.html

d96c159b-46b1-32cb-b494-baf9b887654e

INFN

Infinera CorporationSAN JOSE, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Infinera (NASDAQ: INFN) announced today that IONOS, the largest web hosting company in Europe, deployed Infinera’s GX Series Compact Modular Platform to expand its network and interconnect data centers across Europe with reliable, high-capacity, high-performance connectivity services.IONOS offers small- and medium-sized businesses web hosting and cloud services, managing more than 6 million customers and hosting over 22 million domains in its own regional data centers in Europe and in the U.S. With the Infinera GX G30 compact modular solution, IONOS can cost-effectively scale capacity and deliver 100 GbE and 400 GbE services to meet increased demand for data center connectivity to keep up with its growing cloud business.“We continue to advance the capabilities of our network infrastructure and invest in best-in-class technologies to meet ever-increasing data center traffic volumes driven by today’s bandwidth-intensive end-user applications,” said Sebastian Hohwieler, IONOS Head of Network Infrastructure. “Infinera’s industry-leading compact modular solution met our stringent performance requirements for scalable, flexible, resilient, and secure optical transport.”The GX G30 solution also enables IONOS to address its sustainability goals by delivering the lowest power-per-bit transport and providing support for upcoming technology generations.“We are constantly improving the energy efficiency of our networks,” said Daniel Heinze, SVP Network at IONOS. “Our target is to lower energy consumption despite traffic growth. Although green electricity is the main source of supply for our data centers in all countries, the best is if energy is not consumed at all.”“We are delighted that IONOS selected Infinera as its technology partner of choice for this important network expansion project,” said Nick Walden, Senior Vice President, Worldwide Sales, Infinera. “This deployment represents further validation of our leadership in compact modular solutions and provides IONOS the ability to meet the relentless growth in data center bandwidth with speed, scale, and efficiency.”Story continuesContacts:Media: Anna VueTel. +1 (916) [email protected]:Amitabh PassiHead of Investor RelationsTel. +1 (669) [email protected] InfineraInfinera is a global supplier of innovative open optical networking solutions and advanced optical semiconductors that enable carriers, cloud operators, governments, and enterprises to scale network bandwidth, accelerate service innovation, and automate network operations. Infinera solutions deliver industry-leading economics and performance in long-haul, submarine, data center interconnect, and metro transport applications. To learn more about Infinera, visit www.infinera.com, follow us on Twitter and LinkedIn, and subscribe for updates.Infinera and the Infinera logo are registered trademarks of Infinera Corporation.About IONOSIONOS is the leading European digitalization partner for small and medium-sized businesses (SMB). The company serves more than 6 million customers and operates across 18 markets in Europe and North America, with its services being accessible worldwide. With its Web Presence & Productivity portfolio, IONOS acts as a “one-stop shop” for all digitalization needs – from domains and web hosting to classic website builders and doit-yourself solutions, from e-commerce to online marketing tools. In addition, the company offers Cloud Solutions to enterprises who are looking to move to the cloud as their businesses evolve.This press release contains forward-looking statements, including but not limited to the technical, performance and financial benefits of Infinera’s GX G30 compact modular solution. These statements are not guarantees of results and should not be considered as an indication of future activity or future performance. Actual results may vary materially from these expectations as a result of various risks and uncertainties. Information about these risks and uncertainties, and other risks and uncertainties that affect Infinera’s business, is contained in the risk factors section and other sections of Infinera’s Quarter Report on Form 10-Q for the Fiscal Quarter ended July 1, 2023 as filed with the SEC on August 9, 2023, as well as any subsequent reports filed with or furnished to the SEC. These reports are available on Infinera’s website at www.infinera.com and the SEC’s website at www.sec.gov. Forward-looking statements include statements regarding our expectations, beliefs, intentions, or strategies and can be identified by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will,” and “would” or similar words. Infinera assumes no obligation to, and does not currently intend to, update any such forward-looking statements.

GlobeNewswire

Web Hosting Provider IONOS Deploys Infinera’s GX Compact Modular Solution for High-Performance Data Center Connectivity

https://finance.yahoo.com/news/hosting-provider-ionos-deploys-infinera-120000234.html

c6bc592f-204a-3d73-847a-5a9e8fe4205e

INFN

Infinera CorporationSAN JOSE, Calif, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Infinera (NASDAQ: INFN) has been awarded a Telecom Infra Project (TIP) Requirements Compliant Bronze Badge for its Transcend Open Wave Manager Solution, validating its compliance with the open and standard software-defined networking (SDN) API requirements defined by the Mandatory Use Cases for SDN Transport (MUST), a subgroup of the Open Optical Packet Transport (OOPT) Project Group.The TIP MUST project subgroup is an initiative driven by leading operators including Telia Company, Vodafone, Telefónica, Orange, Deutsche Telekom, MTN, TIM, Turkcell and Colt, and is responsible for identifying key SDN use cases and defining interoperability requirements for network devices, management and automation software, and their APIs.Infinera’s Transcend Open Wave Manager’s vendor-agnostic optical domain controller was awarded for its compliance with TIP’s controller Southbound Interface (SBI) requirements. Open Wave Manager is a software solution that simplifies the deployment, operation, and troubleshooting of disaggregated DWDM networks where open optical terminals and coherent pluggable transceivers from multiple vendors operate across third-party optical line systems.“Infinera is committed to open networking and we are proud to receive the TIP award for our Open Wave Manager solution,” said Ron Johnson, General Manager, Optical Systems and Solutions Group at Infinera. “Open networking solutions provide network operators the opportunity to choose the best-in-class technologies from the open market resulting in more choice, faster innovation, and improved economics. Open Wave Manager is a key enabler to the realization of open optical networking.”“Infinera’s ongoing collaboration with TIP and adoption of the MUST’s open and standard API requirements plays a critical role in enabling open and disaggregated networks,” said Arturo Mayoral López de Lerma, Technical Program Manager at Telecom Infra Project. “We are excited about testing Infinera’s products, and we look forward to more compliant solutions getting listed on TIP Exchange soon.”Story continuesContacts:Media: Anna VueTel. +1 (916) [email protected]:Amitabh PassiHead of Investor RelationsTel. +1 (669) 295-1489 [email protected] About InfineraInfinera is a global supplier of innovative open optical networking solutions and advanced optical semiconductors that enable carriers, cloud operators, governments, and enterprises to scale network bandwidth, accelerate service innovation, and automate network operations. Infinera solutions deliver industry-leading economics and performance in long-haul, submarine, data center interconnect, and metro transport applications. To learn more about Infinera, visit www.infinera.com, follow us on Twitter and LinkedIn, and subscribe for updates.Infinera and the Infinera logo are registered trademarks of Infinera Corporation.This press release contains forward-looking statements, including but not limited to the technical, performance and financial benefits of Infinera’s Transcend Open Wave Manager Solution. These statements are not guarantees of results and should not be considered as an indication of future activity or future performance. Actual results may vary materially from these expectations as a result of various risks and uncertainties. Information about these risks and uncertainties, and other risks and uncertainties that affect Infinera’s business, is contained in the risk factors section and other sections of Infinera’s Quarter Report on Form 10-Q for the Fiscal Quarter ended July 1, 2023 as filed with the SEC on August 9, 2023, as well as any subsequent reports filed with or furnished to the SEC. These reports are available on Infinera’s website at www.infinera.com and the SEC’s website at www.sec.gov. Forward-looking statements include statements regarding our expectations, beliefs, intentions, or strategies and can be identified by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will,” and “would” or similar words. Infinera assumes no obligation to, and does not currently intend to, update any such forward-looking statements.

GlobeNewswire

Infinera’s Transcend Open Wave Manager Receives Telecom Infra Project Award

https://finance.yahoo.com/news/infinera-transcend-open-wave-manager-120000114.html

ccf27d13-7224-327e-9e4f-f2e577c4abcb

INGR

In this piece, we will take a look at the 15 stocks with lowest short interest. If you want to skip our introduction to short interest, then check out 5 Stocks With Lowest Short Interest. Short selling is also quite entertaining if you're watching from the sidelines. And it was one aspect of the market that caught media waves by storm during the peak of the coronavirus pandemic. The conditions created by the virus, namely lockdowns that left people with nothing much to do but sit in front of their computer screens and receive money from the government in the form of stimulus checks, created a rather interesting set of conditions. The retail investing boom of the pandemic is a well known fact by now, and one way in which it materialized was in the form of serious share price action around GameStop Corp. (NYSE:GME).GameStop is a well known retailer and is a one-stop shop for anyone's gaming needs. However, like other traditional brick and mortar retailers, the firm has struggled to adapt to a digital age, and its operations were particularly harmed when video game developers cut the middle man and allowed gamers to directly download games. Not only did this reduce the price that gamers paid for their favorite titles, but firms also managed to reduce the costs of selling games, in a win win situation for both that left GameStop scratching its head.Analysts and hedge funds were as hawk eyed as ever and had shorted GameStop's shares as they believed that the firm would continue to bleed cash and lose market share. However, retail investors teamed up on Reddit and started buying the company's shares in bulk. These purchases were large enough to boost GameStop's share price from roughly $2.5 in April 2020 to a stunning $483 in January 2021 roughly three weeks after the meme buying frenzy started on Reddit. In the immediate aftermath of the retail stock frenzy, short sellers in GameStop had lost $6 billion and some hedge funds even went out of business.Story continuesSince then, even though GameStop buffeted its cash reserves by issuing more shares, the firm has been unable to successfully undertake a turnaround. GameStop has gone through multiple chief executive officers and chief financial officers and experimented with non fungible tokens (NFTs). The firm continues to post annual losses and its quarterly revenues continue to remain flat. However, GameStop still has plenty of cash left from its earlier share sales, so the jury's still out about the firm. As to what analysts think, the average share price target is $13.10 for a $5 downside from the current share price of $18.37. Analysts have also rated the shares as Underperform which have lost 35% over the past 12 months but made modest 6% gains this year.So, looks like short sellers are often on the dot when they short stocks, and today we'll look at some stocks with the lowest short interest. As a primer, short interest measures the number of shares of a firm that are sold short on the market, and if you're interested in learning even more details about short selling and different strategies, then take a look at 16 Most Shorted Stocks Right Now. Some top stocks on today's list are Honeywell International Inc. (NASDAQ:HON), Mercantile Bank Corporation (NASDAQ:MBWM), and Intercontinental Exchange, Inc. (NYSE:ICE).15 Stocks with Lowest Short InterestPhoto by AlphaTradeZoneOur Methodology To compile our list of the stocks with the lowest short interest, we simply ranked the top fifteen stocks with the lowest short interest as a percentage of their float. Only companies with a market capitalization greater than $300 million were chosen since micro cap and other smaller stocks often have limited liquidity which makes short selling difficult.Stocks with Lowest Short Interest15. California Water Service Group (NYSE:CWT)Short Interest Percentage: 1.23%California Water Service Group (NYSE:CWT) is a utility company. The firm has slowly been expanding its operational portfolio this year through acquisitions and investments but these are yet to bear fruit as it has missed analyst EPS estimates in three of its four latest quarters.By the end of this year's second quarter, 14 out of the 910 hedge funds surveyed by Insider Monkey had bought the firm's shares. California Water Service Group (NYSE:CWT)'s largest stakeholder is Ian Simm's Impax Asset Management through a stake worth $78.6 million.Along with Mercantile Bank Corporation (NASDAQ:MBWM), Honeywell International Inc. (NASDAQ:HON), and Intercontinental Exchange, Inc. (NYSE:ICE), California Water Service Group (NYSE:CWT) is one stock with the lowest short interest.14. Gambling.com Group Limited (NASDAQ:GAMB)Short Interest Percentage: 1.11%Gambling.com Group Limited (NASDAQ:GAMB) is not a gambling company. Instead, it provides a marketing platform for online gambling service providers and owns several gambling websites. The stock has posted impressive 56% gains year to date and the firm's second quarter saw it grow revenue by 63% annually.As of June 2023, 19 out of the 910 hedge funds polled by Insider Monkey had invested in Gambling.com Group Limited (NASDAQ:GAMB).  The firm's biggest hedge fund investor is Josh Goldberg's G2 Investment Partners Management since it owns 2 million shares that are worth $21 million.13. Amdocs Limited (NASDAQ:DOX)Short Interest Percentage: 0.85%Amdocs Limited (NASDAQ:DOX) is a technology company that provides a cloud computing platform. Despite a high rate and inflationary environment, the firm has either met or beat analyst EPS estimates in four of its latest quarters.During this year's second quarter, 26 hedge funds out of the 910 surveyed by Insider Monkey had bought the firm's shares. Amdocs Limited (NASDAQ:DOX)'s largest hedge fund stakeholder is Richard S. Pzena's Pzena Investment Management since it holds a $456 million stake.12. MGE Energy, Inc. (NASDAQ:MGEE)Short Interest Percentage: 0.97%MGE Energy, Inc. (NASDAQ:MGEE) is an electricity provider with operations in Wisconsin and Iowa. It is one of the weakest companies on our list, as analysts have penned in a $6 downside to the shares and rated them Underperform on average.Only five investors out of the 910 part of Insider Monkey's database had invested in MGE Energy, Inc. (NASDAQ:MGEE) as of Q2 2023 end. Out of these, the biggest shareholder is Peter Algert and Kevin Coldiron's Algert Coldiron Investors since it owns 23,065 shares that are worth $1.8 million.11. Hawkins, Inc. (NASDAQ:HWKN)Short Interest Percentage: 0.97%Hawkins, Inc. (NASDAQ:HWKN) is a chemicals company that serves the needs of a wide array of industries. Its shares are up a strong 62% year to date, helped by factors such as strong annual net income growth.By the end of this year's second quarter, seven out of the 910 hedge funds surveyed by Insider Monkey had bought and invested in Hawkins, Inc. (NASDAQ:HWKN)'s stock. Small cap guru Chuck Royce's Royce & Associates is the biggest hedge fund shareholder since it owns 89,940 shares that are worth $4.2 million.10. Vulcan Materials Company (NYSE:VMC)Short Interest Percentage: 0.96%Vulcan Materials Company (NYSE:VMC) provides building and construction materials in several American states. The firm's gross profit and earnings per share grew in the second quarter, in a positive development for the construction industry.As of June 2023, 49 out of the 910 hedge funds polled by Insider Monkey had held a stake in the company. Vulcan Materials Company (NYSE:VMC)'s largest hedge fund stakeholder is Sharlyn C. Heslam's Stockbridge Partners courtesy of its $461 million investment.Honeywell International Inc. (NASDAQ:HON), Mercantile Bank Corporation (NASDAQ:MBWM), Intercontinental Exchange, Inc. (NYSE:ICE), and Vulcan Materials Company (NYSE:VMC) are some stocks that have low short interest.9. Ingredion Incorporated (NYSE:INGR)Short Interest Percentage: 0.95%Ingredion Incorporated (NYSE:INGR) provides starch products for food production and textile use. 89% of its stock is owned by institutional investors, leaving the shares quite vulnerable to large and sudden downswings.After digging through 910 hedge funds for their second quarter of 2023 shareholdings, Insider Monkey discovered that 30 had bought Ingredion Incorporated (NYSE:INGR)'s shares. Out of these, the largest hedge fund investor is Donald Yacktman's Yacktman Asset Management through a $236 million investment.8. American International Group, Inc. (NYSE:AIG)Short Interest Percentage: 0.95%American International Group, Inc. (NYSE:AIG) is a diversified insurance company headquartered in New York City. Following the trend in the industry to benefit from high interest rates, the firm has beaten analyst EPS estimates in all four of its latest quarters.43 out of the 910 hedge funds polled by Insider Monkey for this year's June quarter had invested in the company. American International Group, Inc. (NYSE:AIG)'s biggest stakeholder among these is Natixis Global Asset Management's Harris Associates through its $1.2 billion stake.7. Johnson Controls International plc (NYSE:JCI)Short Interest Percentage: 0.85%Johnson Controls International plc (NYSE:JCI) is an industrial product company that serves the needs of the construction industry. It has either met or beaten analyst EPS estimates in four of its latest quarters and the stock is rated Buy on average.Insider Monkey scouted 910 hedge funds for their investments during 2023's second quarter and discovered 39 Johnson Controls International plc (NYSE:JCI) investors. Ken Fisher's Fisher Asset Management is the biggest shareholder since it owns a $818 million stake.6. SLR Investment Corp. (NASDAQ:SLRC)Short Interest Percentage: 0.85%SLR Investment Corp. (NASDAQ:SLRC) is a financial firm that provides debt to companies. The firm missed analyst EPS estimates for its second quarter and the stock is rated Buy on average.As of June 2023, four out of the 910 hedge funds part of Insider Monkey's research had invested in the company. SLR Investment Corp. (NASDAQ:SLRC)'s largest investor out of these is Robert B. Gillam's McKinley Capital Management through its $1.9 million stake.Honeywell International Inc. (NASDAQ:HON), SLR Investment Corp. (NASDAQ:SLRC), Mercantile Bank Corporation (NASDAQ:MBWM), and Intercontinental Exchange, Inc. (NYSE:ICE) are stocks with the lowest short interest. Click to continue reading and see 5 Stocks with Lowest Short Interest. Suggested Articles:17 Highest Paying Countries for Pilots10 Best Value Penny Stocks To Buy25 Most Civilized Countries in the WorldDisclosure: None. 16 Stocks with Lowest Short Interest is originally published on Insider Monkey.

Insider Monkey

15 Stocks with Lowest Short Interest

https://finance.yahoo.com/news/15-stocks-lowest-short-interest-120055625.html

6d964e8b-fd56-303a-b9dd-6a7e89466f51

INGR

The Consumer Staples group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Ingredion (INGR) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Ingredion is a member of our Consumer Staples group, which includes 193 different companies and currently sits at #12 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Ingredion is currently sporting a Zacks Rank of #2 (Buy).Over the past 90 days, the Zacks Consensus Estimate for INGR's full-year earnings has moved 1.4% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.Based on the most recent data, INGR has returned 5% so far this year. Meanwhile, stocks in the Consumer Staples group have lost about 2% on average. This shows that Ingredion is outperforming its peers so far this year.Another Consumer Staples stock, which has outperformed the sector so far this year, is PepsiCo (PEP). The stock has returned 0.2% year-to-date.Over the past three months, PepsiCo's consensus EPS estimate for the current year has increased 2.6%. The stock currently has a Zacks Rank #2 (Buy).Looking more specifically, Ingredion belongs to the Food - Miscellaneous industry, which includes 47 individual stocks and currently sits at #147 in the Zacks Industry Rank. Stocks in this group have lost about 6.5% so far this year, so INGR is performing better this group in terms of year-to-date returns.In contrast, PepsiCo falls under the Beverages - Soft drinks industry. Currently, this industry has 17 stocks and is ranked #42. Since the beginning of the year, the industry has moved +7.4%.Story continuesInvestors interested in the Consumer Staples sector may want to keep a close eye on Ingredion and PepsiCo as they attempt to continue their solid performance.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportIngredion Incorporated (INGR) : Free Stock Analysis ReportPepsiCo, Inc. (PEP) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Is Ingredion (INGR) Outperforming Other Consumer Staples Stocks This Year?

https://finance.yahoo.com/news/ingredion-ingr-outperforming-other-consumer-134009037.html

03eda930-826c-3d56-907e-46ac7da09199

INN

HERZLIYA, Israel and CALGARY, AB, Aug. 29, 2023 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the results of a clinical study regarding the pain-relieving effects and safety of the Company's subcutaneous liposomal CBD (Innocan's LPT platform) for dogs with osteoarthritis. Published in the Frontiers in Veterinary Science Journal, under the research topic "Use of Cannabis Derivatives in Veterinary Medicine" (the "Study"). The Study highlights that CBD plasma levels were detected for six weeks following a single subcutaneous dose of Liposomal-CBD, causing minimal side effects and effectively decreasing pain, leading to improved well-being in affected dogs.Figure 1: Plasma cannabidiol (CBD) concentrations (ng/mL) in 6 dogs with osteoarthritis before and up to 42 days (6 weeks) following a single subcutaneous liposomal CBD injection at 5 mg/kg.In the study, six dogs with naturally-occurring osteoarthritis, unresponsive to conventional medications, were treated with a single injection of five mg/kg liposomal-CBD (in addition to their routine medications). The subsequent observations spanned six weeks and included measuring CBD plasma concentrations, blood work, collar activity data, and evaluations of well-being and pain. The results were encouraging; dogs exhibited a substantial drop in pain levels and an uptick in activity.Key findings include: Prolonged CBD detection in the plasma with a peak concentration of 45.2 (17.8-72.5) ng/mL.Significant decrease in pain and increase in well-being for several weeks.Significant increase in activity (objectively measured) by the fifth and sixth weeks.Minor swelling at the injection site in five out of six dogs, which resolved within a few days without any treatment.The study underscores the effectiveness and increased bioavailability of LPT-CBD tested as part of a multimodal pain management in dogs with osteoarthritis. With the drug's plasma concentrations detectable for six weeks and high exposure in terms of AUC (area under the concentration-time curve), the research suggests that this liposomal formulation could become a useful addition to pain management strategies for improving the quality of life in dogs with osteoarthritis.Story continuesRead the full study on Frontiers in Veterinary Science:Frontiers | Therapeutic efficacy and pharmacokinetics of liposomal-cannabidiol injection: a pilot clinical study in dogs with naturally-occurring osteoarthritis (frontiersin.org)Innocan Pharma's CEO, Iris Bincovich, expressed her gratitude to the dedicated team of scientists at their Liposome technology labs in Jerusalem: "Our results, covered by one of the world's leading publications, stand as a testament to the potential of our innovative formulations and drug delivery systems. I'm profoundly proud of our team's groundbreaking work." This is an important milestone since publications in the scientific community provide guided information that impacts future drug development decisions and regulatory approval. Our publication clearly provides positive impact on both efficacy and safety parameters of LPT-CBD.Innocan's relationship with The Hebrew UniversityInnocan Pharma Ltd., a wholly owned subsidiary of the Company, has entered into a worldwide exclusive research and license agreement with Yissum Research and Development Company ("Yissum"), the commercial arm of The Hebrew University of Jerusalem, with respect to the design, preparation, characterization and evaluation of hydrogels containing CBD (or other cannabinoids) loaded liposomes. The research and development initiative is led by Professor Chezy Barenholz, head of the Membrane and Liposome Research Department at The Hebrew University, which is the inventor of over fifty-five patent families, two of which underlie Doxil®, an FDA-approved drug for breast cancer treatment. This unique liposome platform technology may have a wide range of applications, such as epilepsy, pain relief, inflammation and central nervous system disorders. A patent was filed covering this technology on October 7, 2019.About Innocan Innocan Pharma is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Pharma and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administered by inhalation, will be tested against a variety of lung infections.Innocan Pharma signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administered by injection. Innocan Israel plans, together with Professor Barenholz, to test the liposome platform on several potential conditions. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.Caution regarding forward-looking informationCertain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedar.com.Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.Photo - https://mma.prnewswire.com/media/2196814/Innocan_Pharma_Corporation.jpgLogo - https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpgFor further information, please contact: For Innocan Pharma Corporation:Iris Bincovich, [email protected] Pharma Corporation logo (PRNewsfoto/Innocan Pharma Corporation)CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/innocan-pharma-announces-clinical-study-results-evidence-of-reduced-osteoarthritis-pain-in-dogs-after-liposomal-cbd-injection-301912743.htmlSOURCE Innocan Pharma CorporationCisionView original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2023/29/c8006.html

CNW Group

Innocan Pharma Announces Clinical Study Results: Evidence of Reduced Osteoarthritis Pain in Dogs After Liposomal CBD Injection

https://finance.yahoo.com/news/innocan-pharma-announces-clinical-study-200100384.html

f9f27893-c6f6-3c71-b452-3988562154c2

INN

Innocan hair care cream efficacy trial observes enhanced hair growth in male and female participants in a 14day period.91 % of participants reported stronger hair and 100% of participants reported reduced hair loss The trial, revealed significant hair growth improvements.These promising results further expand Innocan's rapidly growing portfolio of indication offerings, reinforcing the Company's commitment to diversifying and enhancing its range of impactful wellness solutions.HERZLIYA, Israel and CALGARY, Alberta, Sept. 5, 2023 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative wellness products, announced today the successful results of a controlled efficacy test (the "Trial") regarding its hair care cream (the "Product").Area measured for hair length before (A) and after 14 days of using the product (B)The Trial's findings underscore the effectiveness of Innocan's product, which is enriched with cannabinoids, peptides, and other natural ingredients. The Trial's findings demonstrate that the Product enhances hair growth, resulting in increased hair density and thickness."We are profoundly encouraged by the outcomes of this trial and the evident benefits our hair care cream brought to the participants," said Iris Bincovich, CEO of Innocan. "Our dedication remains unwavering: to innovate and deliver products that genuinely make a difference in people's lives, and this achievement underscores that commitment."The 120-day Trial engaged a diverse group of male and female volunteers experiencing non-seasonal hair loss. The Trial's primary benchmark - a statistically significant increase in hair growth - was observed as early as 14 days post-application, with hair length elongation evident throughout the Trial and showing a 22.5% increase in hair length.Hair length after 14 days% increase in hair length after 14 days in the presence of the productWithout Product3.82 mm22.5 %With Product4.68 mm Story continuesFurthermore, 91% of the volunteers reported that their hair was stronger, 100% were satisfied from the attenuation in their hair loss, 87% stated that their hair is denser and thicker as if they have more hair and 100% of the volunteers will recommend the use of the product to others.  Area measured for hair length before (A) and after 14 days of using the product (B)Innocan's unique blend of cannabinoids and other natural ingredients presents a wholesome solution for those battling hair loss, aiming to not only prevent it but also promote the regrowth of fuller, thicker hair.About InnocanInnocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients' quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. (ii) CLX CBD-loaded exosomes platform that may hold the potential to provide a highly synergistic effect of regenerating and anti- inflammatory properties targeting the Central Nervous System (CNS). In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/For further information, please contact:For Innocan Pharma Corporation:Iris Bincovich, CEO15162104025++972-54-3012842+442037699377info@innocanpharma.comNEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.Caution regarding forward-looking informationCertain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedar.com.Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.Photo - https://mma.prnewswire.com/media/2202058/Innocan_Pharma_Corporation.jpgLogo - https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpgInnocan Pharma Corporation logo (PRNewsfoto/Innocan Pharma Corporation)CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/innocan-pharma-announces-promising-results-from-hair-care-cream-efficacy-test-301918230.htmlSOURCE Innocan Pharma Corporation

CNW Group

Innocan Pharma Announces Promising Results from Hair Care Cream Efficacy Test

https://finance.yahoo.com/news/innocan-pharma-announces-promising-results-200100604.html

06d761eb-177b-3355-a829-869c6244aff1

INNV

InnovAgeInnovAge Strengthens Board with Appointment of New Independent DirectorInnovAge Appoints Teresa Sparks to its Board of DirectorsDENVER, Aug. 14, 2023 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced the appointment of Teresa Sparks to its Board of Directors, effective immediately.Sparks joins InnovAge’s Board as Sean Traynor of Welsh, Carson, Anderson & Stowe steps down. The InnovAge team and Board thank Mr. Traynor for his service.“Teresa’s diverse experience across multiple sectors, including in financial services, life sciences, specialty pharmacy, healthcare services, and technology, is a huge asset and complement to our Board,” said Chairman Jim Carlson. “We are thrilled to have her on our team.”“We are excited to welcome Teresa to the InnovAge Board,” said Patrick Blair, President and CEO. “Teresa has spent decades working with large public and private companies that operate in highly regulated, healthcare-focused industries. We believe her experience will be incredibly valuable to our mission and goals as an organization.”“InnovAge has the most incredible mission serving, supporting, and empowering the most vulnerable seniors in communities around country,” said Sparks. “I am eager to bring a culmination of my life’s work and experience to the table and proud to join this dedicated team, committed to serving people who truly need our help.”Sparks serves on the Board of ATI Physical Therapy, providing research-based rehabilitation services and Harrow Health, engaged in the development of ophthalmic pharmaceutical products. She also serves as a board member and advisor to privately held, innovative healthcare companies; including Valtruis with a focus on advancing value-based care.She previously served as the Executive Vice President and Chief Financial Officer for Envision, a leading provider of physician-led and post-acute care services, where she helped transform and modernize the company’s infrastructure. Prior to Envision, she was the interim Chief Financial Officer at Brookdale Senior Living, and prior to that, she served as Executive Vice President and Chief Financial Officer of Surgery Partners, which acquired Symbion where she served in various positions, including Senior Vice President and Chief Financial Officer. Sparks began her career as an auditor at Deloitte.Story continuesAbout InnovAgeInnovAge is a market leader in managing the care of high-cost, dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE). With a mission of enabling older adults to age independently in their own homes for as long as safely possible, InnovAge’s patient-centered care model is designed to improve the quality of care its participants receive while reducing over-utilization of high-cost care settings. InnovAge believes its PACE healthcare model is one in which all constituencies — participants, their families, providers, and government payors — “win.” As of March 31, 2023, InnovAge served approximately 6,310 participants across 17 centers in five states. https://www.innovage.com/.Investor Contact:Ryan [email protected] Contact:Lara [email protected] photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4f9a23f8-3c4c-4455-8228-298182ea0225

GlobeNewswire

InnovAge Strengthens Board with Appointment of New Independent Director

https://finance.yahoo.com/news/innovage-strengthens-board-appointment-independent-120000091.html

ead1dd45-9e2e-3634-9025-b752a6c86d37

INNV

InnovAgeDENVER, Aug. 29, 2023 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced it will release its 2023 fiscal fourth quarter financial results on Tuesday, September 12, 2023, after market close. In conjunction, the Company will host a conference call to review the results at 5 p.m. E.T.Conference Call DetailsA live audio webcast of the call will be available on the Company’s website, https://investor.innovage.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for a limited time. To access the call by phone, please go to this link (registration link), for dialing instructions and a unique access pin. We encourage participants to dial into the call fifteen minutes ahead of the scheduled start time.About InnovAgeInnovAge is a market leader in managing the care of high-cost, dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE). With a mission of enabling older adults to age independently in their own homes for as long as safely possible, InnovAge’s patient-centered care model is designed to improve the quality of care its participants receive while reducing over-utilization of high-cost care settings. InnovAge believes its PACE healthcare model is one in which all constituencies — participants, their families, providers, and government payors — “win.” As of March 31, 2023, InnovAge served approximately 6,310 participants across 17 centers in five states. https://www.innovage.com/.Investor Contact:Ryan [email protected] Contact:Lara Hazenfield [email protected]

GlobeNewswire

InnovAge to Announce Fiscal Fourth Quarter 2023 Financial Results and Host Conference Call Tuesday, September 12, 2023

https://finance.yahoo.com/news/innovage-announce-fiscal-fourth-quarter-120000362.html

0211fe42-8f46-3f4b-9c38-370119d70051

INPX

PALO ALTO, Calif., Aug. 4, 2023 /PRNewswire/ -- Inpixon® (Nasdaq: INPX), a leading provider of real-time location systems (RTLS), today announced it will host a conference call presentation at 4:30 p.m. Eastern Time on Monday, August 14, 2023 to provide a business update as well as a presentation by the management of XTI Aircraft Company ("XTI") following the recently announced definitive merger agreement between Inpixon and XTI. Inpixon plans to release its financial results for the second quarter of 2023 after market close the same day.(PRNewsfoto/Inpixon)Interested parties may access the conference call presentation at https://www.webcaster4.com/Webcast/Page/2235/48894 or at the link on Inpixon's Investor Relations section of the website, ir.inpixon.com/ir-news-events/ir-calendar. A webcast replay will be available on Inpixon's Investor Relations section of the website (ir.inpixon.com/ir-news-events/ir-calendar).Shareholders and other interested parties are invited to submit questions to Inpixon management prior to the beginning of the call via email to [email protected] InpixonInpixon® (Nasdaq: INPX) is the innovator of Indoor Intelligence®, delivering actionable insights for people, places and things. Combining the power of mapping, positioning and analytics, Inpixon helps to create smarter, safer, and more secure environments. The company's Indoor Intelligence and industrial real-time location system (RTLS) solutions are leveraged by a multitude of industries to optimize operations, increase productivity, and enhance safety. Inpixon customers can take advantage of industry leading location awareness, analytics, sensor fusion, IIoT and the IoT to create exceptional experiences and to do good with indoor data. For the latest insights, follow Inpixon on LinkedIn, Twitter, and visit inpixon.com.About XTIXTI Aircraft Company is an aviation business based near Denver, Colorado. XTI is guided by a leadership team with decades of experience, deep expertise, and success bringing new aircraft to market, including more than 40 FAA-certified new aircraft configurations. XTI is founded on a culture of customer-focused problem solving to meet the evolving needs of modern travelers. For information and updates about XTI Aircraft Company and the TriFan 600, visit xtiaircraft.com. For information on reserving a priority position for the TriFan under the company's pre-sales program, contact Mr. Saleem Zaheer at +1-720-900-6928 or [email protected] continuesContactsInpixon ContactsGeneral inquiries:Email: [email protected] Web: inpixon.com/contact-us Investor relations:Crescendo Communications, LLCTel: +1 212-671-1020Email: [email protected] Aircraft ContactsGeneral inquiries:Email: [email protected] Web: xtiaircraft.com/cm/get-involvedInvestor relations:Crescendo Communications for XTITel: +1 212-671-1020Email: [email protected] Information About the Proposed Transaction and Where to Find ItThis press release relates to a proposed transaction between XTI Aircraft Company, a Delaware corporation ("XTI"), and Inpixon, a Nevada corporation ("Inpixon"), pursuant to an agreement and plan of merger, dated as of July 24, 2023, by and among Inpixon, Superfly Merger Sub Inc. and XTI (the "proposed transaction"). Inpixon intends to file a registration statement on Form S-4 (the "Form S-4") with the U.S. Securities and Exchange Commission ("SEC"), which will include a preliminary prospectus and proxy statement of Inpixon in connection with the proposed transaction, referred to as a proxy statement/prospectus. A proxy statement/prospectus will be sent to all Inpixon stockholders as of a record date to be established for voting on the transaction and to the stockholders of XTI. Inpixon also will file other documents regarding the proposed transaction with the SEC.Before making any voting decision, investors and security holders are urged to read the registration statement, the proxy statement/prospectus, and amendments thereto, and the definitive proxy statement/prospectus in connection with Inpixon's solicitation of proxies for its stockholders' meeting to be held to approve the transaction, and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about Inpixon, XTI and the proposed transaction.Investors and securityholders will be able to obtain free copies of the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Inpixon through the website maintained by the SEC at www.sec.gov.The documents filed by Inpixon with the SEC also may be obtained free of charge at Inpixon's website at www.inpixon.com or upon written request to: Inpixon, 2479 E. Bayshore Road, Suite 195, Palo Alto, CA 94303.NEITHER THE SEC NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED IN THIS COMMUNICATION, PASSED UPON THE MERITS OR FAIRNESS OF THE TRANSACTION OR RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS COMMUNICATION. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE.Forward-Looking StatementsThis communication contains certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this communication, including statements regarding the benefits of the proposed transaction, the anticipated timing of the completion of the proposed transaction, the products under development by XTI and the markets in which it plans to operate, the advantages of XTI's technology, XTI's competitive landscape and positioning, and XTI's growth plans and strategies, are forward-looking statements.Some of these forward-looking statements can be identified by the use of forwardlooking words, including "may," "should," "expect," "intend," "will," "estimate," "anticipate," "believe," "predict," "plan," "targets," "projects," "could," "would," "continue," "forecast" or the negatives of these terms or variations of them or similar expressions. All forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. All forward-looking statements are based upon estimates, forecasts and assumptions that, while considered reasonable by Inpixon and its management, and XTI and its management, as the case may be, are inherently uncertain and many factors may cause the actual results to differ materially from current expectations which include, but are not limited to:the risk that the proposed transaction may not be completed in a timely manner or at all, which may adversely affect the price of Inpixon's securities;the failure to satisfy the conditions to the consummation of the proposed transaction, including the adoption of the merger agreement by the shareholders of Inpixon;the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement;the adjustments permitted under the merger agreement to the exchange ratio that could result in XTI shareholders or Inpixon shareholders owning less of the post-combination company than expected;the effect of the announcement or pendency of the proposed transaction on Inpixon's and XTI's business relationships, performance, and business generally;risks that the proposed transaction disrupts current plans of Inpixon and XTI and potential difficulties in Inpixon's and XTI's employee retention as a result of the proposed transaction;the outcome of any legal proceedings that may be instituted against XTI or against Inpixon related to the merger agreement or the proposed transaction;failure to realize the anticipated benefits of the proposed transaction;the inability to meet and maintain the listing of Inpixon's securities (or the securities of the post-combination company) on Nasdaq;the risk that the price of Inpixon's securities (or the securities of the postcombination company) may be volatile due to a variety of factors, including changes in the highly competitive industries in which Inpixon and XTI operate,the inability to implement business plans, forecasts, and other expectations after the completion of the proposed transaction, and identify and realize additional opportunities;variations in performance across competitors, changes in laws, regulations, technologies that may impose additional costs and compliance burdens on Inpixon and XTI's operations, global supply chain disruptions and shortages,national security tensions, and macro-economic and social environments affecting Inpixon and XTI's business and changes in the combined capital structure;the risk that XTI has a limited operating history, has not yet manufactured any non-prototype aircraft or delivered any aircraft to a customer, and XTI and its current and future collaborators may be unable to successfully develop and market XTI's aircraft or solutions, or may experience significant delays in doing so;the risk that XTI is subject to the uncertainties associated with the regulatory approvals of its aircraft including the certification by the Federal Aviation Administration, which is a lengthy and costly process;the risk that the post-combination company may never achieve or sustain profitability;the risk that XTI, Inpixon and the post-combination company may be unable to raise additional capital on acceptable terms to finance its operations and remain a going concern;the risk that the post-combination company experiences difficulties in managing its growth and expanding operations;the risk that XTI's conditional pre orders (which include conditional aircraft purchase agreements, non-binding reservations, and options) are canceled, modified, delayed or not placed and that XTI must return the refundable deposits;the risks relating to long development and sales cycles, XTI's ability to satisfy the conditions and deliver on the orders and reservations, its ability to maintain quality control of its aircraft, and XTI's dependence on third parties for supplying components and potentially manufacturing the aircraft;the risk that other aircraft manufacturers develop competitive VTOL aircraft or other competitive aircraft that adversely affect XTI's market position;the risk that XTI's future patent applications may not be approved or may take longer than expected, and XTI may incur substantial costs in enforcing and protecting its intellectual property;the risk that XTI's estimates of market demand may be inaccurate;the risk that XTI's ability to sell its aircraft may be limited by circumstances beyond its control, such as a shortage of pilots and mechanics who meet the training standards, high maintenance frequencies and costs for the sold aircraft, and any accidents or incidents involving VTOL aircraft that may harm customer confidence;other risks and uncertainties set forth in the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in Inpixon's Annual Report on Form 10-K for the year ended December, 31, 2022, which was filed with the SEC on April 17, 2023 (the "2022 Form 10-K") and Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 filed on May 16, 2023, and in the section entitled "Risk Factors" in XTI's periodic reports filed pursuant to Regulation A of the Securities Act including XTI's Annual Report on Form 1-K for the year ended December 31, 2022, which was filed with the SEC on July 13, 2023 (the "2022 Form 1-K"), as such factors may be updated from time to time in Inpixon's and XTI's filings with the SEC, the registration statement on Form S-4 and the proxy statement/prospectus contained therein. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Neither Inpixon nor XTI gives any assurance that either Inpixon or XTI or the post-combination company will achieve its expected results. Neither Inpixon nor XTI undertakes any duty to update these forward-looking statements, except as otherwise required by law.Participants in the SolicitationXTI and Inpixon and their respective directors and officers and other members of management may, under SEC rules, be deemed to be participants in the solicitation of proxies from Inpixon's stockholders with the proposed transaction and the other matters set forth in the registration statement. Information about Inpixon's and XTI's directors and executive officers is set forth in Inpixon's filings and XTI's filings with the SEC, including Inpixon's 2022 Form 10-K and XTI's 2022 Form 1-K. Additional information regarding the direct and indirect interests, by security holdings or otherwise, of those persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading the proxy statement/prospectus regarding the proposed transaction when it becomes available. You may obtain free copies of these documents as described above under "Important Information About the Proposed Transaction and Where to Find It."No Offer or SolicitationThis press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy, sell or solicit any securities or any proxy, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be deemed to be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/inpixon-schedules-business-update-conference-call-and-presentation-by-xti-aircraft-management-301893402.htmlSOURCE Inpixon

PR Newswire

Inpixon Schedules Business Update Conference Call and Presentation by XTI Aircraft Management

https://finance.yahoo.com/news/inpixon-schedules-business-conference-call-133000535.html

447cf25d-b8ee-3239-b9df-f19148897708

INPX

Entered into a Definitive Merger Agreement with XTI Aircraft; Merger Expected to be Completed during the Fourth Quarter of 2023Business Update Presentation with XTI Aircraft Managementto be Held Today at 4:30 p.m. ETPALO ALTO, Calif., Aug. 14, 2023 /PRNewswire/ -- Inpixon® (Nasdaq: INPX), a leading provider of real-time location systems (RTLS), today provided a business update and reported financial results for the second quarter ended June 30, 2023.(PRNewsfoto/Inpixon)"During the second quarter we continued our work to explore, identify, and pursue strategic alternatives with the goal of delivering additional value for our shareholders," commented Nadir Ali, CEO of Inpixon. "Towards this end, we're excited to have recently announced entering into a definitive merger agreement with XTI Aircraft, an innovative aviation company developing a vertical lift crossover airplane (VLCA). We believe this transaction will be transformational for Inpixon and XTI, resulting in a public company that will be engaged in both advancing the TriFan 600, a fixed wing, vertical takeoff and landing (VTOL) aircraft, and in offering RTLS solutions to industrial markets. With over 700 conditional pre-orders[1], representing the potential for gross revenues of approximately $7.1 billion[2], we believe there is a strong demand for the TriFan 600, and a compelling opportunity for Inpixon and its stockholders. We are enthusiastic about the potential of the combined company and anticipate closing the transaction during the fourth quarter of 2023."Inpixon improved its gross margins during the quarter as a result of lower cost of goods within the IIoT and SAVES business lines. With RTLS enabling customers to digitally track the location of assets, our customers can locate, learn, and leverage information to make data-driven business decisions. In addition, we have preserved a solid balance sheet with over $15.7 million in cash and cash equivalents as of June 30, 2023. Overall, we believe we are undertaking activities that have the potential to provide additional value for shareholders, and I would strongly encourage all our investors to participate in the business update presentation this afternoon, which will include an overview of XTI provided by its management team," concluded Mr. Ali.Story continues[1] Conditional pre-orders refers to a combination of aircraft purchase agreements, non-binding reservation deposit agreements, and options.[2] Based on XTI's current list price of $10 million per aircraft and assuming XTI is able to execute on the development program for the TriFan, secure FAA certification, and deliver the aircrafts.Financial ResultsRevenues for the three and six months ended June 30, 2023 were $2.1 million and $5.2 million, respectively, compared to $2.6 million and $5.2 million, respectively, for the comparable periods in the prior year. This quarter-over-quarter decrease was primarily attributable to the decrease in Indoor Intelligence sales due to delayed shipments and lower sales for the SAVES product line. Gross profit for the three and six months ended June 30, 2023 was $1.7 million and $4.0 million, respectively, compared to $1.7 million and $3.6 million for the 2022 respective periods. The gross profit margin for the three and six months ended June 30, 2023, was 81% and 77%, compared to 67% and 68% for the three and six months ended June 30, 2022, respectively. This increase in gross margin was primarily due to the lower cost of revenues on the SAVES product line.Operating expenses for the three months ended June 30, 2023 were $8.3 million and $11.1 million for the comparable period ended June 30, 2022. This decrease of approximately $2.8 million is primarily attributable to the $2.0 million of goodwill impairment in the three months ended June 30, 2022 and lower compensation, professional fees and legal expenses in the three months ended June 30, 2023. Operating expenses for the six months ended June 30, 2023 were $18.8 million and $22.2 million for the comparable period ended June 30, 2022. This decrease of $3.4 million is primarily attributable to the $2.0 million of goodwill impairment in the six months ended June 30, 2022, lower stock-based compensation and professional fees in the six months ended June 30, 2023 offset by $1.4 million of transaction costs in the 2023 period.Net loss from continuing operations for the three months ended June 30, 2023 was $7.33 million compared to $8.97 million for the comparable period in the prior year. This decrease in loss of approximately $1.6 million was primarily attributable to the goodwill impairment of $2.0 million in the three months ended June 30, 2022 and lower operating expenses in the three months ended June 30, 2023. Net loss from continuing operations for both the six months ended June 30, 2023 and 2022, was $19.7 million. Non-GAAP Adjusted EBITDA for the three and six months ended June 30, 2023 was a loss of $5.0 million and $9.9 million, respectively, compared to a loss of $5.2 million and $11.7 million for the prior year periods, respectively. Non-GAAP Adjusted EBITDA is defined as net income or loss before interest, provision for income taxes, depreciation and amortization plus adjustments for other income or expense items, non-recurring items and non-cash items including stock-based compensation.Proforma non-GAAP net loss per basic and diluted common share for the three and six months ended June 30, 2023 was a loss of $0.18 and $0.79, respectively, compared to a loss of $2.72 and $5.88 for the prior year periods. Non-GAAP net loss per share is defined as net loss per basic and diluted share adjusted for non-cash items including stock-based compensation, amortization of intangibles and one-time charges and other adjustments including impairment of goodwill, provision for valuation allowance on notes, and acquisition costs.Conference Call and Presentation InformationInpixon will host a conference call presentation today at 4:30 p.m. ET to provide a business update as well as a presentation by the management of XTI Aircraft Company ("XTI") following the recently announced definitive merger agreement between Inpixon and XTI.Interested parties may access the conference call presentation at https://www.webcaster4.com/Webcast/Page/2235/48894 or at the link on Inpixon's Investor Relations section of the website, ir.inpixon.com/ir-news-events/ir-calendar. A webcast replay will be available on Inpixon's Investor Relations section of the website (ir.inpixon.com/ir-news-events/ir-calendar).Shareholders and other interested parties are invited to submit questions to Inpixon management via email to [email protected] InpixonInpixon® (Nasdaq: INPX) is the innovator of Indoor Intelligence®, delivering actionable insights for people, places and things. Combining the power of mapping, positioning and analytics, Inpixon helps to create smarter, safer, and more secure environments. The company's Indoor Intelligence and industrial real-time location system (RTLS) solutions are leveraged by a multitude of industries to optimize operations, increase productivity, and enhance safety. Inpixon customers can take advantage of industry leading location awareness, analytics, sensor fusion, IIoT and the IoT to create exceptional experiences and to do good with indoor data. For the latest insights, follow Inpixon on LinkedIn, and Twitter, and visit inpixon.com.About XTIXTI Aircraft Company is an aviation business based near Denver, Colorado. XTI is guided by a leadership team with decades of experience, deep expertise, and success bringing new aircraft to market, including more than 40 FAA-certified new aircraft configurations. XTI is founded on a culture of customer-focused problem solving to meet the evolving needs of modern travelers. For information and updates about XTI Aircraft Company and the TriFan 600, visit xtiaircraft.com. For information on reserving a priority position for the TriFan under the company's pre-sales program, contact Mr. Saleem Zaheer at +1-720-900-6928 or [email protected] Financial MeasuresManagement believes that certain financial measures not in accordance with generally accepted accounting principles in the United States ("GAAP") are useful measures of operations. EBIDTA, Adjusted EBITDA and pro forma net loss per share are non-GAAP measures. Inpixon defines "EBITDA" as net income (loss) before interest, provision for (benefit from) income taxes, and depreciation and amortization. Management uses Adjusted EBITDA as a metric for which it manages the business, and Inpixon defines "Adjusted EBITDA" as EBITDA plus adjustments for other income or expense items, non-recurring items and non-cash items. Inpixon defines "pro forma net loss per share" as GAAP net loss per share adjusted for stock-based compensation, amortization of intangibles and one-time charges including impairment of goodwill and gain on equity securities.Management provides Adjusted EBITDA and pro forma net loss per share measures so that investors will have the same financial information that management uses, which may assist investors in assessing Inpixon's performance on a period-over-period basis. Adjusted EBITDA or pro forma net loss per share is not a measure of financial performance under GAAP and should not be considered an alternative to net income (loss) or any other measure of performance under GAAP, or to cash flows from operating, investing or financing activities as an indicator of cash flows or as a measure of liquidity. Adjusted EBITDA and pro forma net loss per share have limitations as analytical tools and should not be considered either in isolation or as a substitute for analysis of Inpixon's results as reported under GAAP.For more information on our non-GAAP financial measures and a reconciliation of GAAP to non-GAAP measures, please see the "Reconciliation of Non-GAAP Financial Measures" table accompanying this press release.ContactsInpixon ContactsGeneral inquiries:Email: [email protected]: inpixon.com/contact-usInvestor relations:Crescendo Communications for InpixonTel: +1 212-671-1020Email: [email protected] Aircraft ContactsGeneral inquiries:Email: [email protected]: xtiaircraft.com/cm/get-involvedInvestor relations:Crescendo Communications for XTITel: +1 212-671-1020Email: [email protected] Information About the Proposed Transaction and Where to Find ItThis press release relates to a proposed transaction between XTI Aircraft Company, a Delaware corporation ("XTI"), and Inpixon, a Nevada corporation ("Inpixon"), pursuant to an agreement and plan of merger, dated as of July 24, 2023, by and among Inpixon, Superfly Merger Sub Inc. and XTI (the "proposed transaction"). Inpixon has filed a registration statement on Form S-4 (the "Form S-4") with the U.S. Securities and Exchange Commission ("SEC"), which includes a preliminary prospectus and proxy statement of Inpixon in connection with the proposed transaction, referred to as a proxy statement/prospectus. A proxy statement/prospectus will be sent to all Inpixon stockholders as of a record date to be established for voting on the transaction and to the stockholders of XTI. Inpixon will also file other documents regarding the proposed transaction with the SEC.Before making any voting decision, investors and security holders are urged to read the registration statement, the proxy statement/prospectus, and amendments thereto, and the definitive proxy statement/prospectus in connection with Inpixon's solicitation of proxies for its stockholders' meeting to be held to approve the transaction, and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about Inpixon, XTI and the proposed transaction.Investors and securityholders will be able to obtain free copies of the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Inpixon through the website maintained by the SEC at www.sec.gov.The documents filed by Inpixon with the SEC also may be obtained free of charge at Inpixon's website at www.inpixon.com or upon written request to: Inpixon, 2479 E. Bayshore Road, Suite 195, Palo Alto, CA 94303.NEITHER THE SEC NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED IN THIS COMMUNICATION, PASSED UPON THE MERITS OR FAIRNESS OF THE TRANSACTION OR RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS COMMUNICATION. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE.Forward-Looking StatementsThis communication contains certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this communication, including statements regarding the benefits of the proposed transaction, the anticipated timing of the completion of the proposed transaction, the products under development by XTI and the markets in which it plans to operate, the advantages of XTI's technology, XTI's competitive landscape and positioning, and XTI's growth plans and strategies, are forward-looking statements.Some of these forward-looking statements can be identified by the use of forward-looking words, including "may," "should," "expect," "intend," "will," "estimate," "anticipate," "believe," "predict," "plan," "targets," "projects," "could," "would," "continue," "forecast" or the negatives of these terms or variations of them or similar expressions. All forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. All forward-looking statements are based upon estimates, forecasts and assumptions that, while considered reasonable by Inpixon and its management, and XTI and its management, as the case may be, are inherently uncertain and many factors may cause the actual results to differ materially from current expectations which include, but are not limited to:the risk that the proposed transaction may not be completed in a timely manner or at all, which may adversely affect the price of Inpixon's securities;the failure to satisfy the conditions to the consummation of the proposed transaction, including the adoption of the merger agreement by the shareholders of Inpixon;the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement;the adjustments permitted under the merger agreement to the exchange ratio that could result in XTI shareholders or Inpixon shareholders owning less of the post-combination company than expected;the effect of the announcement or pendency of the proposed transaction on Inpixon's and XTI's business relationships, performance, and business generally;risks that the proposed transaction disrupts current plans of Inpixon and XTI and potential difficulties in Inpixon's and XTI's employee retention as a result of the proposed transaction;the outcome of any legal proceedings that may be instituted against XTI or against Inpixon related to the merger agreement or the proposed transaction;failure to realize the anticipated benefits of the proposed transaction;the inability to meet and maintain the listing of Inpixon's securities (or the securities of the post-combination company) on Nasdaq;the risk that the price of Inpixon's securities (or the securities of the postcombination company) may be volatile due to a variety of factors, including changes in the highly competitive industries in which Inpixon and XTI operate,the inability to implement business plans, forecasts, and other expectations after the completion of the proposed transaction, and identify and realize additional opportunities;variations in performance across competitors, changes in laws, regulations, technologies that may impose additional costs and compliance burdens on Inpixon and XTI's operations, global supply chain disruptions and shortages,national security tensions, and macro-economic and social environments affecting Inpixon and XTI's business and changes in the combined capital structure;the risk that XTI has a limited operating history, has not yet manufactured any non-prototype aircraft or delivered any aircraft to a customer, and XTI and its current and future collaborators may be unable to successfully develop and market XTI's aircraft or solutions, or may experience significant delays in doing so;the risk that XTI is subject to the uncertainties associated with the regulatory approvals of its aircraft including the certification by the Federal Aviation Administration, which is a lengthy and costly process;the risk that the post-combination company may never achieve or sustain profitability;the risk that XTI, Inpixon and the post-combination company may be unable to raise additional capital on acceptable terms to finance its operations and remain a going concern;the risk that the post-combination company experiences difficulties in managing its growth and expanding operations;the risk that XTI's conditional pre orders (which include conditional aircraft purchase agreements, non-binding reservations, and options) are canceled, modified, delayed or not placed and that XTI must return the refundable deposits;the risks relating to long development and sales cycles, XTI's ability to satisfy the conditions and deliver on the orders and reservations, its ability to maintain quality control of its aircraft, and XTI's dependence on third parties for supplying components and potentially manufacturing the aircraft;the risk that other aircraft manufacturers develop competitive VTOL aircraft or other competitive aircraft that adversely affect XTI's market position;the risk that XTI's future patent applications may not be approved or may take longer than expected, and XTI may incur substantial costs in enforcing and protecting its intellectual property;the risk that XTI's estimates of market demand may be inaccurate;the risk that XTI's ability to sell its aircraft may be limited by circumstances beyond its control, such as a shortage of pilots and mechanics who meet the training standards, high maintenance frequencies and costs for the sold aircraft, and any accidents or incidents involving VTOL aircraft that may harm customer confidence;other risks and uncertainties set forth in the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in Inpixon's Annual Report on Form 10-K for the year ended December, 31, 2022, which was filed with the SEC on April 17, 2023 (the "2022 Form 10-K") and Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 filed on May 16, 2023, and in the section entitled "Risk Factors" in XTI's periodic reports filed pursuant to Regulation A of the Securities Act including XTI's Annual Report on Form 1-K for the year ended December 31, 2022, which was filed with the SEC on July 13, 2023 (the "2022 Form 1-K"), as such factors may be updated from time to time in Inpixon's and XTI's filings with the SEC, the registration statement on Form S-4 and the proxy statement/prospectus contained therein. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Neither Inpixon nor XTI gives any assurance that either Inpixon or XTI or the post-combination company will achieve its expected results. Neither Inpixon nor XTI undertakes any duty to update these forward-looking statements, except as otherwise required by law.Participants in the SolicitationXTI and Inpixon and their respective directors and officers and other members of management may, under SEC rules, be deemed to be participants in the solicitation of proxies from Inpixon's stockholders with the proposed transaction and the other matters set forth in the registration statement. Information about Inpixon's and XTI's directors and executive officers is set forth in Inpixon's filings and XTI's filings with the SEC, including Inpixon's 2022 Form 10-K and XTI's 2022 Form 1-K. Additional information regarding the direct and indirect interests, by security holdings or otherwise, of those persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading the proxy statement/prospectus regarding the proposed transaction when it becomes available. You may obtain free copies of these documents as described above under "Important Information About the Proposed Transaction and Where to Find It."No Offer or SolicitationThis press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy, sell or solicit any securities or any proxy, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be deemed to be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act. INPIXON AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands, except number of shares and par value data)As of June 30, 2023December 31, 2022(Unaudited)(Audited)ASSETSCurrent AssetsCash and cash equivalents$15,681$10,235Accounts receivable, net of allowances of $237 and $272, respectively1,8031,889Notes and other receivables78586Inventory3,2282,442Note receivable--150Prepaid assets and other current assets2,1812,803Current assets of discontinued operations--12,261Total Current Assets23,67829,866Property and equipment, net1,0091,064Operating lease right-of-use asset, net434531Software development costs, net1,1131,265Investment in equity securities1,414330Long-term investments50716Intangible assets, net2,5732,994Other assets174158Non-current assets of discontinued operations--20,711Total Assets$30,445$57,635LIABILITIES AND STOCKHOLDERS' EQUITYCurrent LiabilitiesAccounts payable$1,665$1,503Accrued liabilities5,3742,619Operating lease obligation, current200211Deferred revenue1,1241,323Short-term debt13,80013,643Acquisition liability--197Warrant Liability1,500--Current liabilities of discontinued operations--5,218Total Current Liabilities23,66324,714Long Term LiabilitiesOperating lease obligations, noncurrent245334Non-current liabilities of discontinued operations--472Total Liabilities23,90825,520Commitments and Contingencies----Stockholders' EquityPreferred Stock - $0.001 par value; 5,000,000 shares authorized.Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of June 30, 2023 and December 31, 2022, respectively; ----Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and 126 outstanding as of June 30, 2023 and December 31, 2022, respectively.----Common Stock - $0.001 par value; 500,000,000 shares authorized; 43,154,195 and 3,570,894 issued and 43,154,194 and 3,570,893 outstanding as of June 30, 2023 and December 31, 2022, respectively.434Additional paid-in capital346,799346,668Treasury stock, at cost, 1 share(695)(695)Accumulated other comprehensive (loss) income(189)1,061Accumulated deficit (337,555)(313,739)Stockholders' Equity Attributable to Inpixon8,40333,299Non-controlling interest(1,866)(1,184)Total Stockholders' Equity6,53732,115Total Liabilities and Stockholders' Equity$30,445$57,635 INPIXON AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(In thousands, except share and per share data)For the Three Months EndedFor the Six Months EndedJune 30,June 30,2023202220232022(Unaudited)Revenues$2,057$2,576$5,161$5,225Cost of Revenues3908561,1801,653Gross Profit1,6671,7203,9813,572Operating ExpensesResearch and development2,0512,4824,0334,576Sales and marketing1,2417542,3571,924General and administrative4,2365,2949,85012,658Acquisition related costs523137687252Transaction costs43--1,443--Impairment of goodwill--2,030--2,030Amortization of intangibles230396450743Total Operating Expenses8,32411,09318,82022,183Loss from Operations(6,657)(9,373)(14,839)(18,611)Other (Expense) IncomeInterest (expense)/ income, net(1,756)168(3,481)169Other income/(expense), net1,183151,212(28)Unrealized gain/(loss) on equity securities(92)247(58)(1,256)Total Other Expense(665)430(2,327)(1,115)Net Loss from Continuing Operations, before tax(7,322)(8,943)(17,166)(19,726)Income tax provision(7)(22)(2,485)(22)Net Loss from Continuing Operations(7,329)(8,965)(19,651)(19,748)Loss from Discontinued Operations, Net of Tax--(11,365)(4,856)(12,139)Net Loss     (7,329)(20,330)(24,507)(31,887)Net Loss Attributable to Non-controlling Interest(363)(458)(667)(804)Net Loss Attributable to Stockholders of Inpixon$(6,966)$(19,872)$(23,840)$(31,083)Accretion of Series 7 preferred stock------(4,555)Accretion of Series 8 Preferred Stock--(6,237)--(6,785)Deemed dividend for the modification related to Series 8 Preferred Stock------(2,627)Deemed contribution for the modification related to Warrants issued in connection with Series 8 Preferred Stock------1,469Amortization premium- modification related to Series 8 Preferred Stock--1,252--1,362Net Loss Attributable to Common Stockholders$(6,966)$(24,857)$(23,840)$(42,219)Net Loss Per Share - Basic and DilutedContinuing Operations$(0.19)$(6.99)$(0.92)$(14.90)Discontinued Operations$--$(5.88)$(0.24)$(6.01)Net Loss Per Share - Basic and Diluted$(0.19)$(12.87)$(1.16)$(20.91)Weighted Average Shares OutstandingBasic and Diluted37,442,3871,931,53520,600,2082,018,295Comprehensive LossNet Loss$(7,329)$(20,330)$(24,507)$(31,887)Unrealized gain on available for sale debt securities--375--375Unrealized foreign exchange loss from cumulative translation adjustments9281(1,250)180Comprehensive Loss$(7,320)$(19,674)$(25,757)$(31,332) INPIXON AND SUBSIDIARIESCONSOLIDATED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)For the Six Months EndedJune 30,20232022(Unaudited)Cash Flows Used In Operating Activities  Net loss$(24,507)$(31,887)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization624650Amortization of intangible assets1,2553,026Amortization of right of use asset158353Stock based compensation5702,274Amortization of warrant liability to redemption value20--Earnout expense valuation benefit--(2,827)Gain on settlement with FOXO(1,142)--Amortization of debt issuance costs1,686(92)Unrealized gain on note--344Unrealized loss on foreign currency transactions(178)--Distribution of equity method investment shares to employees as compensation666--Deferred income tax2,591(1)Unrealized loss on equity securities581,256Impairment of goodwill--7,570Gain on fair value of warrant liability71--Other22181Changes in operating assets and liabilities:Accounts receivable and other receivables(1,016)361Inventory(779)285Prepaid expenses and other current assets8901,357Other assets(4)25Accounts payable(634)(1,498)Accrued liabilities3,796542Income tax liabilities(119)(40)Deferred revenue325(1,096)Operating lease obligation(158)(327)Net Cash Used in Operating Activities$(15,805)$(19,544)Cash Flows Used in Investing Activities   Purchase of property and equipment(45)(140)Investment in capitalized software(135)(306)Purchase of convertible note--(5,500)Sales of treasury bills--43,001Proceeds from repayment of note receivable150--Issuance of note receivable(450)--Net Cash (Used in) Provided By Investing Activities$(480)$37,055Cash From Financing ActivitiesNet proceeds from issuance of preferred stock and warrants$--46,906Net proceeds from promissory note125364Net proceeds from ATM20,383--Cash paid for redemption of preferred stock series 7--(49,250)Taxes paid related to net share settlement of restricted stock units--(336)Net proceeds from issuance of warrants1,409--Repayment of CXApp acquisition liability(197)(1,847)Common shares issued for net proceeds from warrants1--Distribution to shareholders related to spin-off of CXApp(10,003)--Net Cash Provided By (Used in) Financing Activities$11,718$(4,163)Effect of Foreign Exchange Rate on Changes on Cash13(73)Net (Decrease) Increase in Cash and Cash Equivalents(4,554)13,275Cash and Cash Equivalents - Beginning of year20,23552,480Cash and Cash Equivalents  - End of year$15,681$65,755 Reconciliation of Non-GAAP Financial Measures:For the 3 Months EndedFor the 6 Months Ended(In thousands)June 30,June 30,2023202220232022Net loss attributable to common stockholders$      (6,966)$              (24,857)$    (23,840)$  (42,219)Loss from discontinued operations, net of tax-11,3654,85612,139Interest expense/(income), net1,756(168)3,481(169)Income tax provision7222,48522Depreciation and amortization4257378441,418EBITDA(4,778)(12,901)(12,174)(28,809)Adjusted for:Non-recurring one-time charges:Unrealized (gain)/loss on equity securities92(247)581,256Acquisition transaction/financing costs523137687252Professional service fees---8Impairment of goodwill-2,030-2,030     Transaction costs43-1,443-Accretion of series 7 preferred stock---4,555Accretion of series 8 preferred stock-6,237-6,785Deemed dividend for the modification related to Series 8 preferred stock---2,627Deemed contribution for the modification related to warrants issued in connection with the Series 8 Preferred Stock---(1,469)Amortization premium - modification to Series 8 preferred stock-(1,252)-(1,362) Distribution of equity method investment shares to employees as compensation--666-Gain on equity securities(1,142)-(1,142)-Unrealized foreign exchange (gains)/losses2835(145)124Bad debts expense/provision24-24-Reserve for inventory obsolescence16-16-Stock-based compensation – compensation and related benefits2417415702,274Severance costs--12762Adjusted EBITDA$      (4,953)$                (5,220)$      (9,870)$  (11,667)For the 3 Months EndedFor the 6 Months Ended(In thousands, except share data)June 30,June 30,2023202220232022Net loss attributable to common stockholders$      (6,966)$              (24,857)$    (23,840)$  (42,219)Adjustments:Non-recurring one-time charges:Loss from discontinued operations, net of tax-11,3654,85612,139Unrealized (gain)/loss on equity securities92(247)581,256Acquisition transaction/financing costs523137687252      Professional service fees---8      Impairment of goodwill-2,030-2,030     Transaction costs43-1,443-     Accretion of series 7 preferred stock---4,555     Accretion of series 8 preferred stock-6,237-6,785     Deemed dividend for the modification Series 8 preferred stock---2,627     Deemed contribution for the modification related to warrants issued in connection with the Series 8 Preferred Stock---(1,469)     Amortization premium - modification to Series 8 preferred stock-(1,252)-(1,362)   Distribution of equity method investment shares to employees as compensation--666-Gain on equity securities(1,142)-(1,142)-Unrealized foreign exchange (gains)/losses2835(145)124Bad debts expense/provision24-24-Reserve for inventory obsolescence16-16-Stock-based compensation - compensation and related benefits2417415702,274Severance costs--12762Amortization of intangibles2305634491,078Proforma non-GAAP net loss$      (6,911)$                (5,248)$    (16,231)$  (11,860)Proforma non-GAAP net loss per basic and diluted common share $        (0.18)$                  (2.72)$        (0.79)$      (5.88)Weighted average basic and diluted common shares outstanding37,442,3871,931,53520,600,2082,018,295 CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/inpixon-reports-second-quarter-2023-financial-results-and-provides-business-update-301899837.htmlSOURCE Inpixon

PR Newswire

Inpixon Reports Second Quarter 2023 Financial Results and Provides Business Update

https://finance.yahoo.com/news/inpixon-reports-second-quarter-2023-200500132.html

fcaccada-1b28-3444-89dd-9c88723dfeb9

INSG

Fixed Wireless Access revenue grew more than 50% sequentiallyAchieved positive operating cash flow with adjusted EBITDA of $4.5 millionFWA and cloud solutions business comprised 65% of revenue, up 42% year-over-yearSuccessfully launched 2nd generation 5G FWA product SAN DIEGO, August 02, 2023--(BUSINESS WIRE)--Inseego Corp. (Nasdaq: INSG) (the "Company"), a leader in 5G edge cloud solutions, today reported its results for the second quarter ended June 30, 2023. The Company reported second quarter net revenue of $53.6 million, GAAP operating loss of $3.3 million, GAAP net loss of $4.9 million, GAAP net loss of $0.05 per share, adjusted EBITDA of positive $4.5 million, and non-GAAP net loss of $0.02 per share. Unrestricted cash and cash equivalents at quarter end was $15.2 million."We delivered another strong quarter as we continued our transformation into a FWA enterprise company. We delivered positive EBITDA, positive operating cash flow and solid gross margins. We are very pleased with our financial performance in the second quarter, as we continue to work toward our goal of becoming operating cash flow positive on a sustainable basis with a cost structure that will scale well with our revenue growth," said Ashish Sharma, CEO of Inseego. "In Q2, we delivered record FWA revenue with over 50% growth in FWA revenue over the last quarter. As the FWA market continues to scale, we are well positioned for the future on the strength of our market leading 5G and software portfolio."Q2 Business HighlightsFWA and Cloud software revenue comprised 65% of revenue in Q2, up 42% year-over-yearFWA revenue increased more than 50% sequentiallyLaunched the next generation 5G indoor router with US Cellular for FWA applicationsContinued expansion of 5G FWA customer pipelineGAAP Gross margin of 35.3%, up 640 basis points year-over-yearCash operating expense reduction of approximately 29% year-over-year1H Business HighlightsGAAP Gross Margin of 35.6%, up 870 basis points from 26.9% in 2022, as revenue mix continues to shift to higher margin productsAdjusted EBITDA improved by $13.0 million to $8.7 million from ($4.3) million due to improved revenue mix and continued focus on operational efficiencyStory continues"Our second quarter and first half results clearly show our commitment to achieving profitability and positive cash generation." said Bob Barbieri, CFO of Inseego. "Our operating cost structure is now better aligned with our opportunity set and focused to drive profitability as we grow our position in the 5G Enterprise markets. We will continue to maintain strong financial discipline as our core markets continue to grow and develop."Conference Call InformationInseego will host a conference call and live webcast for analysts and investors today at 5:00 p.m. ET. A Q&A session with analysts will be held live directly after the prepared remarks. To access the conference call:Online, visit https://investor.inseego.com/events-presentationsPhone-only participants can pre-register by navigating to https://dpregister.com/sreg/10178932/f9736ea4acThose without internet access or unable to pre-register may dial-in by calling:In the United States, call 1-844-282-4463International parties can access the call at 1-412-317-5613An audio replay of the conference call will be available beginning one hour after the call through August 17, 2023. To hear the replay, parties in the United States may call 1-877-344-7529 and enter access code 2862085 followed by the # key. International parties may call 1-412-317-0088. In addition, the Inseego Corp. press release will be accessible from the Company's website before the conference call begins.About Inseego Corp.Inseego Corp. (Nasdaq: INSG) is the industry leader in 5G Enterprise cloud WAN solutions with millions of end customers and thousands of enterprise and SMB customers on its 4G, 5G and cloud platforms. Inseego’s 5G Edge Cloud combines the industry’s best 5G technology, rich cloud networking features and intelligent edge applications. Inseego powers new business experiences by connecting distributed sites and workforces, securing enterprise data and improving business outcomes with intelligent operational visibility---all over a 5G network. For more information on Inseego, visit www.inseego.com #Putting5GtoWork©2023. Inseego Corp. All rights reserved. The Inseego name and logo are registered trademarks of Inseego Corp. Other company, product or service names mentioned herein are the trademarks of their respective owners.Cautionary Note Regarding Forward-Looking StatementsSome of the information presented in this news release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements often address expected future business and financial performance and often contain words such as "may," "estimate," "anticipate," "believe," "expect," "intend," "plan," "project," "will" and similar words and phrases indicating future results. The information presented in this news release related to our future business outlook, the future demand for our products, as well as other statements that are not purely statements of historical fact, are forward-looking in nature. These forward-looking statements are made on the basis of management’s current expectations, assumptions, estimates and projections and are subject to significant risks and uncertainties that could cause actual results to differ materially from those anticipated in such forward-looking statements. We therefore cannot guarantee future results, performance or achievements. Actual results could differ materially from our expectations.Factors that could cause actual results to differ materially from the Company’s expectations include: (1) the future demand for wireless broadband access to data and asset management software and services; (2) the growth of wireless wide-area networking and asset management software and services; (3) customer and end-user acceptance of the Company’s current product and service offerings and market demand for the Company’s anticipated new product and service offerings; (4) increased competition and pricing pressure from participants in the markets in which the Company is engaged; (5) dependence on third-party manufacturers and key component suppliers worldwide; (6) the impact that new or adjusted tariffs may have on the cost of components or our products, and our ability to sell products internationally; (7) the impact of fluctuations of foreign currency exchange rates; (8) the impact of geopolitical instability and supply chain challenges on our ability to source components and manufacture our products; (9) unexpected liabilities or expenses; (10) the Company’s ability to introduce new products and services in a timely manner, including the ability to develop and launch 5G products at the speed and functionality required by our customers; (11) litigation, regulatory and IP developments related to our products or components of our products; (12) dependence on a small number of customers for a significant portion of the Company’s revenues and accounts receivable; (13) the Company’s ability to raise additional financing when the Company requires capital for operations or to satisfy corporate obligations; (14) the Company’s plans and expectations relating to acquisitions, divestitures, strategic relationships, international expansion, software and hardware developments, personnel matters, and cost containment initiatives, including restructuring activities and the timing of their implementations; (15) the global semiconductor shortage and any related price increases or supply chain disruptions, (16) the potential impact of COVID-19 on the business, and (17) the impact of high rates of inflation and rising interest rates.These factors, as well as other factors set forth as risk factors or otherwise described in the reports filed by the Company with the SEC (available at www.sec.gov), could cause actual results to differ materially from those expressed in the Company’s forward-looking statements. The Company assumes no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future, except as otherwise required pursuant to applicable law and our on-going reporting obligations under the Securities Exchange Act of 1934, as amended.Non-GAAP Financial MeasuresInseego Corp. has provided financial information in this news release that has not been prepared in accordance with GAAP. Adjusted EBITDA, non-GAAP net loss, non-GAAP net loss per share and non-GAAP operating costs and expenses exclude preferred stock dividends, share-based compensation expense, amortization of intangible assets purchased through acquisitions, amortization of discount and issuance costs related to our 2025 Notes and revolving credit facility, fair value adjustments on derivative instruments, a one-time prior period adjustment related to unamortized debt discount and loss on debt extinguishment relating to our 2025 Notes, and other non-recurring legal expenses. Adjusted EBITDA also excludes interest, taxes, depreciation and amortization (unrelated to acquisitions and the 2025 Notes), impairment of capitalized software, impairment of long-lived assets, and foreign exchange gains and losses.Adjusted EBITDA, non-GAAP net loss, non-GAAP net loss per share and non-GAAP operating costs and expenses are supplemental measures of our performance that are not required by, or presented in accordance with, GAAP. These non-GAAP financial measures have limitations as an analytical tool and are not intended to be used in isolation or as a substitute for operating expenses, net loss, net loss per share or any other performance measure determined in accordance with GAAP. We present these non-GAAP financial measures because we consider each to be an important supplemental measure of our performance.We use these non-GAAP financial measures to make operational decisions, evaluate our performance, prepare forecasts and determine compensation. Further, we believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance when planning, forecasting and analyzing future periods. Share-based compensation expenses are expected to vary depending on the number of new incentive award grants issued to both current and new employees, the number of such grants forfeited by former employees, and changes in our stock price, stock market volatility, expected option term and risk-free interest rates, all of which are difficult to estimate. In calculating non-GAAP financial measures, we exclude certain non-cash and one-time items in order to facilitate comparability of our operating performance on a period-to-period basis because such expenses are not, in our view, related to our ongoing operating performance. We use this view of our operating performance for purposes of comparison with its business plan and individual operating budgets and in the allocation of resources.We further believe that these non-GAAP financial measures are useful to investors in providing greater transparency to the information used by management in its operational decision-making. The Company believes that the use of these non-GAAP financial measures also facilitates a comparison of our underlying operating performance with that of other companies in our industry, which use similar non-GAAP financial measures to supplement their GAAP results.In the future, we expect to continue to incur expenses similar to the non-GAAP adjustments described above, and exclusion of these items in the presentation of our non-GAAP financial measures should not be construed as an inference that these costs are unusual, infrequent or non-recurring. Investors and potential investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. The limitations of relying on non-GAAP financial measures include, but are not limited to, the fact that other companies, including other companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting their usefulness as a comparative tool.Investors and potential investors are encouraged to review the reconciliation of our non-GAAP financial measures contained within this news release with our GAAP financial results.INSEEGO CORP.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except share and per share data)(Unaudited)Three Months EndedJune 30,Six Months EndedJune 30,2023202220232022Net revenues:IoT & Mobile Solutions$46,383$54,990$90,010$109,495Enterprise SaaS Solutions7,1746,86614,34113,745Total net revenues53,55761,856104,351123,240Cost of net revenues:IoT & Mobile Solutions31,78940,69461,45183,597Enterprise SaaS Solutions2,8723,2705,8176,503Total cost of net revenues34,66143,96467,26890,100Gross profit18,89617,89237,08333,140Operating costs and expenses:Research and development10,02213,61918,17632,179Sales and marketing5,9747,72112,62017,494General and administrative5,7526,14211,79714,380Amortization of purchased intangible assets424443853887Impairment of capitalized software——504—Total operating costs and expenses22,17227,92543,95064,940Operating loss(3,276)(10,033)(6,867)(31,800)Other (expense) income:Loss on debt conversion and extinguishment, net———(450)Interest expense, net(2,014)(1,664)(4,011)(4,587)Other income (expense), net658(982)1,453(1,387)Total other expense(1,356)(2,646)(2,558)(6,424)Loss before income taxes(4,632)(12,679)(9,425)(38,224)Income tax provision (benefit)304(303)616(625)Net loss(4,936)(12,376)(10,041)(37,599)Series E preferred stock dividends(739)(677)(1,462)(1,338)Net loss attributable to common stockholders$(5,675)$(13,053)$(11,503)$(38,937)Per share data:Net loss per common share:Basic and diluted$(0.05)$(0.12)$(0.10)$(0.37)Weighted-average shares used in computation of net loss per common share:Basic and diluted111,080,287107,511,660109,847,937106,585,684INSEEGO CORP.CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands, except par value and share data)(Unaudited)June 30, 2023December 31, 2022(Unaudited)ASSETSCurrent assets:Cash and cash equivalents$15,165$7,143Accounts receivable, net of provision for credit losses of $761 and $541, respectively25,20325,259Inventories30,52237,976Prepaid expenses and other7,5817,978Total current assets78,47178,356Property, plant and equipment, net of accumulated depreciation of $27,555 and $26,049, respectively4,0915,390Rental assets, net of accumulated depreciation of $7,047 and $5,484, respectively5,2224,816Intangible assets, net of accumulated amortization of $40,736 and $31,629, respectively37,30241,383Goodwill21,92221,922Right-of-use assets6,2296,662Other assets451488Total assets$153,688$159,017LIABILITIES AND STOCKHOLDERS’ DEFICITCurrent liabilities:Accounts payable$34,212$29,018Accrued expenses and other current liabilities21,34327,945Total current liabilities55,55556,963Long-term liabilities:2025 Notes, net159,169158,427Revolving credit facility, net2,5546,919Deferred tax liabilities, net279323Other long-term liabilities6,9466,503Total liabilities224,503229,135Commitments and contingenciesStockholders’ deficit:Preferred stock, par value $0.001; 2,000,000 shares authorized:Series E Preferred stock, par value $0.001; 39,500 shares designated, 25,000 shares issued and outstanding, liquidation preference of $1,000 per share (plus any accrued but unpaid dividends)——Common stock, par value $0.001; 150,000,000 shares authorized, 116,870,194 and 108,468,150 shares issued and outstanding, respectively117108Additional paid-in capital805,177793,855Accumulated other comprehensive loss(6,855)(6,329)Accumulated deficit(869,254)(857,752)Total stockholders’ deficit(70,815)(70,118)Total liabilities and stockholders’ deficit$153,688$159,017INSEEGO CORP.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(Unaudited)Three Months EndedJune 30,Six Months EndedJune 30,2023202220232022Cash flows from operating activities:Net loss$(4,936)$(12,376)$(10,041)$(37,599)Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Depreciation and amortization5,3896,71210,81913,955Provision for (recoveries of) credit losses203(1)244(15)Impairment of capitalized software——504—Provision for excess and obsolete inventory93649310896Share-based compensation expense1,9642,2873,76213,486Amortization of debt discount and debt issuance costs4893729772,022Fair value adjustment on derivative instrument—(293)—(902)Loss on debt conversion and extinguishment, net———450Deferred income taxes(6)(285)95(96)Right-of-use assets(848)728(255)1,070Right-of-use asset impairment469469Changes in assets and liabilities:Accounts receivable2,229(238)2335,239Inventories3,075(9,793)6,172(10,148)Prepaid expenses and other assets2,4103994703,100Accounts payable(439)4,1935,106(6,207)Accrued expenses, income taxes, and other(5,894)(8,559)(6,384)(1,740)Operating lease liabilities823(755)198(1,109)Net cash provided by (used in) operating activities5,021(16,960)-1696000012,679(17,598)Cash flows from investing activities:Purchases of property, plant and equipment(100)(296)(161)(1,059)Additions to capitalized software development costs(1,998)(3,095)(4,441)(6,222)Net cash used in investing activities(2,098)(3,391)(4,602)(7,281)Cash flows from financing activities:Net borrowing (repayment) of bank and overdraft facilities278(85)79(139)Principal payments under finance lease obligations———(62)Proceeds from a public offering5,530—6,059—Principal payments on financed assets—(224)(360)(1,231)Repayments on revolving credit facility(1,214)—(4,598)—Proceeds from stock option exercises and employee stock purchase plan, net of taxes paid on vested restricted stock units(28)5247115Net cash provided by (used in) financing activities4,566(257)1,227(1,317)Effect of exchange rates on cash(1,010)(213)(1,282)744Net increase (decrease) in cash, cash equivalents and restricted cash6,479(20,821)8,022(25,452)Cash, cash equivalents and restricted cash, beginning of period8,68645,1817,14349,812Cash, cash equivalents and restricted cash, end of period$15,165$24,360$15,165$24,360INSEEGO CORP.Reconciliation of GAAP Net Loss Attributable to Common Shareholders to Non-GAAP Net Loss(In thousands, except per share data)(Unaudited)Three Months EndedJune 30, 2023Six Months EndedJune 30, 2023Net LossNet Loss Per ShareNet LossNet Loss Per ShareGAAP net loss attributable to common shareholders$(5,675)$(0.05)$(11,503)$(0.10)Adjustments:Preferred stock dividends(a)7390.011,4620.01Share-based compensation expense1,9640.023,7620.03Purchased intangibles amortization424—8530.01Debt discount and issuance costs amortization(b)489—9390.01Non-GAAP net loss$(2,059)$(0.02)$(4,487)$(0.04)Note: Amounts may not foot due to rounding.(a)Includes accrued dividends on Series E Preferred Stock.(b)Includes the debt discount and issuance costs amortization related to the 2025 Notes, and the issuance costs related to the revolving credit facility.See "Non-GAAP Financial Measures" for information regarding our use of Non-GAAP financial measures.INSEEGO CORP.Reconciliation of GAAP Operating Costs and Expenses to Non-GAAP Operating Costs and ExpensesThree Months Ended June 30, 2023(In thousands)(Unaudited)GAAPShare-basedcompensationexpensePurchasedintangiblesamortizationNon-GAAPCost of net revenues$34,661$223$—$34,438Operating costs and expenses:Research and development10,022445—9,577Sales and marketing5,974390—5,584General and administrative5,752907—4,845Amortization of purchased intangible assets424—424—Total operating costs and expenses$22,172$1,742$424$20,006Total$1,964$424Note:Impairment of right-of-use asset totaled $469 for the three months ended June 30, 2023 as allocated to the above costs and operating expenses.See "Non-GAAP Financial Measures" for information regarding our use of Non-GAAP financial measures.INSEEGO CORP.Reconciliation of GAAP Operating Costs and Expenses to Non-GAAP Operating Costs and ExpensesSix Months Ended June 30, 2023(In thousands)(Unaudited)GAAPShare-basedcompensationexpensePurchasedintangiblesamortizationNon-GAAPCost of net revenues$67,268$406$—$66,862Operating costs and expenses:Research and development18,176693—17,483Sales and marketing12,620719—11,901General and administrative11,7971,945—9,852Amortization of purchased intangible assets853—853—Impairment of purchased intangible assets504——504Total operating costs and expenses$43,950$3,357$853$39,740Total$3,763$853Note:Impairment of right-of-use asset totaled $469 for the six months ended June 30, 2023 as allocated to the above costs and operating expenses.See "Non-GAAP Financial Measures" for information regarding our use of Non-GAAP financial measures.INSEEGO CORP.Reconciliation of GAAP Net Loss Attributable to Common Shareholders to Adjusted EBITDA(In thousands)(Unaudited)Three Months EndedJune 30, 2023Six Months Ended June 30, 2023GAAP net loss attributable to common shareholders(5,675)$(11,503)Preferred stock dividends(a)7391,462Income tax provision (benefit)304616Depreciation and amortization5,38910,819Share-based compensation expense1,9643,762Impairment of capitalized software—504Right-of-use asset impairment469469Interest expense, net(b)2,0144,011Other(c)(658)(1,453)Adjusted EBITDA$4,546$8,687(a)Includes accrued dividends on Series E Preferred Stock.(b)Includes the debt discount and issuance costs amortization related to the 2025 Notes, and the issuance costs related to the revolving credit facility.(c)Primarily includes a benefit recorded related to non-recurring legal settlements and foreign exchange gains and losses.See "Non-GAAP Financial Measures" for information regarding our use of Non-GAAP financial measures.INSEEGO CORP.Quarterly Net Revenues by Product Grouping(In thousands)(Unaudited)Three Months EndedJune 30, 2023March 31,2023December 31,2022September 30,2022June 30, 2022IoT & Mobile Solutions$46,383$43,627$46,272$62,633$54,990Enterprise SaaS Solutions7,1747,1676,6436,5346,866Total net revenues$53,557$50,794$52,915$69,167$61,856View source version on businesswire.com: https://www.businesswire.com/news/home/20230802630753/en/ContactsInvestor Relations Contact:Kurt Scheuerman+1 (858)[email protected]

Business Wire

Inseego Reports Second Quarter 2023 Financial Results

https://finance.yahoo.com/news/inseego-reports-second-quarter-2023-200100353.html

de964f7c-f509-34b0-8f3b-56637d503640

INSG

Inseego (INSG) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this holding company would post a loss of $0.08 per share when it actually produced a loss of $0.02, delivering a surprise of 75%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Inseego , which belongs to the Zacks Internet - Software industry, posted revenues of $53.56 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 3.49%. This compares to year-ago revenues of $61.86 million. The company has topped consensus revenue estimates three times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Inseego shares have lost about 11.5% since the beginning of the year versus the S&P 500's gain of 19.2%.What's Next for Inseego?While Inseego has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Story continuesAhead of this earnings release, the estimate revisions trend for Inseego: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.03 on $54.85 million in revenues for the coming quarter and -$0.09 on $215.46 million in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Software is currently in the top 26% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.Another stock from the same industry, Datadog (DDOG), has yet to report results for the quarter ended June 2023. The results are expected to be released on August 8.This data analytics and cloud monitoring company is expected to post quarterly earnings of $0.28 per share in its upcoming report, which represents a year-over-year change of +16.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.Datadog's revenues are expected to be $500.37 million, up 23.2% from the year-ago quarter.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportInseego (INSG) : Free Stock Analysis ReportDatadog, Inc. (DDOG) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Inseego (INSG) Reports Q2 Loss, Tops Revenue Estimates

https://finance.yahoo.com/news/inseego-insg-reports-q2-loss-212517974.html

17dce497-70b9-3a42-92a1-fcac96f47ba0

INSP

Inspire Medical Systems, Inc. (NYSE:INSP) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The US$6.7b market-cap company posted a loss in its most recent financial year of US$45m and a latest trailing-twelve-month loss of US$41m shrinking the gap between loss and breakeven. As path to profitability is the topic on Inspire Medical Systems' investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate. View our latest analysis for Inspire Medical Systems According to the 13 industry analysts covering Inspire Medical Systems, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$20m in 2025. So, the company is predicted to breakeven approximately 2 years from today. How fast will the company have to grow each year in order to reach the breakeven point by 2025? Working backwards from analyst estimates, it turns out that they expect the company to grow 59% year-on-year, on average, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.earnings-per-share-growthWe're not going to go through company-specific developments for Inspire Medical Systems given that this is a high-level summary, however, bear in mind that generally a high forecast growth rate is not unusual for a company that is currently undergoing an investment period.One thing we’d like to point out is that Inspire Medical Systems has no debt on its balance sheet, which is rare for a loss-making growth company, which usually has a high level of debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.Story continuesNext Steps:This article is not intended to be a comprehensive analysis on Inspire Medical Systems, so if you are interested in understanding the company at a deeper level, take a look at Inspire Medical Systems' company page on Simply Wall St. We've also put together a list of relevant aspects you should further research:Valuation: What is Inspire Medical Systems worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Inspire Medical Systems is currently mispriced by the market.Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Inspire Medical Systems’s board and the CEO’s background.Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

When Can We Expect A Profit From Inspire Medical Systems, Inc. (NYSE:INSP)?

https://finance.yahoo.com/news/expect-profit-inspire-medical-systems-194526358.html

1ba63cd5-6e97-3b4d-aaed-5af2a7143945

INSP

Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” second quarter 2023 investor letter. A copy of the same can be downloaded here. In the second quarter, the fund underperformed the Russell 2000 Growth Index. The Consumer Discretionary and Energy sectors contributed to the fund’s relative performance in the quarter, while Information Technology and Industrials detracted from performance. In addition, you can check the top 5 holdings of the fund to know its best picks in 2023.Alger Small Cap Focus Fund highlighted stocks like Inspire Medical Systems, Inc. (NYSE:INSP) in the second quarter 2023 investor letter. Headquartered in Golden Valley, Minnesota, Inspire Medical Systems, Inc. (NYSE:INSP) is a medical technology company. On September 5, 2023, Inspire Medical Systems, Inc. (NYSE:INSP) stock closed at $234.30 per share. One-month return of Inspire Medical Systems, Inc. (NYSE:INSP) was -11.75%, and its shares gained 26.46% of their value over the last 52 weeks. Inspire Medical Systems, Inc. (NYSE:INSP) has a market capitalization of $6.873 billion.Alger Small Cap Focus Fund made the following comment about Inspire Medical Systems, Inc. (NYSE:INSP) in its Q2 2023 investor letter:"Inspire Medical Systems, Inc. (NYSE:INSP) markets the only FDA-approved implantable neuromodulation device used to treat obstructive sleep apnea (OSA). The device monitors a patient's breathing and delivers electrical stimulation to the hypoglossal nerve in order to maintain an open airway. During the period, the company reported strong fiscal first quarter results, where revenues and earnings beat analyst estimates. Given the positive results and strengthening demand, management raised their fiscal 2023 revenue guidance. We continue to believe the company offers a compelling opportunity within the medical devices industry. given the large and underpenetrated market."health, care, oncologyRomaset/Shutterstock.comStory continuesInspire Medical Systems, Inc. (NYSE:INSP) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 47 hedge fund portfolios held Inspire Medical Systems, Inc. (NYSE:INSP) at the end of second quarter which was 40 in the previous quarter.We discussed Inspire Medical Systems, Inc. (NYSE:INSP) in another article and shared Baron Health Care Fund's views on the company. In addition, please check out our hedge fund investor letters Q2 2023 page for more investor letters from hedge funds and other leading investors. Suggested Articles:11 Best Zinc Stocks to Buy in 202320 Most Addictive Foods According to Science15 Best Countries to Retire in AsiaDisclosure: None. This article is originally published at Insider Monkey.

Insider Monkey

Do You Think Inspire Medical Systems (INSP) Offers Compelling Opportunity in the Industry?

https://finance.yahoo.com/news/think-inspire-medical-systems-insp-065204861.html

3dda24f8-ddd9-3a0c-99d8-4053314c0afd

INTC

Chip giant Intel (NASDAQ: INTC) has been facing a series of problems that have heavily weighed on the stock over the past few years. First and foremost, the company lost its manufacturing advantage to TSMC. Chronic delays and missteps coupled with steady progress from the Taiwan-based foundry have put Intel in a position that would have been unthinkable 10 years ago.Continue reading

Motley Fool

Intel Stock Has Soared 44% in 2023. Is It Still a Buy?

https://finance.yahoo.com/m/df5cd3c2-9aff-39b0-8bd0-0668d5518bf5/intel-stock-has-soared-44-in.html

df5cd3c2-9aff-39b0-8bd0-0668d5518bf5

INTC

Looking for the next big thing in AI stocks? These three top-quality stocks should be at the top of your list.Continue reading

Motley Fool

3 Artificial Intelligence (AI) Winners to Buy Before the Next Bull Run Starts

https://finance.yahoo.com/m/c8433474-3d88-3d33-8040-c64dd84fea50/3-artificial-intelligence.html

c8433474-3d88-3d33-8040-c64dd84fea50

INTG

InterGroup (NASDAQ:INTG) Third Quarter 2023 ResultsKey Financial ResultsRevenue: US$14.4m (up 37% from 3Q 2022).Net loss: US$356.0k (loss narrowed by 24% from 3Q 2022).US$0.16 loss per share (improved from US$0.21 loss in 3Q 2022).earnings-and-revenue-historyAll figures shown in the chart above are for the trailing 12 month (TTM) periodInterGroup shares are up 3.6% from a week ago.Risk AnalysisYou should learn about the 4 warning signs we've spotted with InterGroup (including 3 which make us uncomfortable).Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.Join A Paid User Research SessionYou’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

Simply Wall St.

InterGroup Third Quarter 2023 Earnings: US$0.16 loss per share (vs US$0.21 loss in 3Q 2022)

https://finance.yahoo.com/news/intergroup-third-quarter-2023-earnings-100225425.html

f8100d0f-4d54-3875-8ab0-7968d2ed7738

INTG

The InterGroup Corporation (NASDAQ:INTG) shareholders might be concerned after seeing the share price drop 22% in the last quarter. But at least the stock is up over the last three years. However, it's unlikely many shareholders are elated with the share price gain of 34% over that time, given the rising market.Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business. Check out our latest analysis for InterGroup Given that InterGroup didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.In the last 3 years InterGroup saw its revenue grow at 1.6% per year. That's not a very high growth rate considering it doesn't make profits. It's probably fair to say that the modest growth is reflected in the modest share price gain of 10% per year. A closer look at the revenue and profit trends could uncover help us understand if the company will be profitable in the future.You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).earnings-and-revenue-growthBalance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.A Different PerspectiveInvestors in InterGroup had a tough year, with a total loss of 19%, against a market gain of about 11%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. On the bright side, long term shareholders have made money, with a gain of 5% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. It's always interesting to track share price performance over the longer term. But to understand InterGroup better, we need to consider many other factors. To that end, you should learn about the 4 warning signs we've spotted with InterGroup (including 3 which make us uncomfortable) .Story continuesOf course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.Join A Paid User Research SessionYou’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

Simply Wall St.

InterGroup (NASDAQ:INTG) shareholders have earned a 10% CAGR over the last three years

https://finance.yahoo.com/news/intergroup-nasdaq-intg-shareholders-earned-105129383.html

4f0c42fc-2782-34de-8506-48b6c473bfc5

INTU

Intuit INTU recently introduced a new Generative AI-based feature — Intuit Assist — to all its major solutions, including Intuit TurboTax, Credit Karma, QuickBooks and Mailchimp. This feature consists of both digital and human assistance aspects with a standard user interface.Intuit Assist is powered by GenOS, which is built on OpenAI’s large language model. It leverages Intuit's ecosystem and database to offer personalized recommendations to both B2C and B2B customers.TurboTax utilizes Intuit Assist to customize tax checklists and provide answers, insights and suggestions tailored to customers' needs. It draws upon Intuit's tax expertise, AI-driven Tax Knowledge Engine and proprietary data to provide this facility.The users of Credit Karma can seek personalized financial recommendations, develop strategies and optimize their monthly spending.Intuit Inc. Price and ConsensusIntuit Inc. Price and ConsensusIntuit Inc. price-consensus-chart | Intuit Inc. QuoteLikewise, Intuit Assist will help small businesses using QuickBooks see cash flow hot spots, identify top-selling products and detect spending anomalies.For marketers, Intuit Assist comes with capabilities that can streamline marketing efforts by managing end-to-end campaigns aligned with brand identity and intent. It will also assist in creating customizable emails in Mailchimp, help incorporate QuickBooks data and offer scheduling flexibility for marketing content.Intuit Benefits From a Strong PortfolioIntuit shares have rallied 41.6% year to date, outperforming the Zacks Computer and Technology sector’s return of 41.3%.Intuit is benefiting from strong momentum in online ecosystem revenues and solid professional tax revenues. The TurboTax Live offering is also driving growth in the Consumer tax business. Solid momentum in the company’s lending product, QuickBooks Capital, is an upside.Moreover, the company’s strategy of shifting its business to a cloud-based subscription model will help generate stable revenues. Intuit expects double-digit revenue growth and margin expansion in fiscal 2024.For the fiscal first quarter of 2024, INTU expects revenues to grow between 10% and 11% on a year-over-year basis in the band of $2.86-$2.895 billion. Non-GAAP earnings for the quarter are estimated in the range of $1.94-$2 per share.The Zacks Consensus Estimate for fiscal first-quarter 2024 revenues is pegged at $2.87 billion, indicating 10.6% year over year. The consensus estimate for earnings is pegged at $1.95 per share, unchanged over the past 30 days.Story continuesZacks Rank & Stocks to ConsiderCurrently, Intuit carries a Zacks Rank #3 (Hold).NVIDIA NVDA, Palo Alto Networks PANW and Splunk SPLK are some better-ranked stocks investors can consider from the broader sector.NVIDIA and Splunk each sport a Zacks Rank #1 (Strong Buy), while Palo Alto has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.The long-term earnings growth rate for NVIDIA, Palo Alto and Splunk is pegged at 13.5%, 27.8% and 24.7%, respectively.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportNVIDIA Corporation (NVDA) : Free Stock Analysis ReportIntuit Inc. (INTU) : Free Stock Analysis ReportSplunk Inc. (SPLK) : Free Stock Analysis ReportPalo Alto Networks, Inc. (PANW) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Intuit (INTU) Launches New Generative AI-Powered Assistant

https://finance.yahoo.com/news/intuit-intu-launches-generative-ai-154100414.html

6a9b8ceb-d352-35f7-88c1-ba2cac357a37

INTU

Those TurboTax commercials touting “free free free” tax filing were false false false for most taxpayers, a judge ruled this week.Continue reading

Investopedia

Those TurboTax 'Free Free Free' Tax Filing Ads Were Misleading, Judge Rules

https://finance.yahoo.com/m/d00f6fd6-6e46-3384-ad58-87d588ab8e6e/those-turbotax-free-free.html

d00f6fd6-6e46-3384-ad58-87d588ab8e6e

INVA

Received GSK royalties of $65.7 million, net product revenues of $15.7 million and license revenue of $3.0 million in the second quarter of 2023Received FDA approval for XACDURO® for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of AcinetobacterRepurchased $9.2 million of common stockBURLINGAME, Calif., August 02, 2023--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the second quarter ended June 30, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives.Gross royalty revenue from Glaxo Group Limited ("GSK") for the second quarter 2023 was $65.7 million, which included royalties of $54.4 million from global net sales of RELVAR®/BREO® ELLIPTA® and royalties of $11.3 million from global net sales of ANORO® ELLIPTA® compared to $111.7 million for the second quarter of 2022, which included royalties of $59.3 million from global net sales of RELVAR®/BREO® ELLIPTA® and $9.6 million from global net sales of ANORO® ELLIPTA®, respectively. The decrease was primarily due to the sale of our subsidiary, Theravance Respiratory Company, and its TRELEGY® ELLIPTA® royalty stream in July 2022.Net product sales and license revenue for the second quarter of 2023 was $18.7 million, which included $11.2 million from GIAPREZA® net sales, $4.5 million from XERAVA® net sales and an $3.0 million milestone payment from our partner for FDA approval of XACDURO®.Net income was $1.3 million, or $0.02 basic per share, for the second quarter of 2023, compared to net income of $0.9 million, or $0.01 basic per share, for the second quarter of 2022.Cash and cash equivalents totaled $173.0 million. Royalty, product sales and milestone receivables totaled $81.0 million as of June 30, 2023.Story continues"The second quarter of 2023 was marked by strong revenues stemming from our robust royalty portfolio and historically highest sales from our internal product portfolio," said Pavel Raifeld, Chief Executive Officer of Innoviva. "We ended the quarter on a strong note with the approval of XACDURO® (sulbactam for injection; durlobactam for injection) for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. This is the first pathogen-targeted therapy to be approved for these life-threatening infections caused by Acinetobacter Baumannii-calcoaceticus complex, and we plan to bring this product to patients later this year. We remained disciplined on costs and saw meaningful operational progress among our investees, market volatility notwithstanding. We are excited about the prospects of our business and continue to pursue shareholder value accretive activities, such as share repurchases."Second Quarter 2023 and Recent HighlightsGSK Net SalesSecond quarter 2023 net sales of RELVAR®/BREO® ELLIPTA® by GSK were $363.0 million with $149.8 million in net sales from the U.S. market and $213.2 million from non-U.S. markets.Second quarter 2023 net sales of ANORO® ELLIPTA® by GSK were $173.3 million with $85.5 million net sales from the U.S. market and $87.8 million from non-U.S. markets.Corporate UpdatesDuring the second quarter of 2023, Innoviva repurchased 775,504 shares of its outstanding common stock for $9.2 million.On July 11, 2023, Innoviva’s wholly owned subsidiary, Innoviva Strategic Opportunities, entered into a credit and security agreement with Armata Pharmaceuticals, Inc. (NYSE: ARMP) ("Armata") and invested $25.0 million to advance Armata’s pipeline of therapeutic phage candidates and support the build-out of its state-of-the art cGMP manufacturing facility.On July 11, 2023, Innoviva director, Deborah Birx, resigned from Innoviva Board and joined Armata as Chief Executive Officer.Clinical UpdatesOn May 23, 2023, Innoviva’s wholly owned subsidiary, Innoviva Specialty Therapeutics, received FDA’s approval of XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter). The company is preparing to launch XACDURO® later this year.Recruitment is now complete in the registrational Phase 3 Zoliflodacin study. Oral Zoliflodacin is a novel oral antibiotic in development for the treatment of uncomplicated gonorrhea infection. Top-line results for this ongoing Phase 3 trial are expected in late 2023.About InnovivaInnoviva is a diversified holding company with a portfolio of royalties and other healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ("GSK"), including RELVAR®/BREO® ELLIPTA® (fluticasone furoate/ vilanterol, "FF/VI") and ANORO® ELLIPTA® (umeclidinium bromide/ vilanterol, "UMEC/VI"). Under the Long-Acting Beta2 Agonist ("LABA") Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and hospital assets stemming from acquisitions of Entasis Therapeutics, including XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter) and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults.ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies.Forward Looking StatementsThis press release contains certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. The words "anticipate", "expect", "goal", "intend", "objective", "opportunity", "plan", "potential", "target" and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties, and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®, GIAPREZA®, XERAVA® and XACDURO® in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva’s growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to shareholders; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the impact of the novel coronavirus ("COVID-19"); the timing, manner and amount of capital deployment, including potential capital returns to stockholders; and risks related to the Company’s growth strategy. Other risks affecting Innoviva are described under the headings "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" contained in Innoviva’s Annual Report on Form 10-K for the year ended December 31, 2022 and Quarterly Reports on Form 10-Q, which are on file with the Securities and Exchange Commission ("SEC") and available on the SEC’s website at www.sec.gov. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.INNOVIVA, INC.Condensed Consolidated Statements of Income(in thousands, except per share data)(Unaudited)Three Months EndedSix Months EndedJune 30,June 30,2023202220232022Revenue:Royalty revenue, net (1)$62,265$108,220$119,123$198,279Net product sales15,727-27,241-License revenue3,000-11,000-Total revenue80,992108,220157,364198,279Expenses:Cost of products sold (inclusive of amortization of inventory fair valueadjustments, excluding depreciation and amortization of intangible assets)8,979-17,728-Cost of license revenue--1,600-Selling, general and administrative23,54211,78243,27718,274Research and development14,98913,88427,57719,722Amortization of acquired intangible assets4,958-8,763-Loss on debt extinguishment---20,662Changes in fair values of equity method investments, net19,91142,8234,09454,773Changes in fair values of equity and long-term investments, net8315,7772,24713,238Interest and dividend income(3,553)(724)(6,918)(1,046)Interest expense4,3823,6558,8096,665Other expense, net1,8965283,242778Total expenses75,18787,725110,419133,066Income before income taxes5,80520,49546,94565,213Income tax expense4,525(876)10,8005,984Net income1,28021,37136,14559,229Net income attributable to noncontrolling interest-20,432-42,517Net income attributable to Innoviva stockholders$1,280$939$36,145$16,712Basic net income per share attributable to Innoviva stockholders$0.02$0.01$0.54$0.24Diluted net income per share attributable to Innoviva stockholders$0.02$0.05$0.46$0.24Shares used to compute basic net income per share65,34169,64366,55769,594Shares used to compute diluted net income per share65,48995,65388,17594,692(1) Total net revenue is comprised of the following (in thousands):Three Months EndedSix Months EndedJune 30,June 30,2023202220232022(unaudited)(unaudited)Royalties$65,721$111,676$126,035$205,191Amortization of capitalized fees(3,456)(3,456)(6,912)(6,912)Royalty revenue, net$62,265$108,220$119,123$198,279INNOVIVA, INC.Condensed Consolidated Balance Sheets(in thousands)(unaudited)June 30,December 31,20232022AssetsCash and cash equivalents$173,025$291,049Royalty and product sale receivables80,99664,073Inventory, net46,84655,897Prepaid expense and other current assets22,67132,492Property and equipment, net161170Equity and long-term investments433,001403,013Capitalized fees90,69597,607Right-of-use assets2,7193,265Goodwill14,88226,713Intangible assets243,356252,919Deferred tax assets6,327-Other assets3,5624,299Total assets$1,118,241$1,231,497Liabilities and stockholders’ equityOther current liabilities$32,722$32,322Accrued interest payable3,4224,359Deferred revenue3,2542,094Convertible subordinated notes, due 2023, net-96,193Convertible senior notes, due 2025, net190,937190,583Convertible senior notes, due 2028, net254,264253,597Other long term liabilities68,58470,918Deferred tax liabilities-5,771Income tax payable - long term9,9719,872Innoviva stockholders’ equity555,087565,788Total liabilities and stockholders’ equity$1,118,241$1,231,497INNOVIVA, INC.Cash Flows Summary(in thousands)(unaudited)Six Months Ended June 30,20232022Net cash provided by operating activities$63,866$177,137Net cash used in investing activities(35,722)(145,678)Net cash (used in) provided by financing activities(146,168)50,596Net change$(118,024)$82,055Cash and cash equivalents at beginning of period291,049201,525Cash, cash equivalents and restricted cash at end of period$173,025$283,580View source version on businesswire.com: https://www.businesswire.com/news/home/20230802433840/en/ContactsInvestors and Media Contact: Argot Partners(212) [email protected]

Business Wire

Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

https://finance.yahoo.com/news/innoviva-reports-second-quarter-2023-200500023.html

56629ea3-e0ba-3e26-9743-2baa5360f688

INVA

BURLINGAME, Calif., August 25, 2023--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" and "the Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced the appointment of Stephen Basso as its Chief Financial Officer, effective August 21, 2023."We are excited to welcome Stephen to our executive leadership team and believe the Company will benefit greatly from his background and experience," said Pavel Raifeld, Chief Executive Officer of Innoviva. "I look forward to working with Stephen to advance our strategy and create shareholder value."Mr. Basso brings more than 30 years of experience in the financial services industry and financial leadership in the pharmaceutical industry. Prior to joining Innoviva, Mr. Basso served as Chief Financial Officer and Chief Operating Officer at Cybrexa Therapeutics. Before Cybrexa, Mr. Basso held a variety of finance leadership positions in the industry, including as Senior Vice President of Finance at Inozyme Pharma, Inc., Vice President of North American commercial operations and global finance at Alexion Pharmaceuticals, Inc., and various finance roles at Pfizer, Inc. and Fidelity Investments. Mr. Basso received a Bachelor of Science in business from Providence College and a Master of Business Administration in finance from Boston College.Mr. Basso added, "I am thrilled to join Innoviva at a critical time in its development. Working alongside such a dedicated team, I am confident we will capitalize on many opportunities for value creation and growth."About InnovivaInnoviva is a diversified holding company with a portfolio of royalties and other healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ("GSK"), including RELVAR®/BREO® ELLIPTA® (fluticasone furoate/ vilanterol, "FF/VI") and ANORO® ELLIPTA® (umeclidinium bromide/ vilanterol, "UMEC/VI"). Under the Long-Acting Beta2 Agonist ("LABA") Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other healthcare assets include infectious disease and hospital assets stemming from acquisitions of Entasis Therapeutics, including its lead asset XACDURO® (sulbactam-durlobactam) for the treatment of hospital-acqauire bacterial pneumonia and ventilator-assoicated bacterial pneumonia, and La Jolla Pharmaceutical, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults.ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies.Story continuesForward Looking StatementsThis press release contains certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. The words "anticipate", "expect", "goal", "intend", "objective", "opportunity", "plan", "potential", "target" and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties, and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®, GIAPREZA®, XERAVA® and XACDURO® in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva’s growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to shareholders; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the impact of the novel coronavirus ("COVID-19"); the timing, manner and amount of capital deployment, including potential capital returns to stockholders; and risks related to the Company’s growth strategy. Other risks affecting Innoviva are described under the headings "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" contained in Innoviva’s Annual Report on Form 10-K for the year ended December 31, 2022 and Quarterly Reports on Form 10-Q, which are on file with the Securities and Exchange Commission ("SEC") and available on the SEC’s website at www.sec.gov. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.View source version on businesswire.com: https://www.businesswire.com/news/home/20230825912603/en/ContactsInvestors & Media: Argot Partners(212) [email protected]

Business Wire

Innoviva Appoints Stephen Basso as Chief Financial Officer

https://finance.yahoo.com/news/innoviva-appoints-stephen-basso-chief-205200024.html

80178a91-0ef8-3a56-a670-f2eaefcb83c3

INVH

UDR, Inc. UDR is well-poised to benefit from a diversified portfolio, with a superior product mix of A/B quality properties in urban and suburban communities in both coastal and Sunbelt locations.The company’s efforts to diversify its portfolio with respect to geographies and price points limit its exposure to volatility and concentration risks while assuring stable cash flows. Moreover, in recent quarters, UDR has been experiencing strong pricing power, as evidenced by blended lease rate growth. For 2023, management expects year-over-year same-store revenue growth (on a cash basis) of 6-7%. Our estimate indicates a year over-year increase of 6.7% in same-store revenues in 2023.UDR is also leveraging technological investments and process enhancements to drive innovation and margin expansion. Its Next Generation Operating Platform allows the company to electronically interact with and provide service to residents and prospects throughout its diversified portfolio. These efforts are likely to give UDR a competitive edge over its peers. For 2023, management expects year-over-year same-store net operating income (NOI) growth (on a cash basis) of 6.5-8%. We estimate year-over-year growth of 7.4% in the company’s same-store NOI in the current year.The company maintains a healthy balance sheet position with ample liquidity. It exited the second quarter of 2023 with $1.1 billion liquidity. The company’s debt maturity schedule is well-laddered, with weighted average years to maturity of 6.3 and a weighted average interest rate of 3.21%. Also, 88.4% of its NOI is unencumbered.Solid dividend payouts are arguably the biggest enticement for REIT investors and UDR remains committed to that. The company has increased its dividend five times in the last five years, and the five-year annualized dividend growth rate is 4.21%, which is encouraging.Moreover, backed by healthy operating fundamentals, we expect the FFO as adjusted (FFOA) to increase 8.7% in 2023. Given our FFOA growth projections and UDR’s solid financial position, the latest dividend hike seems sustainable and well covered by cash flow from operations. Such efforts boost investors’ confidence in the stock.Shares of this Zacks Rank #3 (Hold) company have gained 1.8% so far in the year, slightly below its industry’s increase of 2.1%.Story continuesZacks Investment ResearchImage Source: Zacks Investment ResearchHowever, the struggle to lure the renters is likely to persist as the supply volume is expected to remain elevated in a number of its markets. With the ongoing construction standing at a high level, a sizeable number of apartment deliveries are expected in the upcoming period. Particularly, management expects its pricing power across its Sunbelt markets to remain constrained in the near term amid a relatively high level of new supply deliveries in these markets.Furthermore, a high interest rate environment is a concern for UDR. Elevated rates imply high borrowing costs for the company, affecting its ability to purchase or develop real estate. The company has a substantial debt burden and its total debt as of Jun 30, 2023, was $5.4 billion. Our estimate indicates a year-over-year rise of 15.1% in interest expenses in 2023.Stocks to ConsiderSome better-ranked stocks from the REIT sector are Invitation Homes Inc. INVH and American Homes 4 Rent AMH. Both Invitation Homes and American Homes 4 Rent currently carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.The Zacks Consensus Estimate for Invitation Homes’ current-year FFO per share has been revised marginally north over the past two months to $1.79.The Zacks Consensus Estimate for American Homes 4 Rent’s 2023 FFO per share has been revised marginally north in the past month to $1.65.Note: Anything related to earnings presented in this write-up represent funds from operations (FFO) — a widely used metric to gauge the performance of REITs.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportUnited Dominion Realty Trust, Inc. (UDR) : Free Stock Analysis ReportAmerican Homes 4 Rent (AMH) : Free Stock Analysis ReportInvitation Home (INVH) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Is It Wise to Retain UDR Stock in Your Portfolio for Now?

https://finance.yahoo.com/news/wise-retain-udr-stock-portfolio-120100415.html

206abb05-b506-3646-824a-c1336753a5f2

INVH

Times of change are a good time for investors to reflect on whether they should make any changes to their portfolios. Realty Income (NYSE: O), Invitation Homes (NYSE: INVH), and Kimco Realty (NYSE: KIM) are three stocks some Fool.com contributors think investors should take a closer look at this fall. Here's why they believe investors will quickly fall for these dividend stocks and add them to their portfolios.Continue reading

Motley Fool

Fall for These 3 Dividend Stocks in September and Buy Them Hand Over Fist

https://finance.yahoo.com/m/6d6f0b7c-ebba-3bec-b8bb-8ce57edbc247/fall-for-these-3-dividend.html

6d6f0b7c-ebba-3bec-b8bb-8ce57edbc247

IONS

CARLSBAD, Calif., Aug. 30, 2023  /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:(PRNewsfoto/Ionis Pharmaceuticals, Inc.)2023 Wells Fargo Healthcare Conference on Wednesday, September 6, 2023Citi's 18th Annual BioPharma Conference on Thursday, September 7, 2023Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionispharma.com/events-and-presentations/upcoming-events. Replays will be available on the Ionis website within 48 hours and will be archived for a limited time.About Ionis PharmaceuticalsFor more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma. CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-present-at-upcoming-investor-conferences-301912983.htmlSOURCE Ionis Pharmaceuticals, Inc.

PR Newswire

Ionis to present at upcoming investor conferences

https://finance.yahoo.com/news/ionis-present-upcoming-investor-conferences-110500772.html

2297bb2b-2233-3c1e-abb0-5568351966d0

IONS

A month has gone by since the last earnings report for Ionis Pharmaceuticals (IONS). Shares have added about 1.4% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Ionis Pharmaceuticals due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.Q2 Earnings & Sales Beat EstimatesIonis reported a loss of 60 cents per share for second-quarter 2023, which was much narrower than the Zacks Consensus Estimate of a loss of 94 cents. In the year-ago, the company posted a loss of 74 cents per share.The bottom line includes compensation expense related to equity awards. Excluding these special items, the adjusted loss per share was 41 cents per share versus loss of 56 cents per share in the year-ago quarter.Total revenues were $188 million in the second quarter, which significantly beat the Zacks Consensus Estimate of $136.8 million. Revenues rose 40% year over year due to higher payments from partnered programs.Quarter in DetailIonis earns commercial revenues, primarily royalty payments on net sales of Spinraza and R&D revenues from partnered medicines.Commercial revenues were $78 million in the second quarter, flat year over year. Commercial revenues beat our model estimate of $75.1 million as well as the Zacks Consensus Estimate of $74 million.Commercial revenues from Spinraza royalties were $61 million, up 1.6% year over. Spinraza product sales (recorded by Biogen) were flat in the quarter, being partly hurt by competitive pressure. Spinraza royalties fell shy of our model estimate of $61.4 million but beat the Zacks Consensus Estimate of $60 million.Revenues from Tegsedi and Waylivra from distribution fees were $11 million compared with $10 million in the year-ago quarter. License and royalty revenues were $6 million in the quarter compared with $8 million in the year-ago quarter. The commercial revenues included royalty revenues from Biogen for Qalsody/tofersen, which was approved by the FDA in April for treating SOD1-ALS.Story continuesR&D revenues almost doubled to $110 million from the year-ago revenues of $56 million due to rapid advancement in numerous partnered programs. The R&D revenues in the quarter included a $40 million payment from AstraZeneca (including $20 million for costs shared for eplontersen development) and a $16 million milestone payment from Biogen for Qalsody U.S. approval.Adjusted operating costs were up 29.2% year over year to $252 million in the quarter, mainly due to higher R&D costs, as the company rapidly advanced its wholly-owned late-stage pipeline and increased go-to-market activities for eplontersen, olezarsen and donidalorsen.2023 GuidanceIonis reaffirmed its previously issued financial guidance for 2023. The company expects total revenues to be more than $575 million in 2023. Its adjusted operating loss is expected to be less than $425 million.Adjusted operating expense is expected to be in the range of $970-$995 million. Adjusted operating costs are expected to gradually increase in the second half. R&D costs are expected to increase in the range of 20-25% year over year in 2023. SG&A costs are expected to increase approximately $35 million year over year.The company expects its cash and investment to be approximately $2 billion in 2023.How Have Estimates Been Moving Since Then?It turns out, fresh estimates have trended downward during the past month.VGM ScoresCurrently, Ionis Pharmaceuticals has a poor Growth Score of F, however its Momentum Score is doing a bit better with a D. Charting a somewhat similar path, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Ionis Pharmaceuticals has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.Performance of an Industry PlayerIonis Pharmaceuticals belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Corcept Therapeutics (CORT), has gained 8% over the past month. More than a month has passed since the company reported results for the quarter ended June 2023.Corcept reported revenues of $117.72 million in the last reported quarter, representing a year-over-year change of +13.9%. EPS of $0.25 for the same period compares with $0.24 a year ago.Corcept is expected to post earnings of $0.20 per share for the current quarter, representing a year-over-year change of -33.3%. Over the last 30 days, the Zacks Consensus Estimate has changed +1%.The overall direction and magnitude of estimate revisions translate into a Zacks Rank #2 (Buy) for Corcept. Also, the stock has a VGM Score of D.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportIonis Pharmaceuticals, Inc. (IONS) : Free Stock Analysis ReportCorcept Therapeutics Incorporated (CORT) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Why Is Ionis Pharmaceuticals (IONS) Up 1.4% Since Last Earnings Report?

https://finance.yahoo.com/news/why-ionis-pharmaceuticals-ions-1-153027142.html

d8fe0ba3-7eef-31ee-9838-9a7318ba1775

IP

Mark Sutton has spent his entire career at International Paper — almost a decade of it as CEO and chairman — but he's setting the stage for his departure.Continue reading

American City Business Journals

International Paper puts CEO succession plan into motion

https://finance.yahoo.com/m/9a2d2835-c66d-30c2-bc80-a0e026aeb83f/international-paper-puts-ceo.html

9a2d2835-c66d-30c2-bc80-a0e026aeb83f

IP

With a daily gain of 3.13%, a 3-month gain of 10.39%, and an Earnings Per Share (EPS) of 2.91, International Paper Co (NYSE:IP) has attracted significant investor attention. The question remains: is this stock significantly undervalued? This article provides a comprehensive valuation analysis to answer this question. Read on to gain valuable insights into the intrinsic value of International Paper Co.Company OverviewWarning! GuruFocus has detected 6 Warning Signs with IP. Click here to check it out. IP 30-Year Financial DataThe intrinsic value of IPInternational Paper Co, a prominent player in the packaging products and cellulose fibers industry, commands approximately one third of the North American corrugated packaging market. Despite having operations in Brazil, Russia, India, and China, over three-fourths of its sales are generated from North America. The company caters to a diverse range of end markets, including industrial, consumer products, and manufacturing.Considering the current stock price of $34.63 and the GF Value of $53.46, it appears that the stock is significantly undervalued. This discrepancy paves the way for a deeper exploration of the company's intrinsic value.Is International Paper Co (IP) Significantly Undervalued? An In-Depth AnalysisUnderstanding the GF ValueThe GF Value is a unique measure of a stock's intrinsic value, calculated based on historical trading multiples, a GuruFocus adjustment factor derived from past performance and growth, and future business performance estimates. The GF Value Line provides a visual representation of the stock's ideal fair trading value.International Paper Co's stock is believed to be significantly undervalued, according to the GuruFocus Value calculation. The current price of $34.63 per share and a market cap of $12 billion suggest that the stock is trading below its fair value. Given this undervaluation, the long-term return of its stock is likely to be much higher than its business growth.Is International Paper Co (IP) Significantly Undervalued? An In-Depth AnalysisLink: These companies may deliver higher future returns at reduced risk.Evaluating Financial StrengthAssessing the financial strength of a company is a crucial step before investing in its stock. Companies with poor financial strength pose a higher risk of permanent loss. A glance at the cash-to-debt ratio and interest coverage can provide a good understanding of a company's financial strength. International Paper Co has a cash-to-debt ratio of 0.12, which is worse than 75.75% of the companies in the Packaging & Containers industry. The overall financial strength of International Paper Co is 5 out of 10, indicating fair financial strength.Story continuesIs International Paper Co (IP) Significantly Undervalued? An In-Depth AnalysisProfitability and GrowthInvesting in profitable companies, especially those with consistent profitability over the long term, is typically less risky. International Paper Co has been profitable for 10 of the past 10 years. The company had a revenue of $20.20 billion and an Earnings Per Share (EPS) of $2.91 over the past twelve months. Its operating margin is 7.43%, ranking better than 64.11% of the companies in the Packaging & Containers industry. Overall, International Paper Co's profitability is ranked 7 out of 10 by GuruFocus, indicating fair profitability.Growth is a critical factor in a company's valuation. A faster-growing company creates more value for shareholders, especially if the growth is profitable. The 3-year average annual revenue growth of International Paper Co is 7.9%, ranking better than 53.52% of the companies in the Packaging & Containers industry. However, the 3-year average EBITDA growth rate is 3.1%, ranking worse than 58.58% of the companies in the industry.ROIC vs WACCComparing a company's return on invested capital (ROIC) to its weighted average cost of capital (WACC) can provide valuable insights into its profitability. If the ROIC exceeds the WACC, the company is likely creating value for its shareholders. Over the past 12 months, International Paper Co's ROIC was 9.57, while its WACC was 9.16.Is International Paper Co (IP) Significantly Undervalued? An In-Depth AnalysisConclusionIn conclusion, International Paper Co's stock appears to be significantly undervalued. The company has fair financial strength and profitability. However, its growth ranks worse than 58.58% of the companies in the Packaging & Containers industry. For more information about International Paper Co's stock, you can check out its 30-Year Financials here.To discover high-quality companies that may deliver above-average returns, visit GuruFocus High Quality Low Capex Screener.This article first appeared on GuruFocus.

GuruFocus.com

Is International Paper Co (IP) Significantly Undervalued? An In-Depth Analysis

https://finance.yahoo.com/news/international-paper-co-ip-significantly-233212066.html

9fead507-bf2d-31e9-add0-dfcbe6d512a1

IPG

IPG HealthNew multidisciplinary offering addresses industry need for more inclusive clinical trials and product developmentNEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Building on its long-standing commitment to advancing health equity, and specifically clinical equality, IPG Health formally launched an industry-first offering designed to help pharma and healthcare companies diversify their clinical trials and ensure more inclusive treatment innovations. The new offering is a multidisciplinary approach that ensures equitable representation across various dimensions of diversity—from race to gender, age, and other intersectional groups—throughout the clinical trial process.Drawing from IPG Health’s deep medical and engagement strategy, data analytics, software intelligence, and patient experience expertise, the end-to-end offering addresses barriers to inclusion across clinical trial outreach, recruitment, and engagement. This includes everything from understanding patients’ behaviors and predicting their health intentions, to crafting measurable engagement strategies, developing clinical trial support systems, and more.“Too often various communities and populations are underrepresented in clinical trials, even when their lives are at stake. Take type 2 diabetes, for example—only 4% of type 2 diabetes clinical trial participants are Black, yet Black Americans are more likely to experience diabetes complications than White Americans. And in all clinical trials, less than 1% of participants are Native American, even though Native Americans are more likely than White Americans to experience diseases such as type 2 diabetes, obesity, coronary heart disease, and liver cancer,” said Sommer Bazuro, IPG Health’s Chief Medical Officer. “And that’s just looking at disparities along racial lines for only two groups. Excluding any population from clinical trials means sidelining millions of people for new treatments that could improve their health outcomes and potentially save their lives.”Story continuesIPG Health has long advocated for diversity in clinical trials, notably with its award-winning “The Trial for #ClinicalEquality” campaign, which, for over three years now, has galvanized cross-sector stakeholders—from physicians, pharma companies, and advocacy groups to influential tech companies and academic institutions—to help raise awareness and spur innovation that effects change.“We are relentlessly focused on doing what’s right for our clients, their brands, and our people. And we can’t do what’s right unless equity, diversity, and inclusion (EDI) are at the heart of our business,” said IPG Health CEO, Dana Maiman. “This important offering is just another way that we continue to hold ourselves accountable for advancing health equity and being trusted partners to our clients. This clinical trial diversity offering is a pivotal move in helping clients unlock new opportunities and address significant unmet needs in underserved populations and, ultimately, helping to accelerate equity in healthcare.”Bazuro added: “Helping companies produce truly inclusive clinal trials and outcomes requires a deep understanding of the innate complexities of the clinical trial process and the multifactorial barriers within it. That’s something very few health marketing agencies possess. At IPG Health, we’ve invested years into understanding those complexities and variables, and identifying actionable opportunities. And we do it in partnership with leading tech and pharma companies, advocacy organizations, and academic institutions across the full clinical trial spectrum—from the supply and demand ends to the crucial intermediaries in between. All of this demands a depth of medical and scientific expertise, creativity, and specialized capabilities that only IPG Health is uniquely able to provide.”The new offering is an extension of IPG Health’s EDI+You strategy, which includes “inQ” (Inclusion Intelligence Quotient)—a proprietary integrated strategic framework designed to ensure even more inclusive experiences and creative solutions across the network’s 45+ agencies. Rooted in an evidence-based framework inspired by the World Health Organization’s Determinants of Health model, IPG Health’s inQ focuses on understanding how multiple factors and influences impact exclusion or inclusion of people so that no populations are left behind.About IPG HealthIPG Health is a global collective of the world’s most celebrated and awarded healthcare marketing agencies. We are 6,000+ people across six continents driven by a healthy obsession with creating novel marketing solutions and harnessing creativity, technology, science, and data to inspire behaviors that fuel better health. With 45+ agencies, including 18+ specialized units, our integrated approach to the full range of communications capabilities ensures we can help clients improve outcomes and quality of life for healthcare audiences around the world. Our clients include the top 20 global pharmaceutical companies as well as countless start-ups, biotech companies, biopharma companies, and a variety of life science companies. IPG Health companies have earned coveted accolades in 2023, including “Healthcare Network of the Year” on Ad Age A-List and the New York Festivals Health Awards, and “Network of the Year” at the Manny Awards. In 2022, they achieved “Network of the Year” at the London International Awards, MM+M Awards, Manny Awards, Clio Health Awards, and the Cannes Lions Festival. We are part of the Interpublic Group of Companies (NYSE:IPG). Visit ipghealth.com to learn more.Contact:Chido [email protected]

GlobeNewswire

IPG Health Launches Industry’s First Clinical Trial Diversity Offering

https://finance.yahoo.com/news/ipg-health-launches-industry-first-180000486.html

58e2d3dc-9d02-35b3-9934-a4fce95bcd94

IPG

Interpublic Group of Companies, Inc. (The)New York, NY, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Interpublic Group (NYSE: IPG) senior management will present at the BofA Securities Media, Communications & Entertainment Conference on Wednesday, September 13th, 2023, at 8:50 am Eastern time, as scheduled.A link to the live webcast will be posted on the day of the conference on the Investor Relations section of Interpublic's website (http://investors.interpublic.com) where it will remain available for replay for 30 days.# # #About InterpublicInterpublic (NYSE: IPG) (www.interpublic.com) is a values-based, data-fueled, and creatively-driven provider of marketing solutions. Home to some of the world’s best-known and most innovative communications specialists, IPG global brands include Acxiom, Craft, FCB, FutureBrand, Golin, Huge, Initiative, IPG Health, Jack Morton, Kinesso, MAGNA, Matterkind, McCann, Mediabrands, Mediahub, Momentum, MRM, MullenLowe Group, Octagon, R/GA, UM, Weber Shandwick and more. IPG is an S&P 500 company with total revenue of $10.93 billion in 2022. # # #Contact InformationTom Cunningham (Press) (212) 704-1326Jerry Leshne (Analysts, Investors) (212) 704-1439

GlobeNewswire

Interpublic Group to Present at the BofA Securities Media, Communications & Entertainment Conference

https://finance.yahoo.com/news/interpublic-group-present-bofa-securities-203000745.html

5c9665de-c94f-3a3b-8273-e1952f05abfe

IPWR

Emerging GrowthMIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 62nd Emerging Growth Conference on September 6 & 7, 2023.The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.Register for the conference here.Submit Questions for any of the presenting companies to: [email protected] updates, follow us on TwitterDay 1September 6, 202310:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to the registration link and click “Already registered” and enter your email.10:10Introduction10:15 - 10:45Citizens, Inc. (NYSE: CIA)Gerald W. Shields, Vice Chairman / CEO, & Jeff Conklin, CFO10:50 - 11:20NeuroMetrix, Inc. (NASDAQ: NURO)Dr. Shai Gozani, CEO & Thomas Higgins, CFO12:00 - 12:30Cyngn, Inc. (NASDAQ: CYN)Lior Tal, CEO & Director12:35 - 1:05Global Crossing Airlines Group, Inc. (OTCQB: JETMF) (NEO: JET)Ryan Goepel, EVP & CFO1:10 - 1:40GPO Plus, Inc. (OTCQB: GPOX)Brett Pojunis, President / CEO1:45 - 2:15GeoVax Labs, Inc. (NASDAQ: GOVX) David Dodd, Chairman, President / CEO2:55 - 3:05Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF)Dr. Pinia Fishman, Founder & CEO, and Motti Farbstein, COO & CFO3:10 - 3:20Longeveron, Inc. (NASDAQ: LGVN)Mohamed Wa’el Ahmed Hashad, CEO & Director3:25 - 3:35Sigyn Therapeutics, Inc. (OTCQB: SIGY) Inc. (OTCQB: SIGY)James Allen Joyce, CEO3:40 - 3:50dynaCERT Inc. (OTCQX: DYFSF (TSXV: DYA) James Payne President / CEO & DirectorDay 2September 7, 20239:15Virtual Lobby opens.Register for the Conference. If you already registered, go back to the registration link and click “Already registered” and enter your email.9:30IntroductionStory continues9:40 - 10:10Jaguar Health, Inc. (NASDAQ: JAGX)Lisa A. Conte, Founder, CEO, President & Director10:15 - 10:45AGBA Group Holding Limited (NASDAQ: AGBA)Mr. Wing-Fai Ng, CEO10:50 - 11:20Ideal Power (NASDAQ: IPWR)Dan Brdar, President / CEO, & Tim Burns, CFO11:25 - 11:55Steppe Gold, Ltd. (OTCQX: STPGF) (TSX: STGO)Aneel Singh, Exec. VP & Director12:00 - 12:3022nd Century Group, Inc. (NASDAQ: XXII)John Miller, Interm CEO1:10 - 1:40SES AI Corporation (NYSE: SES)Jing Nealis, CFO1:45 - 2:15RedCloud Technologies, a Private CompanyJustin Floyd, CEO2:20 2:50Alpha Tau Medical, Inc. (NASDAQ: DRTS)Raphi Levy, CFO2:55 - 3:05Big Screen Entertainment Group (OTC Pink: BSEG)Kimberley Kates, CEO, and Sandro Monetti, PresidentVisit the following link to register. You will then receive an email containing the link and time to sign into the conference.Register for the conference here.Submit Questions for any of the presenting companies to: [email protected]: Subscribe to our YouTube ChannelAbout EmergingGrowth.comFounded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.About the Emerging Growth ConferenceThe Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients. Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future. In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.If you believe or know of a company that might fit our audience, contact us here.Thank you for your interest in our conference, and we look forward to your participation in future conferences.Contact:Emerging GrowthPhone: 1-305-330-1985Email: [email protected]

GlobeNewswire

Presenting on the Emerging Growth Conference on September 6 and 7 Register Now

https://finance.yahoo.com/news/presenting-emerging-growth-conference-september-110000405.html

3d205bde-bf57-3123-a290-171833ef3fd3

IPWR

Emerging Growth Virtual Conference on September 7, 2023H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11, 2023LD Micro 16th Annual Main Event Conference in Los Angeles on October 4, 2023AUSTIN, TX / ACCESSWIRE / September 5, 2023 / Ideal Power Inc. ("Ideal Power," the "Company," "we," "us" or "our") (Nasdaq:IPWR), pioneering the development and commercialization of the highly efficient and broadly patented B-TRAN™ bidirectional semiconductor power switch, today announced management's plans for participation in upcoming investor conferences.Emerging Growth Virtual Conference on September 7, 2023Ideal Power plans to present at the Emerging Growth Virtual Conference on September 7 at 10:50 AM ET. The live, interactive webcast and slide presentation will be accessible on the Company's Investor Relations website under the Events tab HERE. The webcast will be archived on the website for future viewing.Analysts and investors may submit questions in advance for management HERE or ask questions during the live webcast.H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11, 2023Ideal Power plans to present and participate in one-on-one meetings at the H.C. Wainwright Conference in New York on September 11. Conference attendees are encouraged to register and request a one-on-one in-person or virtual meeting with Ideal Power management on H.C. Wainwright's online conference platform HERE.The live, interactive webcast at the H.C. Wainwright Conference is September 11 at 3:30 PM ET and will be accessible on the Company's Investor Relations website under the Events tab HERE. The webcast will be archived on the website for future viewing.LD Micro 16th Annual Main Event Conference in Los Angeles on October 4, 2023Ideal Power plans to present and participate in one-on-one meetings at the LD Micro Conference in Los Angeles on October 4. Conference attendees are encouraged to register and request a one-on-one meeting with Ideal Power management on LD Micro's online conference platform HERE.Story continuesThe live, interactive webcast and slide presentation will be accessible on the Company's Investor Relations website under the Events tab HERE. The timing of Ideal Power's presentation webcast and additional information about this conference will be provided by the Company when it is available.About Ideal Power Inc.Ideal Power (NASDAQ:IPWR) is pioneering the development and commercialization of its broadly patented bidirectional semiconductor power switch, creating highly efficient and ecofriendly energy control solutions for electric vehicle, electric vehicle charging, renewable energy, energy storage, UPS/data center, solid-state circuit breaker and other industrial and military applications. The Company is focused on its patented Bidirectional, Bipolar Junction Transistor (B-TRAN™) semiconductor technology. B-TRAN™ is a unique double-sided bidirectional AC switch that delivers substantial performance improvements over today's conventional power semiconductors. Ideal Power's B-TRAN™ can reduce conduction and switching losses, complexity of thermal management and operating cost in AC power switching and control circuitry. For more information, visit the Company's website at www.IdealPower.com, on LinkedIn, on Twitter, and on Facebook.Ideal Power Investor Relations Contact:Jeff ChristensenDarrow Associates Investor [email protected]: Ideal PowerView source version on accesswire.com: https://www.accesswire.com/780705/ideal-power-announces-plans-for-upcoming-investor-conferences

ACCESSWIRE

Ideal Power Announces Plans for Upcoming Investor Conferences

https://finance.yahoo.com/news/ideal-power-announces-plans-upcoming-200100830.html

fa42e3c3-28c9-3343-9c76-9935cfe945b7

IQV

IQVIA Holdings shows improving price performance, earning an upgrade to its IBD Relative Strength RatingContinue reading

Investor's Business Daily

IQVIA Holdings Stock Earns Relative Strength Rating Upgrade

https://finance.yahoo.com/m/53de6d0b-e508-3529-8f56-3f5ddca9367d/iqvia-holdings-stock-earns.html

53de6d0b-e508-3529-8f56-3f5ddca9367d

IQV

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. By way of learning-by-doing, we'll look at ROE to gain a better understanding of IQVIA Holdings Inc. (NYSE:IQV).Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors’ money. In short, ROE shows the profit each dollar generates with respect to its shareholder investments. See our latest analysis for IQVIA Holdings How To Calculate Return On Equity?The formula for ROE is:Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' EquitySo, based on the above formula, the ROE for IQVIA Holdings is:19% = US$1.1b ÷ US$5.7b (Based on the trailing twelve months to June 2023).The 'return' refers to a company's earnings over the last year. Another way to think of that is that for every $1 worth of equity, the company was able to earn $0.19 in profit.Does IQVIA Holdings Have A Good ROE?Arguably the easiest way to assess company's ROE is to compare it with the average in its industry. Importantly, this is far from a perfect measure, because companies differ significantly within the same industry classification. As is clear from the image below, IQVIA Holdings has a better ROE than the average (13%) in the Life Sciences industry.roeThat's what we like to see. However, bear in mind that a high ROE doesn’t necessarily indicate efficient profit generation. Especially when a firm uses high levels of debt to finance its debt which may boost its ROE but the high leverage puts the company at risk.How Does Debt Impact ROE?Most companies need money -- from somewhere -- to grow their profits. The cash for investment can come from prior year profits (retained earnings), issuing new shares, or borrowing. In the case of the first and second options, the ROE will reflect this use of cash, for growth. In the latter case, the debt used for growth will improve returns, but won't affect the total equity. That will make the ROE look better than if no debt was used.Story continuesIQVIA Holdings' Debt And Its 19% ROEIt's worth noting the high use of debt by IQVIA Holdings, leading to its debt to equity ratio of 2.40. While its ROE is pretty respectable, the amount of debt the company is carrying currently is not ideal. Investors should think carefully about how a company might perform if it was unable to borrow so easily, because credit markets do change over time.ConclusionReturn on equity is a useful indicator of the ability of a business to generate profits and return them to shareholders. In our books, the highest quality companies have high return on equity, despite low debt. All else being equal, a higher ROE is better.But ROE is just one piece of a bigger puzzle, since high quality businesses often trade on high multiples of earnings. The rate at which profits are likely to grow, relative to the expectations of profit growth reflected in the current price, must be considered, too. So I think it may be worth checking this free report on analyst forecasts for the company.But note: IQVIA Holdings may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Should We Be Delighted With IQVIA Holdings Inc.'s (NYSE:IQV) ROE Of 19%?

https://finance.yahoo.com/news/delighted-iqvia-holdings-inc-nyse-110026389.html

c7a046bf-1000-36cb-8152-72ddbcbe7c3b

IR

Affirm Holdings, Inc. AFRM recently announced a partnership with ATERNAL to serve as the exclusive pay over-time provider in art galleries. Shares of AFRM gained 1.7% on Sep 7, 2023, implying investors’ confidence in the company’s prospects. ATERNAL is an inventory management platform for small to large-scale art galleries, and this partnership is expected to enhance its offerings to merchants, driving growth.This move bodes well, as AFRM will be able to expand its network with new merchants, driving its top-line growth. The partnership is expected to increase gross merchandise value in the future. Initiatives like this will aid AFRM in achieving its expected full-year profitability in fiscal 2024 on an adjusted operating income basis. It expects revenues to be more than $1.9 billion for fiscal 2024.ATERNAL can provide flexible payment options to art buyers, such as pay over time. This will add to ATERNAL’s offerings to art galleries, like improved workflows and insights from transactions. Hence, ATERNAL’s clients will experience increased sales as more customers get attracted to the buy now pay later (BNPL) solutions.The major strength of Affirm is its technology, which aids it in pricing its products and risk assessment. AFRM allows customers to pay overtime and does not charge hidden fees or late payment charges. It charges customers on a simple interest-rate basis and is transparent in displaying exactly what the customer owes, reducing their burden.Affirm is set to grow its business by collaborating with global giants, such as Amazon and Fidelity National Information Services. These partnerships will enable customers to access buy now and pay later options and drive growth in merchant business. AFRM will make money from commissions charged to businesses, boosting its top line in the future.The Zacks Consensus Estimate for AFRM’s fiscal 2024 revenues is pegged at $2.4 billion, indicating 21% year-over-year growth. This trend will likely help the company to become a profitable firm. The company is yet to register operating profit in the quarters ahead. However, modern and exciting products like Debit+ Card and partnerships will bring the company closer to its goals.Story continuesZacks Rank and Price PerformanceAffirm currently has a Zacks Rank #3 (Hold). In the year-to-date period, shares of Affirm have gained 132.5% compared with 2.3% growth of the industry it belongs to.Zacks Investment ResearchImage Source: Zacks Investment ResearchStocks to ConsiderSome better-ranked stocks in the Business Services space are Limbach Holdings, Inc. LMB, Trane Technologies plc TT and Api Group Corporation APG. While Limbach presently sports a Zacks Rank #1 (Strong Buy), Trane Technologies and APi Group currently carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.The bottom line of Limbach outpaced estimates in each of the last four quarters, the average surprise being 81.40%. The Zacks Consensus Estimate for LMB’s 2023 earnings is pegged at $1.36 per share, which has more than doubled from the year-ago reported figure. The consensus mark for revenues suggests growth of 0.8% from the year-ago reported number. The consensus mark for LMB’s 2023 earnings has moved 21.4% north in the past 30 days.Trane Technologies’ earnings outpaced estimates in each of the trailing four quarters, the average surprise being 7.30%. The Zacks Consensus Estimate for TT’s 2023 earnings suggests an improvement of 19.8% from the year-ago reported figure. The same for revenues suggests growth of 10% from the year-ago reported number. The consensus mark for TT’s 2023 earnings has moved 0.6% north in the past 30 days.The bottom line of APi Group outpaced estimates in three of the last four quarters and matched the mark once, the average surprise being 9.85%. The Zacks Consensus Estimate for APG’s 2023 earnings suggests an improvement of 13.5% from the year-ago reported figure. The consensus mark for revenues suggests growth of 7.9% from the year-ago reported number. The consensus mark for APG’s 2023 earnings has moved 0.7% north in the past 60 days.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportTrane Technologies plc (TT) : Free Stock Analysis ReportLimbach Holdings, Inc. (LMB) : Free Stock Analysis ReportAPi Group Corporation (APG) : Free Stock Analysis ReportAffirm Holdings, Inc. (AFRM) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Affirm (AFRM) & ATERNAL to Offer BNPL Solutions to Art Buyers

https://finance.yahoo.com/news/affirm-afrm-aternal-offer-bnpl-173700165.html

1de2b082-48ac-31ad-8b72-5cae4aebdedc

IR

On September 6, 2023, Vikram Kini, the Senior Vice President and CFO of Ingersoll Rand Inc (NYSE:IR), sold 169,153 shares of the company. This move has sparked interest among investors and analysts alike, as insider trading activities often provide valuable insights into a company's financial health and future prospects.Warning! GuruFocus has detected 4 Warning Signs with SD. Click here to check it out. IR 30-Year Financial DataThe intrinsic value of IRVikram Kini has been with Ingersoll Rand Inc for several years, serving in various leadership roles before his current position as Senior Vice President and CFO. His extensive experience and deep understanding of the company's operations make his trading activities particularly noteworthy.Ingersoll Rand Inc is a globally recognized industrial manufacturing company. It specializes in the production of mission-critical flow creation and industrial solutions, including air compressors, tools, material handling systems, and more. The company's products and services are used in a wide range of industries, from manufacturing and construction to mining and energy.Over the past year, Vikram Kini has sold a total of 169,153 shares and purchased 0 shares. This recent sale represents a significant portion of his trading activities during this period.Senior Vice President and CFO Vikram Kini Sells 169,153 Shares of Ingersoll Rand IncThe insider transaction history for Ingersoll Rand Inc shows a trend of more insider sells than buys over the past year. There have been 12 insider sells and 0 insider buys in total. This could suggest that insiders believe the company's stock is currently overvalued, prompting them to sell their shares.On the day of the insider's recent sale, shares of Ingersoll Rand Inc were trading for $69.43 apiece, giving the stock a market cap of $28.07 billion. The price-earnings ratio is 40.36, which is higher than the industry median of 22.38 and the companys historical median price-earnings ratio. This could indicate that the stock is overpriced compared to its earnings.Story continuesSenior Vice President and CFO Vikram Kini Sells 169,153 Shares of Ingersoll Rand IncAccording to the GuruFocus Value, which is an intrinsic value estimate based on historical multiples, a GuruFocus adjustment factor, and future business performance estimates, Ingersoll Rand Inc has a price-to-GF-Value ratio of 1.02. This suggests that the stock is fairly valued. However, the insider's recent sale could indicate that he believes the stock is overvalued, despite its fair valuation according to the GF Value.In conclusion, the insider's recent sale of Ingersoll Rand Inc shares could suggest that he believes the stock is overvalued. However, investors should also consider other factors, such as the company's financial health and future prospects, before making investment decisions.This article first appeared on GuruFocus.

GuruFocus.com

Senior Vice President and CFO Vikram Kini Sells 169,153 Shares of Ingersoll Rand Inc

https://finance.yahoo.com/news/senior-vice-president-cfo-vikram-170103946.html

55e1d0ce-0552-32d2-95ba-9d550f794705

IRDM

MCLEAN, Va., Sept. 6, 2023 /CNW/ -- Iridium Communications Inc. (NASDAQ: IRDM), a leading provider of global voice and data satellite communications, announced today that Xuzhou Construction Machinery Group (XCMG), a leading global heavy original equipment manufacturer (OEM), will deploy Iridium® IoT services on its global fleet of heavy equipment, starting with excavators and expanding to loaders and crane trucks as needed. XCMG will utilize Iridium's global network to maintain critical connectivity with their heavy equipment in key strategic locations including Australia, Southeast Asia, Latin America, Africa, and Central Asia.Photo: Crawler Excavator XE380DK, Credit: XCMGXCMG has chosen Iridium Edge®, a cost-effective, plug-and-play satellite IoT terminal, as it complements terrestrial-based solutions to create a highly reliable connectivity experience worldwide and simplifies implementing Iridium IoT services on their fleet. With easy integration, XCMG can rapidly deploy the terminals to their heavy equipment, allowing them to understand asset condition and performance, efficiently address customer needs, and save on development costs and time to market."As a world class OEM, XCMG continues to demonstrate their forward-thinking approach and innovation in the heavy equipment industry," said Matt Desch, CEO, Iridium. "By leveraging Iridium's truly global, weather-resilient satellite connectivity on their machinery, XCMG is enabling a better user experience with advanced, cutting-edge solutions to their customers worldwide."As of the second quarter of 2023, Iridium's commercial IoT subscribers grew by 19% from the year-ago period, reaching 1,578,000 customers, further cementing the company's place as the premier satellite IoT company. This growth demonstrates the widespread adoption of Iridium's unmatched coverage, reliability, and ease of integration across various industries.To learn more about Iridium, visit: www.iridium.comStory continuesAbout Iridium Communications Inc.Iridium® is the only mobile voice and data satellite communications network that spans the entire globe. Iridium enables connections between people, organizations and assets to and from anywhere, in real time. Together with its ecosystem of partner companies, Iridium delivers an innovative and rich portfolio of reliable solutions for markets that require truly global communications. In 2019, the company completed a generational upgrade of its satellite network and launched its specialty broadband service, Iridium Certus®. Iridium Communications Inc. is headquartered in McLean, Va., U.S.A., and its common stock trades on the Nasdaq Global Select Market under the ticker symbol IRDM. For more information about Iridium products, services and partner solutions, visit www.iridium.com.Forward-Looking StatementsStatements in this press release that are not purely historical facts may constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the deployment of its products and services. Forward-looking statements can be identified by the words "anticipates," "may," "can," "believes," "expects," "projects," "intends," "likely," "will," "to be" and other expressions that are predictions or indicate future events, trends or prospects. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Iridium to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties regarding customer demand for Iridium's products and services; Iridium's ability to maintain the health, capacity and content of its satellite constellation, and the development of and market for Iridium's products and services, as well as general industry and economic conditions, and competitive, legal, governmental and technological factors. Other factors that could cause actual results to differ materially from those indicated by the forward-looking statements include those factors listed under the caption "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission ("SEC") on February 16, 2023, as well as other filings Iridium makes with the SEC from time to time. There is no assurance that Iridium's expectations will be realized. If one or more of these risks or uncertainties materialize, or if Iridium's underlying assumptions prove incorrect, actual results may vary materially from those expected, estimated or projected. Iridium's forward-looking statements are based on information available to it as of the date of this press release and speak only as of the date of this press release, and Iridium undertakes no obligation to update forward-looking statements.Press Contact: Investor Contact:Jordan Hassin Kenneth LevyIridium Communications Inc.Iridium Communications [email protected]@Iridium.com+1 (703) 287-7421+1 (703) 287-7570Twitter: @IridiumcommIridium Communications Inc. (PRNewsfoto/Iridium Communications Inc.)CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/iridium-provides-global-connectivity-for-xcmg-heavy-equipment-301918249.htmlSOURCE Iridium Communications Inc.CisionView original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2023/06/c0077.html

CNW Group

Iridium Provides Global Connectivity for XCMG Heavy Equipment

https://finance.yahoo.com/news/iridium-provides-global-connectivity-xcmg-110100152.html

35a4331c-5891-3081-af82-072137043bb6

IRDM

Iridium Communications IRDM announced a partnership with Xuzhou Construction Machinery Group (“XCMG”) to integrate Iridium’s IoT services into its global fleet of heavy machinery.XCMG will be initially focusing on excavators and later extending to loaders and crane trucks. By leveraging Iridium's extensive global network, XCMG aims to maintain crucial connectivity for its heavy equipment across strategic locations such as Australia, Southeast Asia, Latin America, Africa, and Central Asia.XCMG has opted for Iridium Edge, which complements its existing terrestrial-based solutions, ensuring a highly dependable connectivity experience on a global scale. The adoption of Iridium IoT services through these terminals allows XCMG to quickly deploy them across their heavy machinery, enabling real-time monitoring of asset conditions and performance. This, in turn, streamlines customer support, reduces development costs and accelerates time-to-market for XCMG's offerings.Iridium Communications Inc Price and ConsensusIridium Communications Inc Price and ConsensusIridium Communications Inc price-consensus-chart | Iridium Communications Inc QuoteIridium is the only satellite communications company that offers dedicated commercial global voice and data communications. The company continues to invest heavily in research and development to launch advanced satellite communications services.In July, Iridium unveiled its latest offering — the Iridium Certus aviation commercial service. This service ensures a secure cockpit domain with reliable voice and data capabilities. This marks a significant achievement as it brings Iridium Connected aviation solutions to commercial transport aircraft, business aviation and Uncrewed Aircraft Systems.Prior to that, the company announced that it would integrate its Edge Solar with Laird Connectivity's Sentrius BT610 I/O and BT510+ IoT sensors. The integration will allow Laird’s low-powered sensors to connect with Iridium Edge Solar over Bluetooth Low Energy. As a result, it will help both companies to develop new features and capabilities for wireless and resilient remote operations.Story continuesIridium currently has a Zacks Rank #3 (Hold). Shares of the company have gained 10.4% in the past year compared with the sub-industry’s growth of 9.2%.Zacks Investment ResearchImage Source: Zacks Investment ResearchStocks to ConsiderSome better-ranked stocks in the broader technology space are Woodward WWD, Aspen Technology AZPN and Badger Meter BMI. Woodward and Aspen Technology presently sport a Zacks Rank #1 (Strong Buy), whereas Badger Meter currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.The Zacks Consensus Estimate for Woodward’s fiscal 2023 earnings per share (EPS) has increased 15.9% in the past 60 days to $4.15.WWD’s long-term earnings growth rate is 13.5%. Shares of WWD have gained 37.6% in the past year.The Zacks Consensus Estimate for Aspen Technology’s fiscal 2024 EPS has increased 5.8% in the past 60 days to $6.58.Aspen Technology’s long-term earnings growth rate is 17.1%. Shares of AZPN have declined 12.6% in the past year.The Zacks Consensus Estimate for Badger Meter’s 2023 EPS has increased 6.3% in the past 60 days to $2.86.Badger Meter’s earnings beat the Zacks Consensus Estimate in all the last four quarters, the average being 6.7%. Shares of BMI have surged 69.5% in the past year.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportBadger Meter, Inc. (BMI) : Free Stock Analysis ReportIridium Communications Inc (IRDM) : Free Stock Analysis ReportWoodward, Inc. (WWD) : Free Stock Analysis ReportAspen Technology, Inc. (AZPN) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Iridium's (IRDM) IoT Services Boost XCMG's Heavy Machinery

https://finance.yahoo.com/news/iridiums-irdm-iot-services-boost-153000912.html

c5e1ddea-53d2-3404-8bdb-f94f959e661d

IRM

Iron Mountain Inc (NYSE:IRM) has seen a daily gain of 2.07% and a 3-month gain of 9.61%. With an Earnings Per Share (EPS) (EPS) of 1.29, the question arises - is the stock fairly valued? This article aims to answer this question by providing a detailed valuation analysis of Iron Mountain. The following sections will delve into the company's operations, financial strength, profitability, and growth, offering valuable insights for potential investors.About Iron Mountain IncWarning! GuruFocus has detected 13 Warning Signs with IRM. Click here to check it out. IRM 30-Year Financial DataThe intrinsic value of IRMIron Mountain Inc is a leading provider of record management services, organized as a Real Estate Investment Trust (REIT). The majority of its revenue stems from its storage business, supplemented by value-added services. The company primarily serves enterprise clients in developed markets. Iron Mountain's business segments include Global RIM Business, Global Data Center Business, and Corporate and Other Business. The company's stock price currently stands at $59.78, compared to the GF Value of $55.12, suggesting that the stock is fairly valued.Is Iron Mountain Inc (IRM) Stock Fairly Valued?Understanding GF ValueThe GF Value is a unique measure of a stock's intrinsic value, calculated based on historical trading multiples, a GuruFocus adjustment factor based on past performance and growth, and future business performance estimates. The GF Value Line provides an overview of the stock's fair trading value. If the stock price is significantly above the GF Value Line, it is considered overvalued and its future return is likely to be poor. Conversely, if the stock price is significantly below the GF Value Line, the stock is undervalued and its future return is likely to be higher.The stock of Iron Mountain appears to be fairly valued based on GuruFocus' valuation method. This suggests that the long-term return of its stock is likely to be close to the rate of its business growth.Story continuesIs Iron Mountain Inc (IRM) Stock Fairly Valued?Financial StrengthInvesting in companies with poor financial strength carries a higher risk of permanent capital loss. Therefore, it's crucial to carefully review a company's financial strength before deciding to buy its stock. Iron Mountain's cash-to-debt ratio of 0.01 is worse than 86.57% of the companies in the REITs industry, indicating poor financial strength.Is Iron Mountain Inc (IRM) Stock Fairly Valued?Profitability and GrowthConsistent profitability over the long term reduces risk for investors. Iron Mountain has been profitable 10 out of the past 10 years, indicating fair profitability. The company's 3-year average annual revenue growth of 5.6% is better than 71.79% of the companies in the REITs industry, suggesting good growth.ROIC vs WACCComparing a company's return on invested capital (ROIC) to its weighted cost of capital (WACC) is another way to evaluate its profitability. If the ROIC is higher than the WACC, it indicates that the company is creating value for shareholders. Over the past 12 months, Iron Mountain's ROIC was 6.16, while its WACC came in at 7.39.Is Iron Mountain Inc (IRM) Stock Fairly Valued?ConclusionOverall, Iron Mountain's stock appears to be fairly valued. Despite its poor financial condition, the company has shown fair profitability and good growth. To learn more about Iron Mountain stock, you can check out its 30-Year Financials here.To find out high-quality companies that may deliver above-average returns, please check out GuruFocus High Quality Low Capex Screener.This article first appeared on GuruFocus.

GuruFocus.com

Is Iron Mountain Inc (IRM) Stock Fairly Valued?

https://finance.yahoo.com/news/iron-mountain-inc-irm-stock-153257586.html

e2177d81-e1de-3d6f-b95c-83b39cb2eafa

IRM

Thanks to strong revenue growth, many cybersecurity stocks have attracted growth investors. While some of these companies are seeing high revenue growth and double-digit profit margins, others are trying to minimize losses and turn a profit. Meanwhile, all should flourish because cybersecurity solutions are in heavy demand.  After all, a single hack can cost a company millions of dollars in lost data, legal fees, and lost business. That being said, here are some of the top cybersecurity stocks to accumulate before they rally.Fortinet (FTNT)The Fortinet logo on a wallSource: Sundry Photography / Shutterstock.comFortinet (NASDAQ:FTNT) shares sold off dramatically after the company lowered its guidance for the year. In fact, shares fell about 25%. How bad was the guidance? Definitely not bad enough to warrant a 25% drop. Fortinet merely lowered its 2023 revenue outlook from a range of $5.425 billion to $5.48 billion to a new range of $5.35 billion to $5.45 billion. That is a 1% difference at the midpoint.In addition, billings went from a range of $6.75 billion to $6.81 billion to a new range of $6.49 billion to $6.59 billion. That represents a 3.5% drop at the midpoint. While investors would have preferred to see the company raise guidance, neither of those marks warrants a 25% drop in the stock. It’s no wonder some analysts view the drop as an opportunity.InvestorPlace - Stock Market News, Stock Advice & Trading TipsWe also have to remember that Fortinet is highly profitable and is a dominant player in the cybersecurity industry. The main complaint from investors was the stock’s valuation, but after the earnings hit, Fortinet appeared to be far more attractive.Crowdstrike (CRWD)CrowdStrike sign and logo at headquarters in Silicon Valley. CRWD stock.Source: Michael Vi / ShutterstockCrowdstrike (NASDAQ:CRWD) gained about 40% year-to-date and has more than doubled over the past five years. The cybersecurity firm has incredible top-line growth and reported a 42% year-over-year increase in Q1 of Fiscal 2024.Story continuesCrowdstrike is sitting on almost $3 billion in cash and turned in a profit. As margins improve, the company’s valuation can become more reasonable. Crowdstrike is making investments in artificial intelligence to improve its products and give users more security. Charlotte AI is the company’s new AI security analyst. Crowdstrike is working with AWS to expand its AI capabilities.The company’s high revenue growth model is supported by a steady stream of annual recurring revenue. This stat jumped to $2.73 billion per year as of April 30, 2023. This figure represents a 42% year-over-year increase.Iron Mountain (IRM)Iron Mountain (IRM) logo on truckSource: ShutterstockIron Mountain (NYSE:IRM) stores paper documents for its clients. The paper approach protects these vital documents from hackers since hackers can only get access to online information. The switching costs help Iron Mountain retain many of its clients. Better, Iron Mountain has clients with deep pockets, which include governments and 95% of the Fortune 1000 companies. It also has over 230,000 customers and offers cybersecurity services.Iron Mountain has gained 22% year-to-date and is up by 76% over the past five years. Shares currently trade at a 47 P/E ratio and have a 4.25% dividend yield. Plus, it’s recession-resistant since it’s one of the last expenses its large enterprise clients would consider cutting.Palo Alto Networks (PANW)Palo Alto Networks (PANW) logo on corporate buildingSource: Sundry Photography / Shutterstock.comPalo Alto Networks (NASDAQ:PANW) more than tripled over the past five years and is up by 54% year-to-date. The profitable firm recently reported 24% year-over-year revenue growth and a 26% year-over-year growth in billings. Palo Alto Networks uses several cybersecurity products and services to simplify its customers’ online security. The main focuses are on firewalls and cloud security.Shares currently trade at a forward P/E ratio of 43 and a PEG ratio of 1.34. While both of those metrics can suggest the company is overvalued, Palo Alto Networks shares look attractive for long-term investors. The company’s ability to generate high revenue growth and expand profit margins makes it an attractive pick in the cybersecurity industry.Qualys (QLYS)A Qualys sign hanging on a corporate office in Silicon Valley.Source: Michael Vi / Shutterstock.comQualys (NASDAQ:QLYS) hasn’t enjoyed the same momentum as other cybersecurity stocks over the past few years. However, that trend appears to be changing. Shares are up by over 30% year-to-date and have elevated the company’s P/E ratio to 46.The company’s recent earnings report demonstrates why more investors are piling into this stock. Revenue was up 14% year-over-year, but the big story with this stock is its net income growth. Net income jumped by 33% year-over-year, while other companies are reporting decelerating net income growth or losses. Operating cash flow also increased by 52% year-over-year.Qualys’ Vulnerability Management, Detection, and Response (VMDR) was recently named the best vulnerability management solution in Europe. The accolades and management’s continued focus on growth can help the company gain more market share. Qualys has a $5 billion market cap which is lower than most cybersecurity stocks. Double-digit revenue growth combined with higher net income growth can help the company reward long-term investors.Cisco (CSCO)the cisco (CSCO) logo on a wallSource: Valeriya Zankovych / Shutterstock.comCisco (NASDAQ:CSCO) is a tech conglomerate that has been in business for decades. That type of longevity demonstrates the company’s ability to withstand various economic conditions. While the stock is only up about 21% over the last five years, investors like it for its 3% dividend yield. Cisco also offers several cybersecurity products and even offers cybersecurity certifications for people who want to learn the craft.Security is one of the company’s three major divisions. The other two are cloud and software. Those three divisions helped Cisco report 14% year-over-year revenue growth in the Fiscal 3rd quarter. The company projects 14% to 16% year-over-year revenue growth for its fourth quarter.  In addition, Cisco gives investors exposure to cloud, artificial intelligence, and cybersecurity. Accelerating revenue and net income growth can support higher dividend hikes and more share price appreciation.Zscaler (ZS)Zscaler (ZS) logo on a corporate buildingSource: Sundry Photography / Shutterstock.comZscaler (NASDAQ:ZS) is a high-growth cybersecurity stock that reported 46% year-over-year revenue growth. Although the company has not yet been profitable, leadership made progress on that front. In addition, Zscaler’s Zero Trust security platform has been attracting more customers across all sectors. Plus, Zscaler exceeded its guidance from the previous quarter which is always a good sign for investors.A recent Zscaler report about global ransomware attacks suggests its business model will continue to grow in the upcoming years. According to this report, these types of cyberattacks increased by 40% year-over-year.It’s important to remember how much money cybercriminals can make from their exploits. Cybersecurity solutions are necessary for many companies and can save them from legal fees, losing customers, and corrupted data. Zscaler and other cybersecurity stocks are poised to help businesses and investors.On this date of publication, Marc Guberti held a long position in FTNT. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.Marc Guberti is a finance freelance writer at InvestorPlace.com who hosts the Breakthrough Success Podcast. He has contributed to several publications, including the U.S. News & World Report, Benzinga, and Joy Wallet.More From InvestorPlaceMusk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.ChatGPT IPO Could Shock the World, Make This Move Before the AnnouncementIt doesn’t matter if you have $500 or $5 million. Do this now.The post 7 Cybersecurity Stocks You’ll Regret Not Buying Soon appeared first on InvestorPlace.

InvestorPlace

7 Cybersecurity Stocks You’ll Regret Not Buying Soon

https://finance.yahoo.com/news/7-cybersecurity-stocks-ll-regret-202742156.html

d26e18b3-6f00-35cf-9c13-b889dfe0226d

IRMD

Key InsightsInsiders appear to have a vested interest in IRadimed's growth, as seen by their sizeable ownershipThe top 3 shareholders own 52% of the company 37% of IRadimed is held by InstitutionsTo get a sense of who is truly in control of IRadimed Corporation (NASDAQ:IRMD), it is important to understand the ownership structure of the business. With 41% stake, individual insiders possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.So it follows, every decision made by insiders of IRadimed regarding the company's future would be crucial to them.In the chart below, we zoom in on the different ownership groups of IRadimed. Check out our latest analysis for IRadimed ownership-breakdownWhat Does The Institutional Ownership Tell Us About IRadimed?Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.We can see that IRadimed does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see IRadimed's historic earnings and revenue below, but keep in mind there's always more to the story.earnings-and-revenue-growthOur data indicates that hedge funds own 12% of IRadimed. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. The company's CEO Roger Susi is the largest shareholder with 40% of shares outstanding. In comparison, the second and third largest shareholders hold about 6.2% and 6.1% of the stock.Story continuesA more detailed study of the shareholder registry showed us that 3 of the top shareholders have a considerable amount of ownership in the company, via their 52% stake.While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There is some analyst coverage of the stock, but it could still become more well known, with time.Insider Ownership Of IRadimedThe definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.Our most recent data indicates that insiders own a reasonable proportion of IRadimed Corporation. Insiders own US$246m worth of shares in the US$604m company. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently. General Public OwnershipThe general public-- including retail investors -- own 10% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.Next Steps:While it is well worth considering the different groups that own a company, there are other factors that are even more important. Take risks for example - IRadimed has 2 warning signs (and 1 which makes us a bit uncomfortable) we think you should know about.If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

With a 41% stake, IRadimed Corporation (NASDAQ:IRMD) insiders have a lot riding on the company

https://finance.yahoo.com/news/41-stake-iradimed-corporation-nasdaq-104417754.html

668a9ed2-1bdc-3cad-a614-8d6c3b754edc

IRMD

iRadimed CorporationWINTER SPRINGS, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that the Company will be participating in two upcoming investor conferences.Iradimed management is scheduled to participate in investor meetings at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday and Wednesday, September 12-13, 2023, at the Lotte New York Palace Hotel in New York City. Iradimed management will also be participating in investor meetings at the Lake St. Capital 7th Annual Best Ideas Growth Conference “Big7” on Thursday, September 14 at the Yale Club in New York City.About IRADIMED CORPORATIONIRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services.We are the only provider of a non-magnetic intravenous (“IV”) infusion pump system designed to be safe during MRI procedures. We were the first to develop an infusion delivery system that eliminates many dangers and problems during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI-compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other unique features to deliver anesthesia safely and predictably and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is essential to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.Story continuesOur 3880 MRI-compatible patient vital signs monitoring system has been designed with non-magnetic components and other unique features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The IRADIMED 3880 has a compact, lightweight design allowing it to travel with the patient from the critical care unit to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the IRADIMED 3880 include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The IRADIMED 3880 MRI-compatible patient vital signs monitoring system has an easy-to-use design and effectively communicates patient vital signs information to clinicians.For more information, please visit www.iradimed.com.Media Contact:John Glenn Chief Financial OfficerIRADIMED CORPORATION(407) [email protected]

GlobeNewswire

IRADIMED CORPORATION to Participate at Upcoming Investor Conferences

https://finance.yahoo.com/news/iradimed-corporation-participate-upcoming-investor-200000180.html

00fd6937-8a55-3c3c-99ff-99aa17b5bead

ISDR

RALEIGH, NC / ACCESSWIRE / September 5, 2023 / ACCESSWIRE, a newswire service standout that provides regional, national, and global news to thousands of clients worldwide is pleased to announce the launch of its redesigned website - accesswire.com. As one of the top newswires in the industry, ACCESSWIRE is committed to providing its clients with the best experience and results; it starts with a thoughtfully designed website that redefines the user experience and exemplifies the company's dedication to forward-thinking innovation."Everything we do at ACCESSWIRE is done with our customers in mind, and we knew that as the industry and our customers grow and innovate, we needed to do the same," said Brian R. Balbirnie, Issuer Direct's Chief Executive Officer. "Our website is now as streamlined as our comprehensive communications suite is in helping our clients amplify their message to the masses."ACCESSWIRE's newly redesigned site now includes a combination of its services, as well as the offerings of its parent company, Issuer Direct.These product offerings include:Businesses around the globe are invited to visit the refreshed website and explore its products, use its free resources, read through its educational blog posts, and discover how some of the biggest brands in the world are using its services.Visit accesswire.com for more.###About ACCESSWIRE/Issuer Direct CorporationIssuer Direct is a leading communications company, providing solutions for both Public Relations and Investor Relations Professionals for over 16 years. Our comprehensive solutions are used by thousands of customers from emerging startups to multi-billion-dollar global brands, ensuring their most important moments are reaching the right audiences, via our industry-leading newswire, IR website solutions, events technology, and compliance solutions. For more information, please visit www.issuerdirect.com.Issuer Direct Corporation Media Contacts:Brian R. Balbirnie +1 919-481-4000 [email protected] Hammers +1 919-481-4000 [email protected]: ACCESSWIREStory continuesACCESSWIRE, Wednesday, July 12, 2023, Press release picturePress Release DistributionPress Release OptimizerOnline Media RoomIR WebsitesWebcastingView source version on accesswire.com: https://www.accesswire.com/767322/accesswire-leader-in-press-release-distribution-launches-new-website-unveils-extended-offerings

ACCESSWIRE

ACCESSWIRE, Leader in Press Release Distribution Launches New Website, Unveils Extended Offerings

https://finance.yahoo.com/news/accesswire-leader-press-release-distribution-140000683.html

1043e862-3c2a-3059-9fea-177eb03ffa20

ISDR

It's reported an estimated 8.7 million adults in the United States have attention deficit hyperactivity disorder (ADHD).RALEIGH, NC / ACCESSWIRE / September 5, 2023 / ADHD Online, the leader in ADHD assessment and diagnosis and a Newswire Press Release Optimizer (PRO) client, was recently featured in a Crain's Grand Rapids article.In the article titled "New ADHD Online CEO prepares to 'broaden our aim' for mental health assessments", Keith Brophy, ADHD Online's CEO, had the opportunity to share his insights on several topics, including:Significant barriers with regulatory changes and drug shortagesSecuring capitalBuilding a strong management teamADHD Online was co-founded in 2018 by former CEO Zach Booker and Randall Duthler, a family physician with Corewell Health. Their goal was to provide the gold standard in comprehensive online ADHD screenings to help people get the treatment they need and deserve.This earned media feature in Crain's Grand Rapids was a result of Newswire's Total PRO, a full-service program that provides support with planning and crafting messaging, media outreach and much more."We're a Grand Rapids-based company, so securing this feature in a local publication was an excellent opportunity for us to share our story and build brand awareness," said Brophy. "Newswire's team continues to help us amplify our message so we can help more people living with ADHD get the necessary treatment to improve their quality of life."As part of the Total PRO Plan, ADHD Online has direct access to Newswire's experts who create the right content, curate the right media lists and commercial targets, distribute the right message through comprehensive press release distribution and commercial outreach, pitch the media, monitor and track effectiveness, and showcase the communications in a newsroom that's uniquely tailored to their goals.To learn more about the PRO Plan, contact Newswire today.Story continuesAbout ADHD OnlineADHD Online was founded in 2018 with the mission that everyone should have access to quality ADHD assessments regardless of who and where they are. The ADHD Online team is filled with experts across the United States who share a passion for ADHD and related mental health conditions, and ensuring patients have access to critical mental health services. ADHD Online provides a critical voice for those who might be struggling with ADHD and has a unique offering of HIPAA-secured ADHD assessments online with review and results from licensed psychologists in all 50 states. ADHD Online is a brand under Mentavi Health. Mentavi Health addresses ADHD and adjacent mental health conditions in conjunction with organizational customers.About NewswireNewswire is a media technology company that provides its clients with the Press Release Optimizer, which consists of press release distribution, media databases, media monitoring, and online media rooms that power the Media Advantage: greater brand awareness through earned media, increased online visibility through content strategy and planning as well as greater SEO recognition.Through its disruptive Press Release Optimizer, relentless commitment to customer satisfaction, and passion for customer performance, Newswire is automating media and marketing communications for large and small businesses seeking to deliver the right message to the right audience at the right time for the right purpose.To learn more about Newswire and its Press Release Optimizer, visit Newswire.com and discover why our customers have named us #1 for Customer Satisfaction and Ease of Use for four years in a row. For more information, visit https://www.newswire.com.Newswire is a wholly owned subsidiary of Issuer Direct (NYSE American:ISDR), a leading communications and compliance company, providing solutions for both Public Relations and Investor Relations Professionals. For more information, please visit www.issuerdirect.com.Contact InformationJennifer Hammers Executive Vice President of Sales & Marketing [email protected] 919.481.4000SOURCE: Newswire.View source version on accesswire.com: https://www.accesswire.com/780602/adhd-online-featured-in-local-business-publication-with-newswires-help

ACCESSWIRE

ADHD Online Featured in Local Business Publication With Newswire's Help

https://finance.yahoo.com/news/adhd-online-featured-local-business-172000726.html

d686c4b6-ff21-33e4-844e-6b8ca1bd4045

ISPC

iSpecimen IncCompany to Focus on Core Revenue Drivers, New Revenue Growth Opportunities from Recently Launched Sequencing Procurement Program and Expense ReductionsLEXINGTON, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that the Board of Directors has approved an organizational restructuring plan to improve operational performance and drive shareholder value.iSpecimen announced immediate headcount reductions of approximately 20% of the Company’s total workforce and additional expense reductions after streamlining operations and rationalizing resources to focus on key market opportunities. Recently, the Company completed its implementation of lines of business teams and next day quotes to shorten sales cycles, improve quote-to-purchase order ratios, increase fulfillment and accelerate revenue generation. As a result of these changes, monthly expenses related to headcount, including other employee turnover during the year, as well as all other monthly operational costs, are expected to decrease by approximately 29% and 52%, respectively, compared to the average monthly costs for the first eight months of the year.“The Company believes that the investments made during the first half of the year should allow the iSpecimen Marketplace to remain a leading source for researchers in need of biospecimens. We remain committed to becoming cash flow neutral and then cash flow positive as quickly as possible,” said Tracy Curley, iSpecimen’s CEO.iSpecimen recently announced the launch of its virtual cancer sequencing procurement program aimed at providing researchers with consistent and direct access to cancer tumor tissues. The genetic signatures of cancer tumor tissues provide important information necessary to develop new treatments and diagnostics. Through this new offering, cancer researchers can advance their work by efficiently accessing these highly sought tumor tissues from iSpecimen, overcoming the existing manual, time-consuming and costly process of requesting biospecimen samples from multiple sources and suppliers.Story continuesMs. Curley concluded, “Capitalizing on our market position and leveraging our broad supplier network, we saw a tremendous opportunity to launch our cancer sequencing program. We see strong demand for these highly valuable and challenging-to-obtain samples. This program relieves a major bottleneck in cancer research today, and we are working to realize revenue from this new opportunity as quickly as possible.”About iSpecimeniSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.Forward Looking StatementsThis press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," “believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements.Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.For further information, please contact:Investor ContactsKCSA Strategic CommunicationsPhil Carlson / Erika Kay [email protected] ContactsKCSA Strategic CommunicationsRaquel Cona / Shana Marino [email protected]

GlobeNewswire

iSpecimen Announces Organizational Changes to Enhance Operational Efficiencies and Drive Profitability

https://finance.yahoo.com/news/ispecimen-announces-organizational-changes-enhance-200500047.html

9fcef27c-479e-35da-8487-4ef6f5c797d7

ISPC

Lexington-based iSpecimen Inc. (Nasdaq: ISPC) announced the layoffs as part of broader "organizational changes" late Wednesday. Around six of the people being let go are based in Massachusetts, according to a statement from CEO Tracy Curley sent by spokesperson Raquel Cona.Continue reading

American City Business Journals

Biotech services company iSpecimen company lays off one-quarter of its staff

https://finance.yahoo.com/m/31028774-b8d5-39a2-9734-5704a550bc5d/biotech-services-company.html

31028774-b8d5-39a2-9734-5704a550bc5d

ISRG

Two high-growth Nasdaq 100 stocks are phenomenal businesses hiding in plain sight, while another Nasdaq 100 component comes with outsize risk.Continue reading

Motley Fool

2 Nasdaq 100 Stocks That Are Surefire Buys in September and 1 to Avoid Like the Plague

https://finance.yahoo.com/m/17cd147a-c92c-3abb-ab83-a363a6f38c7f/2-nasdaq-100-stocks-that-are.html

17cd147a-c92c-3abb-ab83-a363a6f38c7f

ISRG

Ken FisherThe best investors will often tell you that one vital ingredient for stock market success is an overlooked and underappreciated one: patience.With this year’s bull market appearing to stall, billionaire stock picker Ken Fisher reminds investors that it’s a quality needed to weather the more difficult periods, which are also a natural component of any bull market.“Volatility isn’t a flaw in this bull market. It is a feature of all bull markets, which proverbially climb a ‘Wall of Worry,’” the Fisher Investments founder recently said. “The bull market born last October should keep delivering worthy returns, but sporadically. Reaping them requires patience, which can be difficult for some.”But sticking with it is Fisher’s advice: “Don’t be fooled – this bull market has legs, and it is crucial you don’t get scared of it now.”Fisher has decades of stock market success behind him and has a net worth of $7.1 billion, so he most definitely knows what he’s talking about here. For investors looking to get ahead in the market, it’s worth finding out which stocks he’s patiently counting on to bring the goods once the upward curve resumes.We’ve started this process and have taken a look at a pair of equities that make up a meaningful chunk of Fisher’s portfolio – both holdings exceed $1 billion in value. But it’s not only Fisher showing big faith in these names; according to the TipRanks database, the analyst consensus rates both as Strong Buys. Let’s see what makes them so.Charles Schwab (SCHW)Fisher holds a big position in one of the most prominent companies in the investing world. Charles Schwab is a brokerage firm that has played a pivotal role in shaping the landscape of online investing and financial services. Founded in 1971 by Charles R. Schwab, it has grown to become one of the largest and most respected financial institutions in the US.The company offers a wide range of services, including stock and bond trading, mutual funds, exchange-traded funds (ETFs), retirement accounts, and wealth management services. Charles Schwab provides a user-friendly and technologically advanced platform for investors and was a pioneer in introducing online trading, which revolutionized the way individuals manage their investments. With a market cap over $106 billion, the company is the U.S.’s biggest publicly traded investment services firm, with ~$8 trillion in client assets.Story continuesThat said, 2023 has been no easy ride, especially earlier in the year when the stock got caught up in the fallout of several prominent bank collapses. The shares went through an almost 40% drop between January and early March. The stock has bounced back a bit since, aided by a better-than-expected Q2 print. While revenue fell by 8.4% year-over-year to $4.66 billion, the figure exceeded Street expectations by $50 million. Likewise, adj. EPS of $0.75 beat the consensus estimate by $0.04.Meanwhile, Fisher must have sensed the pullback offers an opportunity to load up. He bought 1,302,697 shares in Q2, upping his SCHW stake by 8%. His total holdings now stand at more than 18 million shares, currently worth ~$1.04 billion.Assessing the company’s prospects, Piper Sandler analyst Patrick Moley thinks the future looks bright for this financial giant.“While eBrokers typically fall out of investor favor at the end of rate hiking cycles, the unprecedented pace of rate hikes this cycle provides a unique opportunity for NIM expansion and earnings growth even if the Fed starts cutting,” Moley explained. “In our view, SCHW remains a ’24/’25 story as (1) a return of deposit growth, (2) the paydown of temporary ST funding, (3) NIM expansion, and (4) the realization of AMTD integration synergies and incremental expense saves converge to produce strong earnings power and an attractive valuation for LT investors into this industry leading financial services franchise.”As such, Moley rates SCHW shares as Overweight (i.e., Buy), with an $86 price target, indicating potential for ~49% growth over the coming year. (To watch Moley’s track record, click here)Most on the Street agree with Moley’s take. Based on 13 Buys, 2 Holds and 1 Sell, the stock claims a Strong Buy consensus rating. At $73.80, the average target points to 12-month upside of 28%. (See SCHW stock forecast)Intuitive Surgical (ISRG)Patience might be one quality investors should adhere to, but diversification is often seen as another. And in that sense, it is fitting that the next Fisher-backed stock we’ll look at is of an entirely different hue. Fisher holds 4,444,151 shares of medical device maker Intuitive Surgical. These command a market value of more than $1.32 billion.In one way, Intuitive Surgical is similar to Charles Schwab above – it is also a pioneer in its field. It is a healthcare tech company that has revolutionized the field of minimally invasive surgery. The Sunnyvale, California-based firm is best known for its da Vinci Surgical System, a groundbreaking robotic surgical platform. The da Vinci System enables surgeons to perform complex surgical procedures with enhanced precision, dexterity, and control through minimally invasive techniques. This innovative technology has found applications in various medical specialties, including urology, gynecology, general surgery, and cardiothoracic surgery, making it a vital tool in modern healthcare.Its usage is on the up, too. In the most recently reported quarter, for 2Q23, worldwide da Vinci procedures increased by around 22% compared to the same period last year while the company placed 331 systems, vs. the 279 placed in 2Q22. As of the end of the quarter, the installed base stood at 8,042 systems, representing a 13% year-over-year uptick.These activities led to outperformance in both the top and bottom lines. Q2 revenue climbed by 15.8% year-over-year to $1.76 billion, edging ahead of Street expectations by $20 million, while adjusted EPS of $1.42 beat the forecast by $0.09.Piper Sandler analyst Adam Maeder has been keeping a tab on ISRG’s progress and he points out a specific opportunity that might be somewhat underappreciated.“We recently took a renewed look at the China opportunity for Intuitive, which we believe is quite sizable in the coming years,” the 5-star analyst noted. “Not only will ISRG likely place a substantial amount of systems under the new quota, da Vincis in China are some of the highest utilized systems in the world—which should also bode well for procedure growth. Our math suggests that system placements from the new quota coupled with robust procedure volume from a growing install base should result in nicely accretive growth in 2023-2027. We believe ISRG’s China revenue could more-than-double from ~ $300M in 2023 (our estimate) to roughly $650M in 2027. While the Street views China to be an important growth contributor, we do not believe models are fully incorporating the magnitude of this potential growth lever.”These comments underpin Maeder’s Overweight (i.e. Buy) rating while his $385 price target implies shares will appreciate by ~30% over the next year. (To watch Maeder’s track record, click here)Turning now to the rest of the Street, most other analysts are on the same page. With 12 Buys and 2 Holds assigned in the last three months, the word on the Street is that ISRG is a Strong Buy. Additionally, the $377.14 average price target brings the upside potential to ~27%. (See ISRG stock forecast)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

TipRanks

Don’t be fooled, Ken Fisher says – this bull market has legs. Here are 2 stocks he’s using to bet on a bounce

https://finance.yahoo.com/news/don-t-fooled-ken-fisher-131744135.html

4a65f3ca-0f86-3ea8-afa3-372685e2c695

ISUN

Q2 2023 revenues of $25 million, a 51.8% increase from Q2 2022, driven by higher demand and strong execution of company’s strategyReaffirms expectations for total revenue of $95-100 million in 2023, a 24-31% increase over 2022WILLISTON, Vt., August 10, 2023--(BUSINESS WIRE)--iSun, Inc. (NASDAQ: ISUN) (the "Company," or "iSun"), a leading solar energy and clean mobility infrastructure company with 50 years of experience accelerating the adoption of innovative electrical technologies, today announced final financial results for the second quarter of 2023 ended June 30, 2023.Quarterly HighlightsQ2 2023 revenue of $25.0 million, up 51.8% from Q222, as continued commercial and industrial execution drives growthYTD revenue of $42.4 million, up 34.2% over first half of 2022Gross profit of $5.9 million, up 58.2% from Q222Gross margin of 23.7%, up 90 basis points from 22.8% in 2022’s second quarter, as expected synergies taking holdAwarded $8.0 million in new solar and EV infrastructure contracts in Q2 2023, with a total of $40.0 million in first half of 2023Continuing successful execution of growth strategy, leveraging tailwindsManagement Commentary"We are continuing to benefit from positive momentum, especially in our commercial and industrial segment, as we generated 51.8% higher revenue in the 2023 second quarter compared to last year. Our team is focused on executing our growth strategy, leveraging the positive tailwinds from climate legislation and higher customer interest in alternative energy solutions," said Jeffrey Peck, Chief Executive Officer of iSun. "I am very pleased by our continued success in achieving new contract wins, as we added $8 million in the second quarter, for a total of $40 million in the first half of this year, a record pace for iSun. Our improved synergies as we scale, along with higher productivity, enabled us to increase our margins by 90 basis points in the second quarter to 23.7%. We have increased our labor utilization this year, as part of our ongoing efficiency efforts that included the consolidation of our commercial and industrial divisions, which offsets the continuing challenges we experience from supply chain constraints, even as they are lessening compared to last year. All these efforts provide us the confidence to reaffirm our annual revenue guidance for 2023, as we work diligently to implement and complete our many projects."Story continuesSecond Quarter and Year to Date ResultsiSun reported second quarter 2023 revenue of $25.0 million, up 51.8% from $16.5 million in the same period in 2022. YTD revenue was $42.4 million, representing a $10.8 million or 34.2% increase over the same period in 2022. Revenue growth was driven primarily by the fulfillment of commercial and industrial projects across multiple states receiving notice to proceed as well as our residential backlog; total backlog was $161.8 million as of June 30, 2023. iSun also generated new future demand by adding $8 million in new business during the second quarter and a total of $40 million in the first half of 2023, primarily driven by strong demand for commercial and industrial services as well as for focused project origination and design services for partners on large national carport projects.Divisional highlights as of June 30, 2023, include:Residential division generated revenue of $9.3 and $16.2 million in the second quarter and YTD respectively. Customer orders of approximately $13.1 million are expected to be completed within three to five months.The commercial and industrial division, which were consolidated as of January 1, 2023, generated revenue of $15.6 and $25.9 million in the second quarter and YTD respectively; the division has a contracted backlog of approximately $140.7 million expected to be completed within 10-18 months.Utility and development division generated revenue of $0.1 and $0.3 million in the second quarter and YTD respectively. The Utility division has a contracted backlog of approximately $8.0 million and 1.6 GW of projects currently under development expected to achieve NTP in 2023 and early 2024.Gross profit in the second quarter was $5.9 million, up 58.2% from $3.8 million in the second quarter of 2022. Gross margin for the quarter was 23.7%, up 90 basis points from 22.8% in the same period in 2022. YTD gross profit was $9.5 million, up 37% compared to $6.9 million during the same period in 2022. YTD gross margin was 22.4%, up 50 basis points compared to 21.9% during the same period in 2022. Margin is expected to continue to expand in the second half of 2023 consistent with scaling of operations and planned increase in residential implementations, as part of the strategy to expand gross margin each year as synergies among the company’s segments grow.The operating loss in the second quarter was ($1.8) million, a 68.8% improvement compared to a loss of ($5.6) million in 2022’s second quarter, primarily reflecting the higher revenues and lower operating expenses as part of the company’s efficiency focus. YTD operating income was a loss of ($4.4) million, a 61.1% reduction compared to a loss of ($11.3) million during the same period in 2022. Non-cash depreciation and amortization expenses were $0.8 million in the second quarter of 2023, compared to $1.8 million in prior year period. YTD non-cash depreciation and amortization expenses were $1.5 million compared to $3.5 million in the same period in 2022.iSun reported a net loss of ($2.5) million, or ($0.13) per share, in the second quarter of 2023, compared to a net loss of ($5.7) million, or ($0.40) per share, in the same period in 2022. YTD net loss was ($5.5) million or ($0.31) per share compared to a net loss of ($8.6) million or ($0.64) per share in the same period in 2022.Adjusted EBITDA for the second quarter of 2023 was a loss of ($0.6) million or ($0.03) per share, compared to a loss of ($3.2) million or ($0.23) per share in 2022’s second quarter. YTD Adjusted EBITDA was a loss of ($1.8) million or ($0.10) per share compared to a loss of ($3.4) million or ($0.25) per share in the same period in 2022.OutlookiSun’s continuing success in winning new business, from solar projects to EV infrastructure and project origination and development services, along with its sizable and growing backlog, is expected to enable the company to produce total revenue of $95-100 million for the full year 2023, representing a 24-31% increase over total revenues of $76.5 million in 2022. With the positive results from its focus on efficiency so far this year, iSun also anticipates continued gross margin expansion and adjusted EBITDA profitability by the end of 2023.Added Mr. Peck, "We are making excellent progress in tracking against the targets we set for iSun’s performance this year, as we execute on our strategy and fulfill our commitments to investors. We remain confident that our capabilities effectively address the needs of more customers and position us to accelerate our growth in the evolving alternative energy sector. Our success in winning significant contracts with existing and new customers is based upon our platform approach that delivers a suite of services to meet the needs of diverse customers. This year, we are also benefiting from the expertise of our team in executing efficiently on our backlog to address our customers’ needs. Now that our country’s energy policy has been established for the next 10 years through the IRA legislation passed last summer, we expect those macroeconomic factors to help us scale our operations significantly in the next few years, and thus enable us to generate steadily higher revenue and reach operating profitability."Second Quarter 2023 Conference Call DetailsiSun will host a conference call today, Thursday, August 10, at 8:30 AM ET to review the Company’s financial results and discuss its operations and outlook. Participants can access the live conference call via telephone at 1-888-506-0062 (domestic) or 1-973-528-0011 (international), using conference ID 246871 or via webcast in the Investor Relations section of the iSun website at investors.isunenergy.com. An audio replay will be available through Thursday, August 24, 2023, and can be accessed by dialing 1-877-481-4010 (domestic) or 1-919-882-2331 (international), using conference code 48846. A webcast of the conference call will be available beginning approximately one hour after the call is completed at investors.isunenergy.com.iSun, Inc.Condensed Consolidated Balance Sheets as ofJune 30, 2023 (Unaudited) and December 31, 2022(In thousands, except number of shares)June 30, 2023December 31, 2022AssetsCurrent Assets:Cash$6,105$5,455Accounts receivable, net of allowance11,2388,783Contract assets8,3697,324Inventory2,1192,536Other current assets1,5771,625Total current assets29,40825,723Other Assets:Property and equipment, net of accumulated depreciation8,1088,440Operating lease right-of-use assets, net6,6386,960Captive insurance investment270270Intangible assets, net13,23814,038Investments12,02012,020Other assets3030Total other assets40,30441,758Total assets$69,712$67,481Liabilities and Stockholders’ EquityCurrent Liabilities:Accounts payable$16,986$12,941Accrued expenses3,6325,868Operating lease liability601588Contract liabilities8,0205,419Current portion of deferred compensation1531Current portion of long-term debt5,1525,374Total current liabilities34,40630,221Long-term liabilities:Warrant liability-10Operating lease liability, net of current portion6,4056,711Other liabilities2,8323,026Long-term debt, net of current portion5,5088,226Total liabilities49,15148,194Contingencies (Note 1l)Stockholders’ equity:Preferred stock - 0.0001 par value 1,000,000 shares authorized, 0 issued and outstanding as of June 30, 2023 and December 31, 2022--Common stock – 0.0001 par value 49,000,000 shares authorized, 23,435,489 and 15,083,109 issued and outstanding as of June 30, 2023, and December 31, 2022, respectively22Additional paid-in capital80,85274,070Accumulated deficit(60,293)(54,785)Total Stockholders’ equity20,56119,287Total liabilities and stockholders’ equity$69,712$67,481The accompanying notes are an integral part of these consolidated financial statements.iSun, Inc.Condensed Consolidated Statements of Operationsfor the Three and Six Months Ended June 30, 2023, and 2022 (Unaudited)(In thousands, except number of shares and per share data)Three Months endedSix Months endedJune 30,June 30,2023202220232022Earned revenue$25,006$16,476$42,365$31,563Cost of earned revenue19,06912,72332,87924,640Income before operating expenses5,9373,7539,4866,923Warehousing and other operating expenses2201,0174511,367General and administrative expenses6,3345,98211,18311,509Stock based compensation – general and administrative3735917461,835Depreciation and amortization7621,7781,5123,530Total operating expenses7,6899,36813,89218,241Operating loss(1,752)(5,615)(4,406)(11,318)Other income (expenses):Gain on forgiveness of PPP Loan---2,592Change in fair value of the warrant liability4281091Loss on debt conversion(303)-(303)Interest expense, net(448)(87)(797)(716)Other income (expense)(747)(59)(1,090)(1,967)Loss before income taxes(2,499)(5,674)(5,496)(9,351)Tax expense (benefit)12712(765)Net loss$(2,511)$(5,681)$(5,508)$(8,586)Net loss per share of Common Stock - Basic and diluted$(0.13)$(0.40)$(0.31)$(0.64)Weighted average shares of Common Stock - Basic and diluted19,685,04514,070,11717,829,45913,364,352The accompanying notes are an integral part of these consolidated financial statements.Non-GAAP Financial MeasuresIncluded in this presentation are discussions and reconciliations of earnings before interest, income tax and depreciation and amortization ("EBITDA") and EBITDA adjusted for certain non-cash, non-recurring or non-core expenses ("Adjusted EBITDA") to net loss in accordance with GAAP. Adjusted EBITDA excludes certain non-cash and other expenses, certain legal services costs, professional and consulting fees and expenses, and one-time Reverse Merger and Recapitalization expenses and certain adjustments. We believe that these non-GAAP measures illustrate the underlying financial and business trends relating to our results of operations and comparability between current and prior periods. We also use these non-GAAP measures to establish and monitor operational goals.These non-GAAP measures are not in accordance with, or an alternative to, GAAP and should be considered in addition to, and not as a substitute or superior to, the other measures of financial performance prepared in accordance with GAAP. Using only the non-GAAP financial measures, particularly Adjusted EBITDA, to analyze our performance would have material limitations because such calculations are based on a subjective determination regarding the nature and classification of events and circumstances that investors may find significant. We compensate for these limitations by presenting both the GAAP and non-GAAP measures of our operating results. Although other companies may report measures entitled "Adjusted EBITDA" or similar in nature, numerous methods may exist for calculating a company’s Adjusted EBITDA or similar measures. As a result, the methods that we use to calculate Adjusted EBITDA may differ from the methods used by other companies to calculate their non-GAAP measures.The reconciliations of EBITDA and Adjusted EBITDA to net loss, the most directly comparable financial measure calculated and presented in accordance with GAAP, are shown in the table below:Three Months EndedJune 30,Six Months EndedJune 30,2023202220232022Net income (loss)$(2,511)$(5,681)$(5,508)$(8,586)Depreciation and amortization7621,7781,5123,530Interest expense44887797716Stock based compensation3735917461,835Change in fair value of warrant liability(4)(28)(10)(91)Loss on conversion303-303-Income tax (benefit)12712(765)EBITDA(617)(3,246)(2,148)(3,361)Other costs(1)350-35010Adjusted EBITDA(267)(3,246)(1,798)(3,351)Weighted Average shares outstanding19,685,04514,070,11717,829,45913,364,352Adjusted EPS(0.01)(0.23)(0.10)(0.25)(1)Other costs consist of one-time legal expenses related to the settlement of a lawsuit.(2)As the forgiveness of the PPP loan is considered a one-time expense, the Company considered including the forgiveness of $0 million and $2.6 million for the six months ended June 30, 2023 and 2022, respectively, as a reconciling item. The Company excluded the forgiveness on the basis that had it not been awarded a PPP loan, the Company would have terminated, furlough or reduced its workforce during the COVID-19 pandemic shutdown.About iSun Inc.Since 1972, iSun has accelerated the adoption of proven, life-improving innovations in electrification technology. iSun has been the trusted service provider to Fortune 500 companies for decades and has installed clean rooms, fiber optic cables, flight simulators, and over 600 megawatts of solar systems. The Company currently provides a comprehensive suite of solar services across residential, commercial, industrial & municipal, and utility scale projects and provides solar electric vehicle charging solutions for both grid-tied and battery backed solar EV charging systems. iSun believes that the transition to clean, renewable solar energy is the most important investment to make today and is focused on profitable growth opportunities. Please visit www.isunenergy.com for additional information.Forward Looking StatementsThis press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Words or phrases such as "may," "should," "expects," "could," "intends," "plans," "anticipates," "estimates," "believes," "forecasts," "predicts" or other similar expressions are intended to identify forward-looking statements, which include, without limitation, earnings forecasts, effective tax rate, statements relating to our business strategy and statements of expectations, beliefs, future plans and strategies and anticipated developments concerning our industry, business, operations and financial performance and condition.The forward-looking statements included in this press release are based on our current expectations, projections, estimates and assumptions. These statements are only predictions, not guarantees. Such forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict. These risks and uncertainties may cause actual results to differ materially from what is forecast in such forward-looking statements, and include, without limitation, the risk factors described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.All forward-looking statements included in this press release are based on information currently available to us, and we assume no obligation to update any forward-looking statement except as may be required by law.View source version on businesswire.com: https://www.businesswire.com/news/home/20230810497433/en/ContactsFor more information: Investor [email protected]

Business Wire

iSun Inc. Reports Final Second Quarter 2023 Results

https://finance.yahoo.com/news/isun-inc-reports-final-second-120000173.html

763d7740-a530-3882-8a2c-59be38d16142

ISUN

WILLISTON, Vt., September 07, 2023--(BUSINESS WIRE)--iSun, Inc. (NASDAQ: ISUN) (the "Company," or "iSun"), a leading solar energy and clean mobility infrastructure company with 50-years of experience accelerating the adoption of innovative electrical technologies, announced today that the company will participate in several investor events this month:H.C. Wainwright 25th Annual Global Investment Conference, New York CityJohn Sullivan, CFO, will present on Monday, September 11, 2023, at 12:30 pm in the Stanford Room of the Lotte New York Palace Hotel, and host investor meetings on Monday and Tuesday, September 11-12 at the conference.RE+, Las Vegas, NevadaiSun will attend this event and be available for meetings with investors on Wednesday, September 13, 2023, at the Venetian Convention & Expo Center.About iSun Inc.Since 1972, iSun has accelerated the adoption of innovations in energy transition and electrification technology. iSun has been the trusted service provider to Fortune 500 companies for decades and has installed clean rooms, fiber optic cables, flight simulators, and over 600 megawatts of solar systems. The Company currently provides a comprehensive suite of solar services across residential, commercial, industrial & municipal, and utility scale projects and provides solar electric vehicle charging solutions for both grid-tied and battery backed solar EV charging systems. iSun believes that the transition to clean, renewable solar energy is the most important investment to make today and is focused on profitable growth opportunities. Please visit www.isunenergy.com for additional information.View source version on businesswire.com: https://www.businesswire.com/news/home/20230907539968/en/ContactsFor more information: Investor [email protected]

Business Wire

iSun To Participate in Upcoming Investor Events

https://finance.yahoo.com/news/isun-participate-upcoming-investor-events-130500257.html

9a1c00ce-5a6b-390a-9f06-a08488600d77

IT

A month has gone by since the last earnings report for Gartner (IT). Shares have added about 3.2% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Gartner due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.Gartner Surpasses Q2 Earnings & Revenue EstimatesGartner, Inc. reported better-than-expected second-quarter 2023 results.Adjusted earnings (excluding 37 cents from non-recurring items) per share of $2.85 beat the Zacks Consensus Estimate by 14.9% but matched the year-ago reported figure. Revenues of $1.5 billion beat the consensus estimate by 1% and improved 9.2% year over year on a reported basis and 10% on a foreign-currency-neutral basis.Total contract value was $4.6 billion, up 8.9% year over year on a foreign-currency-neutral basis.Quarterly Numbers in DetailRevenues in the Research segment increased 5.7% year over year on a reported basis and 6.5% on a foreign-currency-neutral basis to $1.21 billion. Gross contribution margin was 73.3%, which came to $885 million in the reported quarter.Conferences’ revenues surged 48.8% year over year on a reported basis and 48.4% on foreign-currency-neutral basis to $169 million. Gross contribution margin was 58.3% in the reported quarter.Revenues in the Consulting segment grew 4.8% year over year on a reported basis and 5.9% on a foreign-currency-neutral basis to $126 million. Gross contribution margin was 37.4% in the reported quarter.Adjusted EBITDA of $384 million declined 1.2% year over year on a reported basis and 0.3% on a foreign-currency-neutral basis.Operating cash flow totaled $436 million while free cash flow was $410 million in the reported quarter. Capital expenditures totaled $26 million.Updated 2023 OutlookTotal revenues are expected to be $5.85 billion, up from the previous guidance of $5.90 billion. Adjusted earnings per share is now anticipated to be $10.00, up from the previous guidance of $9.50.Story continuesAdjusted EBITDA is projected to be $1.36 billion, raised from the earlier guidance of $1.33 billion. Free cash flow is anticipated to be $975 million, up from the prior expectation of $920 million.How Have Estimates Been Moving Since Then?In the past month, investors have witnessed an upward trend in fresh estimates.The consensus estimate has shifted -5.94% due to these changes.VGM ScoresCurrently, Gartner has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Following the exact same course, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Gartner has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.Performance of an Industry PlayerGartner is part of the Zacks Consulting Services industry. Over the past month, FTI Consulting (FCN), a stock from the same industry, has gained 1.9%. The company reported its results for the quarter ended June 2023 more than a month ago.FTI Consulting reported revenues of $864.59 million in the last reported quarter, representing a year-over-year change of +14.5%. EPS of $1.75 for the same period compares with $1.43 a year ago.For the current quarter, FTI Consulting is expected to post earnings of $1.84 per share, indicating a change of -14.4% from the year-ago quarter. The Zacks Consensus Estimate has changed -7.2% over the last 30 days.The overall direction and magnitude of estimate revisions translate into a Zacks Rank #5 (Strong Sell) for FTI Consulting. Also, the stock has a VGM Score of C.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportGartner, Inc. (IT) : Free Stock Analysis ReportFTI Consulting, Inc. (FCN) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Gartner (IT) Up 3.2% Since Last Earnings Report: Can It Continue?

https://finance.yahoo.com/news/gartner-3-2-since-last-153124469.html

bd1f18e7-9a6d-3e26-bb82-4d7646cb0012

IT

Gartner Inc. (NYSE:IT) is one of the worlds most renowned research and advisory companies. It is most famous for its Magic Quadrant, in which Gartner assesses companies in order to identify leaders across a variety of industries, from supply chain management software to artificial intelligence.The company reported strong financial results for the second quarter in August, beating both revenue and earnings forecasts.Warning! GuruFocus has detected 8 Warning Signs with WMB. Click here to check it out. IT 30-Year Financial DataThe intrinsic value of ITGartner: Research Powerhouse Continues to RoarWhat makes Gartner special?Gartner has a strong brand and sits at a key point in the market. The business gives buyers an independent review point which can help them pick software and choose business partners.The company is a thought leader across a variety of topics and provides independent research reports to business customers.Gartner is known for its range of conferences, which sponsor various industry sectors. This acts as a great top of the funnel process to entice new customers and offer more value to existing customers.The business also operates a strong consulting service covering a variety of areas, from digital transformation to technology strategy evaluation, IT cost optimization and Big Data.Solid financialsGartner reported solid financial results for the second quarter. Its revenue was $1.5 billion, which beat analyst forecasts by $1.5 billion and rose by 9.2% year over year.The top line also beat analyst forecasts by $23.65 million, driven by strong Research revenue, which increased by 6% year over year or 7% on a constant currency basis. This segment is also its largest and most profitable with a 73% contribution margin, higher than the companys average of 68%.This was further benefited by a range of growing topics, such as artificial Intelligence, cybersecurity, data analytics and even remote work.Gartner: Research Powerhouse Continues to RoarGartner's overall contract value rose by 9% year over year to $4.6 billion. This was driven by double-digit growth of enterprise leaders such as chief financial officer and chief information security officer customers. Tech vendor contract value was a little slower with single-digit growth, which was lower than the mid-teens growth reported in the prior year.Story continuesOverall contract value growth was diverse across industries. This was led by strong growth in the transportation sector, followed by retail and the public sector.Breaking down by segment, global technology sales reached $3.5 billion, up 7% year over year.GTS wallet retention was a solid 102%, which was down slightly from the 107% in the prior year. However, this is still solid as it means customers are sticking with Gartner specifically.Moving on to global business sales, its contract value was $1 billion, which rose by 15% year over year. This was led by the supply chain industry. Upon the reopening of the economy in 2021, many companies suffered with supply chain disruption and thus, this has made it a critical issue for businesses to address.Human resources was also a strong area of growth. This was driven by the rise of remote working, which has created an entirely new setup that is required for organizations.Overall GBS retention was a solid 109%. Again, this was down from the 115% in the prior year, but still positive overall.Consulting revenue continues with strong growth as it rose by 5% year over year to $126 million, at a 37% contribution margin.There was a solid backlog reported for this segment, with $172 million in revenue up 17% year over year.Conferences have had a resurgence now that in-person events are back in vogue. In the second quarter, Gartner reported $169 million in revenue, which beat internal expectations. This was driven by a roadshow of 17 conferences during the quarter. The contribution margin for this product type was also stable at 58%,Finally, contract optimization, a small business segment, reported $22 million in revenue.Profitability and balance sheetMoving on to profitability, Gartner reported operating income of $299 million, which declined by 3.87% year over year. This was driven by a 12.95% increase in selling, general and administrative expenses to $670 million.GBS quota-bearing headcount was up 15% year over year, qhile the overall company headcount rose to 20,104 associates, up 12%. In consultancies, the people are the product and thus, it can be more challenging to cut costs in this area.Gartner: Research Powerhouse Continues to RoarValuationGartner trades with a price-sales ratio of 4.85, which is higher than its five-year average, but lower than its ratio over 6 in 2021.Gartner: Research Powerhouse Continues to RoarBased on historical ratios, past financial performance and analysts' future earnings projections, the GF Value Line also indicates a fair value of $345 per share. Thus, the stock is fairly valued at the time of writing. Final thoughts Gartner is a leading consultancy company that has a unique place in the market. Vendors rely on the company to assess the quality of their product relative to competitors. This effectively gives it a stranglehold on this market and a competitive advantage. Its competitors do offer similar services, but Gartner has the highest focus on enterprises (the most lucrative customer base).This article first appeared on GuruFocus.

GuruFocus.com

Gartner: Research Powerhouse Continues to Roar

https://finance.yahoo.com/news/gartner-research-powerhouse-continues-roar-171406053.html

91552464-e380-3b00-bd35-534b378f9c68

ITAQ

Global Natural Resources and Clean Energy Leader to Help Guide NEXT Ahead of Previously Announced Merger with ITAQHOUSTON, TX / ACCESSWIRE / April 11, 2023 / NEXT Renewable Fuels ("NEXT") announced Stephen Trauber has been appointed to its Board of Directors ahead of the Company's anticipated listing on the Nasdaq Capital Market. NEXT is a next generation fuels company dedicated to sustainably producing clean, low-carbon fuels from organic feedstock."Biofuels will play a significant role in advancing sustainable transportation. NEXT has positioned itself to be a transformational leader in the biofuels sector and it is a privilege to help guide the important and positive impact NEXT will have on implementing energy transitions," said Trauber. "It's an exciting time as we see federal and state climate policies reinforce strong market growth for clean fuels in the United States and around the world."Trauber is widely recognized as one of the most prominent energy investment bankers in the world. He was responsible for initiating and building the Global Clean Energy Transition Team at Citigroup while serving as its Global Head of Natural Resources and Clean Energy Transition. He also played a key role in establishing Citi's plan for decarbonizing its financed emissions. Prior to his retirement in late 2022, Steve played a key role in many of the energy industry's flagship transactions while overseeing hundreds of financings, mergers, and acquisitions.Trauber began his career with Credit Suisse First Boston (1988-1995) and subsequently managed Morgan Stanley's Energy Group in Houston (1995-2003). He joined UBS Investment Bank in 2003 as a Vice Chairman and Global Head of Energy, and joined Citi in 2011 where he managed one of Wall Street's largest global energy investment banking practices."Steve is a recognized leader in business and the energy transition. NEXT is extremely fortunate to have the comprehensive knowledge, insights, and experience he brings to our Board," said Christopher Efird, CEO and Chairperson of NEXT.Story continuesTrauber has earned several recognitions for his community contributions and professional achievements over his 35-year career. Those include the inaugural Barbara Jordan Award for community service and support for children and charities, a Dealmaker magazine top 10 "Wall Street Rain Maker" ranking, and a Rice University Athletics Distinguished "R" award and induction to the Rice Athletics Hall of Fame. Trauber graduated from Rice University with a Bachelor of Arts in Managerial Studies and Economics and earned a Master of Business Administration from Northwestern University's Kellogg Graduate School of Management.Trauber serves several organizations in the Houston area, including as Chairperson of the Board for the Memorial Herman Hospital Foundation, as a Board of Advisors' member for Rice University's Jones Graduate School of Business, and board member of Performing Arts Houston and Theatre Under the Stars.MEDIA CONTACTMichael [email protected] NEXTNEXT is a next generation fuels company dedicated to sustainably producing clean, low-carbon fuels. The company's first project is a 50,000 barrel-per-day / 750 million gallon-per-year Renewable Diesel ("RD") / Sustainable Aviation Fuel ("SAF") refinery in Oregon with easy multi-modal access to the West Coast demand markets. The project is advancing through permitting and expects to begin construction upon completion of an Environmental Impact Statement currently underway with the US Army Corp of Engineers. RD and SAF are high-margin liquid transportation fuels worldwide and there is an urgent global demand for increased supply. To learn more about NEXT, please visit www.nextrenewables.com.About Industrial Tech Acquisitions II, Inc.ITAQ is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. ITAQ is sponsored by Texas Ventures, a leading technology and venture capital firm with expertise in capital markets and structured finance. The firm provides guidance, insight and capital to assist entrepreneurial teams and managers who have the desire and talent to build exceptional companies. The Texas Ventures' approach is to identify emerging trends and opportunities prior to recognition by the broader marketplace, and to take a proactive approach in working with entrepreneurs and managers who they believe have the ability to build world-class companies.NEXT Cautionary Statement Regarding Forward-Looking StatementsAll statements other than statements of historical facts contained in press release are forward-looking statements. Forward-looking statements may generally be identified by the use of words such as "believe," "may," "will," "estimate," "continue," "intend," "expect," "should," "would," "plan," "project," "forecast," "predict," "potential," "seem," "seek," "future," "outlook," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other financial and performance metrics, projections of market opportunity and market share. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of NEXT's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions, and such differences may be material. Many actual events and circumstances are beyond the control of NEXT. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions, including the risk that any required regulatory approvals are not obtained, are delayed, or are subject to unanticipated conditions that could adversely affect the actual results; risks related to the rollout of NEXT's business and the timing of expected business milestones; the effects of competition on NEXT's business. If any of these risks materialize or NEXT's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that NEXT presently does not know or that NEXT currently does not believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect NEXT's expectations, plans or forecasts of future events and views as of the date of this press release. NEXT anticipates that subsequent events and developments will cause NEXT's assessments to change. However, while NEXT may elect to update these forward-looking statements at some point in the future, NEXT specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing NEXT's assessments as of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Neither NEXT nor any of its affiliates have any obligation to update this press release.SOURCE: NEXT Renewable FuelsView source version on accesswire.com: https://www.accesswire.com/748591/NEXT-Renewable-Fuels-Adds-Former-Citigroup-Vice-Chairman-Stephen-Trauber-to-Board-of-Directors

ACCESSWIRE

NEXT Renewable Fuels Adds Former Citigroup Vice Chairman Stephen Trauber to Board of Directors

https://finance.yahoo.com/news/next-renewable-fuels-adds-former-200000331.html

63bccefb-6754-3c92-8553-0f6a24e40440

ITAQ

Repurposing Facility to Produce Renewable Natural Gas from Wood WasteLAKEVIEW, OR / ACCESSWIRE / April 18, 2023 / Lakeview RNG, a wholly owned subsidiary of NEXT Renewable Fuels ("NEXT"), has acquired assets associated with the Red Rock Biofuels development in Lake County, OR effective Friday, April 14, 2023. Lakeview RNG is commencing a redevelopment plan focused on completing construction of certain aspects of the site while replacing or enhancing others. When complete, the Lakeview RNG facility is expected to be capable of converting forest waste into renewable natural gas ("RNG") and clean hydrogen."Acquiring the Lake County clean fuels infrastructure is another advancement in our mission to decarbonize the transportation industry and produce low carbon fuels at scale," said Christopher Efird, CEO and Chairperson of NEXT. "This acquisition represents a major step toward our clean fuel production capabilities and pathways to meet growing demand for clean fuels along the west coast of the United States while helping to address the critical concern of forest health."Lakeview RNG will use wood waste, or "slash," as the feedstock. Wood waste can come from activities like forest thinning, logging, and wildfire management activities on private and state lands. Today, that waste is largely burned in open slash piles, and the subsequent black carbon lands in rivers, on snowpack, and in the community's lungs. Instead, Lakeview RNG will process that wood waste and turn it into a low-carbon gaseous fuel, benefitting environmental and community health in southern Oregon and beyond."Lakeview RNG acquiring Lake County's clean fuels facility is fantastic news for our region," celebrated State Senator Lynn Findley. "Lakeview RNG will bring the promised jobs and tax revenue to the county while finding a clean fuel benefit to our state's wildfire mitigation efforts."Story continuesSenator Findley isn't the only one celebrating. Local Lake County residents and leaders are pleased that the facility has new life, and that the promises of economic development will finally be realized."We have been anxiously awaiting this day and are very happy that the facility will be put into operation rather than sold for parts," said Michele Parry, Lakeview City Manager. "Lakeview's location is strategically important because of our proximity to regenerative feedstock sources and to the pipeline distribution system that can get the clean fuels to market."Lakeview RNG has evaluated the potential feedstock supply in Oregon and determined that all of its wood waste needs could come from within 150 miles of the facility. Wood waste used at the facility will be certified and compliant with applicable regulations for RNG production. Converting forest waste to renewable fuel products helps reduce forest fire fuel loads and provide an additional revenue source to timber communities. The local distribution network in Lake County is anchored by the Ruby pipeline and can deliver renewable fuels to transportation markets in Oregon and along the west coast.The purchase price of the facility has not been disclosed.MEDIA CONTACTMichael [email protected] NEXTNEXT is a next generation fuels company dedicated to sustainably producing clean, low-carbon fuels. The company is permitting and developing a 50,000 barrel-per-day / 750 million gallon-per-year Renewable Diesel ("RD") / Sustainable Aviation Fuel ("SAF") refinery in Oregon with easy multi-modal access to the West Coast demand markets. The project is advancing through permitting and expects to begin construction upon completion of an Environmental Impact Statement currently underway with the US Army Corp of Engineers. RD and SAF are high-margin liquid transportation fuels worldwide and there is an urgent global demand for increased supply. To learn more about NEXT, please visit www.nextrenewables.com.NEXT Cautionary Statement Regarding Forward-Looking StatementsAll statements other than statements of historical facts contained in press release are forward-looking statements. Forward-looking statements may generally be identified by the use of words such as "believe," "may," "will," "estimate," "continue," "intend," "expect," "should," "would," "plan," "project," "forecast," "predict," "potential," "seem," "seek," "future," "outlook," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other financial and performance metrics, projections of market opportunity and market share. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of NEXT's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions, and such differences may be material. Many actual events and circumstances are beyond the control of NEXT. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions, including the risk that any required regulatory approvals are not obtained, are delayed, or are subject to unanticipated conditions that could adversely affect the actual results; risks relating to the availability and cost of the forest product feedstocks; risks as to the ability of NEXT to operate the facility and produce RNG and clean hydrogen profitably, risks relating to the construction of the production facility for the production of RNG and clean hydrogen, including risks relating to the need to obtain the necessary financing for this project as well as NEXT's proposed biofuel refinery with a focus on renewable fuel; risks related to the rollout of NEXT's business and the timing of expected business milestones; the effects of competition on NEXT's business. If any of these risks materialize or NEXT's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that NEXT presently does not know or that NEXT currently does not believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect NEXT's expectations, plans or forecasts of future events and views as of the date of this press release. NEXT anticipates that subsequent events and developments will cause NEXT's assessments to change. However, while NEXT may elect to update these forward-looking statements at some point in the future, NEXT specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing NEXT's assessments as of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Neither NEXT nor any of its affiliates have any obligation to update this press release.###SOURCE: NEXT Renewable FuelsView source version on accesswire.com: https://www.accesswire.com/749709/NEXT-Renewable-Fuels-Inc-Acquires-Southern-Oregon-Clean-Fuels-Assets

ACCESSWIRE

NEXT Renewable Fuels, Inc. Acquires Southern Oregon Clean Fuels Assets

https://finance.yahoo.com/news/next-renewable-fuels-inc-acquires-114500743.html

d3e9e348-0d94-38b4-944f-db30ad7a5c01

ITCI

Intra-Cellular Therapies Inc.NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023 at 12:55 p.m. ET.The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.About Intra-Cellular TherapiesIntra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.Contact:Intra-Cellular Therapies, Inc.Juan Sanchez, M.D. Vice President, Corporate Communications and Investor Relations646-440-9333Burns McClellan, Inc.Cameron [email protected]

GlobeNewswire

Intra-Cellular Therapies to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

https://finance.yahoo.com/news/intra-cellular-therapies-present-morgan-120000257.html

0580f2d3-59e2-3b38-952e-8114e2fdeb18

ITCI

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The US$5.4b market-cap company posted a loss in its most recent financial year of US$256m and a latest trailing-twelve-month loss of US$184m shrinking the gap between loss and breakeven. The most pressing concern for investors is Intra-Cellular Therapies' path to profitability – when will it breakeven? We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate. Check out our latest analysis for Intra-Cellular Therapies According to the 11 industry analysts covering Intra-Cellular Therapies, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$241m in 2025. So, the company is predicted to breakeven approximately 2 years from now. How fast will the company have to grow each year in order to reach the breakeven point by 2025? Working backwards from analyst estimates, it turns out that they expect the company to grow 68% year-on-year, on average, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.earnings-per-share-growthWe're not going to go through company-specific developments for Intra-Cellular Therapies given that this is a high-level summary, though, take into account that generally pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.Story continuesOne thing we’d like to point out is that Intra-Cellular Therapies has no debt on its balance sheet, which is quite unusual for a cash-burning pharma, which typically has high debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.Next Steps:There are key fundamentals of Intra-Cellular Therapies which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Intra-Cellular Therapies, take a look at Intra-Cellular Therapies' company page on Simply Wall St. We've also put together a list of important factors you should look at:Valuation: What is Intra-Cellular Therapies worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Intra-Cellular Therapies is currently mispriced by the market.Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Intra-Cellular Therapies’s board and the CEO’s background.Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Loss-Making Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Expected To Breakeven In The Medium-Term

https://finance.yahoo.com/news/loss-making-intra-cellular-therapies-124919829.html

c0e35ec5-0c10-3ce9-8ee9-ce5e1a34e229

ITW

Illinois Tool Works ITW has chosen veteran Christopher A. O’Herlihy to succeed E. Scott Santi as its new chief executive officer (CEO). Santi is set to retire in early 2024 after having been associated with the company for more than 40 years. He will, however, remain chairman of the board until Mar 1, 2024. Thereafter, he will become non-executive chairman of the ITW Board.Currently serving as the vice chairman of Illinois Tool, O’Herlihy has been named president and elected to the company’s board, besides being appointed as the CEO. He is set to assume his role from Jan 1, 2024 onward.O’Herlihy has been associated with ITW for the past 34 years. He has been serving as the vice chairman of the company since 2015. Prior to this, in 2010, he was appointed as the executive vice president of the company’s Food Equipment Group.Illinois Tool Works Inc. PriceIllinois Tool Works Inc. PriceIllinois Tool Works Inc. price | Illinois Tool Works Inc. QuoteSanti has been serving as CEO of Illinois Tool since 2012. Along with his position as CEO, he was appointed as the chairman in 2015. Under his leadership, since 2012 to date, ITW’s market capitalization has increased from $23 billion to $74 billion.Illinois Tool is benefiting from stable underlying demand and improving supply chains. Strength across all regions and strong organic growth is boosting revenues in the Automotive Original Equipment Manufacturer (OEM) segment (revenues up 10.3% year over year in the first half of 2023). The Food Equipment unit is being aided by growth across both North America and International operations and strength across institutional end markets. Revenues from the segment jumped 9.2% in the first half of 2023.Strength in the capital equipment business bodes well for the Test & Measurement and Electronics segment (revenues inched up 1.6% in the first half of 2023). Solid industrial and consumables businesses are aiding the Welding segment (revenues up 5% in the first six months of 2023). It remains to be seen how ITW’s growth story unfolds with O’Herlihy at its helm.Story continuesZacks Rank & Key PicksIllinois Tool presently carries a Zacks Rank #3 (Hold).Some better-ranked stocks within the broader Industrial Products sector are as follows:Flowserve Corporation FLS presently sports a Zacks Rank #1 (Strong Buy). The company pulled off a trailing four-quarter earnings surprise of 6.2%, on average. You can see the complete list of today’s Zacks #1 Rank stocks.Flowserve has an estimated earnings growth rate of 79.1% for the current year. The stock has jumped 30.9% so far this year.Graham Corporation GHM currently flaunts a Zacks Rank #1. The company pulled off a trailing four-quarter earnings surprise of 243.1%, on average.Graham has an estimated earnings growth rate of 400% for the current fiscal year. The stock has rallied 71.8% so far this year.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportIllinois Tool Works Inc. (ITW) : Free Stock Analysis ReportFlowserve Corporation (FLS) : Free Stock Analysis ReportGraham Corporation (GHM) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Illinois Tool (ITW) Picks O'Herlihy as CEO, Santi to Retire

https://finance.yahoo.com/news/illinois-tool-itw-picks-oherlihy-162000324.html

a08067fe-b1a4-33aa-8d19-d6fa12da2c47

ITW

Illinois Tool Works Inc. (NYSE:ITW) has announced that it will be increasing its dividend from last year's comparable payment on the 12th of October to $1.40. This will take the annual payment to 2.3% of the stock price, which is above what most companies in the industry pay. Check out our latest analysis for Illinois Tool Works Illinois Tool Works' Earnings Easily Cover The DistributionsA big dividend yield for a few years doesn't mean much if it can't be sustained. The last dividend was quite easily covered by Illinois Tool Works' earnings. This indicates that a lot of the earnings are being reinvested into the business, with the aim of fueling growth.The next year is set to see EPS grow by 16.7%. If the dividend continues on this path, the payout ratio could be 50% by next year, which we think can be pretty sustainable going forward.historic-dividendIllinois Tool Works Has A Solid Track RecordEven over a long history of paying dividends, the company's distributions have been remarkably stable. Since 2013, the dividend has gone from $1.52 total annually to $5.60. This means that it has been growing its distributions at 14% per annum over that time. So, dividends have been growing pretty quickly, and even more impressively, they haven't experienced any notable falls during this period.The Dividend Looks Likely To GrowSome investors will be chomping at the bit to buy some of the company's stock based on its dividend history. Illinois Tool Works has impressed us by growing EPS at 13% per year over the past five years. Shareholders are getting plenty of the earnings returned to them, which combined with strong growth makes this quite appealing.Illinois Tool Works Looks Like A Great Dividend StockOverall, we think this could be an attractive income stock, and it is only getting better by paying a higher dividend this year. Earnings are easily covering distributions, and the company is generating plenty of cash. All in all, this checks a lot of the boxes we look for when choosing an income stock.Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. At the same time, there are other factors our readers should be conscious of before pouring capital into a stock. Taking the debate a bit further, we've identified 1 warning sign for Illinois Tool Works that investors need to be conscious of moving forward. If you are a dividend investor, you might also want to look at our curated list of high yield dividend stocks.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Illinois Tool Works' (NYSE:ITW) Shareholders Will Receive A Bigger Dividend Than Last Year

https://finance.yahoo.com/news/illinois-tool-works-nyse-itw-122507120.html

c58f5d97-0caf-3097-9d3a-cb8999b38e96

IVAC

ParticipantsDaniel B. Wolfe; President, CFO, Chief Compliance Officer, Portfolio Manager & Director; 180 Degree Capital Corp.Kevin M. Rendino; Chairman, CEO & Portfolio Manager; 180 Degree Capital Corp.James ElbaorZach Liggett; Portfolio Manager; Financial & Investment Management Group LtdUnidentified ShareholderPresentationDaniel B. WolfeGood morning, and welcome to 180 Degree Capital Corp.'s Second Quarter 2023 Financial Results Update Call. This is Daniel Wolfe, President, Portfolio Manager of 180 Degree Capital. Kevin Rendino, our Chief Executive Officer and Portfolio Manager, and I would like to welcome you to our call this morning. (Operator Instructions) I would like to remind participants that this call is being recorded, and that we will be referring to a slide deck that we have posted on our Investor Relations website at ir.180degreecapital.com under Financial Results.Please turn to our Safe Harbor statement on Slide 2. This presentation may contain statements of a forward-looking nature related to future events. Statements contained in this presentation that are forward-looking statements are intended to be made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed herein.Please see the company's filings with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with our business that could affect our actual results. Except as otherwise required by federal securities laws, 180 Degree Capital Corp. undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties.I would now like to turn the call over to Kevin.Story continuesKevin M. RendinoThank you, Daniel, and good morning, everyone. We'll start on Slide 3. We purposely waited a little longer to report our earnings this cycle because we wanted some of our portfolio holdings to report and announce some of their own news, news that we were well aware was occurring behind the scenes. You'll see the news from Arena Group last night of a transformational, game-changing announcement of a strategic investment and elimination of any concerns with their debt. We'll have more on that later. In fact, I'll focus most of this call on specific companies that we own and the activism that we have pursued.For the quarter itself, it wasn't a good one. Our NAV declined 4.6% on the back of a 5.8% decline in our public holdings. This was led by declines in IVAC, Parabellum, RYAM and Comscore. We did have good quarters from our holdings in Potbelly, Commercial Vehicle Group and Quantum D-Wave, but all in all, it was a very disappointing quarter. As noted in our prior press release, we did purchase 373,679 shares of our outstanding stock at $4.41 because despite what was a challenging quarter and sort of a nothing year through these first 6 months, our share price still trades at a 30% discount for our book value and actually less than the cash and liquid securities that we have on our balance sheet.Moving ahead to Slide 5. This is a chart of the trend in our cash and securities of public companies. We were able to quadruple the amount from the time we started until November of 2021, but the performance of our holdings through this bear market in the last 18 months has led to a decline in the value of these assets. All that said, our share price, which I have said, traded at nearly a 30% discount to our book value and also trades at a 20% discount to our cash and liquid securities.Skipping to Slide 6, we had an opposite quarter than our first quarter. To say this has been a trying, frustrating market to wade through was quite the understatement. Despite an economy that hasn't rolled over, ingenerably favorable news from the majority of our holdings were virtually flat year-to-date, slightly behind the Russell Microcap Index and slightly ahead of the Russell Microcap Value Index. Through June, the Russell Microcap Index has advanced 1.8%. This compares to the almost 40% gain for the NASDAQ 100.We're back to a market that focused on 7 companies, companies that -- companies like NVIDIA, Meta, Apple, Microsoft and a few others, at the expense of almost anything else. It's beyond frustrating. That said, just because we haven't been rewarded for our investments in our holdings doesn't mean we won't eventually. We've been through plenty of bear markets and soft performance periods to know that when we come out of it, we will enjoy significant price appreciation in the value of so many of our holdings, and our NAV will advance as a result. We aren't sitting back waiting for things to happen. We have used our activist approach across many of our holdings. Some of the activism you see and some of you don't, but it might make sense to highlight how and where we have used it.On Slide 12 is where we started the discussion with many of our names. First, Intevac. After doubling since our initial purchase where we took some money off the table, IVAC decreased from $7.33 to $3.75 this past quarter. The company noted in its Q1 '23 earnings call that its program with Corning was delayed at least a quarter due to Corning's customers pushing out adoption of the new glass IVAC's tool was expected to enable. IVAC had used cash to build inventory for the delivery of its tools with the expectation that the ramp would be faster than it is now expected. Following that announcement, IVAC noted that Seagate canceled over $50 million worth of tool orders that are expected to ship in 2024.What have we done? We have sent the company a Board-level letter behind the scenes and have spoken with management and the Board highlighting 2 key points. One, while we're bullish on IVAC's new glass tool, it was no longer acceptable for the company to continue to invest in inventory and bleed down the cash for the balance sheet, not until the business actually shows up with actual revenues. The company needs to come up with either an operating plan that is self-sustaining in the short term, or find some alternative to restore value.Subsequent to those conversations, the company has declared it's running a strategic process and announced it had retained Houlihan Lokey to explore strategic alternatives. The company also initiated a cost-cutting program designed to ensure it remains cash flow positive starting as seemly as this year. All in all, the stock is at a silly price. It essentially trades at near cash, with cash likely to grow from here, and the company is in the final stages of qualification with Corning. We like the stock at this price.Comscore decreased from $1.23 to $0.80 this quarter. Although SCOR missed top line estimates for Q1 in what was a seasonally slow quarter, it reiterated its guidance for significant free cash flow from operations and exiting 2023 with an EBITDA margin of close to 15%. In fact, EBITDA estimates were met last quarter and exceeded this past quarter. That said, SCOR's Board and its preferred holders did not take any steps to resolve concerns and ambiguity -- I can never say the word.Daniel B. WolfeAmbiguity.Kevin M. RendinoThank you. Ambiguity around the potential special dividend and misalignment between incentives for common and preferred holders. We continue our activist campaign, both with public and private lenders, highlighting lack of corporate governance alignment of interest for all stakeholders to increase the price of Comscore's common stock. SCOR's preferred holders elected to defer their annual dividend of $15 million for future payments estimated to occur by the end of 2023 to provide additional cash for SCOR to invest in its business.You've seen our activism. It's been public, and it will continue because there was so much inherent value that has not yet been unlocked by this company. The market continues to discount the same news over and over and over again. Generally speaking, Comscore's stock has gone from $5 to a 52-week low of $0.63 because its Board of Directors has thus far failed to act on suggestions that we and other investors have independently provided to them that we believe can reverse the trend of the shareholder destruction that has occurred under their watch.Our activism can be seen in many ways, sometimes in public letters to SCOR and other times behind the scenes. Our intention is always to be constructive and collaborative with the companies that we own. In the case of SCOR, we started with a sense of collaboration regarding our ideas for the company, but came to realize that its Board was being dismissive and unresponsive. We got back the usual, thank you for your letter, and we will share with Board, and then no action or only partial, immaterial action would be taken.We realized quickly that the Board was either supremely arrogant, confused with how to create value for all stakeholders or incapable of coming together and agreeing to take action given the different perspectives from the different Board members. Unfortunately, SCOR has been instead focused solely on creating value for themselves and the preferred stockholders. Board compensation is entirely too high, especially considering the track record of failed oversight and shareholder value disruption.The Board has taken us up on several of our suggestions and finally reduced its compensation by an average of 26% in 2023, but they've only taken small steps when more substantial action is immediately required. We have told the Board how this would play out for the common stock if they continue along their do-nothing path. We take no solace in having been right in our analysis, because being right has led up to us being wrong for 180. We just never thought they wouldn't do anything to attack the capital structure and show better alignment amongst all stakeholders.So should SCOR's Board continue to ignore their fiduciary responsibility to common shareholders, we'll resort through a series of fact-based public letters regarding the individuals on the Board who have hijacked what we believe to be SCOR's valuable collection of data assets from the common shareholders and the employees of the company. If they don't want to see their names attached to their level of performance they have generated over the duration of their oversight, then they should fix it with a series of actions and improve the capital structure, align themselves with common shareholders and reverse the trend of the stock performance that has collapsed since their investment.I don't care that we are small and the players on the Board are represented by John Malone's Liberty Broadband or folks at Cerberus or Charter Communications. SCOR's board has a fiduciary duty to represent all stakeholders. This is all just common sense stuff at this point. While it's patently obvious to anyone that the decline in the stock revolves around the inactivity of the SCOR Board, does that mean that this is the right price for the business? Hardly. In our view, there is no chance this is the right price for Comscore. The Comscore had the same structure 2 years ago when the stock traded at $5. What has changed?Actually, in spite of weakness in the advertising market and increasing interest rates, SCOR's fundamentals have materially improved. Two years ago when the stock was $5, SCOR's EBITDA was $32 million. The consensus analyst estimate according to Bloomberg for this year is $43 million, and next year is $58 million. Somehow, the story has evolved into an incessant, redundant snakepit of shareholder obsession regarding the capital structure and the intention of the preferred holders.And while we obviously understand the terms of the preferred stocks, we find it hard to fathom how this issue is the reason for the stock to continue to decline every single day. We believe that the current share price isn't the right price of the business. It would help if the Board would actually get a sense of urgency, get some Wall Street smarts, some leadership and act like fiduciaries. If it does, the stock will go meaningfully higher from where we are today. It really isn't quite complicated.On Synchronoss, we helped the company fix its balance sheet 2 years ago at a much higher price by replacing a very expensive perpetual preferred stock that limited the company's flexibility to streamline its business with materially low cost for financing and equity. Since then, what's happening? Management has run a much better business, achieving EBITDA estimates consistently higher than consensus analyst projection. The result has been Synchronoss' stock goes down.In March '23, B. Riley presented a nonbinding offer to purchase Synchronoss for $1.15. The offer kickstarted a full strategic alternatives process. The result, Synchronoss' stock cannot just trade consistently above $1. Synchronoss sells one of its noncore and least contributing asset that nobody even asks about when discussing the performance of the company for up to $14 million, with $7.5 million received at closing. The result, Synchronoss' stock goes down.In July '23, Synchronoss successfully negotiated an extension of by far its largest contract to run Verizon's Personal Cloud through 2030, an unbelievable extension of 5 years. The result, Synchronoss' stock increases by 2%. There's always a bear case. In Synchronoss' case, it's reported aggregate revenues which aren't showing growth. That said, the underlying business with the most value is growing and has the highest margins of all of its businesses.Of course, the company -- every company has pluses and minuses. In the case of Synchronoss, however, the majority of the news has been good, not bad. The action of the common stock is a complete head scratcher to us. I often ask myself what would happen to actually have Synchronoss go and trade up to fair value. Coming up with a cure for cancer? An engine that would enable a plane to go from New York to London in 2 hours? It's remarkable and frustrating all at the same time.We have written the Board several notes over the years and are firmly -- and they are firmly aware of our views revolving around them. One, generating free cash flow; and two, asking them whether or not this should be a public company. They are running a process. B. Riley has already bid for the business, and as important, they are right at the critical moment where they are moving from using cash to generating cash. That Verizon contract has been extended and the management team has done a very, very nice job. What started out as what it should have been a floor price of $1.15 because of B. Riley's bid has turned into a bid of a ceiling price. This company, in our estimation, should be worth more than last sale because of its valuable assets.Arena Group is another one. In a challenging ad environment, Arena Group continues to execute better than its peers with growing revenue and generating $100 million improvement in its EBITDA. The result has been the stock goes down. In July of '23, The Wall Street Journal noted that Group Black is in talks to buy a stake in the company. The result, Arena's stock increases briefly, but then resumes its decline. Arena's largest stockholder, and coincidentally, it's largest debt holder, purchased over $1 million of Arena's stock in the open market. The result of that, Arena's stock goes down.Why is that the case? The only reason we can possibly come up with is that Arena has had a material amount of debt on its balance sheet that technically comes due at the end of '23. The debt is held by Arena's largest shareholder, B. Riley, who has been purchasing common stock in the open market during this period of price weakness. Does anyone think that B. Riley would be purchasing common stock if it did not plan to renegotiate the debt and be the continued strong supporter of Arena and its common shareholders as they have always been? Are investors that naive? The stock has cost us nearly $1 drop in our NAV over the last year and currently trades at a price that makes little sense to us.We have seemingly been over the wall and firmly aware of what was happening for the last few months. Last night's announcement is a game changer for Arena Group. First and foremost, the stock has precipitously declined because of the debt due at the end of this year. We can take that off the table now because B. Riley extended the terms 3 years and have taken a straight 10% interest rate on their debt, and this market couldn't be more supportive than B. Riley has been through Arena, and that alone should allow for the stock to double or triple.Then, we have a new sponsor. A wildly successful billionaire who started 5-Hour Energy, who has media assets vis-a-vis local TV stations as well as Bridge Media Network assets, NEWSnet and Sports News, run over the top of streaming sites like Roku and Apple TV. Last night, the story for Arena changed for the better. We don't have to worry about the balance sheet anymore, and the new sponsor is a successful billionaire who wants to own the business and make significant inroads in media. Arena is now part of this platform.And finally, Potbelly. Sometimes there's nothing for us to do other than see if the activism that we initiated works. In the case of Potbelly, I think we've succeeded. The company -- when we invested in Potbelly, it was because we thought they had a wonderful brand with great customer loyalty, a terrific product, but one that simply needed better Board governance and a new leadership team. Led by Privet and Ancora, the Board changed. We filed a 13D in early 2000, and then soon thereafter, the Board named Steve Cirulis from Panera Bread as their CFO, and Bob Wright from Wendy's as the CEO.We were fortunate that the Board had already put in place a plan to change the management team. Now under this amazing leadership team, the business is operating better, the company is growing again, and we should be staring in a multiyear growth trajectory which would take the stock significantly higher than where it currently is, which is a price much higher than where we started buying it at back in 2020. We think Potbelly hasn't even started yet in terms of its own growth.Finally, on Slide 22. While this has been a painful period, we remade our company around our new strategy. It isn't new anymore. Nearly 90% of our book is in cash and liquid securities, and as I look at the NAV, I view it more as a bear market book value. Most of our names have nearly 100% upside, which means so does our NAV, which means so does our share price, and that is the reason why I am the second biggest holder of TURN stock and Daniel is the sixth. We plan on making a bunch of money alongside all of our shareholders over the ensuing years, and while this has been a painful year, a painful 18 months actually, we're not deterred in our focus for where we want to take 180 down the road. Daniel?Daniel B. WolfeThank you, Kevin. Please turn to Slides 23 and 24. 180's remaining private portfolio has only 1 material position, and that's AgBiome. The total remaining value of our remaining legacy private portfolio is approximately $8.6 million, of which $6.1 million is AgBiome and approximately $1.3 million is cash, the proceeds that we expect to receive in April '24 from the sale of TARA to Valo.This past quarter, we had a markup in AgBiome based on market adjustment factors derived from comparable public companies. In total, the private portfolio raised our NAV by $0.06. There's really not much more to add regarding the legacy portfolio. As Kevin mentioned, it represents approximately 14% of our net assets, and we've taken a business that was headed to 0 and created a new business with a real future and a stable balance sheet.Please turn to the next slide. For Q2 '23, our regular operating expenses were approximately $879,000 versus $741,000 the prior year -- $741,000 in the prior year. We will maintain a lean cost structure outside of fixed expenses for being a public company and focusing our expenses on activities solely designed to enhance our investment performance or increase our revenues from managing outside capital. The increase in operating expenses this year was primarily due to the addition of Matt Epstein to our investment team late last summer, and we are pleased to have him aboard.Please turn to Slide 26 and 27. We provide these slides each quarter to enable our shareholders to look at the trend of our total expenses and compensation related as a percentage of net assets. This year, the percentage has increased primarily because of the decline in net assets. We continue to anticipate the reductions in our net operating expenses and will -- our operating expenses as a percentage of net assets will be based on growth in our net assets rather than further reductions in our expenses. We remain committed to treating every dollar of shareholder money with the utmost care and consideration.We would now like to open the line for questions.Question and Answer SessionDaniel B. Wolfe(Operator Instructions) We have no questions in the queue.Kevin M. RendinoOkay. With that, we are always available for any questions that you may have vis-a-vis e-mail. We prefer, obviously, always to be -- to get on the phone with you. So if you have any follow-up or anything that you want to add or ask us...Daniel B. WolfeAll right, we actually do have a couple of questions that came through. I apologize. Let's go right here.James ElbaorIt's James Elbaor of Marlton. Can you talk a little bit about the share buyback program and how you're thinking about that and return of capital in general?Kevin M. RendinoSure. Thank you for asking. We -- generally speaking, we -- you would always want to buy back stock when your stock trades at such a significant discount to NAV. That's just Graham and Dodd value investing that we've always believed. Having said that, our business is one of investing capital in other businesses, and at 180, the fortunate thing for us is that we have permanent capital in our closed-end funds.And so once we return that capital vis-a-vis either a dividend and/or a share repurchase program, capital is gone forever, and that is the most precious capital. And by doing that over a long period of time or if you do that too often, you're not going to have a lot of capital to invest in the companies that we want to invest in. So while it's counterintuitive, buying back stock actually hinders our business over the long term because we won't have that capital to invest.So we've stated from time to time if our stock trades at such a wild discount to our NAV, then we certainly -- we'd be willing to support it, but that's not really part of what -- we don't want to be in a position, especially where our assets are today, that we're buying back stock. We'd much rather -- especially where we are in this cycle of investing, where the upside for many of our holdings far exceeds the upside of just buying our stock at a discount.So we viewed what we did in Q1 as a one-off. We don't view what we do personally as one-offs. You've seen the management team consistently in the market buying stock for our personal accounts. You'll see that again, I'm sure, this quarter once the restriction is taken. But share repurchase is really not something that's going to be a consistent part of our strategy. We've got to find companies, have them perform like they did in our first 5 years of existence, then our NAV will grow, the discount will narrow, we'll have more assets, and that's really the strategy for 180.Daniel B. WolfePlease go ahead.Unidentified Shareholder[Jonathan Rothchild], long-time shareholder. You guys are obviously really smart guys and well experienced, and you saved the old 180 Degree or pre-180 Degree Harris & Harris from bankruptcy. But the small cap environment right now is something that's really off radar to most institutional investors. It's unfortunate that this is the sphere of influence that you're involved in right now.And as you mentioned, the mega cap tech stocks are where most dollars are flowing at this point at the expense of many very good companies that are undervalued. So I wonder what is your projection as a Dodd -- I'm sorry, a Benjamin Graham value investor, in this sector of microcap stocks, some of which are even selling well below intrinsic value. Do you see any trend that would justify a continuation of even working in this area?Kevin M. RendinoI think one of the -- good to hear from you again, Jonathan. Thanks for the question. There's a lot of things to think through there. I guess, number one, it wasn't a really good environment for small caps when we started in 2017, but we generated off-the-charts performance in the first 5 years of our -- of doing this, and you can see that in our slide deck. So I think just because -- and but we haven't done well in the last 18 months. I own that. I'm the first person to admit that. I'm the second biggest shareholder. This has been painful for me.But we don't necessarily need the microcap stocks to outperform the large cap stocks for us, 180, to do well, because we did do well through that first 5 years when really, the only focus was large caps. So I think that's number one, and our stock picking is going to determine whether or not we're successful. And we have an activist approach. We tried to highlight how we're using that for our current holdings. And hopefully, we'll be able to recycle through some of our holdings which, quite frankly, have become stale.I think to some extent, we're -- we've become stockholders waiting for exits which we think will occur, and then we can recycle that into newer names. We have a lot of reasons why microcaps have been lousy. Number one, it's been a risk-off environment. And who wants to own Comscore when you can own NVIDIA and feel safe about what it is that you own? Even though the valuation discrepancy is a joke, right? Like NVIDIA is incredibly expensive and Comscore is quite [unbelievably inexpensive], but everyone's worried about their shadows and why do I want to take any risk in owning stock?So let me just own what I perceive as safe and are going to be companies we don't have to worry about. So that's going on. We need a better macro backdrop in order for the microcaps to do well. And until we get there, you're going to -- I mean, this level of performance is so dramatic. It's mind-boggling. I've never seen an environment where one group of companies is up 40% and another group of companies is up 1%. That's just absurd. So the environment needs to get -- we need to get back to a little bit of a risk-on environment where investors are willing to invest more of their assets in companies outside of the Magnificent 7.Because the world isn't ending, the economy isn't holding, interest rates have stopped going up, and therefore, I could be more diversified in what I own. So we think we're at the point where that's going to happen. The economy has had sustained resilience. We haven't imploded. Interest rates are probably at or near their cycle highs. The next move for the Fed could well be down, not necessarily up. We've seen earnings hits this year, and we see earnings growth going forward. We're out of the pandemic, the supply chain has eased.Like there's a lot of reasons why things are getting better, not worse. And as they do get better, not worse, and as the environment and the headlines get better and not worse, then the market will, we think, diversify itself outside of just being in the hands of 7 stocks that basically dictate whether or not the market is going to go up or down. Small caps do well in inflationary environments because they're able to pass through those price increases a lot faster.Many of them are domestic. They don't have to deal with the global supply chain issues that have occurred, so I mean, there's a lot of -- and then, of course, activism, that's part of the reason why we use it is because many of these companies probably shouldn't be public to begin with, and that's really where we could step in and try and hopefully engineer some sort of conclusion for some of these companies so that the value that actually is inherent in their business can actually occur, and sometimes it occurs vis-a-vis a sale.And like I said earlier in my prepared remarks, you've seen our activism behind the scenes, as I think, led to or at least been part of some strategic alternative process being led by some of the companies that we own. So I don't know if that is a really succinct answer. We believe in what we do. We don't necessarily need the microcap index to outperform NVIDIA for us to be successful, I think we've proved that in the last 5 months or 5 years. But we've just got to do a better job of picking stock than we have in the last 12 months, and that's part of just investing.You're going to win some years and lose other years. And for those people that want to criticize us or think we've lost our way or think we don't know how to invest anymore, I mean, that's your perspective. You're entitled to it. We just know that at the end of the day, we're going to be able to create value for our shareholders because some of the stock prices that we're investing in are at these crazy prices, and one day, that will change. And I hope that day starts today, but it will change, I promise. Sorry for the long-winded answer.Unidentified ShareholderWell, using your own term of some of your investments in companies, they don't deserve to be public to begin with. If I look at 180 Degree Capital and others in the group, I ask the same question, Safeguard Scientifics and others, you're not the only one in this space that has suffered a share price.In fact, you're probably the only one where you have insider buybacks and company buybacks, and it's -- the discount to NAV is also consistent even in good times. And then there's an expense ratio, which I'm not begrudging salaries and even with clawbacks in place and all that. And I wonder, have you ever considered liquidating the company and returning the cash to shareholders? Maybe not at this time, but maybe when things recover a little bit?Kevin M. RendinoYes. We're not here to clip coupons for ourselves. We're here for shareholders, which is why we're significant ones. The answer to your question is yes. But the answer to your question is no, that's not something that we should consider now at the bottom of the cycle. Like can we liquidate everything that we own today and return it back to shareholders and get people close to the $6.22 that our book value is? Yes. But is there an opportunity to do that at a much higher price? Yes. Will we do that at a higher price? We will.So Jonathan, the answer to your question is yes. At some point, this company will not exist anymore. We will liquidate it, we will hand the assets back to shareholders, and we will move on. But doing that at this point in time or even having this discussion at this time is pointless because we think there's a path to creating a lot more value because of what we own at a much higher price. So let's see if we can get to the other side of this, get a much higher NAV. The discount will either narrow or won't, and at some point, we'll liquidate and hand the money back to shareholders.I don't want to be doing this -- and by the way, the Board of Directors has to agree with my thesis there, and I'm not saying they will or they won't. That is my thesis. The Board has to agree with it. I think Daniel agrees with me. We talk about this all the time. I just think there's a time and a place for that discussion, and the time isn't today. But I don't own 700,000 shares of the stock that I bought with my own money out of my pocket -- after-tax dollars because I want the stock to go up a lot, first, and then we'll liquidate.We need a happy ending for this company. This company has had a checkered history. As Daniel said, it was on its way to 0 before we got here. We created a business. We grew it for 5 years. We've struggled in the last 18 months. We'll grow it again and then we'll make a good strategic decision for all the shareholders, which probably will lead to a liquidation of the assets that will narrow inevitably the discount that exists, and then we'll all move on to our next lives. That's the plan.Unidentified ShareholderNo, no. But in fairness, to me, I said not at this time. I said in the future.Kevin M. RendinoOkay. Thank you for that. There's others that want us to do it today, so I appreciate that. We're going to -- everything that we do is for shareholders. It really is. I don't sit around here and...Unidentified ShareholderNo, I mean there's a real vote of confidence from you buying back shares personally.Kevin M. RendinoYes. So like I said, we don't...Daniel B. WolfeWe're going to keep doing it.Kevin M. RendinoWe're going to keep doing it. I just know the last 18 months has been -- if you invest for as long as I'm sure you have and I have, you're going to go through these periods. You just do. You are. We're not as smart as we were 5 years -- 1.5 years ago after that 5-year performance run. We're not as dumb as everyone thinks we are today. Reality sits somewhere in between. We know what we're doing and we're going to get there for all of our stakeholders and shareholders over the next 2 or 3 years.Daniel B. WolfeThanks, Jonathan. Did you have anything else? Good to hear from you. Zach, go ahead.Zach LiggettI was wondering if you could give us a quick autopsy on the Parabellum. Just walk through why you guys invested in that, and sort of any lessons learned. And then the other question I had is just on the D-Wave, and if you guys -- I can't remember. Do you still have restrictions on that? Or what's the overall game plan with D-Wave? That doesn't really seem to fit with your overall philosophy.Kevin M. RendinoDo you want to take that?Daniel B. WolfeYes. So D-Wave real fast. We are unrestricted on that. The restrictions came off February 5. We have sold a little bit as it ran from the bottom. I think as we look at D-Wave, you're right, it's not a traditional company that we would invest in today. We do have a lot of knowledge behind it, and as you think about AI, et cetera, there is a significant place for it in the market, we believe. It's a small part of our assets, but it has -- in this area, it has the opportunity to run.I think one of the things that -- one of the worries around it has always been can it survive because of its balance sheet, and they've been resolving that through their line of credit. And so I think we're opportunistic around sales of that position, but it's also not a core position. I don't know, Kevin, if there's anything else you want to add to that?Kevin M. RendinoNo, I would agree with that. On Parabellum, never again. We invested in the management team from Adesto that we had a lot of respect for. Really, really -- we made a lot of money in Adesto, as you know. We told them they should do a SPAC. We found a target company.Daniel B. WolfeWe found 2.Kevin M. RendinoWe found 2 target companies. They were real businesses. We spent a ton of time on it. We loved the opportunity. We actually think one of our companies is going to own one of the businesses that we targeted, it was that good of a business. We unfortunately ran into a situation where we couldn't get funded. I mean, it was simple as that. The market just shut down for SPACs.We bought Alta Group, which was a B. Riley SPAC, right end of '19, beginning part of '20. A very successful SPAC, a very successful company, and it was a real business. And so we felt as though we can do this with -- by investing in Ron and Narbeh, and they'll find the business, and we'll invest just like we did in Alta. Alta is one of the best performing SPACs there has been.We just ran into a situation where the funding -- we couldn't get funding, and we weren't alone. And the stain from the other SPACs, the plethora of ones that came to the market, the lousy businesses that they became, the underlying businesses, cast a stain on the entire group, and we got lumped into that.So unfortunately, our diligence led to a great investment, but our inability to raise money around that investment was the reason why we had to shut it down. So I think the lesson learned there was just going to focus on what we started to focus on in 2017, which is small public companies, use our activist approach, Graham and Dodd value. And it was a mistake. It didn't -- it cost us what, Daniel, $2.5 million?Daniel B. WolfeYes, about that.Kevin M. RendinoI mean it wasn't catastrophic by any stretch of imagination. I mean, Arena Group's gone down 4x the amount that Parabellum cost us. So -- and Comscore's gone down 4x more than Parabellum's cost us. So it was a mistake. It was disappointing. It didn't cost us a ton of problems from that perspective. It was time consuming, and we just -- we're not going to do it again. I mean, lesson learned. Just do what you're doing.We thought we were doing the right thing there, but as it turns out, we just did not get the market right in terms of understanding that the SPAC market would just fall apart at the seams, and every SPAC would be looked at the same way, not just -- they wouldn't be differentiated amongst the ones that had lousy businesses and the ones that had good businesses. So that was the lesson learned there.Zach LiggettGreat. And one more for me. On Potbelly, which is -- you sound enthused about the go forward, but how are you thinking about concentration within your portfolio and maybe limits there?Kevin M. RendinoYes. We're probably at the high end there of where we would like it to be. I mean, we run a concentrated portfolio. But because it's up and everything else that we own is down, we haven't been adding to it. It's gotten there based on its own performance. So I would say that we have to be mindful of not falling in love with something so much that it's going to take up a ridiculous amount of our assets.So we're probably at the upper limit. We've just got to figure out what that means. We don't have any -- this is not BlackRock or Vanguard where we have risk people and parameters around and guidelines and rules and regulations. I mean, we're -- that's not who we are, but we also don't want to have all of our eggs in one basket even though that one basket is doing really, really well. We have to figure this one out from that perspective.20% of -- where it is right now is at the upper end of where we're comfortable. We've had other positions that have gone to this point, and we've taken money off the table. It's not a signal, but we just need to be mindful. It'd be nice actually for Potbelly's weighting to go a lot lower, not because it goes down, it's because the rest of the portfolio that we own goes up. If we can get the rest of the portfolio back to valuations that make sense, Potbelly's weighting will be considerably lower than it is today, so...Daniel B. WolfeAnd I think the only thing that I would add that is we continuously look at our investment thesis around each of our names. And with Potbelly, they put out metrics a few years ago that they were targeting to reach in 2024. They actually have reached those about a year early, and now it's where -- what are the next set of targets that they're going to be going towards, and that's something they have to figure out. We have our models for how we think about where this business can scale, and we continuously look at that as we think about size of positions, and so it is something that we look at every day.We have no further questions.Kevin M. RendinoThank you, everyone. As I said earlier, if you have any follow-up, please feel free to e-mail. I'd be happy to get on the phone with you at any given point in time. We wish you the very best rest of the summer. Have a good third quarter, and we'll speak to you again when we report our Q3. Thank you.Daniel B. WolfeThank you. You can all now disconnect.

Thomson Reuters StreetEvents

Q2 2023 180 Degree Capital Corp Earnings Call

https://finance.yahoo.com/news/q2-2023-180-degree-capital-054923302.html

d0af1205-6d3b-3fd9-908d-4befc0562505

IVAC

180 Degree Capital Corp., an investment management firm, recently released its second quarter 2023 investor letter. A copy of the same can be downloaded here. The quarter was rough for the portfolio, which lost 5.8% compared to a 5.3% increase for the Russell Microcap Index. In addition, please check the fund’s top five holdings to know its best picks in 2023.180 Degree Capital highlighted stocks like Intevac, Inc. (NASDAQ:IVAC) in the second quarter 2023 investor letter. Headquartered in Santa Clara, California, Intevac, Inc. (NASDAQ:IVAC) develops thin-film processing systems. On August 17, 2023, Intevac, Inc. (NASDAQ:IVAC) stock closed at $3.4500 per share. One-month return of Intevac, Inc. (NASDAQ:IVAC) was -3.36%, and its shares lost 29.16% of their value over the last 52 weeks. Intevac, Inc. (NASDAQ:IVAC) has a market capitalization of $89.439 million.180 Degree Capital made the following comment about Intevac, Inc. (NASDAQ:IVAC) in its second quarter 2023 investor letter:"Intevac, Inc. (NASDAQ:IVAC): IVAC noted in its Q1 2023 earnings call that its program with Corning was delayed at least a quarter due to Corning's customer pushing out adoption of the new glass IVAC's tool was expected to enable. IVAC had used cash to build inventory for delivery of its tools with the expectation that the ramp would be faster than is now expected. Following that announcement, IVAC noted that Seagate cancelled over $50 million of tool orders that were expected to ship beginning in 2024. On June 13, 2023, IVAC announced its Board had retained Houlihan Lokey to explore strategic alternatives for the business. 180 sold 11% of its position at an average sale price of $7.06 per share. For the quarter, IVAC decreased NAV $0.25, or $2.5 million."Intevac, Inc. (NASDAQ:IVAC) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 11 hedge fund portfolios held Intevac, Inc. (NASDAQ:IVAC) at the end of second quarter which was 12 in the previous quarter.Story continuesWe discussed Intevac, Inc. (NASDAQ:IVAC) in another article and shared 180 Degree Capital Corp.'s views on the company in the previous quarter. In addition, please check out our hedge fund investor letters Q2 2023 page for more investor letters from hedge funds and other leading investors. Suggested Articles:10 Healthcare Stocks with Insider Buying10 Best New Penny Stocks to Buy Now11 Best Biotech Penny Stocks to Buy NowDisclosure: None. This article is originally published at Insider Monkey.

Insider Monkey

Here’s What Happened with Intevac (IVAC)

https://finance.yahoo.com/news/happened-intevac-ivac-072343625.html

8e363904-7734-301c-9070-a22767e65345

IVZ

In this article, we discuss long-term returns of Nelson Peltz's activist targets. If you want to see more stocks in this selection, check out Long Term Returns of Nelson Peltz's 5 Activist Targets.Nelson Peltz is a popular name when it comes to activism on Wall Street. The billionaire investor has made a name for himself by serving several boards and pushing for drastic changes to unlock shareholder value. He helped cofound Trian Partners, a hedge fund focused on investing in high-quality but highly undervalued and underperforming public companies.Although Peltz is consistently open to cooperative efforts with management teams and boards to unlock value, he is not hesitant to initiate proxy battles when necessary. An average return of 38.12% since 2013 underscores why he is a revered activist investor on Wall Street.At the height of the bear run in 2022, Trian Partners was down by 10.6%, outperforming the S&P 500, which ended the year down 19%. Trian's performance was much better, considering on average hedge funds lost 17.2% in 2022.As an activist investor, Peltz often lobbies for changes within companies he is engaged in proxy battles. For starters, he may push for higher dividends, share buybacks, cost cuts, and management changes. He may sometimes push for company dissolution or the sale of some units. After acquiring a $1.3 billion stake in PepsiCo Company in 2013, he called the CEO and demanded the company acquire Mondelez International, a company in which he owned $1 billion in stakes.After acquiring a 9.9% stake in asset manager Invesco and Janus Henderson in 2020, the activist investor pushed for a merger for the two companies. While the deal never materialized, he succeeded in turning Invesco's fortune around, with its operating margins and earnings more than doubling. While Janus did underperform, Peltz continued to ramp up stakes, becoming its largest shareholder after that.Story continuesIn the most recent past, Peltz has waged a proxy battle with Disney after formally launching a bid for a board seat. The activist investor insists he wants to rescue the company from what he calls a crisis of overspending on the streaming business, the purchase of 21st Century Fox, and failed succession planning. Peltz's latest onslaught is seen as a serious challenge to Bob Iger, one of the most famous executives who returned from retirement to lead the company for a second time.Long Term Returns of Nelson Peltz's Activist TargetsNelson Peltz of Trian PartnersOur methodologyPeltz's activist campaigns have generated an average of 9.6% over the past 15 years. While some campaigns have been extremely successful, generating returns of more than 30%, some have been a disappointment, losing as much as 15%, as was the case with General Electric.We have compiled a list of some of the top activist campaigns engineered by the billionaire investor since founding Trian Partners in 2005. The campaigns are ranked chronologically based on when they occurred.Long-Term Returns of Nelson Peltz's Activist Targets12. Unilever PLC (NYSE:UL)Activist Investment: 2022 Long Term Returns Since Peltz's Investment: 11.87% S&P 500 Gain: 8.63%Unilever PLC (NYSE:UL) is a consumer goods company that operates through beauty and well-being, Personal Care Nutrition, and Ice Cream Segments. The company also deals in hair care products such as shampoo, conditioner, and styling.Peltz started building a position in the British Consumer goods company in 2022. The activist investor has since pushed for management changes, having approached former CEOs of consumer goods companies to take up the top job at the Dove soap maker. He has also committed to helping drive Unilever's strategy operations sustainability and shareholder value.11. The Walt Disney Company (NYSE:DIS)Activist Investment: 2022 Long Term Returns Since Peltz's Investment: -16.98% S&P 500 Gain Since Peltz's Investment: 17.33%A conglomerate in the entertainment industry, The Walt Disney Company (NYSE:DIS) is best known for its leading role in creating and providing entertainment and information. The company also operates some of the biggest theme parks. The company saw a slew of activist investor activity in 2022, led by Peltz and Daniel Loeb.Peltz increased his stake in The Walt Disney Company (NYSE:DIS) in early 2023 in an attempt to gain sizable influence on the company's future roadmap. With his hedge fund Trian Partners, the activist investor was forced to end a proxy battle in February after Disney agreed to restructure its business and launch an effort to reduce costs by about $5.5 billion.With the changes, Peltz ended his quest for a board seat after CEO Iger laid out plans for cutting 7,000 jobs as part of the cost-cutting measures. The CEO has also agreed to consider the sale of the company's linear networks like ABC Freeform and National Geographic.10. Invesco Ltd. (NYSE:IVZ)Activist Investment: 2020 Long Term Returns Since Peltz's Investment: 142% S&P 500 Gain Since Peltz's Investment: 45.38%Invesco Ltd. (NYSE:IVZ) is an independent asset investment management company that provides a range of investment capabilities and outcomes to help clients achieve various objectives. Activist investor Peltz first took an interest in Invesco in 2020 and started engaging the company regarding various strategic and operational initiatives.The activist investor pushed for two board seats and discussed board refreshments. Through Trian Partners, the hedge fund manager also encouraged Invesco Ltd. (NYSE:IVZ) to explore strategic combinations with one or more companies in asset management. Peltz wanted the company to merge with Janus, where he held some stakes.A proposed merger with Janus did not happen, and Peltz ended up stepping down from the board following his appointment to the Board of Janus Henderson Group. Trian Partners trimmed its stake in Invesco to 33.9 million in May 2023 from 55.6 million shares.9. The Procter & Gamble Company (NYSE:PG)Activist Investment: 2017 Long Term Returns Since Peltz's Investment: 68.60% S&P 500 Gain Since Peltz's Investment: 87.5%The Procter & Gamble Company (NYSE:PG) is a multinational consumer goods company with a wide portfolio of product portfolio including conditioners, shampoo male and female blades, and razors. The activist investor first aimed at the company in 2017 and took a more surgical approach in lobbying for a single board seat.Peltz would later allege that The Procter & Gamble Company (NYSE:PG) had wasted about $100 million to block his attempt to get on the board, terming it the dumbest thing.The activist investor would win the board seat with the slightest margin after waging one of the biggest proxy fights in the history of the $220 billion consumer goods giant.He joined the board, having struck a truce with the management agreeing to end the proxy fight. He would exit the board four years later, terming his tenure successful in creating tremendous value for all stakeholders.8. Sysco Corporation (NYSE:SYY)Activist Investment: 2015 Long Term Returns Since Peltz's Investment: 104% S&P 500 Gain Since Peltz's Investment: 101%With its subsidiaries, Sysco Corporation (NYSE:SYY) engages in marketing and distributing foods and other related products, small wares, kitchen equipment, and table-on items for restaurants. The company was the subject of an activist investor takeover in 2015 when Peltz confirmed a 7% stake in the giant food distributor.In its filing, Trian Partners reiterated that the company boasts several competitive operating and financial performance advantages but continued to underperform relative to its potential. In the regulatory filing, the hedge fund reiterated that it could adopt a strategic and operating initiative to improve margins and enhance working capital efficiency.Days after the announcement, Peltz got his wish and was added to the company's board. With his addition to the board, the activist investor pushed for an increase in dividends, the repurchase of shares, and the divestment of non-core business.7. Mondelez International, Inc. (NASDAQ:MDLZ) Activist Investment: 2013 Long Term Returns Since Peltz's Investment: 60.71% S&P 500 Gain Since Peltz's Investment: 43%Mondelez International, Inc. (NASDAQ:MDLZ) manufactures, markets, and sells snack food and beverage products. Activist investor Peltz disclosed stakes in Mondelez in 2013 as the stock had tumbled significantly following the company's split from Kraft Foods.There were reports that the activist investor intended to push for a merger between Mondelez International, Inc. (NASDAQ:MDLZ) and PepsiCo. The reports came at a time when PepsiCo was in the process of exploring restructuring options for its underperforming North American beverage business. Speculation was rife that it could buy Mondelez.Peltz discussed with Mondelez management the company's operations capital structure and corporate governance. In early 2014, Mondelez announced Peltz was to join the board after criticizing the company for doing little to cut costs. He joined the board as part of a compromise agreement that resulted in him ending his push to have PepsiCo acquire Mondelez International, Inc. (NASDAQ:MDLZ).Peltz continued to rack up stakes in the company until 2015 but left the board in 2016, reiterating satisfaction with the progress made at the confectionery company.6. PepsiCo, Inc. (NASDAQ:PEP)Activist Investment: 2013 Long Term Returns Since Peltz's Investment: 44.4% S&P 500 Gain Since Peltz's Investment: 46.94%PepsiCo, Inc. (NASDAQ:PEP) manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company was the subject of an activist investment from Peltz in 2013 when it was undergoing restructuring amid struggles with its North American operations. The company was reviewing a potential spinoff of its beverage business, which remained a significant drag despite massive investments.In 2014, the activist investor renewed his struggle to force PepsiCo, Inc. (NASDAQ:PEP) to spin-off the beverage unit from its flourishing snacks division."Two leaner and more entrepreneurial companies" through the spinoff would boost sales and margins in the snacks business, while the drinks business would generate a stable flow of cash that could be returned to shareholders, Peltz said.CEO Indra Nooyi shot down the spin-off efforts, insisting that a split up would hurt PepsiCo, Inc. (NASDAQ:PEP)'s ability to negotiate with retail customers. The feud only came to an end when PepsiCo agreed to allow a representative of Peltz's fund to join the board.Trian Partners exited its position in the beverage giant in 2016, three years after launching a campaign to have PepsiCo, Inc. (NASDAQ:PEP) split into two.Click to continue reading and see Long Term Returns of Nelson Peltz's 5 Activist Targets.Suggested articles:20 Best Companies to Work For in 2023100 Most Popular Songs of All Time on Spotify15 Countries That Produce the Most E-waste in the WorldDisclosure: None. Long-Term Returns of Nelson Peltz's Activist Targets is originally published on Insider Monkey.

Insider Monkey

Long-Term Returns of Nelson Peltz’s Activist Targets

https://finance.yahoo.com/news/long-term-returns-nelson-peltz-120045142.html

8694fc29-2746-388b-b7a4-624e73c34e89

IVZ

The tech giant Apple Inc. AAPL shed nearly $200 billion in market value in just two days amid the reports of China planning to expand a ban on the use of iPhones to government-backed agencies and state companies. Notably, China is Apple’s third-largest market, accounting for 18% of the company’s total revenues last year.The Wall Street Journal disclosed on Wednesday that Beijing had issued a directive instructing officials within central government agencies not to bring iPhones into their workplaces or use them for professional purposes. Bloomberg News later reported that this prohibition could extend to employees of state-owned enterprises and government-affiliated institutions.Bernstein analyst believes an iPhone ban on all Chinese government employees could cut Apple's phone sales in China by as much as 5%. However, most analysts are also calling the reaction overblown, considering China is a much larger market beyond government agencies. Wedbush Securities thinks the ban would affect less than 5,00,000 iPhones of the roughly 45 million he expects to be sold in the country over the next 12 months.The rumored restriction on iPhones comes closely after Huawei, a Chinese tech giant, launched its new premium smartphone. Bank of America analysts found the timing of these events to be noteworthy.Growth ProspectsOne of the primary motivations to invest in Apple is its dominant presence in the consumer tech landscape, positioning it favorably for expansion into rapidly growing sectors like artificial intelligence (AI) and virtual/augmented reality (VR/AR). These areas are anticipated to see compound annual growth rates exceeding 30% until 2030 (read: Guide to Artificial Intelligence ETFs).Historically, Apple has demonstrated an ability to penetrate new markets and swiftly capture significant market share. With the recent launch of its VR/AR headset, the Vision Pro, in June, Apple's growth potential seems even more promising.Additionally, the iPhone maker is expanding into new markets. Apple's Services segment, which includes the App Store, iCloud, Apple Music, Apple TV+ and Apple Arcade, has been a significant growth driver. With a growing global user base, these services are expected to generate massive revenues.Story continuesSolid Zacks EstimatesApple boasts the world’s highest stock market valuation, at nearly $2.8 trillion. It has seen positive earnings estimate revision of a penny for both the current and the next fiscal year over the past 30 days.Apple currently has an average brokerage recommendation (ABR) of 1.64 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations made by 29 brokerage firms. The current ABR compares to an ABR of 1.64 a month ago based on 29 recommendations. Of the 29 recommendations deriving the current ABR, 18 are Strong Buy and three are Buy. Strong Buy and Buy, respectively, account for 62.07% and 10.34% of all recommendations. A month ago, Strong Buy made up 62.07%, while Buy represented 10.34%.Based on short-term price targets offered by 27 analysts, the average price target for Apple comes to $205.07. The forecasts range from a low of $140.00 to a high of $240.00.Currently, Apple carries a Zacks Rank #3 (Hold) and a Growth Score of B, suggesting that the iPhone maker is primed for growth. Apple stock is cheap, trading at a P/E ratio of 30.26 compared with Amazon’s AMZN 60.66 times, Netflix’s NFLX 37.41 times and Microsoft’s MSFT 30.54 times  (see: all the Technology ETFs here).Buy Opportunity!That said, investors should consider the declining prices in Apple to be a better entry point. Several ETFs have the largest allocation to the tech titan. Technology Select Sector SPDR Fund XLK, Vanguard Information Technology ETF VGT, MSCI Information Technology Index ETF FTEC, iShares US Technology ETF IYW and Invesco QQQ QQQ have Apple as the top or second firm with a double-digit allocation and carry a Zacks Rank #1 (Strong Buy) or 2 (Buy).Technology Select Sector SPDR Fund (XLK)Technology Select Sector SPDR Fund targets the broad technology sector and follows the Technology Select Sector Index. It holds about 65 securities in its basket, with Apple making up for a 21.7% share. Technology Select Sector SPDR Fund is the most popular and heavily traded ETF, with AUM of $51.6 billion and an average daily volume of 6 million shares. The fund charges 10 bps in fees per year.Vanguard Information Technology ETF (VGT)Vanguard Information Technology ETF manages about $54 billion in its asset base and provides exposure to 323 technology stocks. It currently tracks the MSCI US Investable Market Information Technology 25/50 Index. Here, Apple accounts for a 22.7% share. Vanguard Information Technology ETF has an expense ratio of 0.10%, while volume is solid at nearly 537,000 shares (read: Don't Fear Higher Rates: Tech ETFs to Rule on Nvidia & Allies).MSCI Information Technology Index ETF (FTEC)MSCI Information Technology Index ETF is home to 311 technology stocks with AUM of $7.3 billion. It follows the MSCI USA IMI Information Technology Index. Apple accounts for a 22.3% allocation. MSCI Information Technology Index ETF has an expense ratio of 0.08%, while volume is solid at 228,000 shares a day.iShares US Technology ETF (IYW)iShares Dow Jones US Technology ETF tracks the Russell 1000 Technology RIC 22.5/45 Capped Index, giving investors exposure to 135 U.S. electronics, computer software and hardware, and informational technology companies. Apple makes up 17.5% of the assets. iShares Dow Jones US Technology ETF has AUM of $11.4 billion and charges 40 bps in fees and expenses. Volume is good as it exchanges 924,000 shares a day.Invesco QQQ (QQQ)Invesco QQQ provides exposure to the 101 largest domestic and international non-financial companies listed on the Nasdaq by tracking the Nasdaq 100 Index. Apple accounts for an 11.1% share. Invesco QQQ is one of the largest and most popular ETFs in the large-cap space, with an AUM of $207 billion and an average daily volume of 46 million shares. It charges investors 20 bps in annual fees.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportAmazon.com, Inc. (AMZN) : Free Stock Analysis ReportApple Inc. (AAPL) : Free Stock Analysis ReportMicrosoft Corporation (MSFT) : Free Stock Analysis ReportNetflix, Inc. (NFLX) : Free Stock Analysis ReportInvesco QQQ (QQQ): ETF Research ReportsTechnology Select Sector SPDR ETF (XLK): ETF Research ReportsFidelity MSCI Information Technology Index ETF (FTEC): ETF Research ReportsiShares U.S. Technology ETF (IYW): ETF Research ReportsVanguard Information Technology ETF (VGT): ETF Research ReportsTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

What Lies Ahead for Apple ETFs After iPhone Use Ban?

https://finance.yahoo.com/news/lies-ahead-apple-etfs-iphone-151000902.html

da0c6dcd-2130-3994-a7d5-44a65361af34

J

Largest capital program in district's history addresses aging infrastructure and community developmentDALLAS, Sept. 5, 2023 /PRNewswire/ -- Jacobs (NYSE: J) was selected by Austin Independent School District (ISD) in Austin, Texas to provide program management services in support of the district's capital improvement program. The program will implement more than $2.4 billion in capital works for Austin ISD facilities including modernization of 25 schools through full or phased renovations, districtwide security improvements, technology upgrades and maintenance.Jacobs to Manage Austin Independent School District Modernization ProgramJacobs was chosen as one of three program managers that will each lead a segment of the capital improvement program. Jacobs' five-year contract is to manage approximately $517 million worth of capital projects, specifically overseeing the development of ten schools within Austin ISD."Jacobs' core values and those of Austin ISD are very closely aligned with a common vision of developing our next generation of leaders," said Jacobs People and Places Solutions Americas South Senior Vice President and General Manager Katus Watson. "In addition, this historic voter-approved bond program supports Austin ISD in addressing critical aging infrastructure that will deliver enduring benefits to the community for decades to come."In addition to heating, air conditioning, plumbing and roofing replacements, planned improvements include the addition of school mental health centers and community pantries, visual and performing arts and athletic facility updates, upgrades to early learning and special education classrooms and kitchen/serving areas, and new playground and outdoor learning spaces."As a key team member helping to deliver Austin ISD's 2022 Bond, Jacobs has been an invaluable resource to the district and our Construction Management Department," said Executive Director of Construction Management Michael Mann. "Working alongside our staff and other program managers, Jacobs has proven they have both the technical expertise, as well as a culture of collaboration and teamwork, that is necessary to deliver the largest bond in Austin ISD history. It is truly a pleasure working with the Jacobs team, and we look forward to continued success in delivering the 2022 Bond."Story continuesTo manage the program, Jacobs is teamed with Turner & Townsend Heery, and specialist minority-owned subconsultant firms Encotech Engineering Consultants, Olivier, Inc., and Project Management Group, LLC who represent approximately 30% of the project team. These firms were selected based on their core expertise and to promote local minority businesses.Established in 1881, Austin ISD is the eighth largest school district in the state of Texas with more than 73,000 enrolled students in 113 schools across one of the fastest growing metroplexes in the country.Jacobs previously provided program management services in support of Austin ISD's $450 million "Children First Bond Program" between 1996 and 2001.At Jacobs, we're challenging today to reinvent tomorrow by solving the world's most critical problems for thriving cities, resilient environments, mission-critical outcomes, operational advancement, scientific discovery and cutting-edge manufacturing, turning abstract ideas into realities that transform the world for good. With approximately $15 billion in annual revenue and a talent force of more than 60,000, Jacobs provides a full spectrum of professional services including consulting, technical, scientific and project delivery for the government and private sector. Visit jacobs.com and connect with Jacobs on Facebook, Instagram, LinkedIn and Twitter.Certain statements contained in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that do not directly relate to any historical or current fact. When used herein, words such as "expects," "anticipates," "believes," "seeks," "estimates," "plans," "intends," "future," "will," "would," "could," "can," "may," and similar words are intended to identify forward-looking statements. We base these forward-looking statements on management's current estimates and expectations, as well as currently available competitive, financial and economic data. Forward-looking statements, however, are inherently uncertain. There are a variety of factors that could cause business results to differ materially from our forward-looking statements including, but not limited to, the timing of the award of projects and funding and potential changes to the amounts provided for under the Infrastructure Investment and Jobs Act, as well as general economic conditions, including inflation and the actions taken by monetary authorities in response to inflation, changes in interest rates and foreign currency exchange rates, changes in capital markets, the possibility of a recession or economic downturn, geopolitical events and conflicts, and the impact of the COVID-19 pandemic, including the related reaction of governments on global and regional market conditions, among others. For a description of some additional factors that may occur that could cause actual results to differ from our forward-looking statements, see the discussions contained under Item 1 - Business; Item 1A - Risk Factors; Item 3 - Legal Proceedings; and Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recently filed Annual Report on Form 10-K, and  Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations; Item 1 - Legal Proceedings; and Item 1A - Risk Factors in our most recently filed Quarterly Report on Form 10-Q, as well as the company's other filings with the Securities and Exchange Commission. The company is not under any duty to update any of the forward-looking statements after the date of this press release to conform to actual results, except as required by applicable law.For press/media inquiries:[email protected] Logo (PRNewsfoto/Jacobs)CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/jacobs-to-manage-austin-independent-school-district-modernization-program-301916088.htmlSOURCE Jacobs

PR Newswire

Jacobs to Manage Austin Independent School District Modernization Program

https://finance.yahoo.com/news/jacobs-manage-austin-independent-school-114500675.html

bd323278-f9e9-380c-ad73-c68b100549a1

J

Supports use of data analytics and technology to improve critical transportation infrastructureContract drives efficient travel and commerce via traffic management systemsDALLAS, Sept. 7, 2023 /PRNewswire/ -- Jacobs (NYSE:J) was selected to operate and maintain Intelligent Transportation Systems (ITS) and manage traffic operations for Florida's Turnpike Enterprise, a division of the Florida Department of Transportation. Jacobs will operate, manage and maintain more than 500 miles of ITS-connected roadway infrastructure across the state.Jacobs to Manage Intelligent Transportation System for Florida’s TurnpikeUnder the five-year, $28 million contract, Jacobs will deliver a broad range of engineering, monitoring and support services. With full-time staff in place at turnpike locations, Jacobs will manage traffic operations, perform traffic engineering services, operate and manage ITS infrastructure including maintenance contracts, network and data security.Jacobs also will manage contingency plans and response for emergencies and weather events and work with Florida's Turnpike Enterprise to consider and evaluate advanced data systems to improve safety and mobility on the transportation network. These systems promote safe and efficient travel and freight transport and apply innovative operating technology to assist motorists. "Our 30-year relationship with Florida's Turnpike Enterprise combines innovative program management with advanced transportation technology," said Jacobs People and Places Solutions Americas South Senior Vice President and General Manager Katus Watson. "Together we bring the enterprise tools and knowledge to make travel smarter, safer and more connected for Florida's residents and visitors."Florida's Turnpike Enterprise has demonstrated its commitment to a safer and more connected future for road transportation. As an early adopter of transportation technologies, the Enterprise has developed and built a research facility known as SunTrax, dedicated to the discovery, development and adoption of tools designed to enhance safe and efficient travel. Construction on Florida's Turnpike began in the mid-1950s. The tollway network now handles more than three million motorist trips a day from Orlando to cities along the state's Atlantic coast.Story continuesAt Jacobs, we're challenging today to reinvent tomorrow by solving the world's most critical problems for thriving cities, resilient environments, mission-critical outcomes, operational advancement, scientific discovery and cutting-edge manufacturing, turning abstract ideas into realities that transform the world for good. With approximately $15 billion in annual revenue and a talent force of more than 60,000, Jacobs provides a full spectrum of professional services including consulting, technical, scientific and project delivery for the government and private sector. Visit jacobs.com and connect with Jacobs on Facebook, Instagram, LinkedIn and Twitter.Certain statements contained in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that do not directly relate to any historical or current fact. When used herein, words such as "expects," "anticipates," "believes," "seeks," "estimates," "plans," "intends," "future," "will," "would," "could," "can," "may," and similar words are intended to identify forward-looking statements. We base these forward-looking statements on management's current estimates and expectations, as well as currently available competitive, financial and economic data. Forward-looking statements, however, are inherently uncertain. There are a variety of factors that could cause business results to differ materially from our forward-looking statements including, but not limited to, the timing of the award of projects and funding and potential changes to the amounts provided for under the Infrastructure Investment and Jobs Act, as well as general economic conditions, including inflation and the actions taken by monetary authorities in response to inflation, changes in interest rates and foreign currency exchange rates, changes in capital markets, the possibility of a recession or economic downturn, geopolitical events and conflicts, and the impact of the COVID-19 pandemic, including the related reaction of governments on global and regional market conditions, among others. For a description of some additional factors that may occur that could cause actual results to differ from our forward-looking statements, see the discussions contained under Item 1 - Business; Item 1A - Risk Factors; Item 3 - Legal Proceedings; and Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recently filed Annual Report on Form 10-K, and  Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations; Item 1 - Legal Proceedings; and Item 1A - Risk Factors in our most recently filed Quarterly Report on Form 10-Q, as well as the company's other filings with the Securities and Exchange Commission. The company is not under any duty to update any of the forward-looking statements after the date of this press release to conform to actual results, except as required by applicable law.For press/media inquiries:[email protected] Jacobs Logo (PRNewsfoto/Jacobs)CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/jacobs-to-manage-intelligent-transportation-system-for-floridas-turnpike-301920296.htmlSOURCE Jacobs

PR Newswire

Jacobs to Manage Intelligent Transportation System for Florida's Turnpike

https://finance.yahoo.com/news/jacobs-manage-intelligent-transportation-system-114500308.html

803405d5-22b8-3ce1-883c-689e84ba4e5c

JAGX

Emerging GrowthMIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 62nd Emerging Growth Conference on September 6 & 7, 2023.The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.Register for the conference here.Submit Questions for any of the presenting companies to: [email protected] updates, follow us on TwitterDay 1September 6, 202310:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to the registration link and click “Already registered” and enter your email.10:10Introduction10:15 - 10:45Citizens, Inc. (NYSE: CIA)Gerald W. Shields, Vice Chairman / CEO, & Jeff Conklin, CFO10:50 - 11:20NeuroMetrix, Inc. (NASDAQ: NURO)Dr. Shai Gozani, CEO & Thomas Higgins, CFO12:00 - 12:30Cyngn, Inc. (NASDAQ: CYN)Lior Tal, CEO & Director12:35 - 1:05Global Crossing Airlines Group, Inc. (OTCQB: JETMF) (NEO: JET)Ryan Goepel, EVP & CFO1:10 - 1:40GPO Plus, Inc. (OTCQB: GPOX)Brett Pojunis, President / CEO1:45 - 2:15GeoVax Labs, Inc. (NASDAQ: GOVX) David Dodd, Chairman, President / CEO2:55 - 3:05Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF)Dr. Pinia Fishman, Founder & CEO, and Motti Farbstein, COO & CFO3:10 - 3:20Longeveron, Inc. (NASDAQ: LGVN)Mohamed Wa’el Ahmed Hashad, CEO & Director3:25 - 3:35Sigyn Therapeutics, Inc. (OTCQB: SIGY) Inc. (OTCQB: SIGY)James Allen Joyce, CEO3:40 - 3:50dynaCERT Inc. (OTCQX: DYFSF (TSXV: DYA) James Payne President / CEO & DirectorDay 2September 7, 20239:15Virtual Lobby opens.Register for the Conference. If you already registered, go back to the registration link and click “Already registered” and enter your email.9:30IntroductionStory continues9:40 - 10:10Jaguar Health, Inc. (NASDAQ: JAGX)Lisa A. Conte, Founder, CEO, President & Director10:15 - 10:45AGBA Group Holding Limited (NASDAQ: AGBA)Mr. Wing-Fai Ng, CEO10:50 - 11:20Ideal Power (NASDAQ: IPWR)Dan Brdar, President / CEO, & Tim Burns, CFO11:25 - 11:55Steppe Gold, Ltd. (OTCQX: STPGF) (TSX: STGO)Aneel Singh, Exec. VP & Director12:00 - 12:3022nd Century Group, Inc. (NASDAQ: XXII)John Miller, Interm CEO1:10 - 1:40SES AI Corporation (NYSE: SES)Jing Nealis, CFO1:45 - 2:15RedCloud Technologies, a Private CompanyJustin Floyd, CEO2:20 2:50Alpha Tau Medical, Inc. (NASDAQ: DRTS)Raphi Levy, CFO2:55 - 3:05Big Screen Entertainment Group (OTC Pink: BSEG)Kimberley Kates, CEO, and Sandro Monetti, PresidentVisit the following link to register. You will then receive an email containing the link and time to sign into the conference.Register for the conference here.Submit Questions for any of the presenting companies to: [email protected]: Subscribe to our YouTube ChannelAbout EmergingGrowth.comFounded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.About the Emerging Growth ConferenceThe Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients. Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future. In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.If you believe or know of a company that might fit our audience, contact us here.Thank you for your interest in our conference, and we look forward to your participation in future conferences.Contact:Emerging GrowthPhone: 1-305-330-1985Email: [email protected]

GlobeNewswire

Presenting on the Emerging Growth Conference on September 6 and 7 Register Now

https://finance.yahoo.com/news/presenting-emerging-growth-conference-september-110000405.html

3d205bde-bf57-3123-a290-171833ef3fd3

JAGX

Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024Dr. Brunke to present at the October 30-November 2, 2023 World Orphan Drug Congress in Barcelona and the November 6-8, 2023 BIO-Europe® conference in MunichSAN FRANCISCO, CA / ACCESSWIRE / September 7, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX), a commercial-stage pharmaceuticals company developing first-in-class plant-based gastrointestinal (GI) prescription medicines, today announced that Karen Brunke, PhD, the company's EVP of Corporate and Business Development, has become a member of the Biotechnology Innovation Organization's (BIO) Rare Disease and Orphan Drugs Committee.BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations."I am very happy to have joined BIO's Rare Disease and Orphan Drugs Committee," said Dr. Brunke. "The committee provides an important forum for BIO members with a particular focus on rare diseases to discuss BIO's major advocacy issues and policies in relation to the development and marketing of orphan products. Jaguar has a core focus on two rare disease indications - short bowel syndrome (SBS) and microvillus inclusion disease (MVID) with intestinal failure - and I look forward to presenting at the October 30-November 2, 2023 World Orphan Drug Congress in Barcelona, Spain and the BIO-Europe conference in Munich, Germany to review the company's development efforts in this area."BIO's Rare Disease and Orphan Drugs Committee is cross-functional, reviewing both FDA and development issues as well as market access and commercialization policies (including reimbursement). As such, the committee identifies and raises rare disease-specific issues to BIO's Health Care Reform and Reimbursement Committee. In 2020, the Rare Disease and Orphan Drug Committee prioritized developing consensus on, and advocating for, the Rare Pediatric Disease Priority Review Voucher program. The committee is currently working on developing a robust agenda for discussion with the FDA in a forthcoming meeting.Story continuesJaguar is supporting investigator-initiated and investigator IND proof-of-concept studies of crofelemer for MVID and SBS with intestinal failure in the US, European Union, and Middle East/North Africa (MENA) regions, with results expected before the end of 2023 and in 2024. In accordance with the guidelines of specific EU countries, published data from such clinical investigations could support reimbursed early patient access to crofelemer for SBS or MVID, potentially in 2024, for these debilitating conditions.MVID is a catastrophic medical situation for pediatric patients, and there are currently no approved drug treatments. The company's Investigational New Drug application for crofelemer for the treatment of MVID was activated by the U.S. Food and Drug Administration (FDA) August 7, 2023.Crofelemer has been granted Orphan Drug Designation (ODD) by the FDA and the European Medicines Agency for both MVID and SBS with intestinal failure. The ODD programs in the US and EU qualify sponsors to receive potential incentives to develop therapies for the diagnosis, prevention, or treatment of rare diseases or conditions.About CrofelemerCrofelemer is the only oral prescription drug approved by the FDA under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Jaguar family company Napo Pharmaceuticals has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities.About the Jaguar Health Family of CompaniesJaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp., is focused on developing novel prescription medicines derived from plants for mental health indications.For more information about Jaguar Health, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo Therapeutics, visit napotherapeutics.com. For more information about Magdalena Biosciences, visit magdalenabiosciences.com.Forward-Looking StatementsCertain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Dr. Brunke will present at the 2023 World Orphan Drug Congress and the 2023 BIO-Europe conference, Jaguar's expectation that the results of investigator-initiated and investigator IND proof-of-concept studies of crofelemer for MVID and SBS with intestinal failure will be available before the end of 2023 and in 2024, and Jaguar's expectation that published data from such clinical investigations could support reimbursed early patient access to crofelemer for SBS or MVID in European Union countries, potentially in 2024. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.Contact:[email protected]://jaguar.healthhttps://www.linkedin.com/company/jaguar-health/https://twitter.com/Jaguar_Healthhttps://www.instagram.com/jaguarhealthcommunity/Jaguar-JAGXSOURCE: Jaguar Health, Inc.View source version on accesswire.com: https://www.accesswire.com/781439/jaguar-healths-executive-vp-dr-karen-brunke-joins-bios-rare-disease-and-orphan-drugs-committee

ACCESSWIRE

Jaguar Health's Executive VP Dr. Karen Brunke Joins BIO's Rare Disease and Orphan Drugs Committee

https://finance.yahoo.com/news/jaguar-healths-executive-vp-dr-123000752.html

697ab97c-e011-34ef-b4f9-a2d462e5066b

JBHT

A month has gone by since the last earnings report for JB Hunt (JBHT). Shares have lost about 1.3% in that time frame, outperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is JB Hunt due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.Earnings Miss at J.B. Hunt in Q2J.B. Hunt Transport Services' second-quarter 2023 earnings of $1.81 per share missed the Zacks Consensus Estimate of $1.97 and declined 25.2% year over year.Total operating revenues of $3,132.6 million also lagged the Zacks Consensus Estimate of $3,347.5 million and fell 18.4% year over year. The downfall was due to decline in revenue per load of 24% in Integrated Capacity Solutions (ICS), 13% in Intermodal (JBI), 21% in Truckload (JBT), and a 4% decline in productivity in Dedicated Capacity Solutions (DCS), on the back of changes in customer rate, freight mix and lower fuel surcharge revenue.Total operating revenues, excluding fuel surcharges, decreased 14% year over year.Operating income for the second quarter decreased 23% year over yearto $270.7 million, owing to lower revenue across all of the business segments, lower volume and customer rates.Net interest expense for the second quarter increased 14% year over yeardue to higher effective interest rates.Operating expenses fell 17.9% to $2,861.91 million.On Jan 1, 2023, J.B. Hunt transferred most of JBT’s company-owned trucking operations to DCS and transferred its less-than-truckload brokerage operations from ICS to FMS.Segmental HighlightsIntermodal division generated quarterly revenues of $1.49 billion, down 19% year over year, owing to a 7% decrease in volume and a 13% decrease in gross revenue per load, resulting from changes in the mix of freight, customer rates, and fuel surcharge revenues. Revenue per load, excluding fuel surcharge revenue, fell 7% year-over-year. Eastern network loads declined 6%, while transcontinental loads fell 8%.Story continuesOperating income fell 29%year over yearin the second quarter owing to lower customer rate and volume, and the resulting impact on absorbing network and equipment costs.Dedicated Contract Services segment revenues fell 2% from the year-ago period to $888 million due to a 4% decrease in productivity (revenue per truck per week) versus the prior period.Operating income grew 21% year over yeardue to the maturing of new business onboarded over the trailing 12 months. This benefit was partially offset by higher professional driver and non-driver wages and benefits, and equipment-related and maintenance expenses.Integrated Capacity Solutions revenues decreased 43% year over year to $344 million. Segmental volumes decreased 26%. Revenue per load fell 24% owing to lower contractual and transactional rates and changes in customer freight mix.JBHT reported an operating loss of $4.4 million against the operating income of $23.2 million in the year-ago quarter. The loss wasowing to lower gross profit, partially offset by lower personnel and insurance-related expenses, and reduced technology costs.Truckload revenues fell 16% to $192 million. Excluding fuel surcharge revenues, segmental revenues fell 15% primarily owing to 20% decline in revenue per load excluding fuel surcharge revenue partially offset by a 6% increase in load volume. At the second-quarter end, total tractors and trailers were 2,068 and 15,358 compared with the year-ago quarter’s figures of 2,015 and 12,770, respectively.Operating income fell 81% year over year to $3.8 million due to decline in revenue.Final Mile Services revenues fell 19% year over year to $224 million due to general weakness in demand across many of the industry verticals served.Operating income increased 12% year over year on the back of internal efforts to improve revenue quality and managing costs.Liquidity & BuybackJ.B. Hunt exited the second quarter with cash and cash equivalents of $295.92 million compared with $52.60 million at the end of first-quarter 2023. Long-term debt was $1,195.30 million compared with $991.71million at the end of first-quarter 2023.Net capital expenditures for the first quarter were $473.94 million compared with $308.96 million in the year-ago period.In the second quarter of 2023, JBHT purchased almost 315,000 shares for $53 million. As of Jun 30, 2023, JBHT had approximately $467 million remaining under its share repurchase authorization.How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in fresh estimates.The consensus estimate has shifted -9.57% due to these changes.VGM ScoresCurrently, JB Hunt has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with a C. Following the exact same course, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise JB Hunt has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportJ.B. Hunt Transport Services, Inc. (JBHT) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

JB Hunt (JBHT) Down 1.3% Since Last Earnings Report: Can It Rebound?

https://finance.yahoo.com/news/jb-hunt-jbht-down-1-153011836.html

3fb135b6-119b-344c-93a1-f37b5852623e

JBHT

LOWELL, Ark., September 01, 2023--(BUSINESS WIRE)--J.B. Hunt Transport Services, Inc. (NASDAQ: JBHT) President Shelley Simpson and Executive Vice President of Sales and Marketing Spencer Frazier will address the Morgan Stanley 11th Annual Laguna Conference at 8:45 a.m. PDT on September 13, 2023.Investors may access the live presentation by visiting the Investor Relations section of our website. A presentation replay will also be available on J.B. Hunt’s website following the event.Information presented at the conference may contain forward-looking statements made by the company that involve risks, assumptions, and uncertainties difficult to predict. Actual results may differ materially from those currently anticipated due to a number of factors, including, but not limited to, those discussed in Item 1A of our Annual Report filed on Form 10-K for the year ended December 31, 2022. J.B. Hunt assumes no obligation to update any forward-looking statements to the extent the company becomes aware they will not be achieved for any reason.Interested parties may view this press release on the company’s website.About J.B. HuntJ.B. Hunt Transport Services Inc. is on a mission to create the most efficient transportation network in North America. The company’s industry-leading solutions and mode-neutral approach generate value for customers by eliminating waste, reducing costs and enhancing supply chain visibility. Powered by one of the largest company-owned fleets in the country with more than 162,000 pieces of trailing equipment and nearly one million accessible trucks through its J.B. Hunt 360°® digital freight marketplace, J.B. Hunt can meet the unique shipping needs of any business, from first mile to final delivery, and every shipment in-between. Through disciplined investments in its people, technology and capacity, J.B. Hunt is delivering exceptional value and service that enable long-term growth for the company and its stakeholders.Story continuesJ.B. Hunt Transport Services Inc. is a Fortune 500 company, an S&P 500 company and a component of the Dow Jones Transportation Average. Its stock trades on NASDAQ under the ticker symbol JBHT. J.B. Hunt Transport Inc. is a wholly owned subsidiary of JBHT. The company’s services include intermodal, dedicated, refrigerated, truckload, less-than-truckload, flatbed, single source, last mile, transload and more. For more information, visit www.jbhunt.com.View source version on businesswire.com: https://www.businesswire.com/news/home/20230901031475/en/ContactsBrad DelcoSr. Vice President – Finance(479) 820-2723

Business Wire

J.B. Hunt Transport Services, Inc. Announces Participation in the Morgan Stanley 11th Annual Laguna Conference

https://finance.yahoo.com/news/j-b-hunt-transport-services-130000746.html

e5ffcb0e-e1d7-3b40-afff-0ef160a375db

JCI

Johnson Controls, in collaboration with the International WELL Building Institute, CBRE and WiredScore, publishes new whitepaper providing key references and insights for Southeast Asia's smart city initiatives. The whitepaper presents a roadmap for building smart cities that create safer, healthier spaces for a growing urban population while helping the region meet its net zero goals.SINGAPORE, Sept. 6, 2023 /PRNewswire/ -- Despite their governments' smart city ambitions, many developing cities in Southeast Asia still lack adequate smart building technologies and initiatives to transform into data-driven, sustainable cities, according to the new "Pioneering a Sustainable Future – Building Smarter Net Zero Cities" whitepaper released by Johnson Controls [NYSE:JCI], the global leader for smart, healthy, and sustainable buildings.Johnson Controls Logo (PRNewsfoto/Johnson Controls)Written in collaboration with the International WELL Building Institute, CBRE and WiredScore, the whitepaper represents diverse expertise across the smart and healthy building industry. It provides a roadmap for the industry, calling for greater investment and collaboration to help Southeast Asian cities realise their goal of creating a sustainable, net zero environment for their citizens. With nearly 40% of global greenhouse gas emissions coming from buildings, smart buildings increasingly play a critical role towards helping cities realise their visions."Southeast Asia's journey to transform its smart cities requires collaboration, innovation, and a holistic approach", said Anu Rathninde, president, Asia Pacific, Johnson Controls, who was speaking at the Built Environment Leaders' Summit in Singapore for the International Built Environment Week (IBEW) 2023."We see the challenges facing our industry, but more importantly we see the willingness from both public and private sectors to collaborate and scale up technologies available to solve these challenges. To help achieve the aspirations of a growing population, we must work together to leverage the latest smart building innovations to enhance urban living, create sustainable environments, and ensure safe and healthy spaces for people to thrive and grow".Story continuesTo enable this, the whitepaper highlights three key areas for Southeast Asia to urgently address: first, more investment needed for deploying and maintaining smart building systems; second, maximising AI technology to monitor and optimise the built sector's environmental impact; and third, strengthening regulatory environments to facilitate collaboration, standardisation and data sharing between the public and private sectors.Smart Building Systems: Significant investment is needed to deploy smart city sensors and Internet of Things (IoT) devices, and analyse the smart city data collected to improve the overall efficiency of buildings and promote individuals comfort and health. Whereas before, each building system could be improved only on its own, the potential to connect all of them, enabled by smart city technologies, will open up a new dimension of holistic building performance.Adopting AI Technology: AI-powered systems have a strong potential to help buildings reduce their environmental impact by monitoring and analysing energy consumption patterns, optimising energy usage, and managing waste and water consumption. They also can predict when maintenance is needed to prevent equipment failures and reduce downtime and costs.Robust Regulatory Environments: Policies that encourage collaborations between the public and private sector can help leverage resources, expertise, and funding to drive smart city initiatives. This can overcome the funding and technical expertise barriers to smart city adoption and better integrate governance structures to create more cohesive, streamlined processes among agencies and jurisdictions.The whitepaper also highlighted Singapore's pioneering achievements in harnessing technology to create a more efficient and interconnected society while driving net-zero goals. Some of these projects that had involved Johnson Controls include:Transport: The Land Transport Authority (LTA) implemented its Intelligent Transport System, which uses real-time data to optimise traffic flow and reduce congestion. By 2024, traffic controllers for Fort Canning Tunnel will be able to remotely monitor and manage in-tunnel sub-systems, such as jet fans and fire protection systems, to ensure road safety.Aviation: Singapore Airlines (SIA) was able to achieve a high level of sophisticated security at its operating sites throughout Changi Airport, with a fully integrated Building Security System featuring intelligent card readers, fingerprint biometrics, and distributed intelligence at all layers of the system design.For these to happen, more skilled talent is also needed to advance the built environment sector. Labour supply issues, particularly around a digital skills gap, continue to challenge the industry, exacerbated by an ageing workforce and the COVID-19 pandemic. The whitepaper highlighted the role that government agencies, industry players and academic institutions must perform together to nurture a digitally savvy workforce that supports their smart city initiatives.Johnson Controls has partnered with SkillsFuture Singapore since 2022 to mentor small- and medium-sized enterprises (SMEs) in the built environment sector over a 3-year period. As a SkillsFuture Queen Bee, they helped SMEs to develop their digital capabilities and transform their businesses to be more sustainable. The SkillsFuture Queen Bee programme has benefitted over 2,300 organisations to-date.The whitepaper was launched at BEX Asia, the region's leading built environment exhibition as part of the International Built Environment Week (IBEW) 2023. At the event, Johnson Controls also presented a panel discussion with industry leaders Lendlease, Beca, CBRE and WiredScore to discuss the evolution of sustainable smart cities in Asia, and what must be done to accelerate a smarter net zero future.Download the whitepaper here at: https://www.johnsoncontrols.com/en_sg/events/johnson-controls-at-bex-asia-2023Media Contacts: Genevieve Leong                                                            Ashley SongWeber Shandwick (for Johnson Controls)                      Johnson ControlsEmail: [email protected]          Email: [email protected] Johnson Controls: At Johnson Controls (NYSE:JCI), we transform the environments where people live, work, learn and play. As the global leader in smart, healthy and sustainable buildings, our mission is to reimagine the performance of buildings to serve people, places and the planet.Building on a proud history of nearly 140 years of innovation, we deliver the blueprint of the future for industries such as healthcare, schools, data centers, airports, stadiums, manufacturing and beyond through OpenBlue, our comprehensive digital offering.Today, with a global team of 100,000 experts in more than 150 countries, Johnson Controls offers the world`s largest portfolio of building technology and software as well as service solutions from some of the most trusted names in the industry.Visit www.johnsoncontrols.com for more information and follow @JohnsonControls on social platforms.CisionView original content to download multimedia:https://www.prnewswire.com/apac/news-releases/more-investment-and-collaborations-needed-to-accelerate-smart-city-vision-for-southeast-asia-301918983.htmlSOURCE Johnson Controls

PR Newswire

More Investment and Collaborations Needed to Accelerate Smart City Vision for Southeast Asia

https://finance.yahoo.com/news/more-investment-collaborations-needed-accelerate-094800676.html

1ccaaae0-5e7f-311e-a187-48e908ec70ab

JCI

The brand’s comprehensive suite of loss prevention solutions can help retailers address shrink, eroding profit, and organized retail crime activity so they can effectively navigate today’s retail landscape.NEUHAUSEN, Switzerland, September 06, 2023--(BUSINESS WIRE)--Sensormatic Solutions, the leading global retail solutions portfolio of Johnson Controls, shows its continued commitment to supporting retailers through innovation. Today, the brand released "Secure Retail in the New World," a resource to help industry leaders understand the future of loss prevention and guide holistic operational improvements that help mitigate the impact of shrink by leaning on connectivity, leading with data, and regaining control of their environments."Not only has the financial impact of organized retail crime grown significantly in recent years, but so have safety concerns for both shoppers and associates," said Craig Szklany, vice president and product general manager, Loss Prevention & Liability at Sensormatic Solutions. "These changes have made it necessary for retailers around the globe to reconsider what it means to protect their stores. Adopting a data-led approach rooted in holistic operational insight and supported by emerging technology can help brands not only improve their loss prevention tactics today but prepare for new challenges that arise tomorrow."Sensormatic Solutions loss prevention solutions work together to provide retailers a comprehensive view of their operations to better understand what’s working, what isn’t, and how to improve their strategies accordingly. Datasets from throughout the store come together to put control back into retailers’ hands and inform more effective, holistic loss prevention strategies built on:Connectivity. Retailers have been using electronic article surveillance (EAS), tags, and other loss prevention technologies for decades. Advancements in connected solutions have made these tools more powerful than ever before, giving leaders a comprehensive, real-time view of their stores.Context. Computer vision, radio-frequency identification (RFID), store exit monitoring, and other tools come together to help retailers understand not just what was taken and when but the tactics retail criminals are using. Connecting these systems sheds light on what today’s crime looks like in the context of a specific retail location or enterprise to provide actionable, data-driven insights that guide more effective deployments.Control. Visual and physical deterrents—like hard tags, safers and wraps, smart sensors, and public view monitors—can help harden defenses no matter how they’re deployed. However, when retailers use operational and loss prevention data to guide their deployment strategies, they’ll be able to use existing tools more effectively and mitigate shrink without compromising customer experiences.Story continuesSensormatic Solutions loss prevention portfolio empowers retailers with the holistic solutions they need to remain agile and effective in the face of rising retail crime. The brand’s solutions are designed for easy adoption, helping retailers seamlessly integrate advanced hardware and software into existing loss prevention systems.To learn more about the benefits of adopting a holistic approach to loss prevention and how to get started, download Sensormatic Solutions latest white paper: Secure Retail in the New World.About Johnson ControlsAt Johnson Controls (NYSE:JCI), we transform the environments where people live, work, learn and play. As the global leader in smart, healthy and sustainable buildings, our mission is to reimagine the performance of buildings to serve people, places and the planet.Building on a proud history of nearly 140 years of innovation, we deliver the blueprint of the future for industries such as healthcare, schools, data centers, airports, stadiums, manufacturing and beyond through OpenBlue, our comprehensive digital offering.Today, with a global team of 100,000 experts in more than 150 countries, Johnson Controls offers the world's largest portfolio of building technology and software as well as service solutions from some of the most trusted names in the industry.Visit www.johnsoncontrols.com for more information and follow @Johnson Controls on social platforms.About Sensormatic SolutionsSensormatic Solutions is the leading global retail solutions portfolio of Johnson Controls powering operational excellence at scale and enabling smart and connected shopper engagement. Our intelligent digital operating platform – Sensormatic IQ – combines the full Sensormatic Solutions portfolio, including third-party data to deliver unmatched insights into shopper experience, inventory intelligence, loss prevention and operational effectiveness with advanced technologies, like AI and Machine Learning. This enables retailers to act on prescriptive and predictive data-driven outcomes to confidently move into the future. Please visit Sensormatic Solutions or follow us on LinkedIn, Twitter, and our YouTube channel.View source version on businesswire.com: https://www.businesswire.com/news/home/20230906842496/en/ContactsMediaJaclyn MessinaSensormatic Solutions by Johnson ControlsWork: +1 [email protected] TorranceMatter on behalf of Sensormatic SolutionsWork: [email protected]

Business Wire

Sensormatic Solutions holistic loss prevention tools support retailers in escalating fight against theft and shrink

https://finance.yahoo.com/news/sensormatic-solutions-holistic-loss-prevention-133000956.html

e342e451-91f9-374e-a86a-e36082e9fb73

JEF

Investors are always looking for stocks that are poised to beat at earnings season and Jefferies Financial Group Inc. JEF may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Jefferies is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for JEF in this report.In fact, the Most Accurate Estimate for the current quarter is currently at 31 cents per share for JEF, compared to a broader Zacks Consensus Estimate of 29 cents per share. This suggests that analysts have very recently bumped up their estimates for JEF, giving the stock a Zacks Earnings ESP of +8.77% heading into earnings season.Jefferies Financial Group Inc. Price and EPS SurpriseJefferies Financial Group Inc. Price and EPS SurpriseJefferies Financial Group Inc. price-eps-surprise | Jefferies Financial Group Inc. QuoteWhy is this Important?A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).Given that JEF has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Clearly, recent earnings estimate revisions suggest that good things are ahead for Jefferies, and that a beat might be in the cards for the upcoming report.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportStory continuesJefferies Financial Group Inc. (JEF) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Is a Surprise Coming for Jefferies (JEF) This Earnings Season?

https://finance.yahoo.com/news/surprise-coming-jefferies-jef-earnings-123800642.html

02fa28cd-5283-3426-b637-830a71533e14

JEF

Goldman Sachs (GS) CEO David Solomon said in a Friday interview with Yahoo Finance that he is encouraged by a string of initial public offerings expected in the coming weeks, predicting a "pickup in the capital markets activity" over the course of the fall.If the IPOs go well, he said, it could create a "virtuous cycle" that attracts other companies still waiting on the sidelines.Goldman also stands to benefit. It is among the banks leading the underwriting for IPOs from SoftBank Group’s Arm Holdings and grocery delivery service Instacart, which would both be among the year's biggest."Obviously an environment with more capital markets activity is a good environment for Goldman Sachs," he said.Solomon is under pressure to improve Goldman's results after reporting the firm's lowest quarterly profits in three years. He is wrestling with everything from job cuts and a two-year-long investment banking slump to reports of partner unrest and questions about his leadership style.He declined during the interview to address some recent media stories about his leadership, saying "I've talked plenty about the noise and the press." His focus each day, he said, is on the company and its clients and delivering for shareholders — "that's the discussion inside Goldman Sachs."Clients, he added, "have enormous confidence in Goldman Sachs. The feedback from our clients around Goldman Sachs and the work we do for them continues to be very, very strong."Goldman Sachs CEO David Solomon pictured in April of this year in Washington. (Elizabeth Frantz/REUTERS)Goldman’s stock is down 5.5% so far this year. It has outperformed Bank of America (BAC) and Citigroup (C) while underperforming Morgan Stanley (MS) and JPMorgan Chase (JPM). The KBW Nasdaq US bank index (^BKX) is down 21% for the same period.Since Solomon became CEO in October 2018, Goldman's stock is up 45%. That is better than many Wall Street banks, except rivals Morgan Stanley and Jefferies (JEF). The KBW index has fallen 23% over the same time.Story continuesThe new fall lineup of IPOs, which also includes marketing automation software firm Klaviyo and German shoe maker Birkenstock, comes just in time for banks like Goldman that hope to end an extended dealmaking slump that followed a boom in 2021.Clients turned cautious about everything from the direction of interest rates to relations with China to the larger US economy, dampening the optimism needed to go public, buy other companies, or take on more debt.As dealmaking dried up, Goldman and other firms across Wall Street slashed bonuses and staff, announcing cuts of roughly 20,000 jobs since the end of 2022."We've been through a really tough year for capital markets activity," Solomon said Friday."We went from a very robust environment in 2021 to obviously a much different environment after the war in Ukraine started and obviously ... very, very high rampant inflation" that the Federal Reserve tried to tamp down with the most aggressive series of interest rate hikes in decades.This content is not available due to your privacy preferences.Update your settings here to see it.But the US economy, he said, "has been a lot more resilient over the last 12 months than we would have expected. I think the chance for a softer landing right now is much higher than we would have anticipated a year ago."Goldman's chief economist Jan Hatzius, who has been one of the most outspoken voices on Wall Street about a reduced risk of a recession, lowered expectations for a recession further earlier this week.While Goldman waits out the tepid period of dealmaking, Solomon is also attempting a tricky retreat from a costly push into consumer banking and backing away from offering financial advice to mass market customers so that the firm can focus on its core ultrarich clients.This content is not available due to your privacy preferences.Update your settings here to see it.He said Friday that Goldman has no plans to buy a bank and is focused on its principal businesses: investment banking and markets and wealth management."That's where the lion's share of the firm's focus is at this point in time."Click here for the latest stock market news and in-depth analysis, including events that move stocksRead the latest financial and business news from Yahoo Finance

Yahoo Finance

Goldman CEO Solomon: New IPOs could create a 'virtuous cycle'

https://finance.yahoo.com/news/goldman-ceo-solomon-new-ipos-could-create-a-virtuous-cycle-174859660.html

808d23d6-1341-4ed4-8d14-2c2e9fafe26d

JEQ

PHILADELPHIA, PA / ACCESSWIRE / June 7, 2023 / abrdn Japan Equity Fund, Inc. (the "Fund") (NYSE:JEQ) announced today that William Maher has been appointed to the Board of Directors of the Fund as a Class III Director effective June 6, 2023. William Maher has also been appointed as a member of the Audit Committee and the Nominating and Corporate Governance Committee.As stated in the press release issued on May 25, 2023, Mr. P. Gerald Malone resigned as a Director of the Board of Directors of the Fund effective May 25, 2023. The Board of Directors would like to extend their sincere gratitude to Mr. Malone and acknowledge the valuable contributions he has made to the Fund during his tenure.Important InformationIn the United States, abrdn is the marketing name for the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, abrdn Australia Limited, abrdn Asia Limited, Aberdeen Capital Management, LLC, abrdn ETFs Advisors LLC and abrdn Alternative Funds Limited.Closed-end funds are traded on the secondary market through one of the stock exchanges. The Fund's investment return and principal value will fluctuate so that an investor's shares may be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value (NAV) of the Fund's portfolio. There is no assurance that the Fund will achieve its investment objective. Past performance does not guarantee future results.https://www.abrdnjeq.com/# # #For More Information Contact:abrdn U.S. Closed-End FundsInvestor [email protected]: abrdn Japan Equity Fund, Inc.View source version on accesswire.com: https://www.accesswire.com/759935/abrdn-Japan-Equity-Fund-Inc-Announces-Appointment-of-William-Maher-as-Director

ACCESSWIRE

abrdn Japan Equity Fund, Inc. Announces Appointment of William Maher as Director

https://finance.yahoo.com/news/abrdn-japan-equity-fund-inc-220000497.html

f8954bd3-16ca-3884-a6f0-4e3ab25bc5f0

JEQ

Please note that no performance numbers or rates have changed from the August 9th press release. This update is simply to include some additional language around the Funds that default to paying in stock, unless otherwise elected.PHILADELPHIA, PA / ACCESSWIRE / August 15, 2023 / The following abrdn U.S. Closed-End Funds announced today that the closed end funds in the chart directly below will pay the distributions indicated on a per share basis on August 31, 2023 to all shareholders of record as of August 24, 2023 (ex-dividend date August 23, 2023). These dates apply to the Funds listed below with the exception of the abrdn Australia Equity Fund, Inc. (IAF), the India Fund, Inc. (IFN) and the abrdn Japan Equity Fund, Inc. (JEQ) which will pay on September 29, 2023, to all shareholders of record as of August 24, 2023 (ex-dividend date August 23, 2023).TickerExchangeFundAmountACPNYSEabrdn Income Credit Strategies Fund$ 0.1000AGDNYSEabrdn Global Dynamic Dividend Fund$ 0.0650AODNYSEabrdn Total Dynamic Dividend Fund$ 0.0575ASGINYSEabrdn Global Infrastructure Income Fund$ 0.1200AWPNYSEabrdn Global Premier Properties Fund$ 0.0400FAXNYSE AmericanAbrdn Asia-Pacific Income Fund, Inc.$ 0.0275FCONYSE Americanabrdn Global Income Fund, Inc.$ 0.0700IAFNYSE Americanabrdn Australia Equity Fund, Inc.$ 0.1200IFNNYSEThe India Fund, Inc.$ 0.4100JEQNYSEabrdn Japan Equity Fund, Inc.$ 0.1100VFLNYSE Americanabrdn National Municipal Income Fund$ 0.0325At the end of each calendar year, a Form 1099-DIV will be sent to shareholders, which will state the amount and composition of each fund's distributions and provide information with respect to their appropriate tax treatment for the prior calendar year. You should not draw any conclusions about any of these Funds' investment performance from the amount of the distributions.MANAGED DISTRIBUTION POLICY FUNDS ANNOUNCE DISTRIBUTION PAYMENT DETAILSabrdn Global Infrastructure Income Fund ("ASGI")abrdn Australia Equity Fund, Inc. ("IAF")The India Fund, Inc. ("IFN")abrdn Japan Equity Fund, Inc. ("JEQ")The above-noted abrdn U.S. Closed-End Funds (the "Funds" or individually the "Fund"), today announced that the Funds will pay the distributions noted in the chart above on August 31, 2023, on a per share basis to all shareholders of record as of August 24, 2023 (ex-dividend date August 23, 2023). These dates apply to the Funds listed below with the exception of the abrdn Australia Equity Fund, Inc. (IAF), the India Fund, Inc. (IFN) and the abrdn Japan Equity Fund, Inc. (JEQ) which will pay on September 29, 2023, to all shareholders of record as of August 24, 2023 (ex-dividend date August 23, 2023).Story continuesFor the abrdn Australia Equity Fund, Inc. ("IAF"), the India Fund, Inc. ("IFN") and the abrdn Japan Equity Fund, Inc. ("JEQ"), this stock distribution will automatically be paid in newly issued shares of the Fund unless otherwise instructed by the shareholder. Shares of common stock will be issued at the lower of the net asset value ("NAV") per share or the market price per share with a floor for the NAV of not less than 95% of the market price. The valuation date for this stock distribution is September 21, 2023. Fractional shares will generally be settled in cash, except for registered shareholders with book entry accounts at Computershare Investor Services who will have whole and fractional shares added to their account.Shareholders may request to be paid their quarterly distributions in cash instead of shares of common stock by providing advance notice to the bank, brokerage or nominee who holds their shares if the shares are in "street name," or by filling out in advance an election card received from Computershare Investor Services if the shares are in registered form. To receive the quarterly distribution payable in September 2023 in cash instead of shares of common stock, the bank, brokerage or nominee who holds the shares must advise the Depository Trust Company as to the full and fractional shares for which they want the distribution paid in cash by September 18, 2023, and written notification for the election of cash by registered shareholders must be received by Computershare Investor Services prior to September 18, 2023.Each Fund has adopted a distribution policy to provide investors with a stable distribution out of current income, supplemented by realized capital gains and, to the extent necessary, paid-in capital in reliance on an exemptive order granted by the Securities and Exchange Commission.Under applicable U.S. tax rules, the amount and character of distributable income for each Fund's fiscal year can be finally determined only as of the end of the Fund's fiscal year. However, under Section 19 of the Investment Company Act of 1940, as amended (the "1940 Act") and related rules, the Funds may be required to indicate to shareholders the estimated source of certain distributions to shareholders.The following tables set forth the estimated amounts of the sources of the distributions for purposes of Section 19 of the 1940 Act and the rules adopted thereunder. The tables have been computed based on generally accepted accounting principles. The tables include estimated amounts and percentages for the current distributions to be paid as well as for the cumulative distributions paid relating to fiscal year to date, from the following sources: net investment income; net realized short-term capital gains; net realized long-term capital gains; and return of capital. The estimated compositions of the distributions may vary because the estimated composition may be impacted by future income, expenses and realized gains and losses on securities and currencies.Each Fund's estimated sources of the current distributions to be paid and for its current fiscal year to date are as follows:Estimated Amounts of Current Distribution per ShareFundDistribution AmountNet Investment IncomeNet Realized Short-Term Gains*Net Realized Long-Term GainsReturn of CapitalASGI$0.1200$0.033628%$0.00847%$0.078065%--IAF$0.1200$0.060050%$0.00242%$0.012010%$0.045638%IFN$0.4100--$0.00411%$0.405999%--JEQ$0.1100$0.017616%$0.00111%--$0.091383%Estimated Amounts of Fiscal Year to Date Cumulative Distributions per ShareFundFiscal Year** to Date Distribution AmountNet Investment IncomeNet Realized Short-Term Gains*Net Realized Long-Term GainsReturn of CapitalASGI$1.3200$0.369628%$0.09247%$0.858065%--IAF$0.5000$0.250050%$0.01002%$0.050010%$0.190038%IFN$1.2300--$0.01231%$1.217799%--JEQ$0.4100$0.065616%$0.00411%--$0.340383%* includes currency gains** ASGI has a 9/30 fiscal year end; IAF and JEQ have a 10/31 fiscal year end; IFN has a 12/31 fiscal year end.Where the estimated amounts above show a portion of the distribution to be a "Return of Capital," it means that Fund estimates that it has distributed more than its income and capital gains; therefore, a portion of your distribution may be a return of capital. A return of capital may occur for example, when some or all the money that you invested in a Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund's investment performance and should not be confused with "yield" or "income."As of August 4, 2023, after giving effect to this payment, JEQ estimates it has a net deficit of $5,829,000. A net deficit results when the Fund has net unrealized losses that are in excess of any net realized gains that have not yet been distributed.The amounts and sources of distributions reported in this notice are only estimates and are not being provided for tax reporting purposes. The final determination of the source of all distributions for the current year will only be made after year-end. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during the remainder of the fiscal year and may be subject to change based on tax regulations. After the end of each calendar year, a Form 1099-DIV will be sent to shareholders for the prior calendar year that will tell you how to report these distributions for federal income tax purposes.The following table provides the Funds' total return performance based on net asset value (NAV) over various time periods compared to the Funds' annualized and cumulative distribution rates.Fund Performance and Distribution Rate InformationFundAverage Annual Total Return on NAV for the 5 Year Period Ending 07/31/2023¹Current Fiscal Period's Annualized Distribution Rate on NAV²Cumulative Total Return on NAV¹Cumulative Distribution Rate on NAV²ASGI39.30%36.76%21.41%5.63%IAF6.30%10.30%15.46%7.68%IFN4.41%9.40%10.14%4.82%JEQ1.05%5.74%22.09%4.30%1 Return data is net of all fund expenses and fees and assumes the reinvestment of all distributions reinvested at prices obtained under the Fund's dividend reinvestment plan, with the exception of the most recent distribution.2 Based on the Fund's NAV as of July 31, 2023.3 The Fund launched within the past 5 years; the performance and distribution rate information presented reflects data from inception (July 29, 2020) through July 31, 2023.Shareholders should not draw any conclusions about a Fund's investment performance from the amount of the Fund's current distributions or from the terms of the distribution policy (the "Distribution Policy").While NAV performance may be indicative of the Fund's investment performance, it does not measure the value of a shareholder's investment in the Fund. The value of a shareholder's investment in the Fund is determined by the Fund's market price, which is based on the supply and demand for the Fund's shares in the open market.Pursuant to an exemptive order granted by the Securities and Exchange Commission, the Funds may distribute any long-term capital gains more frequently than the limits provided in Section 19(b) under the 1940 Act and Rule 19b-1 thereunder. Therefore, distributions paid by the Funds during the year may include net income, short-term capital gains, long-term capital gains and/or a return of capital. Net income dividends and short-term capital gain dividends, while generally taxable at ordinary income rates, may be eligible, to the extent of qualified dividend income earned by the Funds, to be taxed at a lower rate not to exceed the maximum rate applicable to your long-term capital gains. Distributions made in any calendar year in excess of investment company taxable income and net capital gain are treated as taxable ordinary dividends to the extent of undistributed earnings and profits, and then as a return of capital that reduces the adjusted basis in the shares held. To the extent return of capital distributions exceed the adjusted basis in the shares held, capital gain is recognized with a holding period based on the period the shares have been held at the date such amount is received.The payment of distributions in accordance with the Distribution Policy may result in a decrease in the Fund's net assets. A decrease in the Fund's net assets may cause an increase in the Fund's annual operating expense ratio and a decrease in the Fund's market price per share to the extent the market price correlates closely to the Fund's net asset value per share. The Distribution Policy may also negatively affect the Fund's investment activities to the extent that the Fund is required to hold larger cash positions than it typically would hold or to the extent that the Fund must liquidate securities that it would not have sold, for the purpose of paying the distribution. Each Fund's Board has the right to amend, suspend or terminate the Distribution Policy at any time. The amendment, suspension or termination of the Distribution Policy may affect the Fund's market price per share. Investors should consult their tax advisor regarding federal, state and local tax considerations that may be applicable in their particular circumstances.Circular 230 disclosure: To ensure compliance with requirements imposed by the U.S. Treasury, we inform you that any U.S. tax advice contained in this communication (including any attachments) is not intended or written to be used, and cannot be used, for the purpose of (i) avoiding penalties under the Internal Revenue Code or (ii) promoting, marketing or recommending to another party any transaction or matter addressed herein.In the United States, abrdn is the marketing name for the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, abrdn Asia Limited, Aberdeen Capital Management, LLC, abrdn ETFs Advisors LLC and abrdn Alternative Funds Limited.Closed-end funds are traded on the secondary market through one of the stock exchanges. A Fund's investment return and principal value will fluctuate so that an investor's shares may be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value (NAV) of the fund's portfolio. There is no assurance that a Fund will achieve its investment objective. Past performance does not guarantee future results.https://www.abrdn.com/en-us/cefinvestorcenterFor More Information Contact:abrdn U.S. Closed-End FundsInvestor [email protected]: abrdn U.S. Closed-End FundsView source version on accesswire.com: https://www.accesswire.com/774385/abrdn-US-Closed-End-Funds-Announce-Distribution-Payment-Details

ACCESSWIRE

abrdn U.S. Closed-End Funds Announce Distribution Payment Details

https://finance.yahoo.com/news/abrdn-u-closed-end-funds-214000511.html

4abade99-b7fa-3650-9e82-2b6e78259f0a

JKHY

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Jack Henry & Associates, Inc. (NASDAQ:JKHY) is about to go ex-dividend in just 4 days. The ex-dividend date occurs one day before the record date which is the day on which shareholders need to be on the company's books in order to receive a dividend. The ex-dividend date is of consequence because whenever a stock is bought or sold, the trade takes at least two business day to settle. In other words, investors can purchase Jack Henry & Associates' shares before the 7th of September in order to be eligible for the dividend, which will be paid on the 28th of September.The company's next dividend payment will be US$0.52 per share, on the back of last year when the company paid a total of US$2.08 to shareholders. Looking at the last 12 months of distributions, Jack Henry & Associates has a trailing yield of approximately 1.3% on its current stock price of $158.08. Dividends are an important source of income to many shareholders, but the health of the business is crucial to maintaining those dividends. That's why we should always check whether the dividend payments appear sustainable, and if the company is growing. Check out our latest analysis for Jack Henry & Associates Dividends are typically paid out of company income, so if a company pays out more than it earned, its dividend is usually at a higher risk of being cut. Fortunately Jack Henry & Associates's payout ratio is modest, at just 40% of profit.Generally speaking, the lower a company's payout ratios, the more resilient its dividend usually is.Click here to see the company's payout ratio, plus analyst estimates of its future dividends.historic-dividendHave Earnings And Dividends Been Growing?Companies that aren't growing their earnings can still be valuable, but it is even more important to assess the sustainability of the dividend if it looks like the company will struggle to grow. If earnings fall far enough, the company could be forced to cut its dividend. It's not encouraging to see that Jack Henry & Associates's earnings are effectively flat over the past five years. We'd take that over an earnings decline any day, but in the long run, the best dividend stocks all grow their earnings per share.Story continuesAnother key way to measure a company's dividend prospects is by measuring its historical rate of dividend growth. In the last 10 years, Jack Henry & Associates has lifted its dividend by approximately 16% a year on average.The Bottom LineShould investors buy Jack Henry & Associates for the upcoming dividend? Jack Henry & Associates has seen its earnings per share stagnate in recent years, although the company reinvests more than half of its profits in the business, which could bode well for its future prospects. We think this is a pretty attractive combination, and would be interested in investigating Jack Henry & Associates more closely.Ever wonder what the future holds for Jack Henry & Associates? See what the 16 analysts we track are forecasting, with this visualisation of its historical and future estimated earnings and cash flowGenerally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Should You Buy Jack Henry & Associates, Inc. (NASDAQ:JKHY) For Its Upcoming Dividend?

https://finance.yahoo.com/news/buy-jack-henry-associates-inc-120517370.html

4eb4d855-1943-3521-af2e-ff8cbf3c40b8

JKHY

Jack Henry & Associates is a financial technology company and payment processing service for the financial services industry. Its stock price has soared higher for decades but a major change in direction appears to be underway. In this daily bar chart of JKHY, below, I can see that prices have weakened the past year.Continue reading

TheStreet.com

Jack Henry: The Bigger the Top the Bigger the Drop?

https://finance.yahoo.com/m/37687b8f-0fc6-343f-84e7-6224b2464722/jack-henry-the-bigger-the.html

37687b8f-0fc6-343f-84e7-6224b2464722

JLL

The star broker spoke to the Business Journal about the move and his perspective on where the region’s life sciences and health care real estate market is headed.Continue reading

American City Business Journals

Here’s why star broker Bob Richards left Cushman for JLL

https://finance.yahoo.com/m/db287cff-6af4-3782-b622-289b8d105adf/here%E2%80%99s-why-star-broker-bob.html

db287cff-6af4-3782-b622-289b8d105adf

JLL

While Jones Lang LaSalle Incorporated (NYSE:JLL) might not be the most widely known stock at the moment, it saw a decent share price growth in the teens level on the NYSE over the last few months. As a mid-cap stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock. However, could the stock still be trading at a relatively cheap price? Let’s take a look at Jones Lang LaSalle’s outlook and value based on the most recent financial data to see if the opportunity still exists. Check out our latest analysis for Jones Lang LaSalle Is Jones Lang LaSalle Still Cheap?According to my price multiple model, which makes a comparison between the company's price-to-earnings ratio and the industry average, the stock price seems to be justfied. I’ve used the price-to-earnings ratio in this instance because there’s not enough visibility to forecast its cash flows. The stock’s ratio of 25.67x is currently trading slightly below its industry peers’ ratio of 30.38x, which means if you buy Jones Lang LaSalle today, you’d be paying a decent price for it. And if you believe Jones Lang LaSalle should be trading in this range, then there isn’t much room for the share price to grow beyond the levels of other industry peers over the long-term. Is there another opportunity to buy low in the future? Since Jones Lang LaSalle’s share price is quite volatile, we could potentially see it sink lower (or rise higher) in the future, giving us another chance to buy. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.What kind of growth will Jones Lang LaSalle generate?earnings-and-revenue-growthInvestors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Jones Lang LaSalle's earnings over the next few years are expected to double, indicating a very optimistic future ahead. This should lead to stronger cash flows, feeding into a higher share value.Story continuesWhat This Means For YouAre you a shareholder? JLL’s optimistic future growth appears to have been factored into the current share price, with shares trading around industry price multiples. However, there are also other important factors which we haven’t considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at JLL? Will you have enough confidence to invest in the company should the price drop below the industry PE ratio?Are you a potential investor? If you’ve been keeping tabs on JLL, now may not be the most advantageous time to buy, given it is trading around industry price multiples. However, the optimistic forecast is encouraging for JLL, which means it’s worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.So while earnings quality is important, it's equally important to consider the risks facing Jones Lang LaSalle at this point in time. For instance, we've identified 2 warning signs for Jones Lang LaSalle (1 doesn't sit too well with us) you should be familiar with.If you are no longer interested in Jones Lang LaSalle, you can use our free platform to see our list of over 50 other stocks with a high growth potential.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Is It Time To Consider Buying Jones Lang LaSalle Incorporated (NYSE:JLL)?

https://finance.yahoo.com/news/time-consider-buying-jones-lang-110357910.html

40680984-8ba8-354b-9313-08b1e0a94ae5

JNJ

The market may be sleeping on this dividend stock, down 19% in its short history as a stand-alone business.Continue reading

Motley Fool

Bargain Hunting With $100? This New S&P 500 Dividend Stock Is a No-Brainer to Buy on the Dip

https://finance.yahoo.com/m/4a8d767e-8ff4-33f9-845d-e4724aee910e/bargain-hunting-with-100-.html

4a8d767e-8ff4-33f9-845d-e4724aee910e

JNJ

In this piece, we will take a look at the 25 most biodiverse countries in the world. To skip our analysis of global biodiversity, its ecological and economic impacts, as well as some companies that operate within this space, go ahead and see the 5 Most Biodiverse Countries in the World.Biodiversity, or biological diversity, refers to the variety of life on Earth, including the diversity of species, genes, and ecosystems. It encompasses all living organisms, from the smallest microorganisms to the largest mammals, and the interactions they have with each other and their environments. The term biodiversity is often considered a measure of the health and resilience of ecosystems, and its loss can have far-reaching ecological, economic, and societal consequences. Although sustainability commitments are increasingly prevalent in corporate strategic planning, there remains a significant gap in attention to the critical investment required for the preservation and augmentation of global biodiversity.As per the World Economic Forum (WEF), over 50% of the global Gross Domestic Product (GDP) relies significantly or to a moderate extent on ecosystem services. These services encompass natural resources, groundwater, and the essential role of pollination in food production. However, biodiversity investment goes beyond sustainability; it also presents a compelling business proposition. In the coming decade, the WEF projects that safeguarding natural ecosystems and enhancing biodiversity could unlock business prospects valued at a staggering $10 trillion yearly while concurrently spawning approximately 400 million fresh employment opportunities. These opportunities span various sectors, including enhancing energy efficiency in construction and implementing circular economy solutions within the automotive, electronics, and textile industries.See also: 25 Most Environmentally Friendly Companies in the WorldThus, declining ecosystems hold massive financial repercussions for companies. Similar to the asset-price bubble of 2008, this phenomenon eludes straightforward linear understanding. However, once set in motion, its consequences can far surpass the ordinary. Such a scenario holds substantial significance for businesses, affecting them in both the immediate and long-term contexts. As an illustration, the Intergovernmental Science-Policy Platform on Biodiversity and Ecosystem Services (IPBES), a body associated with the United Nations, has calculated that the economic worth of food production directly reliant on pollinating insects ranges from $235 billion to $577 billion on a global scale. Additionally, the UNDP states that degrading ecosystem could trigger a downward spiral of approximately $2.7 trillion in global GDP by 2030.Story continuesBusinesses perceived as environmentally conscious often cultivate an image of responsibility, yielding advantages in both public perception and practicality that extend beyond their immediate operations. Nevertheless, prioritizing cost savings through reduced energy consumption takes precedence. In addition to curbing energy use, these forward-thinking organizations allocate resources to R&D, and actively champion social initiatives aimed at fostering eco-friendly products and internal procedures. For instance, Ford Motor Company (NYSE:F) has adhered to a comprehensive ten-point environmental policy over an extended period. The corporation incorporates sustainable fabrics into its vehicles, with an impressive 80% recyclability rate for both the Focus and Escape models. Furthermore, Ford boasts ownership of one of the world's largest green roof. Aside from Ford Motor Company (NYSE:F), companies like Hewlett Packard Enterprise Company (NYSE:HPE), Starbucks Corporation (NASDAQ:SBUX), and Johnson & Johnson (NYSE:JNJ) have several initiatives that are aimed at marking a positive impact on global biodiversity, either by reducing emissions and cutting back on toxic substances used in manufacturing products.25 Most Biodiverse Countries in the Worldvovan/Shutterstock.comOur MethodologyTo compile our list of the 25 most biodiverse countries in the world, we made use of the Global Biodiversity Index presented by social research firm 'The Swiftest' which ranks 201 countries based on six ranking factors including the number of bird, amphibian, fish, mammal, reptile, and plant species present in each nation.Most Biodiverse Countries in the World25. PanamaGlobal Biodiversity Index: 170.54 Panama boasts one of the world's greatest levels of natural diversity. Its tropical climate, characterized by elevated temperatures and humidity, provides a nurturing environment for a plethora of plant and animal species. In total, Panama is home to more than 10,462 distinct plant species, encompassing a rich assortment of 1,200 orchid varieties, 678 fern species, and 1,500 tree varieties. Additionally, the country boasts 252 mammal species, 972 native bird species, and 228 diverse amphibian species.24. CameroonGlobal Biodiversity Index: 172.41Cameroon is home to approximately 9,000 recognized plant species, and new ones are continuously being discovered by scientists each year. Among these, just over 500 species are exclusive to Cameroon, meaning they exist nowhere else on Earth. This remarkable biodiversity is a result of the diverse range of ecosystems found within the country, encompassing a coastline, savannas, deserts, mountains, and tropical rainforests. Cameroon is often aptly described as a 'miniature Africa' due to this remarkable variety of environments it harbors.23. KenyaGlobal Biodiversity Index: 179.42Kenya boasts an extensive range of ecological zones and habitats, encompassing lowland and mountain forests, both wooded and open grasslands, semi-arid scrubland, dry woodlands, inland aquatic environments, and coastal and marine ecosystems. Wetlands play a crucial role in Kenya's economy, contributing significantly to agriculture, livestock production, energy generation (via hydroelectric projects), fisheries, and tourism. Despite robust efforts to safeguard Kenya's biodiversity, there are numerous unprotected regions facing rapid degradation due to various threats, resulting in a multitude of conservation challenges.22. PhilippinesGlobal Biodiversity Index: 186.92The Philippines is renowned as a mega-diversity country with regards to its remarkable biodiversity. This archipelago of over 7,000 islands in Southeast Asia boasts an astonishing array of species and ecosystems. Numerous islands within the archipelago are thought to exhibit exceptionally high levels of endemism, encompassing a minimum of 25 plant genera and accounting for 50% of the terrestrial wildlife. The nation is a habitat to more than 52,000 documented species, with over half of them existing exclusively within its borders. When considering the area-to-diversity ratio, it's likely that the Philippines contains a greater variety of life forms than any other country on Earth.21. ArgentinaGlobal Biodiversity Index: 198.74Given its diverse range of habitats, Argentina naturally boasts abundant biodiversity. The country is home to slightly over 1,000 bird species, a wealth of flora, and numerous hundreds of mammal, reptile, and amphibian species, among them the likes of Jaguars, Orcas, and critically endangered frogs.20. ThailandGlobal Biodiversity Index: 200.77Situated in the tropical expanse of Southeast Asia, Thailand spans 513,120 square kilometers and is home to a population of approximately 69 million. As an upper-middle-income economy, Thailand is blessed with a diverse ecosystem and abundant biodiversity, which hold significant importance for both local communities and the nation's overall development. Ranking among the most biodiverse countries in Southeast Asia, Thailand reaps substantial benefits from the ecosystems, terrains, and habitats that nurture its exceptional array of biodiversity.19. South AfricaGlobal Biodiversity Index: 207.94South Africa's wealth of topographical features, climatic variations, geological formations, and diverse population offers a broad spectrum of natural and cultural assets. Hence, it comes as no surprise that it is internationally recognized as one of the most biodiverse countries in the world, thanks to its extensive range of species, high rate of endemism, and a plethora of diverse ecosystems.18. BoliviaGlobal Biodiversity Index: 209.55Positioned within the heart of the Tropical Andes Biodiversity Hotspot, Bolivia stands out as one of the most biodiverse countries in the world. It boasts an impressive roster of roughly 13,644 plant species, 799 fungal species, 13,719 insect species, 313 reptile species, 251 amphibian species, and 908 species of freshwater fish.17. TanzaniaGlobal Biodiversity Index: 213.10Tanzania, located in East Africa, is renowned for its expansive wilderness regions. These encompass the Serengeti National Park, a renowned safari destination inhabited by the iconic "big five" (elephant, lion, leopard, buffalo, rhino), as well as Kilimanjaro National Park, which is home to Africa's tallest mountain. Along its coastline, you'll find tropical islands like Zanzibar, infused with Arabic influences, and Mafia, boasting a marine park that shelters whale sharks and vibrant coral reefs.16. Democratic Republic of CongoGlobal Biodiversity Index: 214.43The Democratic Republic of Congo (DRC) holds a paramount position in Africa's biodiversity conservation efforts. Within its borders, the DRC shelters an array of extraordinary endemic species, including the okapi, Grauer's gorilla, bonobo, and Congo peacock. It possesses over half of Africa's tropical forests, with dense woodlands and forests spanning more than half of its vast land area of 2.3 million square kilometers. These ecosystems play a vital role in regulating global climatic patterns.15. MalaysiaGlobal Biodiversity Index: 214.71Malaysia, known for its remarkable biodiversity, ranks among the world's megadiverse nations. In this regard, the country has consistently demonstrated its dedication to the sustainable preservation and management of its rich biodiversity. During the 1992 United Nations Conference on Environment and Development in Rio de Janeiro, Malaysia pledged its commitment to ensure that at least 50% of its land would remain under forest tree cover. As of today, Malaysia's forest cover has exceeded this commitment, reaching 54.6%, which corresponds to 18.04 million hectares of its total land area.14. VietnamGlobal Biodiversity Index: 216.97Vietnam, located in the eastern part of the Indochina Peninsula, spans over 15 latitudes, covering a distance of 1,650 kilometers. Its extensive marine territory comprises a coastline stretching 3,260 kilometers and is dotted with numerous islands. The country boasts abundant freshwater ecosystems, encompassing over 10 million hectares of wetlands. Vietnam exhibits remarkable biodiversity across its landscapes, featuring a diverse array of fauna, flora, and microorganisms. On the terrestrial front, it has identified more than 13,200 flora species and approximately 10,000 fauna species, along with over 3,000 aquatic species thriving in its inland wetlands. The tropical marine region encompasses over 20 distinctive ecosystems and is home to a staggering 11,000 marine species. Moreover, with 16 crop groups and an impressive array of more than 800 distinct species, Vietnam is globally recognized as a prominent hub for plant breeding.13. MyanmarGlobal Biodiversity Index: 221.77Myanmar boasts remarkable biodiversity, thanks to its diverse range of ecosystems spanning from sea level to towering mountain peaks. Among these ecosystems, forests are pivotal for environmental stability. However, the country also hosts a wide array of freshwater environments, ranging from swift mountain streams to expansive, slow-moving lowland rivers, along with lakes and non-flowing wetlands. Additionally, Myanmar possesses some of the most extensive and least disturbed coastal and marine ecosystems in mainland Southeast Asia.The extensive coastline encompasses around half a million hectares of brackish and freshwater swamplands, providing crucial ecological functions and serving as habitats for spawning, nursery, and feeding grounds for economically significant aquatic organisms such as fish, prawns, and other aquatic flora and fauna. In total, Myanmar boasts an impressive biodiversity, including 11,800 vascular plant species (including gymnosperms and angiosperms), 251 mammal species, 1,056 bird species, 279 reptile species, 82 amphibian species, 841 medicinal plants, 96 varieties of bamboo, and numerous tropical crop species.12. Papua New GuineaGlobal Biodiversity Index: 226.57Papua New Guinea, known for its significant share of the world's biodiversity, boasts a diverse landscape featuring breathtaking highland valleys, expansive grasslands, extensive tropical rainforests, ancient swamplands, and intricate mangrove ecosystems. Within this remarkable setting, the country is a sanctuary for a rich variety of wildlife, including an estimated 150,000 species of insects, 314 species of freshwater fish, over 641 species of amphibians and reptiles, 740 bird species, and 276 mammal species. Among these, notable inhabitants include the Queen Alexandra Birdwing, the world's largest butterfly, the largest species of tree frog, the planet's sole poisonous birds, and 12 of the 14 recognized tree kangaroo species.11. VenezuelaGlobal Biodiversity Index: 273.39Venezuela's remarkable geographic and biological diversity encompasses the Andes Mountains, Amazon Basin, Guiana Shield, Caribbean Sea, and Atlantic Ocean, securing its position among the most biodiverse countries in the world. This rich tapestry of ecosystems provides habitat to numerous endemic species. The nation's wildlife is equally varied, featuring over 250 mammal species, including elusive cats like pumas and jaguars, as well as howler monkeys, sloths, and the capybara, which holds the title of the world's largest rodent, among other notable species.10. United StatesGlobal Biodiversity Index: 280.13The United States stands as a worldwide hub of diversity for numerous organism groups, particularly those dependent on aquatic environments, such as salamanders, freshwater mussels, and freshwater turtles. However, the country, like many others across the globe, is undergoing a biodiversity crisis. While initiatives like the America the Beautiful initiative sets a nationwide goal to conserve 30% of U.S. lands and waters by 2030, in line with the global 30 by 30 goal, a recent U.S. wildlife conservation report highlights that 40% of animal species, 34% of plant species, and 40% of ecosystems across the country are currently facing significant risks.9. EcuadorGlobal Biodiversity Index: 291.58Ecuador stands out on the global stage for its abundant floral diversity, a hidden gem often threatened by human activities. This nation boasts an impressive statistic – it is estimated to harbor more plant species per unit area than any other South American country. Ecuador's natural landscape can be broadly classified into four distinct geographical zones: the coastal region, the mountainous terrain, the lush Amazon rainforest, and the renowned Galapagos Islands. When it comes to conservation efforts, Ecuador is typically categorized into continental Ecuador and the Galapagos Islands, although the distribution of such initiatives is not the same across the nation. Within its borders, Ecuador hosts an array of 26 distinct habitat types, each characterized by unique flora patterns dictated by factors like altitude and precipitation levels.8. IndiaGlobal Biodiversity Index: 301.63From a biogeographical perspective, India occupies a strategic position at the confluence of three distinct realms: the Afro-tropical, Indo-Malayan, and Paleo-Arctic realms. Consequently, India boasts characteristic elements from each of these realms. This fusion of three distinct biogeographical realms endows the country with a wealth of biological diversity, rendering it exceptionally rich and unique. According to the International Union for Conservation of Nature (IUCN), India is a megadiverse country that claims 2.4% of the world's land area, yet accounts for 7-8% of all recorded species of flora and fauna.7. PeruGlobal Biodiversity Index: 330.12Peru, situated in the western region of South America, spans over 1.2 million square kilometers and is divided into three distinct regions: the Coast, Highlands, and Jungle. Its current population surpasses 31.5 million residents. According to the Global Biodiversity Index, Peru ranks among the top ten most biodiverse countries in the world and is home to the second-largest expanse of the Amazon rainforest on the planet. This combination accounts for a staggering 70% of the world's total biodiversity.6. AustraliaGlobal Biodiversity Index: 337.18Australia boasts a diverse range of ecosystems owing to its unique geographical positioning, providing a haven for numerous species found nowhere else on the planet. However, the menace of deforestation poses a grave threat to many of these plants and animals. Among the endemic wildlife found here, one can encounter the common ringtail possum, kangaroo, Parma wallaby, Tasmanian devil, galah, gang-gang cockatoo, and the Common wombat. Click to continue reading and see the 5 Most Biodiverse Countries in the World.  Suggested Articles:20 Most Dog Friendly Cities in the US12 Best Places to Retire in Ecuador20 Most Popular Liquor Brands in AmericaDisclosure: None. 25 Most Biodiverse Countries in the World is originally published on Insider Monkey.

Insider Monkey

25 Most Biodiverse Countries in the World

https://finance.yahoo.com/news/25-most-biodiverse-countries-world-195307367.html

2f46db5c-cd58-333d-aa98-923fef136849

JNPR

Juniper’s AI-driven and API-centric wireless network provides the automation, insight and assurance needed for world-class lighting, security, climate and entertainment experiencesSUNNYVALE, Calif., August 31, 2023--(BUSINESS WIRE)--Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Savant Systems, a global leader in smart home and energy solutions, has selected Juniper’s AI-Driven Enterprise solutions, including wireless access, to help revolutionize the home automation experience by bringing intelligent controls to millions of homes.Today’s homeowners want to be surrounded by comfort, convenience and efficiency. Savant smart homes unite automated controls for security, lighting, temperature, power and simplified wireless networking, but they need remote management, visibility and proactive remediation to keep them up and running while delivering amazing user experiences.With extensive experience in the smart home industry, Savant Systems has been providing its software to millions of homes for over 17 years and is committed to delivering the highest quality smart home and energy solutions. To make the customer experience even better, Savant needed a wireless infrastructure that is easy to configure and reliable to operate, with extensive insight into user experiences for all smart home components. Savant chose Juniper’s wireless access solution, driven by Mist AI, as the network foundation for the company’s smart home solutions.As the leader in wireless access, Juniper provides Savant with a variety of unique yet essential AI networking features, such as customizable wireless service levels, proactive AI-driven troubleshooting and self-driving operations that keep customer networks running smoothly. In addition, Savant developers leveraged Juniper’s open API-centric architecture to build a customized AI-driven dashboard that allows dealers to seamlessly manage, monitor and support individual customer networks. Dealers can provision and activate a customer’s network all from their Savant dashboard, eliminating the need to learn a new user interface and thus accelerating time to revenue and reducing overhead for their installation team.Story continues"Savant Systems is thrilled to be partnering with Juniper solutions and Mist AI to help our dealers reduce the discovery and resolution time of any Wi-Fi issue," said Aaron Gutin, Product Category Director at Savant Systems. "Our integrators and end users are happy when the Wi-Fi’s great—which means we’re happy too."Additional Resources:Savant Case StudyJuniper Wireless Access PointsJuniper Mist™ Wi-Fi AssuranceAbout Juniper NetworksJuniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on X (Twitter), LinkedIn and Facebook.Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.View source version on businesswire.com: https://www.businesswire.com/news/home/20230831945636/en/ContactsMedia Relations:Kelsey AkersonJuniper Networks+1 (503) [email protected]

Business Wire

Savant Systems Selects Juniper Networks as Strategic Wi-Fi Partner to Jointly Deliver First AI-Driven Smart Home Automation Solution

https://finance.yahoo.com/news/savant-systems-selects-juniper-networks-114500487.html

9cd7d9c3-8a2c-3c96-85c9-b6e838bbe072

JNPR

Juniper Networks, Inc. JNPR announced that Savant Systems, a leader in smart home and energy solutions, will leverage its AI-driven enterprise solutions to enhance the home automation experience. Juniper will offer a wide range of AI networking capabilities, encompassing proactive AI-powered troubleshooting and customizable wireless service levels among others.There is a rising demand for smart home automation solutions, propelled by a combination of factors that align with the changing lifestyle trends such as an increasing desire for comfort, convenience, energy savings, security and more. Users can tailor automation routines to their specific needs and preferences. Such flexibility enables homeowners to create living spaces that suit their unique lifestyles. Additionally, the shift toward remote work has highlighted the importance of well-equipped home environments, further boosting interest in smart home technology.Amid this backdrop, Savant is seeking to deploy a wireless infrastructure that will be easy to configure and reliable to operate. Savant smart home offerings comprise automated control for various components like security, lighting, temperature and power. But to maintain the optimum functionality of the system, remote management, comprehensive visibility and detailed insight about all smart home components are essential.To address these critical requirements and elevate the overall customer experience, Savant has opted for Juniper's wireless access solution. Juniper WIFI Assurance is a cloud service powered by Mist AI. It effectively replaces manual troubleshooting tasks with automated wireless operations to augment the predictability and reliability of WIFI networks. It also enriches dealers with unique visibility into the user experience. Additionally, the automated anomaly detection features immensely reduce resolution times for any WIFI-related issues.Notably, Juniper's open API-centric architecture empowers Savant’s developers to craft a customized AI-driven dashboard. This dashboard significantly improves visibility into each individual network, enabling dealers to accurately monitor and manage these networks. One of the great advantages of this AI dashboard is that it eliminates the need for a complex user interface evolution process. This streamlines the process of activating a customer’s network and maximizes revenue potential.Juniper is leveraging the 400-gig cycle to capture hyperscale switching opportunities inside the data center. The company is set to capitalize on the increasing demand for data center virtualization, cloud computing and mobile traffic packet/optical convergence. It is witnessing encouraging trends across various areas of its business, including solid momentum in Mist Systems and strength in the services organization. Juniper introduced new features within the AI-driven enterprise portfolio that enable customers to simplify the rollout of wireless networks while bringing greater insight to network operators.With the growing usage of smartphones and tablets, mobile data traffic has gone up. This has resulted in higher demand for advanced networking architecture, leading service providers to spend more on routers and switches. Investments in customer solutions and sales organizations have enabled the company to capitalize on the solid demand across end markets. Juniper is expected to benefit from the higher spending pattern among carriers to upgrade their networks and support the incremental growth in data traffic.The stock has gained 3.5% in the past year against the industry's fall of 13%.Story continuesZacks Investment ResearchImage Source: Zacks Investment ResearchJuniper currently carries a Zacks Rank #3 (Hold).Stocks to ConsiderMotorola Solutions, Inc. MSI, sporting a Zacks Rank #1 (Strong Buy) at present, delivered an earnings surprise of 5.62%, on average, in the trailing four quarters. In the last reported quarter, it pulled off an earnings surprise of 5.58%. You can see the complete list of today’s Zacks #1 Rank stocks here.It provides services and solutions to government segments and public safety programs, along with large enterprises and wireless infrastructure service providers. It develops and services both analog and digital two-way radio, voice and data communications products and systems for private networks, wireless broadband systems and end-to-end enterprise mobility solutions to a wide range of enterprise markets.Workday Inc. WDAY, currently sporting a Zacks Rank #1, delivered an earnings surprise of 15.38%, on average, in the trailing four quarters. In the last reported quarter, it pulled off an earnings surprise of 14.40%.Workday is a provider of enterprise-level software solutions for financial management and human resource domains. The company’s cloud-based platform combines finance and HR in a single system, which makes it easier for organizations to provide analytical insights and decision support.NVIDIA Corporation NVDA, currently sporting a Zacks Rank #1, delivered an earnings surprise of 9.79%, on average, in the trailing four quarters. In the last reported quarter, it pulled off an earnings surprise of 29.19%.NVIDIA is the worldwide leader in visual computing technologies and the inventor of the graphic processing unit or GPU. Over the years, the company’s focus has evolved from PC graphics to artificial intelligence-based solutions that now support high-performance computing, gaming and virtual reality platforms.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportJuniper Networks, Inc. (JNPR) : Free Stock Analysis ReportNVIDIA Corporation (NVDA) : Free Stock Analysis ReportMotorola Solutions, Inc. (MSI) : Free Stock Analysis ReportWorkday, Inc. (WDAY) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Juniper (JNPR) AI Solution to Enhance Home Automaton Experience

https://finance.yahoo.com/news/juniper-jnpr-ai-solution-enhance-144400261.html

2e4d28e4-0ed7-351d-9ca2-901f78ebb759

JOB

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, September 7th:GEE Group Inc. JOB: This professional and industrial staffing and placement services company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 100% over the last 60 days.GEE Group Inc. Price and ConsensusGEE Group Inc. Price and ConsensusGEE Group Inc. price-consensus-chart | GEE Group Inc. QuoteGEE Group has a PEG ratio of 0.41 compared with 1.46 for the industry. The company possesses a Growth Score  of A.GEE Group Inc. PEG Ratio (TTM)GEE Group Inc. PEG Ratio (TTM)GEE Group Inc. peg-ratio-ttm | GEE Group Inc. Quote   Splunk Inc. SPLK: This software and cloud solutions company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 20.1% over the last 60 days.Splunk Inc. Price and ConsensusSplunk Inc. Price and ConsensusSplunk Inc. price-consensus-chart | Splunk Inc. QuoteSplunk has a PEG ratio of 1.34 compared with 11.94 for the industry. The company possesses a Growth Score of B.Splunk Inc. PEG Ratio (TTM)Splunk Inc. PEG Ratio (TTM)Splunk Inc. peg-ratio-ttm | Splunk Inc. QuoteUrban Outfitters, Inc. URBN: This consumer products retailer and wholesaler carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 15.6% over the last 60 days.Urban Outfitters, Inc. Price and ConsensusUrban Outfitters, Inc. Price and ConsensusUrban Outfitters, Inc. price-consensus-chart | Urban Outfitters, Inc. QuoteUrban Outfitters has a PEG ratio of 0.43 compared with 0.78 for the industry. The company possesses a Growth Score of B.Urban Outfitters, Inc. PEG Ratio (TTM)Urban Outfitters, Inc. PEG Ratio (TTM)Urban Outfitters, Inc. peg-ratio-ttm | Urban Outfitters, Inc. Quote See the full list of top ranked stocks here. Learn more about the Growth score and how it is calculated here.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportStory continuesUrban Outfitters, Inc. (URBN) : Free Stock Analysis ReportSplunk Inc. (SPLK) : Free Stock Analysis ReportGEE Group Inc. (JOB) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Best Growth Stocks to Buy for September 7th

https://finance.yahoo.com/news/best-growth-stocks-buy-september-102300525.html

88c86b62-c8fe-3d93-949b-c46e77c57f15